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Abstract 
Colorectal cancer is an increasingly important cause of mortality, whose 
incidence is inversely correlated with cruciferous vegetable consumption, 
from which can be obtained isothiocyanates such as sulforaphane. These 
are well-characterised regarding their cytoprotective and anti-tumour effects, 
thus believed to contribute to the observed diet-risk correlation; great interest 
lies in their potential use for chemoprevention and/or improvement of 
chemotherapy. While some mechanisms of action are well-established, such 
as their induction of antioxidant responses via the Nrf2 pathway, questions 
remain regarding its other mechanisms of action that appear to be vast and 
complex, more knowledge of which could shine a light upon means of safe 
and effective clinical application. There is evidence that sulforaphane can 
modulate the expression of microRNAs, which play major roles in 
development and disease by regulating gene expression, particularly in 
carcinogenesis. This study explored sulforaphane-induced microRNA 
modulation in adenocarcinoma Caco-2 and non-cancerous CCD-841 
colorectal cells, and the potential role of such in the interactions between 
sulforaphane and colorectal carcinogenesis. The experimental system was 
initially validated by confirming the expected induction of Nrf2 and Nrf2-
controlled genes at the mRNA and/or protein levels, by sub-cytotoxic doses 
of sulforaphane. Based upon data from the following miRNA-Seq-based 
expression profiling and individual microRNA assays, sulforaphane 
upregulated let-7f-5p and let-7g-5p expression in Caco-2 but not in CCD-841 
cells, and upregulated miR-10a-5p and downregulated miR-193b-3p in Caco-
2. The direct interaction of let-7f-5p with computationally-predicted mRNA-3’-
UTR binding sites of cell division cycle 25 homolog A and high-mobility group 
AT-hook 2 was confirmed by luciferase assays. Future experiments to 
confirm the effects of sulforaphane and/or let-7f-5p on these genes at the 
protein/mRNA levels could be informative, as could tests for synergistic 
and/or antagonistic interactions between sulforaphane and let-7f-5p. Insights 
from such experiments could eventually lead towards the development of 
more effective chemopreventative and chemotherapeutic strategies based 
upon sulforaphane and/or specific microRNA mimics/inhibitors. 
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miRNAs listed in miRBase with each new version, according to the miRBase 
Blog. ............................................................................................................. 97 
Figure 14: The effects of SFN on Caco-2 cell viability at 24 h and 48 h. Caco-
2 cells were treated for 24 or 48 h, by adding to culture medium in 
sextuplicate, DMSO-diluted SFN at various concentrations, or DMSO 
(control) (final DMSO concentrations were 0.1% (v/v)). Cell viability was 
measured by the MTT assay and evaluated as (OD670 – OD570) at each 
concentration in proportion to the same of the control, and data are 
represented as the mean ± S.E.M. of sextuplicates (*P<0.05). .................. 133 
Figure 15: The effect of SFN on CCD-841 cell viability at 24 and 48 h. CCD-
841 cells were treated for 24 or 48 h by adding to culture medium in 
sextuplicate, DMSO-diluted SFN at various concentrations, or DMSO 
(control) (final DMSO concentrations were 0.1% (v/v)). Cell viability was 
measured by the MTT assay and evaluated as (OD670 – OD570) at each 
concentration in proportion to the same of the control, and data are 
represented as the mean ± S.E.M. of sextuplicates (*P<0.05). .................. 134 
Figure 16: The effects of H2O2 on Caco-2 cell viability at 24 h and 48 h. 
Caco-2 cells were treated for 24 or 48 h by adding to culture medium in 
sextuplicate, water-dissolved H2O2 at various concentrations, or water 
22 | P a g e  
 
(control). Cell viability was evaluated as (OD670 – OD570) at each 
concentration in proportion to the same of the control, and data are 
represented as the mean ± S.E.M. of sextuplicates (*P<0.05). .................. 135 
Figure 17: The effect of H2O2 on CCD-841 cell viability at 24 h and 48 h. 
CCD-841 cells were treated for 24 or 48 h by adding to culture medium in 
sextuplicate, water-dissolved H2O2 at various concentrations, or water 
(control). Cell viability was evaluated as (OD670 – OD570) at each 
concentration in proportion to the same of the control, and data are 
represented as the mean ± S.E.M. of sextuplicates (*P<0.05). .................. 136 
Figure 18: The effects of SeMSC on Caco-2 cell viability at 24 h. Caco-2 
cells were treated for 24 h by adding to culture medium in sextuplicate, 
water-dissolved SeMSC at various concentrations, or water (control). Cell 
viability was evaluated as (OD670 – OD570) at each concentration in 
proportion to the same of the control, and data are represented as the mean 
± S.E.M. of sextuplicates (*P<0.05). ........................................................... 138 
Figure 19: The effects of 24 h SFN treatment on the TrxR-1 mRNA transcript 
level in Caco-2 cells. Cells were treated by adding to culture medium in 
triplicate, DMSO-diluted SFN (2.5, 5, 10 or 20µM) or DMSO (control) (final 
DMSO concentrations were 0.1% (v/v)). Relative TrxR-1 mRNA levels were 
assayed via TaqMan RT-qPCR as described in Methods, using 18S as an 
internal control. Relative TrxR-1 expression is evaluated by the Pfaffl method 
from CT values, taking into account efficiencies derived from standard curve 
data. Data are represented as mean ± S.E.M. of triplicates (*P<0.05). ...... 139 
Figure 20: The effects of 24 h SFN treatment on the TrxR-1 mRNA transcript 
level in CCD-841 cells. Cells were treated by adding to culture medium in 
triplicate, DMSO-diluted SFN (2.5, 5, 10 or 20µM) or DMSO (control) (final 
DMSO concentrations were 0.1% (v/v)). Relative TrxR-1 mRNA levels were 
assayed via TaqMan RT-qPCR as described in Methods, using 18S as an 
internal control. Relative TrxR-1 expression is evaluated by the Pfaffl method 
from CT values, taking into account efficiencies derived from standard curve 
data. Data are represented as mean ± S.E.M. of triplicates (*P<0.05). ...... 140 
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Figure 21: The effect of 48 h SFN treatment on TrxR-1 protein levels in 
Caco-2 cells. Cells were treated for 48 h by adding to culture medium in 
duplicate, DMSO-diluted SFN (5, 10 or 20µM) or DMSO (control) (final 
DMSO concentrations were 0.1% (v/v)). Selenium was supplemented by 
adding SeMSC (200nM), to culture medium. Relative protein levels were 
assayed via Western Blotting as described in Methods, using β-actin as an 
internal control for normalisation. Induction is evaluated and illustrated in the 
graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for each 
sample relative to the same for the control (see Methods). Data are 
represented as the mean of duplicates ± (upper value – lower value)/2. ... 142 
Figure 22: The effect of SFN treatment on TrxR-1 protein levels in Caco-2 
cells, with or without selenium supplementation. Cells were treated by adding 
to culture medium in duplicate, DMSO-diluted SFN (10µM) or DMSO 
(control) (final DMSO concentrations were 0.1% (v/v)). Selenium was 
supplemented by adding SeMSC (200nM). Relative protein abundance was 
assayed via Western Blotting as described in Methods, using β-actin as an 
internal control for normalisation. Induction is evaluated and illustrated in the 
graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for each 
sample relative to the same for the control (see Methods). Data are 
represented as the mean of duplicates ± (upper value – lower value)/2. ... 143 
Figure 23: The effect of SFN treatment on TrxR-1 protein levels in CCD-841 
cells, with or without selenium supplementation. Cells were treated for 24 h 
by adding to culture medium, DMSO-diluted SFN (2.5 or 5µM) or DMSO 
(control) (final DMSO concentrations were 0.05% (v/v)). Selenium was 
supplemented by adding SeMSC (200nM), to culture medium. Relative 
protein levels were assayed via Western Blotting as described in Methods, 
using β-actin as an internal control. Induction is evaluated and illustrated in 
the graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for 
each sample relative to the same for the control (see Methods). Data are 
representative of a single experiment. ....................................................... 144 
Figure 24: The effect of SFN treatment on TrxR-1 protein levels in CCD-841 
cells, with or without selenium supplementation. Cells were treated for 48 h 
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by adding to culture medium in duplicate, DMSO-diluted SFN (5, 10 or 20µM) 
or DMSO (control) (final DMSO concentrations were 0.1% (v/v)). Selenium 
was supplemented by adding SeMSC (200nM), to culture medium. Relative 
protein levels were assayed via Western Blotting as described in Methods, 
using β-actin as an internal control for normalisation. Induction is evaluated 
and illustrated in the graph as [(TrxR-1 band intensity)/(Internal control band 
intensity)] for each sample relative to the same for the control (see Methods). 
Data are represented as the mean of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 145 
Figure 25: The effect of SFN treatment on TrxR-1 protein levels in CCD-841 
cells, with or without selenium supplementation. Cells were treated by adding 
to culture medium in duplicate, DMSO-diluted SFN (10µM) or DMSO 
(control) (final DMSO concentrations were 0.1% (v/v)). Selenium was 
supplemented by adding SeMSC (200nM) to culture medium. Relative 
protein abundance was assayed via Western Blotting as described in 
Methods, using β-actin as an internal control. Induction is evaluated and 
illustrated in the graph as [(TrxR-1 band intensity)/(Internal control band 
intensity)] for each sample relative to the same for the control (see Methods). 
Data are represented as the mean of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 146 
Figure 26: The effect of 24 h SFN treatment on UGT1A protein levels in 
Caco-2 cells. Cells were treated by adding to culture medium in duplicate, 
DMSO-diluted SFN (5, 10 or 20µM) or DMSO (control) (final DMSO 
concentrations were 0.05% (v/v)). Relative protein abundance was assayed 
via Western Blotting as described in Methods, using β-actin as an internal 
control for normalisation. Induction is evaluated and illustrated in the graph 
as [(TrxR-1 band intensity)/(Internal control band intensity)] for each sample 
relative to the same for the control (see Methods). Data are represented as 
the mean of duplicates ± (upper value – lower value)/2. ............................ 147 
Figure 27: The effect of 72 h SFN treatment on UGT1A protein levels in 
Caco-2 cells. Cells were treated by adding to culture medium in duplicate, 
DMSO-diluted SFN (5, 10 or 20µM) or DMSO (control) (final DMSO 
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concentrations were 0.05% (v/v)). Relative protein abundance was assayed 
via Western Blotting as described in Methods, using β-actin as an internal 
control for normalisation. Induction is evaluated and illustrated in the graph 
as [(TrxR-1 band intensity)/(Internal control band intensity)] for each sample 
relative to the same for the control (see Methods). Data are represented as 
the mean of duplicates ± (upper value – lower value)/2. ............................ 148 
Figure 28: The effect of SFN treatment on nuclear accumulation of Nrf2 in 
Caco-2 cells. Cells were treated for 4, 8, 12 or 24 h with SFN (10µM) or for 4 
h with SFN (5 or 20µM) by adding to culture medium in duplicate, DMSO-
diluted SFN (5, 10 or 20µM) or DMSO (control) (final DMSO concentrations 
were 0.05% (v/v)). Relative protein levels were assayed via Western Blotting 
as described in Methods, using Sam68 as an internal control for 
normalisation. Induction is evaluated and illustrated in the graph as [(Nrf2 
band intensity)/(Internal control band intensity)] for each sample relative to 
the same for the control (see Methods). Data are represented as the mean of 
duplicates ± (upper value – lower value)/2. ................................................ 150 
Figure 29: Caco-2 cells were seeded at densities sufficient that confluent 
monolayers were formed by 24 h. Scratch wounds were created in confluent 
monolayers using a pipette tip, and cells were then treated by adding to 
culture medium in triplicate SFN (5 to 20µM) or DMSO; final DMSO 
concentrations were 0.05% (v/v). Cells were subsequently incubated for 72 
h, then fixed, stained and photographed (with 5 photographs along the 
vertical axis of each scratch wound). The 4th image of every wound is 
shown. The average gap width between leading cells was calculated in each 
image, then data across all 5 images per well were averaged. Data from 
image analyses are represented in the graph as the means of three 
biological replicates ± S.E.M. ..................................................................... 152 
Figure 30: CCD-841 cells were seeded so as to form confluent monolayers 
at 24 h. Scratch wounds were then created in confluent monolayers with a 
pipette tip, and cells were then treated by adding to culture medium in 
triplicate SFN (5 to 20µM) or DMSO; final DMSO concentrations were 0.05% 
(v/v). Cells were subsequently incubated for 48 h, then fixed, stained and 
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photographed (with 5 photographs along the vertical axis of each scratch 
wound). The 4th image of every wound is shown. The average gap width 
between leading cells was calculated in each image, then data across all 5 
images per well were averaged. Data from image analyses are represented 
in the graph as the means of three biological replicates ± S.E.M. (*P<0.05).
 ................................................................................................................... 154 
Figure 31: Caco-2 cells were seeded at low density (400 cells/well) in 6-well 
plates (surface area/well = 9.5cm2) and then incubated for 48 h prior to 
treatment. After 48 h, cells were treated by adding to culture medium in 
sextuplicate, DMSO-diluted SFN (5-20µM) or DMSO (control); final DMSO 
concentrations were 0.05% (v/v). Cells were then incubated for a further 14 
days, after which cells were fixed and stained, and the number of colonies in 
each well was counted under an inverted microscope. Absolute colony 
counts are presented in the table and relative colony formation is illustrated 
in the graph, where data are represented as means of six biological 
replicates ± S.E.M. (*P<0.05). .................................................................... 156 
Figure 32: Caco-2 cells were cultured to 70-80% confluence in 24-well plates 
(surface area/well = 1.9cm2), then treated with DMSO-diluted SFN (5, 10 or 
20µM) or DMSO; final DMSO concentrations were 0.05% (v/v). 
Subsequently, cells were detached using trypsin and then re-seeded at low 
density (400 cells/well) in 6-well plates (surface area/well = 9.5cm2). Cells 
were then incubated for a further 14 days after which cells were fixed and 
stained, and the number of colonies in each well was counted. Relative 
colony formation is illustrated in the graph, where data are represented as 
means of six biological replicates ± S.E.M. ................................................ 157 
Figure 33: Normalised read numbers for hsa-let-7f-5p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars.... 169 
Figure 34: The effect of SFN treatment on the level of hsa-let-7f-5p in Caco-2 
cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO 
27 | P a g e  
 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed 
via Northern Blotting as described in Methods, using U6 as an internal 
control for normalisation. Induction is expressed as [(miRNA band 
intensity)/(U6 band intensity)] for each sample relative to the control mean, 
and data are represented as means of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 170 
Figure 35: Normalised read numbers for hsa-let-7g-5p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 171 
Figure 36: The effect of SFN treatment on the level of hsa-let-7g-5p in Caco-
2 cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed 
via Northern Blotting as described in Methods, using U6 as an internal 
control for normalisation. Induction is expressed as [(miRNA band 
intensity)/(U6 band intensity)] for each sample relative to the control mean, 
and data are represented as means of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 172 
Figure 37: Normalised read numbers for hsa-let-7f-5p in CCD-841 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 173 
Figure 38: Normalised read numbers for hsa-let-7g-5p in CCD-841 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 173 
Figure 39: The effect of SFN treatment on the level of hsa-let-7f-5p in CCD-
841 cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed 
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via Northern Blotting as described in Methods, using U6 as an internal 
control for normalisation. Induction is expressed as [(miRNA band 
intensity)/(U6 band intensity)] for each sample relative to the control mean, 
and data are represented as means of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 174 
Figure 40: The effect of SFN treatment on the level of hsa-let-7g-5p in CCD-
841 cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed 
via Northern Blotting as described in Methods, using U6 as an internal 
control for normalisation. Induction is expressed as [(miRNA band 
intensity)/(U6 band intensity)] for each sample relative to the control mean, 
and data are represented as means of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 175 
Figure 41: A test of the cross-reactivity of the probe anti-sense to hsa-let-7f-
5p with other let-7 family members. Positive sense oligomers composed of 
the sequences of each miRNA were blotted onto a membrane, which was 
then probed against hsa-let-7f-5p. ............................................................. 176 
Figure 42: A test of the cross-reactivity of the probe anti-sense to hsa-let-7g-
5p with other let-7 family members. Positive sense oligomers composed of 
the sequences of each miRNA were blotted onto a membrane, which was 
then probed against hsa-let-7g-5p. ............................................................ 176 
Figure 43: Normalised read numbers for hsa-miR-10a-5p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars.... 177 
Figure 44: The effect of SFN treatment on the level of hsa-miR-10a-5p in 
Caco-2 cells at 4, 8, 12, 24 and 48 h. Cells were treated by adding to culture 
medium in triplicate, DMSO-diluted SFN (10µM) for 4, 8, 12, 24 or 48 h, or 
DMSO; final DMSO concentrations were 0.05% (v/v). Relative miRNA 
abundance was assayed via TaqMan RT-qPCR as described in Methods, 
29 | P a g e  
 
using U6 as an internal control for normalisation. Induction was evaluated by 
the Pfaffl method as described in Methods, and data are represented as 
means of triplicates ± S.E.M. (*p<0.05). ..................................................... 178 
Figure 45: The effect of 24 h SFN treatment on the level of hsa-miR-10a-5p 
in Caco-2 cells. Cells were treated for 24 h by adding to culture medium in 
triplicate, DMSO-diluted SFN (5, 10 or 20µM) or DMSO (control); final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed 
via TaqMan RT-qPCR as described in Methods, using U6 as an internal 
control for normalisation. Induction was evaluated by the Pfaffl method as 
described in Methods, and data are represented as means of triplicates ± 
S.E.M. (*p<0.05). ....................................................................................... 179 
Figure 46: The effect of SFN treatment on the level of hsa-miR-10a-
5p|[isomiR]|21_42| in Caco-2 cells at 8 and 24 h. Cells were treated by 
adding to culture medium in duplicate, DMSO-diluted SFN (10µM) for 8 or 24 
h, or DMSO; final DMSO concentrations were 0.05% (v/v). Relative miRNA 
abundance was assayed via Northern Blotting as described in Methods, 
using U6 as an internal control for normalisation. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the 
control mean, and data are represented as means of duplicates ± (upper 
value – lower value)/2. ............................................................................... 180 
Figure 47: Normalised read numbers for hsa-miR-10b-5p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 181 
Figure 48: The effect of SFN treatment on the level of hsa-miR-29b-3p in 
Caco-2 cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed 
via Northern Blotting as described in Methods, using U6 as an internal 
control for normalisation. Induction is expressed as [(miRNA band 
intensity)/(U6 band intensity)] for each sample relative to the control mean, 
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and data are represented as means of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 182 
Figure 49: Normalised read numbers for hsa-miR-29b-3p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars.... 183 
Figure 50: Normalised read numbers for hsa-miR-193b-3p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars.... 184 
Figure 51: The effect of SFN treatment on the level of hsa-miR-193b-3p in 
Caco-2 cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed 
via Northern Blotting as described in Methods, using U6 as an internal 
control for normalisation. Induction is expressed as [(miRNA band 
intensity)/(U6 band intensity)] for each sample relative to the control mean, 
and data are represented as means of duplicates ± (upper value – lower 
value)/2. ..................................................................................................... 185 
Figure 52: Normalised read numbers for hsa-miR-182-5p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars.... 186 
Figure 53: Normalised read numbers for hsa-miR-192-5p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars.... 187 
Figure 54: Normalised read numbers for hsa-miR-17-3p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars.... 187 
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Figure 55: Normalised read numbers for hsa-miR-1296-5p in Caco-2 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 188 
Figure 56: Normalised read numbers for hsa-miR-182-5p in CCD-841 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 189 
Figure 57: Normalised read numbers for hsa-miR-106b-5p in CCD-841 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 190 
Figure 58: Normalised read numbers for hsa-miR-181a-5p in CCD-841 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 191 
Figure 59: Normalised read numbers for hsa-miR-345-5p in CCD-841 cells 
following SFN treatment for 8 or 24 h, or in controls. Data are represented as 
medians across library replicates, with the maximum and minimum values of 
replicate sets represented as the upper and lower bounds of error bars. .. 192 
Figure 60: Data from luciferase assays performed after co-transfecting 
HCT116 cells with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-
7f-5p inhibitor (Qiagen) and/or AllStars Negative Control siRNA (Qiagen). 
The pmiRGLO vector contained an insert consisting of four repeats of 
sequence antisense to that of let-7f-5p. Luciferase assays were performed at 
48 h post-transfection using the Dual-Glo Luciferase Assay Kit, and then 
relative Firefly and Renilla luciferase expression levels were evaluated by 
measuring the luminescence of metabolised substrates. Blank-corrected 
Firefly luminescence values were divided by blank-corrected Renilla 
luminescence values, and then ratios were normalised to controls (AllStars 
Negative Control siRNA at 200nM). Normalised data are represented as 
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triplicate means ± S.E.M. (*p<0.05 according to two-tailed Student’s T-test).
 ................................................................................................................... 197 
Figure 61: Data from luciferase assays performed after co-transfecting 
HCT116 cells with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-
7f-5p inhibitor (Qiagen) and/or AllStars Negative Control siRNA (Qiagen). 
The pmiRGLO vector contained an insertion of either a part of the BACH1 3’-
UTR containing two predicted let-7f-5p binding sites, or a modified form of 
this 3’-UTR portion with the predicted binding sites mutated. Luciferase 
assays were performed at 48 h post-transfection using the Dual-Glo 
Luciferase Assay Kit, and then relative Firefly and Renilla luciferase 
expression levels were evaluated by measuring the luminescence of 
metabolised substrates. Blank-corrected Firefly luminescence values were 
divided by blank-corrected Renilla luminescence values, and then ratios 
were normalised to controls (AllStars Negative Control siRNA at 200nM). 
Normalised data are represented as triplicate means ± S.E.M. (*p<0.05 
according to two-tailed Student’s T-test). ................................................... 198 
Figure 62: Data from luciferase assays performed after co-transfecting 
HCT116 cells with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-
7f-5p inhibitor (Qiagen) and/or AllStars Negative Control siRNA (Qiagen). 
The pmiRGLO vector contained an insertion of either a part of the CDC25A 
3’-UTR containing a predicted let-7f-5p binding site, or a modified form of this 
3’-UTR portion with the predicted binding site mutated. Luciferase assays 
were performed at 48 h post-transfection using the Dual-Glo Luciferase 
Assay Kit, and then relative Firefly and Renilla luciferase expression levels 
were evaluated by measuring the luminescence of metabolised substrates. 
Blank-corrected Firefly luminescence values were divided by blank-corrected 
Renilla luminescence values, and then ratios were normalised to controls 
(AllStars Negative Control siRNA at 200nM). Normalised data are 
represented as triplicate means ± S.E.M. (*p<0.05 according to two-tailed 
Student’s T-test). ........................................................................................ 199 
Figure 63: Data from luciferase assays performed after co-transfecting 
HCT116 cells with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-
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7f-5p inhibitor (Qiagen) and/or AllStars Negative Control siRNA (Qiagen). 
The pmiRGLO vector contained an insertion of either a part of the HMGA2 
3’-UTR containing three predicted let-7f-5p binding sites, or a modified form 
of this 3’-UTR portion with the predicted binding sites mutated. Luciferase 
assays were performed at 48 h post-transfection using the Dual-Glo 
Luciferase Assay Kit, and then relative Firefly and Renilla luciferase 
expression levels were evaluated by measuring the luminescence of 
metabolised substrates. Blank-corrected Firefly luminescence values were 
divided by blank-corrected Renilla luminescence values, and then ratios 
were normalised to controls (AllStars Negative Control siRNA at 200nM). 
Normalised data are represented as triplicate means ± S.E.M. (*p<0.05 
according to two-tailed Student’s T-test). ................................................... 200 
Figure 64: Data from luciferase assays performed after co-transfecting 
HCT116 cells with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-
7f-5p inhibitor (Qiagen) and/or AllStars Negative Control siRNA (Qiagen). 
The pmiRGLO vector contained an insertion of either a part of the MYC 3’-
UTR containing a predicted let-7f-5p binding site, or a modified form of this 
3’-UTR portion with the predicted binding site mutated. Luciferase assays 
were performed at 48 h post-transfection using the Dual-Glo Luciferase 
Assay Kit, and then relative Firefly and Renilla luciferase expression levels 
were evaluated by measuring the luminescence of metabolised substrates. 
Blank-corrected Firefly luminescence values were divided by blank-corrected 
Renilla luminescence values, and then ratios were normalised to controls 
(AllStars Negative Control siRNA at 200nM). Normalised data are 
represented as triplicate means ± S.E.M. (*p<0.05 according to two-tailed 
Student’s T-test). ........................................................................................ 201 
Figure 65: Data from luciferase assays performed after co-transfecting 
HCT116 cells with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-
7f-5p inhibitor (Qiagen) and/or AllStars Negative Control siRNA (Qiagen). 
The pmiRGLO vector contained an insertion of either a part of the KRAS 3’-
UTR containing a predicted let-7f-5p binding site, or a modified form of this 
3’-UTR portion with the predicted binding site mutated. Luciferase assays 
were performed at 48 h post-transfection using the Dual-Glo Luciferase 
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Assay Kit, and then relative Firefly and Renilla luciferase expression levels 
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Chapter 1: Introduction 
Links between an individual’s dietary and lifestyle habits and their risk of 
developing cancers have long been observed, and are highlighted by various 
epidemiological studies (Huxley, Ansary-Moghaddam et al. 2009). In 
particular, inverse correlations between the intake of fruits and vegetables 
and the risk of developing chronic diseases such as cancers have been 
suggested since the 1950s. Various explanations have been sought for this 
apparent connection, ranging from the dietary displacement of cancer-
promoting foods and improved micronutrient intake, to (more recently) the 
direct activity of non-nutritive yet bioactive compounds found in fruits and 
vegetables, referred to as phytochemicals. Phytochemicals are believed to 
play a number of roles in plants, from imparting colour and flavour, to acting 
as endogenous pesticides and fungicides. The potential benefits to human 
health of such phytochemicals have become increasingly apparent over 
recent decades. 
Globally, colorectal cancer (CRC) was the third most commonly diagnosed 
cancer in 2012 according to the World Cancer Research Fund International, 
accounting for 10% of total cancer diagnoses (World Cancer Research Fund 
International 2015). The incidence of CRC by country is positively associated 
with economic development, and is most notably on the rise in countries 
experiencing rapid economic development and/or increased adoption of 
‘Western’ dietary habits. As is also the case for other cancers, 
epidemiological studies link various lifestyle and dietary factors to one’s risk 
of developing CRC (Haggar and Boushey 2009). 
The isothiocyanates (ITCs) are a particular group of phytochemicals that are 
obtained by the consumption of cruciferous vegetables, and to which the 
relatively strong inverse correlations between cruciferous vegetable intake 
and cancer risk have often been attributed. Interest in the potential of ITCs to 
directly inhibit the development of chronic diseases has intensified since the 
1980s. 
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1.1 Cruciferous Vegetables and Isothiocyanates 
1.1.1 Cruciferous Vegetables 
As mentioned above, epidemiological studies have shown an inverse 
correlation between the consumption of cruciferous vegetables - such as 
broccoli, cabbage and Brussel sprouts - and the risk of developing various 
cancers, such as those of the lung (Lam, Gallicchio et al. 2009) and colon 
(Tse and Eslick 2014), independently of overall vegetable intake. Found 
particularly in the cruciferous variety of vegetables are phytochemicals called 
glucosinolates (GCNs), which are broken down upon vegetable consumption 
to form several types of product, including ITCs. ITCs per se have been 
extensively studied in vitro for their potential to inhibit the proliferation, 
migration and invasiveness of tumour cell lines, whilst promoting cell cycle 
arrest and apoptosis. Additionally, they have been shown to have 
chemopreventative potential in animal carcinogenesis models, thought to be 
largely due to the preservation of macromolecular integrity. Together, these 
studies imply that ITCs are highly likely to be one, if not the only, causative 
factor for the observed inverse correlation between cruciferous vegetable 
intake and cancer risk. 
1.1.2 Isothiocyanates and Redox Status 
ITCs are believed to have evolved to defend the plants against microbial and 
small animal (mostly insect) attack. The breakdown of the biologically 
inactive GCNs is mediated by the action of hydrolytic myrosinase enzymes. 
Intact plant tissues separately compartmentalise the GCNs in S-cells 
(Koroleva, Davies et al. 2000) and myrosinases in myrosin cells 
(Andréasson, Jørgensen et al. 2001), thus preventing the myrosinase-
mediated hydrolysis of the GCNs. Only when the cells are ruptured e.g. by 
food processing and/or chewing, or by microbial infection, are the 
myrosinases able to interact with, and thus hydrolyse, the GCNs. This 
hydrolysis has the potential to form different types of compound, including 
ITCs, thiocyanates and nitriles (Burow, Bergner et al. 2007). Of these, the 
ITCs are to date the best characterised for their bioactivity. 
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The GCNs and ITCs are each groups of related compounds; a specific ITC is 
typically generated by the hydrolysis of a specific GCN. Broccoli and broccoli 
sprouts are abundant in a particular GCN called glucoraphanin, whose 
hydrolysis gives rise to the ITC sulforaphane (SFN). SFN per se has been 
frequently studied for its potential to inhibit the development of various 
chronic health conditions such as osteoarthritis (Davidson, Jupp et al. 2016), 
cardiovascular diseases (Bai, Wang et al. 2015), autism (Singh, Connors et 
al. 2014) and cancers (Clarke, Dashwood et al. 2008), which is believed to 
be largely attributable to its broad anti-inflammatory, antioxidant and 
chemoprotective properties. 
Glucosinolate Isothiocyanate
Myrosinase
 
Figure 1: The general structural formulae of the glucosinolates and isothiocyanates are 
shown. The hydrolysis of a glucosinolate by myrosinases can produce an 
isothiocyanate. Different members of the glucosinolates and isothiocyanates differ at 
the positions indicated by the letter ‘R’. 
The mechanisms underlying the multitude of reported anti-cancer effects of 
ITCs in vitro and in vivo are likely to be wide-ranging, complex and 
interlinked. One of the longest-established effects of ITCs, as of some other 
phytochemicals, is the induction of nuclear factor (erythroid-derived 2)-like 2 
(Nrf2): a transcription factor that activates many genes coding for reductive 
(antioxidant) proteins that reduce oxidative reactive oxygen species (ROS), 
thereby inhibiting oxidative stress i.e. a deleteriously excessive shift of 
cellular redox status towards oxidation (Li and Kong 2009). 
Reductive i.e. antioxidant effects have traditionally been thought of as 
overwhelmingly beneficial to human health, due to the potential of ROS to 
react non-specifically with and thereby damage macromolecules such as 
carbohydrates, lipids, proteins and nucleic acids. Such reactions promote 
inflammatory signalling that is linked to the pathogeneses of chronic 
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diseases such as atherosclerosis, neurodegenerative disorders and cancers, 
as well as the general age-related decline of organ function. ROS can also 
disrupt homeostatic cell signalling, promote the apoptotic death of neurons 
and hepatocytes, and increase the frequency of potentially carcinogenic 
mutations, due to DNA oxidation. In fact, a hypothesis popular in the middle 
of the 20th century pinned ROS as the direct cause of the ‘ageing process’, 
and proposed that ageing might be halted by artificially eliminating ROS 
(Harman 1956). 
However, it has since come to light that ROS are not simply undesirable by-
products of aerobic metabolism as previously characterised. Specific ROS 
such as the superoxide anion and hydrogen peroxide play vital roles in cell 
signalling and immune cell activity, while oxidative shifts in redox status are 
important for the promotion of cell growth and differentiation in particular 
contexts. An example of the importance of ROS in cell signalling is the 
dependence of pancreatic β-cell insulin secretion upon the glucose uptake-
induced generation of ROS, as demonstrated by the fact that a deficiency of 
ROS impairs glucose-stimulated insulin secretion (Pi, Zhang et al. 2010). 
James Watson accordingly hypothesised in 2014 that a deficiency of ROS 
actually contributes to the development of type 2 diabetes. On the other 
hand, excessive oxidation inevitably promotes pancreatic β-cell death, so 
balance is crucial. Another example of ROS-mediated signalling is the 
promotion of protein kinase C (PKC) activity induced by the binding of 
hydrogen peroxide to PKC regulatory domains (Gopalakrishna and 
Gundimeda 2002). PKC activation leads to the upregulation of anti-apoptotic 
and proliferation-stimulating signalling pathways. 
Although ITCs are often described as having reducing (antioxidant) effects, 
they are not directly reductive – their acute effects in the cells are actually 
oxidative because they deplete intracellular reductants such as glutathione 
(GSH). In the medium term, however, cellular responses to ITCs are such 
that their net effects tend to be ‘U-shaped’, in that they lead to a reduction of 
ROS at moderate doses, while significantly elevating them at very high 
doses. This makes ITCs particularly interesting with regards to their potential 
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for protecting non-cancerous cells whilst simultaneously exerting toxicity 
towards cancer cells. This will be discussed in further detail below. 
1.2 Colorectal Cancer 
CRC – also known as colon, bowel or rectal cancer - originates from the 
oncogenic transformation of epithelial cells that line the colon or rectum. The 
rising global incidence of CRC was about 1.4 million in 2012 (World Health 
Organization: International Agency for Research on Cancer 2016), and in 
2010, 715 000 mortalities were directly attributable to CRC: 46% more than 
were so in 1990 (Lozano, Naghavi et al. 2012). CRC was the third most 
commonly diagnosed cancer in 2012 according to the World Cancer 
Research Fund International, as mentioned above.  
Reported CRC incidence is considerably higher in more economically 
developed countries (MEDCs) than in less economically developed countries 
(LEDCs) (Ferlay, Shin et al. 2010), and is rising most notably in countries 
experiencing rapid economic growth and/or cultural adoption of ‘Westernised’ 
dietary habits. One expects the incidence of chronic diseases such as 
cancers to naturally increase as mortality from communicable diseases 
drops, as tends to occur with economic development due to improvements in 
medical and public health infrastructure. Additionally, an increase in reported 
incidence does not directly imply an increase in actual incidence, since the 
former could be a result of improved diagnosis. Nevertheless, there is 
compelling evidence that a number of dietary and lifestyle factors do affect 
one’s risk of developing CRC, particularly concerning patterns of fruit, 
vegetable and meat consumption, fibre intake, and energy balance. 
Typical warning signs of CRC are considered to include worsening 
constipation, reduced stool calibre, blood in stools, weight loss, loss of 
appetite, nausea/vomiting and/or anaemia, present in an individual aged 50 
or over. Formal diagnosis is made through a colonoscopy or sigmoidoscopy 
of the bowel. The degree to which a cancer has spread is assessed via X-ray 
computed tomography scans of the chest, abdomen and pelvis, after which 
the tumour is graded according to the TNM Classification of Malignant 
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Tumours system based on spread, lymph node involvement, and the number 
of metastases. 
Although early-stage colorectal tumours are now treatable with a high 
success rate, obvious symptoms of CRC tend not to present until the often-
terminal late adenoma/malignant stage (Smith, Ballal et al. 2006). Thus, the 
screening of asymptomatic individuals is essential for the diagnosis of early 
stage CRCs. Under the NHS of the UK, individuals judged to be at high risk 
(based on age, family history and current conditions) are invited for routine 
screening, via faecal occult blood tests and sigmoidoscopies or 
colonoscopies. This screening strategy can detect CRC up to 3 years prior to 
the hypothetical emergence of tangible symptoms (Cunningham, Atkin et al. 
2010). A screening programme for all individuals aged ≥ 55 years is also in 
the process of being implemented across the UK. 
In addition to seeking early detection of CRC, there is increasing focus on 
prevention via dietary and lifestyle intervention strategies. According to 
Bowel Cancer UK, one’s risk of developing CRC is reduced by: 
• Eating a diet high in fibre, fruits and vegetables. 
• Limiting red meat and alcohol consumption. 
• Keeping physically active. 
In recent years the focus on the potential use of phytochemicals from fruits, 
vegetables and herbs has intensified, both for chemoprevention in healthy 
individuals, and/or chemotherapeutic application against tumours in cancer 
patients. As mentioned previously, the consumption of fruits and vegetables 
has long been inversely associated with the development of chronic diseases 
such as cancers, neurodegenerative disorders and cardiovascular disease, 
often presumed to be owing to their content of micronutrients, 
phytochemicals, fibre, and/or dietary displacement of cancer-promoting 
foods. However, vegetables of the cruciferous variety are more strongly 
linked to reduced risks of cancer than vegetables in general. Cruciferous 
vegetables are distinct in that they contain GCNs, from which are derived 
ITCs, whose chemopreventative and/or chemotherapeutic potential has 
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become of particular interest over the past 30 years. The colorectal tissues 
are inevitably better predisposed than many others of the body to encounter 
orally ingested compounds prior to their hepatic metabolism (Pappa, Bartsch 
et al. 2007), thus observable effects of the compounds in vitro are more likely 
to bear physiological relevance. 
1.2.1 Pathogenesis 
1.2.1.1 Classic Vogelstein Model 
Many models for the pathogenesis of CRC have been proposed, the most 
well-known of which is that proposed by Vogelstein (Fearon and Vogelstein 
1990), which is summarised in Figure 2 and is as follows: 
1. Adenomatous polyposis coli (APC) – a promoter of β-catenin 
degradation - becomes mutationally inactivated. β-catenin thus 
accumulates in the cytoplasm, then translocates to the nucleus where 
it transcriptionally upregulates several proto-oncogenes such as MYC 
that promote stem cell renewal and proliferation, leading to the 
development of an aberrant crypt focus (ACF). 
2. The ACF continues to grow and its intracellular and intercellular 
organisation becomes more abnormal, eventually giving rise to an 
early adenoma. Constitutively-activating mutations occur in members 
of the RAS growth factor gene family, often K-RAS (Frank 2007), 
further promoting proliferation. 
3. Several genes located in the long arm of chromosome 18 (18q) 
become deleted - particularly those in band 1 of region 2 of 18q 
(18q21), including important tumour suppressor genes (TSGs) such 
as deleted in colorectal carcinoma (DCC), Mothers against 
decapentaplegic homolog 2 (SMAD2) and Mothers against 
decapentaplegic homolog 4 (SMAD4). DCC promotes apoptosis in the 
absence of netrin-1 (Mazelin, Bernet et al. 2004). SMAD2  and 
SMAD4 are transforming growth factor beta (TGFβ)-activated genes 
that may mediate TGFβ’s tumour-suppressive effects in the context of 
CRC (Frank 2007). The loss of these TSGs facilitates the 
development of a late adenoma. TGFβ is multifunctional and its net 
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role may become oncogenic once the pathways of TGFβ-mediated 
growth inhibition, such as those mediated by SMAD2 and SMAD4, are 
inactivated. 
4. The loss of TP53 is the final trigger for progression of the adenoma to 
malignant cancer (Frank 2007). Its protein, p53, is a crucial tumour 
suppressor that usually promotes apoptosis in response to DNA 
damage. Interestingly, it has also been shown to inhibit glycolysis and 
promote oxidative phosphorylation by increasing fructose-2,6-
bisphosphate levels, thus opposing the proliferation-facilitating 
glycolytic metabolic switch observed in cancer cells (i.e. the Warburg 
effect) (Gonzalez, Alvarez et al. 2014). 
Interestingly, SFN has been shown to inhibit β-catenin signalling and to 
suppress the growth of human breast cancer cell lines and xenograft models 
(Li, Zhang et al. 2010), thus indicating SFN’s potential to inhibit the formation 
of ACFs and/or the development of early adenomas. 
Chromosomal instability (CIN) results from the disruption of genes governing 
chromosome duplication and/or segregation. CIN can promote the loss of 
entire chromosomes and loss of heterozygosity (LOH) (Frank 2007), thus 
promoting the loss of important TSGs such as APC, therefore potentially 
triggering and/or accelerating classic Vogelstein pathogenesis. 
1.2.1.2 Other Mechanisms 
Microsatellite instability (MSI) is a general term used to describe the situation 
in which the pathways of DNA mismatch repair (MMR) are disrupted such 
that repetitive sequences - such as microsatellite regions - become 
significantly more prone to mutation, resulting in gene mutational inactivation 
and/or hyperactivation. MSI has been demonstrated to trigger 
hyperactivating mutations in the β-catenin gene itself, and thus initiate an 
APC-independent pathway of tumorigenesis. Interestingly, most CRCs 
exhibit either CIN or MSI, but not both (Frank 2007). 
The initiators and facilitators of pathogenesis discussed so far are all genetic 
in nature. However, there is increasing evidence for the importance of 
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epigenetic changes in CRC pathogenesis, which could complement the 
genetic changes described in the Vogelstein model: 
• The loss of APC activity facilitates enhanced β-catenin accumulation 
in the first step of pathogenesis according to the Vogelstein model. 
This is usually attributed to inactivating mutation, but hypermethylation 
of APC is also often observed in CRC vs. non-cancerous colorectal 
tissues (Hiltunen, Alhonen et al. 1997). 
• DCC, a pro-apoptotic gene, is lost via the deletion of chromosomal 
region 18q21 in the transition from early to late adenoma according to 
the Vogelstein model. However, this pro-apoptotic gene also has a 
tendency to be hypermethylated in CRC cell lines (Derks, Bosch et al. 
2009). 
• MutL homolog 1, colon cancer, nonpolyposis type 2 (MLH1) is a gene 
that is important for effective MMR and the hypermethylation of its 
promoter can promote MSI, thus increasing the occurrence of 
potentially carcinogenic mutations. 
• O6-alkylguanine DNA alkyltransferase (MGMT) is a gene that is 
important for the effective removal of mutagenic guanine adducts, and 
its hypermethylation has been demonstrated to play an important role 
in the promotion of mutation (Frank 2007).  
• The secreted frizzled-related proteins (SFRPs) are a group of tumour-
suppressive proteins that inhibit the accumulation of β-catenin, and 
their genes are frequently found to be hypermethylated in CRC 
samples (Lao and Grady 2011). 
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Figure 2: A summary of colorectal cancer pathogenesis according to the Vogelstein 
model. 
Recent genomic studies have revealed that there are on average nine 
oncogenic mutations in protein-coding genes observable per CRC 
(Yamagishi, Kuroda et al. 2016). Such studies have not elucidated a panel of 
specific frequent driver mutations, but rather a panel of specific signalling 
pathways upon which various driver mutations tend to converge regarding 
their impact, namely: the Wnt, TGFβ, phosphoinositide 3-kinase (PI3K), 
receptor tyrosine kinase-RAS and p53 signalling pathways (Yamagishi, 
Kuroda et al. 2016). 
1.2.1.2.1 The Warburg Effect 
As first observed and reported by Otto Heinrich Warburg in the early 20th 
century, the metabolism of tumour cells shifts such that a greater proportion 
of ATP is generated from glycolysis than from oxidative phosphorylation, 
despite an abundant supply of oxygen. It involves the metabolism of pyruvate 
being shifted to favour the generation of lactate rather than of acetyl-
coenzyme A, which can be achieved by the suppression of mitochondrial 
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pyruvate entry, the inhibition of mitochondrial pyruvate metabolism to 
generate acetyl-coenzyme A, and/or the upregulation of enzymes that 
metabolise pyruvate to lactate. Efficient mitochondrial pyruvate entry is 
facilitated by the mitochondrial pyruvate carrier (MPC) proteins. The Warburg 
effect drastically reduces ATP generation per glucose, yet can actually 
increase ATP production per time given sufficient glucose abundance. 
Therefore, glucose uptake by tumour cells is characteristically high – a 
phenomenon that is exploited in the clinic to visualise tumours by positron 
emission tomography with fluorescently-labelled glucose analogues. Another 
consequence of the Warburg effect is the increased production of 
intermediates necessary for anabolism, which facilitates more rapid 
proliferation. Therefore, it is unsurprising that the Warburg effect can also be 
observed in rapidly-dividing healthy cells. 
Interestingly, the genes coding for MPCs are often inactivated in CRC cell 
lines, in which their forced re-expression is able to inhibit anchorage-
independent growth and suppress stem cell markers (Schell, Olson et al. 
2014). Also interesting is that the expression of MPC1 has been shown to 
correlate positively with that of APC (Schell, Olson et al. 2014), and 
negatively with that of MYC (Schell, Olson et al. 2014). One may therefore 
postulate that interactions between dietary components and MPCs or other 
proteins influencing the balance between ATP-generating pathways might 
contribute to the observed links between diet and carcinogenesis. 
1.3 Isothiocyanates, Nuclear Factor (Erythroid-Derived 2)-
Like 2 (Nrf2) and Metabolism 
1.3.1 Nuclear Factor (Erythroid-Derived 2)-Like 2 (Nrf2) 
Nrf2 is a transcription factor best characterised for its role in defending cells 
against oxidative stress by transcriptionally upregulating reducing 
(antioxidant) enzymes. Its functions are now known to be vast in number and 
complexity, to extend far beyond redox homeostasis, and to include the 
modulation of cell proliferation, differentiation, cell fate determination and 
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stem cell maintenance in context- and cell-type-specific manners (Murakami 
and Motohashi 2015). 
Basally, most of the Nrf2 in a given cell is located in cytoplasm where it is 
bound to a repressor protein called Kelch like-ECH-associated protein-1 
(Keap1), whose binding both prevents the translocation of Nrf2 to the 
nucleus, and targets Nrf2 for 26S proteasomal degradation by recruiting the 
ubiquitin E3 ligase (Cullinan, Gordan et al. 2004). Keap1-Nrf2 binding is 
facilitated by phosphoglycerate mutase family member 5 protein threonine 
phosphatase (PGAM5), via which they are both tethered to the outer 
mitochondrial membrane (Xue, Momiji et al. 2015).  
Oxidative stress triggers the release of Nrf2 from Keap1-mediated 
repression, partly via the oxidative modification of Keap1 at its Cys273 and 
Cys288 residues. Released Nrf2 is subsequently phosphorylated by casein 
kinase-2, which facilitates its translocation to the nucleus via importins α5 
and β1. Nuclear Nrf2 heterodimerises with small Maf (sMAF) proteins, with 
which it binds to the antioxidant response element (ARE) present in the 5’ 
flanking regions of various Nrf2-activated genes, in a manner that tends to 
promote their transcription. Such genes include those coding for reducing 
(antioxidant) enzymes such as: 
• Glutathione S-transferases (GSTs) 
• Thioredoxin reductase 1 (TrxR-1) 
• NADPH:quinone reductase 1 (NQO1) 
• Haem oxygenase 1 (HO-1) 
• Uridine 5'-diphospho-glucuronosyltransferases (UGTs) 
Nuclear Nrf2 is eventually inactivated via acetylation. The phosphorylation of 
Nrf2 by Fyn kinase promotes its export from the nucleus by chromosomal 
maintenance 1 (Crm1). Fyn kinase itself can be activated upon interaction 
with the PGAM5 that is liberated and thus able to translocate to the nucleus 
when the cytoplasmic Nrf2-Keap1-PGAM5 complex is disrupted, thus 
forming part of a negative feedback loop (Xue, Momiji et al. 2015). The return 
of Nrf2 to the cytoplasm makes it once again liable to Keap1-directed 
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ubiquitination and degradation. Bach1 can inhibit the Nrf2-mediated 
transcriptional activation of ARE-regulated genes by competing with Nrf2 for 
sMAF binding; while Bach1-sMAF complexes are often able to bind to AREs, 
they tend to either not activate transcription or be less activating than Nrf2-
sMAF complexes. However, Bach1 does not repress all Nrf2-targeted target 
genes equally; it has been demonstrated that Bach1 can significantly repress 
the Nrf2-induced expression of HO-1, but not that of TrxR-1 (Reichard, Motz 
et al. 2007). Bach1 can be directly inactivated by oxidation, and such is 
sufficient for the oxidative stress-mediated induction of HO-1 independently 
of cytoplasmic Nrf2 activation and nuclear translocation, because the basal 
nuclear levels of Nrf2 – albeit low - are sufficient to facilitate this. 
As well as promoting the nuclear translocation of cytoplasmic Nrf2 protein, 
ROS can upregulate Nrf2 at both the transcriptional and translational levels. 
The Nrf2 messenger RNA (mRNA) transcript is one of many stress-
responsive transcripts containing an internal ribosomal entry site (IRES) 
within the 5’-untranslated region (5’-UTR); the IRES enables translation to be 
initiated independently of cap-binding proteins (Li, Thakor et al. 2010). 
Oxidative stress can promote the translation of such cap-independent stress-
responsive mRNAs, whilst simultaneously repressing the cap-dependent 
translation of typical mRNA transcripts (Li, Thakor et al. 2010).  
The reductive (antioxidative) shift in redox status mediated by Nrf2 is most 
associated with cytoprotection, by helping to protect against oxidative 
damage to macromolecules. However, this redox shift also plays roles in cell 
fate determination. For example, an Nrf2-mediated reduction of ROS in 
macrophages can inhibit their differentiation to osteoclasts (Murakami and 
Motohashi 2015). Nrf2 can also influence cell fate determination in a redox-
independent fashion, such as by transcriptionally upregulating 
CCAAT/enhancer-binding protein β (CEBPβ) and proliferator-activated 
receptor γ (PPARγ): two promoters of adipocyte differentiation (Murakami 
and Motohashi 2015). Nrf2 is continuously synthesised and degraded, so an 
increase in cellular Nrf2 levels often results from a synthesis-favouring 
perturbation of the basal steady-state synthesis-degradation balance.  
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Figure 3: A diagram illustrating the interaction of ROS and electrophiles with the Nrf2-
Keap1 complex, and the subsequent induction of Nrf2 activity and reducing 
(antioxidant) enzyme expression. (1) ROS and electrophiles interact with cysteine 
residues of Keap1, inducing modifications that weaken Keap1’s association with Nrf2. 
(2) Nrf2 thus avoids proteasomal degradation, and can translocate to the nucleus. (3) 
Nrf2 binds to the ARE which is found in the 5’ flanking region of many genes, some of 
which act to shift cellular redox balance in a reductive direction. 
1.3.2 Phase I and II Enzymes 
The breakdown of xenobiotics and endogenous hormones typically consists 
of several steps, the first being their metabolism by phase I enzymes, which 
include the cytochrome P450 (CYP) family of haemoproteins. These 
enzymes covalently modify their substrates by hydroxylation; their products 
tend to be highly reactive (often electrophilic or nucleophilic), and thus able 
to induce oxidative stress and macromolecular damage (Lewis 2002). The 
enzymes that metabolise these reactive intermediates are called phase II 
enzymes, and include the Nrf2-activated reducing enzymes described 
previously. The products of phase II enzyme-catalysed reactions tend to be 
hydrophilic, and thus liable to excretion. 
An appropriate balance between phase I and phase II enzyme activity is 
crucial for limiting the accumulation of the reactive intermediates, and 
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consequent oxidative stress and macromolecular damage. In fact, there are 
environmental carcinogens that are not particularly detrimental per se, but 
whose intermediate metabolic products (i.e. the products of phase I 
metabolism) exhibit the associated deleterious, oncogenic effects. 
Interestingly, ITCs have been demonstrated to inhibit the expression and/or 
activity of the CYP phase I enzyme family in certain contexts. For example, 
treatment of primary rat hepatocytes with aliphatic ITCs (40µM) was shown 
to repress both CYP1A1 and CYP1A2 at the transcriptional level (La Marca, 
Beffy et al. 2012). The combination of phase I enzyme-repression and phase 
II enzyme-induction (e.g. via Nrf2) by ITCs acts to stem the accumulation of 
cytotoxic and/or carcinogenic phase I metabolites. 
61 | P a g e  
 
Xenobiotic
Benign end-product
Phase I enzymes
Phase II enzymes
SFN
(+)
Reactive 
metabolite
Cytochrome
p450
GST-α
HO-1
NQO-1
TrxR-1
• Oxidative stress
• Carcinogenesis
Phase I 
metabolism
Phase II 
metabolism
SFN
SFN
 
Figure 4: A diagram illustrating the metabolism of xenobiotics by phase I and phase II 
enzymes, and the influence of the ITC SFN upon the activities of each. SFN can inhibit 
CYP enzymes, and also induce phase II enzymes such as GST-α, HO-1, NQO-1 and 
TrxR-1. This shifts the balance between phase I and II metabolism to inhibit the 
accumulation of the undesirable intermediate metabolites. 
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1.3.3 Mechanisms of Nrf2 Induction by Isothiocyanates 
Multiple and synergistically-acting mechanisms through which ITCs may 
induce Nrf2 have been elucidated, but there is no clear consensus on the 
most significant contributors. Although ITCs are sometimes referred to as 
antioxidants (reductants), their acute effects are actually oxidative, primarily 
due to depletion of the major intracellular electron donor protein GSH. GSH 
is conjugated to the ITCs by GSTs to form complexes that are exported from 
the cell (Higgins, Kelleher et al. 2009). Interestingly, SFN can also directly 
induce ROS generation in mitochondria, by inhibiting complex III of the 
mitochondrial respiratory chain, leading to the accumulation of 
ubisemiquinone, which donates electrons to molecular oxygen to generate 
the superoxide anion and hydrogen peroxide (Sestili, Paolillo et al. 2010).  
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Figure 5: A diagram illustrating the process of ITC-GS conjugation in the cell 
cytoplasm, and the release of ITCs in the plasma. (1) ITCs are conjugated to GSH under 
the action of GST enzymes. (2) ITC-GS conjugates are exported from the cell. (3) In the 
plasma, ITC-GS conjugates are hydrolysed, resulting in the regeneration of ITC 
molecules. (4) The ITC molecules can enter the same cell, or another (Zhang 2000). 
Inevitably, the acute oxidant effects of ITCs themselves contribute to the 
ability of ITCs to induce Nrf2 (Higgins, Kelleher et al. 2009). One hypothesis 
is that acute oxidative stress is the primary mediator of Nrf2 induction by 
ITCs, and that the medium-term antioxidant (reducing) effects observed 
following treatment with ITCs at moderate doses occur simply by the activity 
of Nrf2-induced reducing enzymes and increased GSH synthesis eventually 
outweighing the initial oxidant effects. In support of this, treatment of 
hepatocellular carcinoma HepG2-C8 cells with 25µM SFN was shown to 
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reduce cellular GSH levels at 4 h, but to increase them 2.2-fold at 24 h 
versus controls (Kim, Hu et al. 2003). 
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Figure 6: The acute oxidative effect induced by a hormetic dose of ITCs contributes to 
their ability to induce Nrf2, and ultimately generates a net medium-term reducing effect 
in cells. 
On the other hand, it has been demonstrated that redox-independent effects 
of ITCs can contribute to Nrf2 activation, such as the inhibition of p38 
mitogen-activated protein kinase (MAPK) activity. P38 MAPK can repress the 
activity of Nrf2 by phosphorylating it in a manner that promotes its binding to 
Keap1 (Keum, Yu et al. 2006). 
1.3.4 Isothiocyanates and Nrf2: Two Double-Edged Swords? 
The net medium-term effect of ITC exposure can be either oxidative or 
reductive (antioxidative), depending upon the dose to which a cell is 
exposed. At low-to-moderate doses of ITCs, the reductive effects of Nrf2 
induction are observed to outweigh the acute oxidative effects, producing an 
overall medium-term reductive (antioxidative) effect. For this reason, ITCs 
are sometimes referred to as ‘indirect antioxidants’ and are frequently 
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observed to have ‘antioxidant’ effects. However, at very high doses, the 
acute oxidant effects can be strong enough to induce significant 
macromolecular damage and/or ROS-dependent apoptosis before the cell 
can mount a sufficient reductive (antioxidant) response (Zanichelli, Capasso 
et al. 2012). In fact, such ROS-driven cytotoxic effects are thought to underlie 
the ability of ITCs to defend cruciferous vegetable plants against insects and 
microorganisms (Tierens, Thomma et al. 2001). 
This phenomenon of a distinctly non-linear relationship between dose and 
response, in that low-dose exposure exerts beneficial effects, whereas high-
dose exposure to the same stimulus exhibits adverse and opposite effects, is 
known as hormesis. Hormesis is an ancient concept by which various 
traditional herbal preparations and/or poisons are characterised, in addition 
to a number of pharmaceutical drugs, micronutrients, macronutrients and 
phytochemicals. ITCs such as SFN are classic examples of hormetic agents. 
Most studies indicate that the doses of ITCs obtainable in humans through 
the consumption of cruciferous vegetables are far below the cytotoxic 
threshold, thus firmly within the neutral-to-cytoprotective range. For example, 
in one study, plasma concentrations of SFN peaked at 0.65µM following the 
consumption of 100g broccoli (150mL broccoli soup) by participants (Janobi, 
Mithen et al. 2006). In another, the plasma ITC concentration peaked at ~ 
2µM following the consumption by participants of processed broccoli sprout 
preparations, each of which contained 200µmol ITCs (predominantly SFN), 
(Ye, Dinkova-Kostova et al. 2002). Some studies have demonstrated human 
plasma SFN concentrations to reach 10µM following significant broccoli 
sprout consumption (Hsu, Wong et al. 2011): a concentration which most 
studies in vitro or in vivo have indicated to be non-cytotoxic to healthy cells. 
The exhibition of Nrf2’s reductive (antioxidant) effects in healthy cells is 
desirable, due to the conferred protection against DNA oxidation-induced 
mutation. ROS can oxidise guanine bases in DNA to 8-oxoguanine, which 
may then pair with adenine instead of cytosine, generating a G:C to T:A point 
mutation. Studies have shown Nrf2-knockout mice to be more susceptible to 
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the carcinogenic effects of common environmental carcinogens than control 
mice (Ramos-Gomez, Kwak et al. 2001).  
Unfortunately, the cytoprotective effects of Nrf2 do not occur exclusively in 
non-cancerous cells, but also in cancer cells, and can thereby increase the 
resistance of the cancer cells to ROS-dependent chemotherapy, and 
promote their proliferation (Ohta, Iijima et al. 2008). In fact, Nrf2 
hyperactivation is observed in certain cancers, and promotes their 
aggressiveness and chemoresistance by helping to protect the tumour cells 
against oxidative stress-induced cytotoxicity and/or cytostasis. 
The net role that Nrf2 plays in cancer cells is nevertheless highly complex; 
Nrf2 has been shown to actually exert anti-proliferative effects in certain 
contexts. For example, the activation of Nrf2 by the miR-200c-5p-mediated 
repression of Keap1 inhibited the proliferation of human lung cancer cell 
lines. Nrf2 bound in combination with the polyamine-modulation factor 1 
(PMF1) to the polyamine-responsive element (PRE) in the promoter region of 
the gene coding for the spermidine/spermine N1-acetyltransferase (SSAT) 
enzyme, leading to its transcriptional upregulation. The SSAT enzyme 
breaks down growth-stimulating polyamines, so the Nrf2-mediated 
upregulation of SSAT inhibited proliferation (Murray-Stewart, Hanigan et al. 
2013). 
Aside from ITCs, there are various dietary inducers of Nrf2 studied for their 
chemopreventative potential, such as resveratrol from red grapes, 
epigallocatechin gallate from green tea, and allicin from garlic. Allicin is 
demonstrated to be able to inhibit cell proliferation and induce apoptosis at 
sufficiently high doses. One study surprisingly demonstrated that the anti-
proliferative effects of moderate-dose allicin in HCT116 cells were abrogated 
by the siRNA knockdown of Nrf2 (Bat-Chen, Golan et al. 2010), implying that 
Nrf2 counterintuitively played a positive role in allicin’s anti-proliferative 
effects. Perhaps this is partially attributable to the reduction of specific 
proliferation-promoting ROS. Researchers also demonstrated that the livers 
of mice genetically engineered to have constitutively-active Nrf2 regenerated 
more slowly following carbon tetrachloride-induced damage, compared to 
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those of control mice. They also showed that the genes coding for the cyclin-
dependent kinase inhibitor p15 and for the pro-apoptotic Bim could both be 
transcriptionally upregulated by Nrf2, based on chromatin 
immunoprecipitation sequencing (ChIP-Seq) data (Kohler, Kurinna et al. 
2014). 
Nrf2 has been shown to induce the Notch-1 protein, which itself has been 
reported to act in context-dependent oncogenic (Jin, Gong et al. 2013) or 
tumour suppressive (Sriuranpong, Borges et al. 2001) fashions. Nrf2 also 
has the potential to induce the expression of interleukin (IL)-17D on the 
surface of tumour cell lines, thus potentially facilitating natural killer cell-
mediated induction of cell death in vivo (Saddawi-Konefka, Seelige et al. 
2016). Interestingly, hypoxia-inducible factor 1-alpha (HIF-1α), which is often 
upregulated in the hypoxic conditions of cancer cells, and is a promoter of 
angiogenesis, can repress Nrf2 (Loboda, Jozkowicz et al. 2012). 
Further complicating the picture of Nrf2’s role in cancer is a report suggesting 
that Nrf2’s effects on proliferation depend upon its localisation. Most studies 
of Nrf2 activity to date have focussed only upon the activity of Nrf2 in the 
nucleus, since it has often been assumed that cytoplasmically-localised Nrf2 
is inactive. However, Lin et al. suggest distinct proliferative and pro-invasive 
functions for cytoplasmic Nrf2 via its upregulation of the ‘proteasome 26S 
subunit, non-ATPase 4’ 26S proteasome subunit, which degrades p53; p53 
is a repressor of Crm1 expression, which as mentioned previously exports 
nuclear Nrf2 to the cytoplasm (Lin, Chang et al. 2016). They also report from 
clinical tumour studies that the predominance of cytoplasmic rather than 
nuclear Nrf2 localisation in tumours was associated with worse clinical 
outcomes (Lin, Chang et al. 2016). One might speculate that the oncogenic 
effects of inactivating Keap1 mutations observed in certain malignancies are 
attributable to increased cytoplasmic Nrf2 activity, although contribution from 
increased nuclear Nrf2 activity would nevertheless be highly probable. 
The relationship between redox status and cancer is clearly very complex. 
SFN has repeatedly been shown to exert tumour suppressive activity 
towards various cancer cell lines at moderate-to-high doses, by inhibiting 
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proliferation and promoting cell cycle arrest and apoptosis, which is at least 
partly attributable to ROS-dependent cytotoxicity. SFN has been shown to 
induce lipid peroxidation, and thus the accumulation of 4-hydroxynonenal 
(HNE), which is itself a promoter of cell cycle arrest and apoptosis (Sharma, 
Sharma et al. 2012).  
As previously mentioned, specific ROS function as important cell signalling 
molecules. For example, intracellular levels of specific ROS such as 
hydrogen peroxide are increased upon exposure to high glucose conditions,  
and these ROS promote the secretion of insulin by pancreatic β-cells, in 
which experimental Nrf2 overexpression can impair the insulin-mediated 
control of blood glucose levels (Zhang, Pi et al. 2010). Moderate general 
increases in ROS, i.e. an oxidative shift in redox status, can promote 
proliferation via the activation of particular extracellular signal-regulated 
kinase (ERK) and MAPK signalling pathways (Trachootham, Zhou et al. 
2006). ROS reportedly interact with the tumour suppressor protein 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in a 
manner that inhibits its phosphatase activity (Leslie, Bennett et al. 2003), but 
that perhaps also inhibits its nuclear-to-cytoplasmic export, promoting its 
phosphatase-independent anti-proliferative effects in the nucleus (Chang, 
Mulholland et al. 2008).  
Excessive oxidative shifts are cytotoxic and promote cell cycle arrest and 
apoptosis. The therapeutic benefits of many anti-cancer drugs are 
themselves attributable to ROS- and DNA damage-dependent cytotoxicity 
towards cancer cells, and their therapeutic window depends largely upon 
their relative selectivity towards target cells. Experimentally increasing ROS 
in SiHa (doxorubicin-resistant cervical cancer) cells increased their sensitivity 
to the anti-cancer drug doxorubicin, whilst experimentally reducing ROS 
made them more resistant (Filippova, Filippov et al. 2014). 
Therefore, on the one hand, Nrf2 expression in cancer cells is often thought 
to be deleterious because it helps to protect them against oxidative stress-
induced death. Nrf2 is overexpressed in several tumours in which it plays an 
important role in their ability to thrive under stressful extracellular conditions, 
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and their chemoresistance (Lau, Villeneuve et al. 2008). On the other hand, 
the ROS-reducing effects of Nrf2 can themselves be anti-proliferative. 
Particularly in early tumour cells, reducing (antioxidant) effects may tend to 
inhibit proliferation by reducing the specific ROS-mediated stimulation of 
ERK and MAPK signalling. Hydrogen peroxide itself is able to activate PKC 
and thus stimulate anti-apoptotic and proliferative pathways (Prasad and 
Mishra 2015). 
Counterintuitively, the induction of Nrf2 in Calu-6 human lung carcinoma cells 
increased their sensitivity to the anti-cancer drug BENSpm, perhaps by 
inducing SSAT and thus increasing the breakdown of endogenous and 
exogenous proliferative and anti-apoptotic polyamines (Murray-Stewart, 
Hanigan et al. 2013). Nrf2 has also been reported to inhibit the Smad-
dependent migration of certain cell lines (Rachakonda, Sekhar et al. 2010). 
1.4 Epigenetics 
Epigenetics is the study of how alterations to gene expression levels, as 
opposed to genetic changes, influence phenotype. The conformation of 
chromatin (the collective term for the DNA-histone complexes that constitute 
eukaryotic chromosomes) varies according to the nature and intensity of the 
DNA-histone interactions, in that tighter interactions tend to repress 
transcription, whilst looser interactions are more transcription-permitting. 
Cytosine residues preceding guanine are prone to being methylated by DNA 
methyltransferases (DNMTs) to 5-methylcytosine, a process generally 
termed ‘DNA methylation’. The nature of DNA-histone interaction is 
influenced by covalent histone modifications (primarily acetylation and 
methylation) and DNA methylation. Methylated DNA recruits histone 
deacetylases (HDACs), and histone methyltransferases (HMTs) via their 
methyl-CpG-binding domains. HDACs remove acetyl groups from the 
histones, permitting tighter DNA-histone interactions that inhibit transcription. 
The methylation of histone H3 at lysine 9 or 27 tends to repress transcription, 
while that at lysine 4 or 36 actually tends to promote transcription. DNA 
methylation can also directly inhibit the binding of transcription factors such 
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as cAMP response element-binding protein, E2F and nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB) (Lao and Grady 2011). 
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Figure 7: Small regions of the genome that are relatively rich in CpG dinucleotides are 
called CpG islands. CpG islands have a strong tendency to be found in a methylated 
state unless located proximal to gene promoters. 
CpG dinucleotides are 75% less abundant in the human genome than would 
be mathematically expected in a random T, G, A, C distribution, which is 
probably an evolutionary consequence of the liability of 5-methylcytosines to 
spontaneously deaminate to thymine, which can result in deleterious C to T 
point mutations. 
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Figure 8: A diagram illustrating the recruitment of HDACs to methylated cytosine 
residues, and the subsequent repression of gene transcription. (1) Methylated 
cytosine residues are bound by the methyl-CpG-binding domain of an HDAC, 
recruiting the HDAC to the site. (2) The HDAC removes acetyl groups, exposing 
positive charge on the histone tails, which interact with the negatively charged 
phosphate backbone of DNA. This causes the local chromatin to become more 
compact, thus sterically inhibiting the binding of transcription factors and machinery. 
ITCs are often demonstrated to inhibit the activity of particular HDACs (Nian, 
Delage et al. 2009), and general HDAC inhibition has itself been 
demonstrated to be tumour suppressive in a number of contexts via the 
transcriptional reactivation of TSGs that promote cell cycle arrest and 
apoptosis. SFN downregulated HDAC3 in the CRC cell line HCT116, in 
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which basal HDAC3 was demonstrably higher than in several non-cancerous 
colonic cell lines (Rajendran, Kidane et al. 2013). The activity of HDAC3 can 
influence genomic stability and cell survival (Rajendran, Kidane et al. 2013). 
MicroRNAs (miRNAs) are small, non-coding RNA molecules best 
characterised as post-transcriptional, translation-inhibiting, regulators of gene 
expression. One definition of epigenetics that is favoured by some 
publications includes only heritable, expression-influencing changes to 
chromatin status, and thus excludes transient modulations of gene 
expression such as those exerted by miRNAs. However, according to a 
broader definition of epigenetics that includes all modulation of gene 
expression in lieu of genetic change, the roles of miRNAs can be included. 
1.5 MicroRNAs 
As described above, miRNAs are small, non-coding RNA molecules. They 
are generally 18-25 nucleotides in length and participate in the post-
transcriptional control of gene expression via interaction with mRNAs. They 
originate from various genetic loci such as those in: 
• The introns of protein-coding genes. 
• The exons of (and adjacent to) protein-coding genes. 
• Long exonic clusters that code for multiple miRNAs, also known as 
miRNA arrays. 
1.5.1 Biogenesis 
The canonical pathway of miRNA expression in animals is as follows: 
1. A genetic locus is transcribed by RNA polymerase II as a 5’-capped 
and 3’-polyadenylated transcript, typically several hundred nucleotides 
long, which adopts a secondary structure containing hairpin-loops. 
This is the primary miRNA transcript (pri-miRNA). A pri-miRNA can 
contain multiple hairpin-loops motifs that each ultimately give rise to a 
different miRNA. 
2. DiGeorge Syndrome Critical Region 8 (DGCR8) binds to a pri-miRNA 
hairpin-loop motif and recruits the Drosha enzyme, which excises the 
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hairpin-loop structure from the pri-miRNA. The excised entity has a 3’ 
2-nucleotide overhang and is called a precursor miRNA (pre-miRNA). 
3. Exportin-5 recognises the 3’ 2-nucleotide overhang of a pre-miRNA 
and transports it from the nucleus into the cytoplasm, where Dicer 
subsequently recognises the same 3’ 2-nucleotide overhang and 
cleaves open the loop region of the pre-miRNA to generate a linear 
RNA duplex, with a 3’ overhang on both strands. 
4. This linear duplex is unwound and one of the strands (typically that 
with the lower stability at its 5’ end) remains bound to Dicer. The 
miRNA-Dicer complex associates with Argonaute (AGO) proteins, 
which protect the miRNA against degradation, and enables additional 
proteins to bind thus leading to the formation of an RNA-induced 
silencing complex (RISC).  
5. The other strand dissociates from Dicer. It was once believed that this 
‘alternative’ strand was typically degraded. However, evidence has 
since shown that many of these ‘alternative’ strands actually associate 
with other AGOs to form other active RISCs. 
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Figure 9: A diagram illustrating the canonical pathway of miRNA expression in animal 
cells. (1) A genetic locus is transcribed by RNA polymerase II, producing a pri-miRNA, 
which is several hundred nucleotides long. (2) The pri-miRNA is bound by DGCR8, 
which recruits Drosha, which cleaves the pri-miRNA into pre-miRNAs that are about 
70 nucleotides long and have 2-nucleotide overhangs at their 3’ ends. (3) The 3’ 2-
nucleotide overhangs are recognised by Exportin 5, which uses GTP to transport 
them from the nucleus to the cytoplasm. (4) Dicer recognises the same 3’ overhang 
and makes a nick in the loop region of the pre-miRNA, generating an imperfectly 
paired linear RNA duplex, each strand of which bears a 3’ 2-nucleotide overhang. (5) 
The linear RNA duplex is unwound; one strand remains associated with Dicer as the 
mature miRNA, and becomes part of a RISC upon association with AGOs. 
Pri-miRNA transcription and processing are not the only means of pre-
miRNA generation. Introns are excised from the early mRNA transcripts of 
protein-coding genes and released as lariat structures. Some of these lariat 
structures actually contain miRNA precursor sequences (Westholm and Lai 
2011) and can be directly converted to pre-miRNAs by the lariat debranching 
enzyme (Ldbr), as illustrated in Figure 10. 
Pre-miRNAs of a particular secondary structure can be processed 
independently of Dicer, such that the pre-miRNA itself is directly processed 
73 | P a g e  
 
by AGO2 to form an intermediate that is subsequently uridylated and/or 
trimmed to generate the mature miRNA (Cifuentes, Xue et al. 2010). Hsa-
miR-451a is an example of a miRNA generated in such a fashion (Cifuentes, 
Xue et al. 2010).  
MiRNA biogenesis was classically characterised as a process generating two 
specific mature miRNAs per pre-miRNA; one from each of the 5’ and 3’ 
arms. However, evidence from deep sequencing experiments revealed that 
multiple isoforms of each mature miRNA are produced, differing slightly 
according to length and/or sequence, despite originating from the same pre-
miRNA. One source of such variation is the fact that Dicer can cleave a pre-
miRNA ‘imprecisely’, thus resulting in ‘additional’ or ‘missing’ nucleotides at 
the 5’ or 3’ ends. A more upstream source of variation is the fact that Drosha 
can cleave pri-miRNA transcripts with similar ‘imprecision’. Post-
transcriptional modifications of pre-miRNAs and/or mature miRNAs by 
exonucleases or base-modifying enzymes further diversify the pool of 
isoforms. Variant miRNA isoforms are called isomiRs.  
One or two isomiRs of a named miRNA tend to dominate in most contexts. 
The miRNA sequences listed in miRBase are defined as the canonical forms, 
and tend to be either the most abundant forms found at the time of accession 
of the miRNA, or consensus sequences derived from pooled experimental 
sequencing data. These canonical forms are not necessarily the dominant 
isoforms in every biological context; there is evidence that the relative 
abundances of particular isoforms of a given miRNA can vary according to 
cell and tissue type, and also between the normal and tumour cell 
counterparts of a tissue (Tan, Chan et al. 2014). Additionally and 
interestingly, the preferred pre-miRNA cleavage site can be influenced by the 
association of particular proteins with Dicer. Thus, the abundances of 
different Dicer-associating proteins can influence the isomiR distribution for a 
given miRNA (Fukunaga, Han et al. 2012). 
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Figure 10: A diagram illustrating the generation of a pre-miRNA from a lariat structure, 
itself excised from the intronic region of an early mRNA transcript. (1) A genetic 
sequence is transcribed by RNA polymerase II. (2) The intronic sequence of the RNA 
transcript is excised in the form of a lariat structure. (3) Ldbr converts the lariat 
structure into a pre-miRNA. 
1.5.2 Canonical Model of Mature MicroRNA Activity 
AGO proteins such as AGO1, AGO2, AGO3 and AGO4 have PAZ domains 
that can interact with the 3’ ends of Dicer-bound miRNAs. At the 5’ end of a 
mature miRNA lies a 6-8 nucleotide seed region, which binds with loci in the 
3’-untranslated region (3’-UTR) of mRNA transcripts to which the seed region 
is at least partially complementary in terms of sequence. This interaction 
tends to facilitate the translational repression and/or degradation of a 
transcript by the RISC. Perfectly complementary base pairing tends to induce 
mRNA degradation via the activation of AGO endonuclease activity. Of the 
four mammalian AGOs: AGO1, AGO2, AGO3 and AGO4, only AGO2 has 
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thus far been demonstrated to possess such endonuclease activity (Liu, 
Rivas et al. 2005). However, complementarity is usually partial rather than 
perfect in animals, and partial complementarity has traditionally been 
described to repress translation of the mRNA without inducing its 
degradation (Bartel 2004). However, recent evidence suggests that mRNA 
degradation occurs even with partial complementarity, more often than 
previously thought. It is likely that multiple mechanisms contribute to miRNA-
mediated repression, the relative significance of each varying according to 
miRNA, target, cell type and environment (Hammell 2008).  
P-bodies and stress granules (SGs) are cytoplasmic loci involved in mRNA 
degradation and translational repression respectively, and the formation of 
both loci can be induced by miRNAs. MiRNAs have been shown to directly 
induce the formation of P-bodies in mammalian cells, and the knockdown of 
Drosha/DGCR8 (Schmittgen 2008) or direct inhibition of RISC formation has 
been shown to inhibit P-body formation (Zhao and Liu 2009). Reciprocally, 
experimentally blocking the formation of P-bodies has been shown to impair 
miRNA-mediated translational repression (Zhao and Liu 2009). RISCs have 
been demonstrated to associate with SGs, suggesting that both SGs and P-
bodies may play important roles in miRNA-mediated repression (Zhao and 
Liu 2009). AGOs can directly interact with SGs in an miRNA-dependent 
manner (Leung, Calabrese et al. 2006). The hydroxylation and/or 
phosphorylation of AGO2 at particular sites can facilitate its association with 
P-bodies (Bonfrate, Altomare et al. 2013). 
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Figure 11: A diagram illustrating the interaction between a mature miRNA, an AGO 
protein, and a target mRNA. The AGO interacts with the miRNA and at the 5’ and 3’ 
ends, via its PIWI and PAZ domains respectively. A 5’ seed region of the miRNA base 
pairs with part of the 3’ untranslated region of a target mRNA, to which it is partially or 
fully complementary. Subsequently, the AGO can interact with the target mRNA to 
inhibit its translation. 
Any given miRNA has the potential to target a multitude of mRNAs, which 
are each themselves susceptible to regulation by various miRNAs. MiRNAs 
are known to regulate the expression of at least 30% of protein-coding genes 
in humans (Lewis, Burge et al. 2005), thereby playing crucial roles in 
development and health. Amongst such miRNA-regulated genes are many 
oncogenes and TSGs i.e. those that regulate apoptosis, cell cycle 
progression, DNA repair, senescence, inflammation and redox status (Calin 
and Croce 2006). 
1.5.3 IsomiRs 
As mentioned above, the cleavage of pre-miRNAs by Dicer does not solely 
generate a specific pair of 5’ and 3’ products, but rather a distribution of 
isoforms called isomiRs, that vary from the canonical forms by having ‘extra’ 
or ‘missing’ nucleotides at the 5’ or 3’ ends, or in rare cases, base pair 
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‘substitutions’. In some cases, such variation might actually alter the seed 
regions and thus change mRNA-targeting activities. As previously 
mentioned, any given mature miRNA has the potential to target multiple 
mRNA transcripts. It is interesting to consider the degree of target overlap 
between particular isomiRs and the implications of such. Particular mRNAs 
that are targeted by multiple isomiRs of a given miRNA may be more 
strongly regulated than those mRNAs that are targeted by the canonical 
isoform alone. It has been hypothesised that this phenomenon may have 
evolved due to the intensification of the desirable regulation of specific 
mRNA targets, whilst diffusing effects on undesirable targets (Cloonan, Wani 
et al. 2011). In this hypothesis, where simply doubling the level of a specific 
canonical form would equally intensify the regulation of both its desirable and 
undesirable targets, alternatively co-expressing a different isoform at an 
equivalent level - an isoform that desirably targets a specific mRNA like the 
canonical form, but that unlike the canonical form does not deleteriously 
target one or several other mRNAs – may prove to be advantageous. This 
hypothesis is illustrated in Figure 12. 
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Figure 12: An illustration of how the generation of isomiRs may help to intensify the 
desirable regulation of a specific target, without the undesirable intensification of 
regulation of another target. (A) The amplification of the canonical miRNA increases 
the regulation of the desired mRNA target, but also undesirably intensifies the 
regulation of an ‘off-target’ mRNA. (B) The generated isomiRs all contribute to the 
desirable regulation of the target mRNA, but do not necessarily share the same ‘off-
target’ mRNAs, thus potentially undesirable effects on ‘off-target’ mRNAs are diluted. 
The extent of target overlap between isoforms is dependent upon the site at 
which they vary; 5’ variants naturally tend to be less conserved in their 
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targeting since it is at the 5’ end that seed regions are located (Tan, Chan et 
al. 2014). 
1.5.4 Alternative Effects and Mechanisms of Activity 
MiRNAs are mostly characterised as translational repressors. However, 
miRNAs can actually upregulate the translation of their targets in certain 
contexts. For example: 
• MiR-369-3p represses the translation of its target - tumour necrosis 
factor-α (TNF-α) - under basal conditions, but actually upregulates its 
translation under serum-starved conditions (Vasudevan, Tong et al. 
2007). The promotion of TNF-α translation is facilitated by the 
association of miR-369-3p specifically with AGO2, which itself 
associates with fragile X mental retardation-related protein 1 (FXR1), 
a protein essential for the association of miR-369-3p with AGO2 
(Vasudevan, Tong et al. 2007). Hypothetically, conditions of serum 
starvation could alter the solubility and subcellular localisation of 
AGO2-FXR1 complexes in a manner facilitating their association with 
the miRNA (Vasudevan, Tong et al. 2007). AU-rich elements present 
at the 3’ end of a transcript tend to increase the transcript’s 
susceptibility to degradation (Chen and Shyu 1995). The TNF-α 
transcript has such an AU-rich element at its 3’ end. However, this 
AU-rich element actually facilitates the miRNA-mediated upregulation 
of TNF-α expression (Vasudevan, Tong et al. 2007). 
• MiR-10a-5p upregulated the translation of ribosomal proteins in E14 
ES mouse embryonic stem cells under amino acid starvation, upon 
binding to 5’-UTRs of ribosomal protein mRNAs at loci immediately 
downstream of their 5’-terminal oligopyrimidine (5’-TOP) motifs (Ørom, 
Nielsen et al. 2008).  
The potential for miRNAs to differentially affect their targets according to 
nutrient status could have implications for their roles in carcinogenesis at 
different stages, and their interactions with cancer therapies. It has been 
postulated that miRNAs generally repress the translation of their targets in 
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dividing cells, whilst instead promoting translation in quiescent cells (Zhao 
and Liu 2009). 
Certain miRNAs can function non-canonically as decoys for RNA-binding 
proteins such as the hnRNP E2 protein: an RNA-binding protein that 
represses the transcription of CCAAT/enhancer-binding protein alpha 
(CEBPα), which is a myeloid differentiation factor that acts as a tumour 
suppressor in chronic myeloid leukaemia (CML). By binding to hnRNP E2, 
miR-328-3p inhibits the hnRNP-mediated repression of the CEBPα gene 
(Wilczynska and Bushell 2015), thus bolstering CEBPα-mediated tumour 
suppression. MiR-328-3p has been shown to be underexpressed in CML 
patients (Wilczynska and Bushell 2015). 
1.6 Links between ITCs, MicroRNAs, Biochemical Pathways 
and Cancer 
A Google Scholar search on 17/02/17 for 
‘intitle:microrna|mirna|micrornas|mirnas|"mir" 
intitle:colorectal|colon|rectal|bowel 
intitle:cancer|tumour|tumor|cancers|tumours|tumors|carcinogenesis|tumorige
nesis’ returned reports of 144 miRNAs as functionally involved in CRC 
pathogenesis. 85 of these were reported as tumour-suppressive, 45 as 
oncogenic, and 14 as ambiguous. 
1.6.1 Reported Modulation of MicroRNAs by Isothiocyanates 
• Benzyl isothiocyanate (BITC) treatment was shown to downregulate 
the oncogenic miR-375 and to upregulate the tumour suppressor miR-
221-3p in pancreatic cancer (Basu, Alder et al. 2011), thus opposing 
the changes in expression observed in cancerous vs. non-cancerous 
cells. 
• Phenethyl isothiocyanate (PEITC) was demonstrated to inhibit 
environmental cigarette smoke-induced oncogenic miRNA modulation 
in a neonatal mouse model (Izzotti, Larghero et al. 2010). 
• ITCs were demonstrated to upregulate the tumour suppressing miR-
23b-3p and miR-27b-3p, and to downregulate the oncogenic miR-155-
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5p, in the NCM460 and NCM356 CRC cell lines (Slaby, Sachlova et 
al. 2013). 
• Slaby et al. screened 754 human miRNAs for 48 h SFN-induced 
modulation by qPCR arrays in two non-cancerous colorectal cell lines 
– NCM460 and NCM356 - using TaqMan Low Density Arrays. The 
data suggested that a number of miRNAs may be modulated by SFN, 
as summarised in Table 1. 
Table 1: A summary of miRNAs reported to be altered by 48 h SFN treatment in 
NCM356 or NCM460 cells according to microRNA low-density array RT-qPCR 
experiments (Slaby, Sachlova et al. 2013), along with potential functions reported in 
the literature. 
  (Table 1 Continued) 
Regulation 
by SFN 
MicroRNA: 
hsa-miR- Reported Functions 
Up 
9-5p 
Was shown to promote motility, invasiveness 
and β-catenin signalling by targeting E-
cadherin in HMLE and SUM149 mammary 
epithelial cells, (Ma, Young et al. 2010), and is 
itself activated by MYC. However, its 
expression was positively associated with 
recurrence-free survival time in clear cell renal 
carcinoma patients, while its hypermethylation 
was negatively associated with such 
(Hildebrandt, Gu et al. 2010). 
9-3p 
Found to inhibit the growth of MDA-MB-231 
breast cancer cells by targeting β1 integrin 
(Zawistowski, Nakamura et al. 2013). 
23b-3p 
Demonstrated to inhibit human hepatocellular 
carcinoma cell migration and proliferation by 
targeting and inhibiting urokinase-type 
plasminogen activator and c-met  
(Salvi, Sabelli et al. 2009). 
27b-5p 
Predicted to target prospero homeobox protein 
1 (DIANA-Lab), which is a promoter of 
colorectal adenocarcinoma progression 
(Petrova, Nykänen et al. 2008). 
27b-3p 
Shown to repress the translation of matrix 
metalloproteinase 13 in human osteoarthritis 
chondrocytes (Akhtar, Rasheed et al. 2010). 
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  (Table 1 Continued) 
Regulation 
by SFN 
MicroRNA: 
hsa-miR- Reported Functions 
30a-3p 
Unclear, although 30a-5p was shown to inhibit 
the growth and promote the cell cycle arrest of 
HCT116 CRC cells, by targeting denticleless 
protein homolog in HCT116 CRC cells 
(Baraniskin, Birkenkamp-Demtroder et al. 
2012). 
135b-3p 
Predicted to target several zinc finger proteins 
(DIANA-Lab); some of which the potential to 
promote cisplatin resistance has been 
demonstrated in several cell lines (Duan, Choy 
et al. 2009). 
145-5p 
Found to inhibit the expression of the 
oncoprotein c-Myc in breast cancer and CRC 
cells (Sachdeva, Zhu et al. 2009), and to inhibit 
the growth of bladder cancer cells (Chiyomaru, 
Enokida et al. 2010). 
146a-5p 
Shown to inhibit the proliferation of hormone-
refractory prostate carcinomas, in which it 
tends to be underexpressed, and to target 
ROCK1, which is putatively involved in 
transformation (Lin, Chiang et al. 2008). Also 
demonstrated to reduce the invasiveness of 
pancreatic cancer cells (Li, VandenBoom et al. 
2010). 
342-3p 
Found to sensitise breast cancer cell lines to 
tamoxifen-induced apoptosis, and has a 
tendency to be underexpressed in tamoxifen-
resistant breast cancer cells (Cittelly, Das et al. 
2010). 
372(-?p) 
‘MiR-372’ (not stated whether -5p or -3p) is 
reportedly oncogenic  in the human gastric 
adenocarcinoma cell line, AGS (Cho, Shin et 
al. 2009). 
486-5p 
Demonstrated to induce senescence and inhibit 
proliferation of human adipose tissue-derived 
mesenchymal stem cells (Kim, Hwang et al. 
2012). 
505-3p 
Found to induce apoptosis in NCF7-ADR 
human breast cancer cells (Yamamoto, 
Yoshioka et al. 2011). 
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  (Table 1 Continued) 
Regulation 
by SFN 
MicroRNA: 
hsa-miR- Reported Functions 
629-5p 
Shown to be able to suppress lung and breast 
carcinogenesis by targeting Nibrin (Li and Lu 
2013). 
758-3p 
Predicted to target BACH2 (DIANA-Lab) – a 
promoter of oxidative stress-induced apoptosis 
(Spira, Beane et al. 2007). 
Down 
106a-3p 
Found to stimulate the proliferation of HCT116 
CRC cells (Wu, Tsai et al. 2011), and predicted 
to target G protein-coupled receptor kinase 5 
(DIANA-Lab).  
155-5p 
Was able to promote the growth of several 
human breast cancer cell lines by targeting 
Suppressor of Cytokine Signalling 1, and to 
promote tumour progression in vivo in mouse 
models, partly by enhancing janus kinase 
(JAK)-signal transducer and activator of 
transcription 3 (STAT) signalling (Jiang, Zhang 
et al. 2010). 
633-3p May target TGF-β1, which has dual roles in 
cancer. 
 
1.6.1.1 Examples of MicroRNA Modulation by ITC-Influenced 
Factors 
ITCs have the potential to modulate miRNA expression by various means, 
for example:  
• By inhibiting the activity of DNMTs and HDACs (Myzak, Hardin et al. 
2006), thus transcriptionally upregulating genetic loci that give rise to 
miRNAs. 
o HDAC3 repressed the expression of the pro-apoptotic miR-
15a-5p/16-1-5p cluster in mantle cell lymphoma, members of 
which target the anti-apoptotic protein Bcl-2 (Zhang, Chen et al. 
2012). SFN and other ITCs (15µM) were shown to inhibit 
HDAC3 activity in HCT116 cells, to promote DNA damage and 
autophagy, and to inhibit proliferation (Rajendran, Kidane et al. 
2013). By contrast, similar treatment of the non-cancerous 
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colonic cell line CCD-841 did not produce similar effects 
(Rajendran, Kidane et al. 2013). Perhaps the steady-state 
redox status of HCT116 cells is more oxidative than that of 
CCD-841 cells, making them more sensitive to the acute pro-
oxidant effects of ITCs. 
• By modulating redox status, to which certain microRNAs are sensitive 
(Xu, Zhang et al. 2012). 
o Oxidative stress has been shown to modulate miRNA 
expression in both mouse hippocampal neuronal cells (Xu, 
Zhang et al. 2012), and normal human fibroblasts (Simone, 
Soule et al. 2009). 
o Oxidative stress has been demonstrated to inhibit Dicer activity 
in JAR trophoblast cells, thus globally downregulating the 
generation of mature miRNAs (Wiesen and Tomasi 2009). 
o DGCR8, which is involved in the cleavage of pri-miRNAs to 
pre-miRNAs, was shown to be inhibited by oxidative stress 
(Cheng, Ku et al. 2013). The HO-1 enzyme catabolises ferric 
haem - a promoter of DGCR8 activity - so the oxidative stress-
induced repression of DGCR8 activity might be due to Nrf2-
HO-1-mediated ferric haem catabolism. 
o Oxidative stress was demonstrated to activate Drosha by the 
induction of the redox-sensitive glycogen synthase kinase 3β 
(GSK3β), which phosphorylates Drosha at Ser300 and Ser302; 
such modification promotes the translocation of Drosha to the 
nucleus where it is able to cleave pri-miRNAs to form pre-
miRNAs (Cheng, Ku et al. 2013). 
o Endoplasmic reticulum (ER) stress is a typical consequence of 
oxidative stress. ER stress induces an ER transmembrane 
kinase–endoribonuclease (RNase) called inositol-requiring 
enzyme 1α (IRE1α), which has been shown to be able to 
degrade the pre-miRNAs giving rise to miR-17-5p, miR-34a-5p, 
miR-96-5p and miR-125b-5p. 
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o Oxidative stress was able to induce the ADP-ribosylation of 
AGO2 in liver cancer HeLa cells, which inhibited AGO2’s ability 
to repress mRNA translation (Leung, Vyas et al. 2011). 
• By inhibiting inflammatory signalling. 
o A pro-inflammatory medium (lipopolysaccharide (LPS)-
stimulated macrophage-condition medium containing the 
cytokines TNF, IL-6, IL-8 and IL-1β) was shown to upregulate 
miR-155-5p in MDA-MB-231, BC-453 and T47D breast cancer 
cells. MiR-155-5p can target anti-mutagenic genes and 
promote proliferation (Tili, Michaille et al. 2011). 
o Treatment of HCT15 and HCT116 CRC cells with a similar 
inflammatory medium increased the expression of miR-146a-5p 
(Tili, Michaille et al. 2011). 
o The transcription factor NF-κB mediates inflammatory 
signalling, and was shown to upregulate miR-34a-5p in EC109 
oesophageal squamous cancer cells (Li, Wang et al. 2012). 
• By influencing the expression of proteins involved in miRNA 
biogenesis, such as RNA polymerase II, Dicer, Drosha, DGCR8, 
Exportin 5, Ldbr and AGO. 
• By inducing Nrf2. 
o Some genetic loci that give rise to miRNAs actually have an 
ARE in their 5’ flanking regions, through which they may be 
liable to Nrf2-mediated transcriptional regulation. 
o ChIP-Seq identified many potential Nrf2-binding sites in SFN-
treated lymphoid cells that were proximal to miR-1, miR-29b-
3p, miR-32-5p, miR-181c-5p, miR-193b-3p miR-200c-3p, miR-
206, miR-365a-3p, miR-550-5p, miR-592, miR-617, and miR-
1207-5p (Shah, Rushworth et al. 2013). MiR-29b-3p expression 
was shown to be downregulated as a consequence of Nrf2 
binding (Shah, Rushworth et al. 2013). 
o Nrf2 was shown to induce the transcription of the pre-miRNAs 
hsa-mir-125b-1 (giving rise to miR-125b-5p and miR-125b-3p) 
and mir-29b-1 (giving rise to miR-29b-5p and miR-29b-3p) in 
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acute myeloid leukaemia cells (Kurinna and Werner 2015). 
Interestingly, miR-125b-5p has been shown to translationally 
repress the tumour suppressing p53 in human CRC cells 
(Nishida, Yokobori et al. 2011). 
o Nrf2 was demonstrated to induce the expression of HDAC4 in 
A549 human lung carcinoma cells, consequently leading to the 
transcriptional repression of the genetic loci giving rise to miR-
1-3p and miR-206, thus an oncogenic effect (Singh, Happel et 
al. 2013). 
o Less directly, the modulation of redox status and inflammatory 
signalling that results from Nrf2 activation can influence the 
expression of various miRNAs 
Further complicating the picture is the fact that HDACs/DNMTs, 
inflammation, Nrf2 and redox status are each able to interact with one 
another, as described in Table 2. 
Table 2: A table illustrating some of the interactions between HDACs/DNMTs, 
inflammation, Nrf2 and redox status. 
   (Table 2 continued) 
 HDACs/DNMTs Inf. Nrf2 Redox Status 
HDACs/ 
DNMTs  
The HDAC 
inhibitor 
ITF2357 was 
shown to inhibit 
inflammatory 
cytokine 
expression in 
LPS-stimulated 
peripheral blood 
mononuclear 
cells (Leoni, 
Fossati et al. 
2005). 
The forced 
downregulation 
of HDAC2 was 
shown to inhibit 
the stabilisation 
and activity of 
Nrf2 in BEAS-
2B bronchial 
epithelial cells 
(Mercado, 
Thimmulappa et 
al. 2011). 
 
The ROS-
generating 
DUOX NADPH 
oxidases have 
a 
demonstrable 
tendency to be 
hyper-
methylated in 
several lung 
cancer cell 
lines (Luxen, 
Belinsky et al. 
2008). 
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   (Table 2 continued) 
 HDACs/DNMTs Inf. Nrf2 Redox Status 
Inf. 
The processes of 
inflammation tend 
to lower 
extracellular pH 
(Bäckdahl, 
Bushell et al. 
2009). Low pH 
can inhibit the 
acetylation of 
histones H3 and 
H4 (McBrian, 
Behbahan et al. 
2013). 
  
Inflammatory 
stimuli were 
shown to 
induce the 
superoxide 
anion-
generator, 
NADPH-
oxidase, in 
phagocytes. 
(Locatelli, 
Canaud et al. 
2003). 
Nrf2 
Nrf2 deletion was 
demonstrated to 
reduce HDAC2 
activity in the 
mouse lung 
(Adenuga, Caito 
et al. 2010). 
Perhaps this was 
due to increased 
ROS, which 
themselves have 
been shown to 
inhibit HDAC2 in 
BEAS-2B cells 
(Ito, Hanazawa et 
al. 2004). 
The 
overexpression 
of Nrf2 was 
shown to  
downregulate 
several 
inflammatory 
proteins in 
human aortic 
endothelial cells 
(Chen, Dodd et 
al. 2006). 
 
As is well-
established, 
Nrf2 activates 
reducing 
(antioxidant) 
enzymes, such 
as TrxR-1, 
GST-α, HO-1, 
NQO1 and 
UGT, upon 
binding to the 
ARE in their 
gene promoter 
regions. 
Redox 
Status 
ROS were 
demonstrated to 
inhibit HDACs 
and activate 
histone 
acetyltransferases 
(Rahman, 
Marwick et al. 
2004). Hydrogen 
peroxide was 
shown to inhibit 
HDAC2 in BEAS-
2B cells (Ito, 
Hanazawa et al. 
Oxidative stress 
was shown to 
promote IκB 
degradation, 
thus 
derepressing 
the pro-
inflammatory 
transcription 
factor NF-κB 
(Poynter and 
Daynes 1998). 
As is well-
established, 
ROS induce 
Nrf2 by various 
means such as 
by modifying 
certain cysteine 
residues of 
Keap1 in a 
manner that 
weakens 
Keap1-Nrf2 
interactions, 
thus enabling 
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   (Table 2 continued) 
 HDACs/DNMTs Inf. Nrf2 Redox Status 
2004). Increased 
ROS inevitably 
stimulates GSH 
synthesis, a 
process that 
inhibits the 
regeneration of 
methionine and 
folate - donors of 
methyl groups 
that are required 
for DNMT-
induced 
methylation 
(Hitchler and 
Domann 2007). 
Nrf2 to 
translocate to 
the nucleus. 
 
1.6.2 Complexities in the Regulation of MicroRNA Abundance and 
Activity 
The known mechanisms by which miRNAs and miRNA-mediated effects are 
able to be modulated extend beyond those described above, and will most 
likely continue to increase with time.  
1.6.2.1 Interfering RNAs 
Competing endogenous RNAs (ceRNAs) are transcripts that are able to 
inhibit the mRNA-targeting activity of miRNAs by acting as miRNA binding 
decoys (Wilczynska and Bushell 2015). An example of a ceRNA is the high-
mobility group AT-hook 2 (HMGA2) mRNA, which can act oncogenically in 
lung cancer independently of its translational protein product; it serves as a 
decoy for miRNAs of the let-7 family, thereby inhibiting their binding to - and 
transcriptional repression of - mRNAs for oncogenes such as TGFβ receptor 
III (Wilczynska and Bushell 2015). 
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There exist pseudogene homologues of protein-coding oncogenes, whose 
transcripts similarly act as decoys for miRNAs. One such example is 
phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 
(PTENP1), whose mRNA transcript has been demonstrated to inhibit the 
binding of miRNAs to - and thus translational repression of - the protein-
coding PTEN transcript (Wilczynska and Bushell 2015). 
Several long non-coding RNAs (lncRNAs) also serve as miRNA decoys, 
such as the Highly Up-regulated in Liver Cancer lncRNA which serves as 
such for miR-372-3p in liver cancer cells (Wilczynska and Bushell 2015). 
Circular RNAs (circRNAs) are a distinctive species formed by the covalent 
linkage of the 5’ and 3’ ends of exonic transcripts by the spliceosome, whose 
circularity enables them to resist linearity-dependent RNA degradation. A 
circRNA called ‘circular RNA sponge for miR-7’ was demonstrated to act as 
a functionally significant decoy for miR-7-5p in brain tissues (Wilczynska and 
Bushell 2015).  
1.6.2.2 Interfering Proteins 
The processing and stability of pri-miRNAs and pre-miRNAs are influenced 
by interactions with various biomolecules. For example, the interaction of 
Receptor-regulated mothers against decapentaplegic (R-Smad) proteins with 
pri-miR-21 has been demonstrated to enhance the Drosha-mediated 
processing of the latter (producing pre-mir-21, which gives rise to miR-21-5p 
and miR-21-3p) (Hata and Lieberman 2015). Interestingly, p53 was shown to 
act as a co-factor of the Drosha microprocessor complex to enhance pri-
miRNA processing, and thereby upregulate the pro-apoptotic miR-203a-3p 
(Hata and Lieberman 2015). The KH-type splicing protein (KSRP) was 
shown to promote the Drosha-dependent processing of pri-mir-21, pri-mir-
125, and the let-7 pri-miRNAs (Hata and Lieberman 2015). The activity of 
KSRP was demonstrated to be enhanced by its own phosphorylation, which 
is induced in response to DNA damage and by the phosphoinositide 3-
kinase-RAC-alpha serine/threonine-protein kinase (PI3K-AKT) pathway 
(Hata and Lieberman 2015). KSRP was also shown to promote the exportin 
5-mediated nuclear-to-cytoplasmic transport of pre-miRNAs, and their 
subsequent processing by Dicer. The p72 RNA helicase, whose own activity 
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can be inhibited by nuclear Yes-associated protein (YAP) via sequestration, 
was shown to facilitate the Drosha-dependent processing of some pri-
miRNAs (Hata and Lieberman 2015). Also, pleckstrin homology domain-
containing family A member 7 (PLEKHA7) was demonstrated to promote the 
processing of pri-mir-30b and pre-mir-30b in the apical regions of cell 
junctions, by interacting with E-cadherin and recruiting Drosha and DGCR8 
(Kourtidis, Ngok et al. 2015). In addition, the endonuclease NCP-induced 
protein 1 was shown to reduce the stability of pre-mir-135b and pre-mir-146a 
upon binding to their terminal loops (Hata and Lieberman 2015). 
At the mature miRNA level, several miRNAs including miR-221-3p, were 
shown to be selectively degraded by the interferon (IFN)-inducible 
exonuclease polyribonucleotide nucleotidyltransferase 1 (PNPT1) in 
melanoma cells (Hata and Lieberman 2015).  
1.6.2.3 Post-transcriptional MicroRNA Modifications 
Pri-miRNAs, pre-miRNAs and mature miRNAs are all potentially susceptible 
to activity-influencing post-transcriptional modifications. Such modifications 
of mature miRNAs or their precursors can affect their stability, for example: 
• The 3’-uridylation of let-7 family pre-miRNAs was shown to promote 
their degradation by DIS3 mitotic control homolog (S. cerevisiae)-like 
2 (Hata and Lieberman 2015). 
• In human breast cancer cells, the demethylation of the 5’ 
monophosphate of pre-mir-145 by the RNA methyltransferase 
‘BCDIN3 domain containing RNA methyltransferase’ inhibited its 
Dicer-dependent processing (Hata and Lieberman 2015). 
• The 3’-adenylation of miR-122-5p by the RNA nucleotidyl transferase 
‘PAP-associated domain containing 4’ was shown to increase its 
stability, while the 3’-uridylation of miR-26a-5p by an RNA nucleotidyl 
transferase called terminal uridylyltransferase 4 repressed its mRNA 
transcript-binding activity (Wyman, Knouf et al. 2011). 
Some post-transcriptional modifications of miRNAs generate variants that do 
not map in sequence with the genetic loci from which they originate, such as 
non-templated additions (NTAs). It has been reported that only a minority of 
91 | P a g e  
 
human miRNAs are susceptible to 3’ NTAs, but the susceptibility of a given 
miRNA may be independent of cell and tissue type and/or disease status 
(Wyman, Knouf et al. 2011). The most frequently observed forms of 3’ NTA 
are mono-adenylation and mono-uridylation, but the relative dominance of 
each form may vary between species (Wyman, Knouf et al. 2011). 
Adenosine deaminases (ADARs) are enzymes that tend to exist in either 
monomeric or dimeric forms. In the latter, they modify adenosine residues to 
inosine in RNAs such as pri- and mature miRNAs, which can have complex 
effects on miRNA regulation. For example, the editing of pri-mir-142 by 
ADAR1 and ADAR2 was shown to inhibit its Drosha-dependent processing 
and to promote its degradation. Additionally, ADAR1 appeared to generally 
inhibit Drosha-dependent pri-miRNA processing by competitively inhibiting 
DGCR8 recruitment (Hata and Lieberman 2015). ADAR-mediated editing of 
miRNAs has the potential to change their mRNA-targeting properties, 
especially if occurring in seed regions (Neilsen, Goodall et al. 2012). 
Interestingly, monomeric ADARs were found to have a tendency to promote 
both the Dicer-dependent processing of pre-miRNAs and the loading of 
mature miRNAs into RISCs.  
As mentioned previously, Drosha and Dicer do not always cleave precisely at 
specific loci of pri-miRNAs and pre-miRNAs, so isomiRs that vary by length 
but that still map to their genetic loci of origin are generated; this is called 
templated variation (Neilsen, Goodall et al. 2012). Templated variation can 
also arise from the action of exonucleases on miRNAs (Neilsen, Goodall et 
al. 2012). 
1.6.2.4 General Regulation 
• Posttranslational modifications of the RNA processing enzymes 
Drosha, DGCR8 and Dicer, have the potential to influence their 
stability, localisation and activity (Hata and Lieberman 2015). 
• The sequence of a given mature miRNA influences its innate 
susceptibility to degradation under certain conditions. 
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• The miR-15/16 family of miRNAs have been demonstrated to undergo 
rapid degradation as cells re-enter the cell cycle from G0 arrest 
(Wilczynska and Bushell 2015). 
1.6.3  Interactions between MicroRNAs and Nrf2 
MicroRNAs can both promote and inhibit Nrf2 activity. For example, the miR-
200-3p/141-3p family were shown to promote Nrf2 activity by repressing 
Keap1 in hepatic stellate cells. Interestingly, SFN (5µM) was shown to 
upregulate miR-200c-3p in T24 cells (Shan, Zhang et al. 2013), thus one 
could speculate that miR-200c-3p induction contributes to the SFN-mediated 
induction of Nrf2. MiR-153-3p was shown to repress Nrf2 and inhibit GSH 
synthesis in human neuroblastoma cells, while miR-34a-5p and miR-93-5p 
were shown to repress Nrf2 in the rat liver (Kurinna and Werner 2015). MiR-
28-5p was also shown to repress Nrf2 in breast cancer cells, and miR-507, 
miR-634, miR-450a-5p and miR-129-5p to do so in oesophageal squamous 
cell carcinoma cells, in which the downregulation of these miRNAs was 
observed to contribute to oncogenesis (Kurinna and Werner 2015). 
The zinc-finger enhancer binding (ZEB) transcription factors can promote 
epithelial-mesenchymal transition (EMT): an important step of oncogenic 
transformation. The miR-200 family of miRNAs have been demonstrated to 
repress the ZEB genes (Burk, Schubert et al. 2008), and their experimental 
overexpression to do so in MDCK cells (Gregory, Bert et al. 2008). ZEB-1 
was shown to downregulate E-cadherin in MCF10A mammary epithelial cells 
(Chua, Bhat-Nakshatri et al. 2006); E-cadherin plays a role in tumour 
suppression, by maintaining physical cell-cell contacts thus repressing cell 
migration, and also via the induction of Twist-activated tumour-suppressive 
signalling (Onder, Gupta et al. 2008). 
1.6.4 MicroRNAs in Colorectal Cancer 
As previously described, many miRNAs have potential roles in CRC 
pathogenesis. 
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1.6.4.1 MicroRNA Interactions with Vogelstein Model 
Pathogenesis 
Several miRNAs are able to interact with elements of the canonical 
Vogelstein CRC pathogenesis model (previously summarised in Figure 2): 
1. The loss of APC leads to the activation of β-catenin, which promotes 
stem cell renewal and proliferation, facilitating the development of an 
ACF. Two miRNAs often overexpressed in CRC - miR-135a-5p and 
miR-135b-5p - can repress APC, and thus potentially promote this 
step of carcinogenesis (Slaby, Svoboda et al. 2009), whilst miR-17-5p 
can promote β-catenin activity (Amirkhah, Schmitz et al. 2015). 
Meanwhile, miR-320a can inhibit tumour growth by repressing β-
catenin (Amirkhah, Schmitz et al. 2015). 
2. Increased KRAS activity typically arises from hyperactivating 
mutations and increases proliferation, facilitating the development of 
the ACF into an early adenoma. The let-7 family of miRNAs, along 
with miR-18a-5p, miR-143-3p (Slaby, Svoboda et al. 2009) and miR-
18a-3p (Amirkhah, Schmitz et al. 2015) have all been shown to 
repress KRAS. 
3. The losses of the pro-apoptotic gene DCC and the TGFβ-driven TSGs 
SMAD2 and SMAD4 facilitate the progression of the adenoma to its 
late stage. The miR-130a/301a/454-3p family and miR-224-5p have 
been shown to repress SMAD4 itself, and miR-106a-5p and miR-21-
5p to repress the TGFβ receptor II (70/80kDa) (Amirkhah, Schmitz et 
al. 2015). 
4. The mutational inactivation of the TP53 gene is canonically 
considered to be the final critical step that facilitates the progression of 
a late adenoma to a metastatic cancer. Some of p53’s tumour-
suppressive effects are mediated by the induction of the miR-34a-c 
family. MiR-34a-5p represses the HDAC sirtuin 1 (SIRT1) and is 
induced in response to DNA damage in a p53-dependent manner 
(Amirkhah, Schmitz et al. 2015). The miR-34a-c family of miRNAs is 
frequently deleted or hypermethylated in CRC (Amirkhah, Schmitz et 
al. 2015). MiR-34a-5p-based therapy is currently undergoing phase I 
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clinical trials for the treatment of liver cancer (Amirkhah, Schmitz et al. 
2015). 
1.6.4.2 Other Potential Interactions between MicroRNAs and 
Colorectal Cancer 
There are various other examples of potential miRNA-CRC interaction. For 
example: 
• MiR-145-5p can repress insulin-like growth factor-1 receptor (IGF-1R) 
and insulin receptor substrate (IRS-1), both of which promote 
proliferation and inhibit apoptosis in response to growth factors such 
as insulin-like growth factor 1 (IGF-1) (Slaby, Svoboda et al. 2009). 
• MiR-126-3p can inhibit the oncogenic PI3K signalling pathway by 
repressing one of its promoters - p85β (Slaby, Svoboda et al. 2009). 
• MiR-21-5p can conversely promote PI3K signalling by repressing the 
PI3K signalling-inhibitor PTEN (Slaby, Svoboda et al. 2009).  
• Interestingly, the oncogene c-Myc can induce miRNAs of the miR-17-
92 cluster (Slaby, Svoboda et al. 2009), including miR-17-5p, which 
can promote β-catenin signalling (Amirkhah, Schmitz et al. 2015). 
• MiR-144-3p can repress the oncogene mammalian target of 
rapamycin (mTOR) (Amirkhah, Schmitz et al. 2015). 
• MiR-25-3p is potentially tumour-suppressive via the repression of 
SMAD7 - which in contrast to SMAD2 and SMAD4 - is oncogenic, due 
to inhibiting TGFβ’s tumour-suppressive activities (Amirkhah, Schmitz 
et al. 2015). 
• MiR-103-3p can repress the TSG Kruppel-like factor 4 (KLF4) 
(Amirkhah, Schmitz et al. 2015). 
• MiR-124-3p was shown to promote apoptosis in DLD-1 and WiDr 
colon cancer cells (Taniguchi, Sugito et al. 2015). 
1.6.4.3 MicroRNA Interactions with the Warburg Effect 
MiR-26a-5p, often overexpressed in CRC, can repress pyruvate 
dehydrogenase protein X component (PDHX) - a key component of the 
pyruvate dehydrogenase complex that catalyses the synthesis of acetyl-
coenzyme A from pyruvate within the mitochondrion (Chen, Liu et al. 2014). 
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By inhibiting acetyl-coenzyme A synthesis, miR-26a-5p can promote a shift 
in metabolism such that the proportion of ATP generated via glycolysis vs. 
that generated by oxidative phosphorylation is increased, thereby 
upregulating the generation of metabolites required for mitosis (Chen, Liu et 
al. 2014). The promotion of the Warburg effect by miR-26a-5p has been 
demonstrated in vitro by the overexpression of the miRNA in CRC cell lines, 
followed by pyruvate, lactate and acetyl-coenzyme A assays. 
1.6.5 Methods to Detect Differences in MicroRNA Expression 
between Samples 
Three methods are widely employed for wide-scale miRNA comparative 
expression profiling: 
o MiRNA array chip hybridisation. 
o MiRNA array quantitative polymerase chain reaction (PCR). 
o MiRNA cloning and deep sequencing. 
1.6.5.1 MicroRNA Array Chip Hybridisation 
MiRNA array chips are media coated with probes of sequence 
complementary to those of known miRNAs, to which RNA samples can be 
hybridised. The expression of a specific miRNA in the sample is thus 
evaluated according to the intensity of signal generated from its 
corresponding probe, which is proportional to the amount of miRNA bound. 
An example of such a system is the miRCURY LNA™ microRNA Arrays kit 
(Exiqon). 
1.6.5.2 MicroRNA Array RT-qPCR 
In a reverse transcription—quantitative polymerase chain reaction (RT-
qPCR) ‘array’, hundreds of RT-PCRs are run in parallel, each specific for a 
different miRNA. An example of a system facilitating this is the TaqMan Low 
Density Array kit with the human miRNA Megaplex RT Primer Pool v3.0 
(Slaby, Sachlova et al. 2013). 
1.6.5.3 MicroRNA Library Cloning and Deep Sequencing 
The small RNAs from RNA samples are captured using oligomeric adapters, 
then reverse transcribed to complementary DNA (cDNA) form. Specific types 
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of primer are used for the reverse transcription and subsequent PCR 
amplification of the captured small RNAs, and then the PCR products can be 
size-fractionated to isolate the miRNA clones, which are then subject to deep 
sequencing. Reads from the sequencing data are annotated based on known 
miRNA sequences (as catalogued in the current version of miRBase), then 
the relative expression of a given miRNA is evaluated by comparing its 
normalised read numbers between libraries. Unlike the above-mentioned 
miRNA array chip hybridisation and RT-qPCR methods, this approach can 
detect and evaluate the expression of novel miRNAs.  
1.6.5.4 Comparison of Methods 
The miRNA array chip hybridisation and quantitative PCR (qPCR) 
approaches tend to be less expensive and time-consuming than library 
cloning and deep sequencing methods. However, the miRNAs for which 
probes are included in the kits are inevitably limited to those known to exist 
at the time of kit development. 
By contrast, library cloning and deep sequencing are able to capture novel 
miRNAs that may be identified as such by computational sequence analysis, 
and data can be re-annotated in the future against newer versions of 
miRBase. The list of known human miRNAs continues to grow. MiRBase 
v.14, which was released at the beginning of 2010, catalogued 894 human 
miRNAs; v.20, released halfway through 2013, 2555; and v.21, 2588. The 
increase in the number of mature human miRNAs catalogued by each new 
version of miRBase is illustrated in Figure 13 (miRBase 2014). The current 
version of miRBase is v. 21 and catalogues 2588 mature human miRNAs. 
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Figure 13: A graph illustrating the increase in the number of mature human miRNAs 
listed in miRBase with each new version, according to the miRBase Blog. 
The benefits of the cloning-sequencing approach, including its greater 
sensitivity, potential to capture novel miRNAs, and ability to quantify miRNA 
expression over a wider dynamic range, were considered to outweigh its 
potential drawbacks of higher cost and time consumption compared with the 
array-based approaches. Therefore, miRNAs were to be cloned in the form 
of DNA-based libraries using the protocol developed by Xu et al. (Xu, 
Billmeier et al. 2015) using Dalmay HD adapters, and then the constructed 
libraries were to be subject to deep sequencing by the Earlham Institute 
(formerly The Genome Analysis Centre) (Norwich, UK). 
1.6.5.5 Challenges in MicroRNA Cloning: Adapter Ligation Bias 
The first step in miRNA cloning is to ligate adapter oligomers to the 5’ and 3’ 
ends of small RNA species. Any given adapter oligomer will inevitably vary in 
its affinity for different miRNAs, so those to which its affinity is greater are 
more likely to become ligated to the adapters. This ligation bias means if two 
given miRNAs are of equal abundance in a sample, but one is preferred by 
the adapter, that which is preferred will have more cDNA clones of itself 
produced and thus be read more frequently upon sequencing of the sample. 
Therefore, the read numbers for different miRNAs relative to one another do 
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not necessarily represent the actual abundances of the miRNAs relative to 
one another. 
Assuming that the same adapter(s) is/are used for all samples, any ligation 
biases should occur equally across all samples and thus should not 
confound the evaluation of fold-differential miRNA expression between 
samples. However, some miRNAs may be so strongly ‘disfavoured’ by the 
ligation process that they are ultimately represented by very low or no read 
numbers in the sequencing data, and therefore go undetected. In this regard, 
ligation bias can impair sensitivity in that there may be differentially 
expressed miRNAs that are undetected because they are too strongly 
‘disfavoured’ by adapter ligation. 
For any given adapter sequence, ligation bias is inevitable. In order to 
mitigate this issue, HD adapter pools were developed by Dalmay and 
Sorefan et al. (Sorefan, Pais et al. 2012), which were generated by taking  
Illumina adapters, then adding 4 nucleotides to the miRNA-ligating ends at 
random. Therefore, from each single adapter are generated a potential pool 
of 44 = 256 variants. Inevitably, each of these variants will have their own 
bias, but any collective bias of the pool will be much lower than that of the 
original single adapter. The HD adapters have been demonstrated to 
dramatically increase read coverage, and enable the detection of previously 
unidentified miRNAs (Sorefan, Pais et al. 2012). 
1.7 Aims and Objectives 
• To investigate the effects of SFN on miRNA expression in cancerous 
and normal human colonic cell lines. 
o The microenvironment of cell culture in vitro is not fully 
representative of that of tumour cells in vivo and cannot factor 
in organism-wide metabolism as can in vivo animal models. 
However, human cells cultured in vitro may in some instances 
be more representative of human tissue than ‘equivalent’ 
tissues in laboratory animals such as mice. Animal models are 
also more time-consuming and expensive to work with. In vitro 
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studies may involve either primary human cells or established 
human cell lines. Since cell lines are widely available, and 
experimental findings in cell lines are more likely to be more 
reproducible and comparable across studies, they were more 
appropriate than primary human cells for these studies. 
o Although an array-based miRNA expression analysis by Slaby 
et al. (2013), using TaqMan Low Density Array qPCR, had 
already indicated the ability of 48 h SFN treatment to modulate 
the expression of several miRNAs in non-cancerous colonic 
cell lines (Slaby, Sachlova et al. 2013), the reported miRNA 
modulations had not been followed up by individual assays for 
confirmation. Differences in expression detected by the wide-
scale analysis in this study were to be validated by single-target 
assays such as RT-qPCR or Northern Blots, in order to confirm 
that such apparent differences in expression were actually true 
as opposed to artefacts of the wide-scale profiling process. 
o The study by Slaby et al. investigated only non-cancerous 
colonic cell lines, but there is a dearth of studies investigating 
the SFN-mediated modulation of miRNAs in their cancerous 
counterparts. It is conceivable that the effects of SFN in 
cancerous colonic cell lines differs from those in their non-
cancerous counterparts, so this study therefore used both 
cancerous and non-cancerous colonic cell lines (Caco-2 and 
CCD-841 respectively). 
o Most wide-scale analyses of differential expression have used 
array-based approaches, such as the RT-qPCR array approach 
adopted by Slaby et al. (2013). While relatively inexpensive and 
quick, this approach is limited to studying the miRNAs that 
were catalogued at the time of array development. The 
TaqMan Low Density Array used by Slaby et al. included 
probes for 754 miRNAs, but the current version of miRBase 
includes 2588 human miRNAs. This study employed the 
miRNA library cloning and deep sequencing approach, which is 
more expensive and time consuming than array-based 
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methods, but has the potential to detect a wider range of 
differentially-expressed miRNAs, including novel miRNAs. 
o Challenges of the miRNA library construction process include 
adapter ligation bias, which can impair the sensitivity with which 
miRNA modulations are detected. Dalmay HD adapters were to 
be used in order to reduce such adapter ligation bias (Sorefan, 
Pais et al. 2012).  
o The temporal dynamics of SFN-mediated miRNA modulation 
can vary widely, due to the plethora of mechanisms by which 
different miRNAs are able to be modulated. The steady-state 
level of a given miRNA depends upon the balance between its 
biogenesis and degradation. A specific miRNA’s rate of 
biogenesis can be modulated at various stages, such as the 
transcription of the genetic loci to pri-miRNAs, the processing 
of pri-miRNAs to pre-miRNAs by Drosha and DGRC8, the 
cleavage of pre-miRNA loops by Dicer, and the loading of 
mature miRNAs into RISCs. Likewise, the rate at which a 
specific miRNA is degraded can be influenced by the degree of 
complementarity between the miRNA and its target mRNA, the 
abundance of the target, and the presence and nature of 
miRNA base modifications (Gantier, McCoy et al. 2011). Due to 
the complexities of miRNA synthesis and degradation, the 
sensitivity of SFN-mediated miRNA modulation detection 
should correlate positively with the number of different time 
points at which miRNA expression is profiled. However, it is 
impractical in terms of time and resources to profile miRNA 
expression at many different time points. Nevertheless, profiling 
expression at two different time points is feasible and expected 
to be significantly more sensitive than that at a single time 
point. This study therefore set out to profile miRNA expression 
at two different time points post-treatment – 8 h and 24 h.  
• To investigate the potential downstream consequences of SFN-
mediated changes to miRNA expression in terms of tumour 
suppression. 
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o Select miRNAs whose differential expression was validated by 
single-target assays were to be studied in vitro by the use of 
specific miRNA mimics and inhibitors for their ability to bind to 
the 3’-UTRs of predicted and/or reported mRNA targets 
relevant to cancer. Following the verification of such, the 
downstream miRNA effects on protein abundance and in vitro 
cancer ‘endpoints’ such as cell migration and invasion, could 
be investigated. 
Hypothesis: SFN modulates the expression of miRNAs in both the 
cancerous Caco-2 and normal CCD-841 colonic cell lines, with some 
differential effects between the two cell lines. MiRNAs whose expression is 
repressed or promoted by SFN are respectively able to promote or inhibit 
cancer development, by directly targeting the mRNA transcripts of TSGs or 
oncogenes, respectively, to repress their translation.  
The investigation of the above-described hypothesis by this study could help 
to inform the future development of anti-CRC therapeutic and/or 
chemopreventative strategies. 
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Chapter 2: Methods 
2.1 Cell Culture 
HCT116, Caco-2 and CCD-841 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing D-glucose (4.5g/L) and non-essential 
amino acids (Sigma), which was supplemented with heat-inactivated foetal 
bovine serum (FBS) to 10% (v/v), Penicillin-Streptomycin (Sigma) to 1% 
(v/v), and L-glutamine to 200nM, in 75cm2 flasks. Cells were maintained in a 
HERAcell® 150 CO2 incubator at 37°C in 5% CO2 and cell work was carried 
out under sterile conditions inside a Class II Biological Safety Cabinet. 
HCT116 and Caco-2 cells were subcultured upon reaching 70-80% 
confluence. To subculture, medium was removed, cells were washed twice 
with 10mL pre-warmed phosphate-buffered saline (PBS), covered in 1mL 
trypsin-EDTA (0.25% (w/v) trypsin and 1mM EDTA), then put into 37°C 
incubation until all cells were detached (typically 1 min for HCT116 and 5 – 
10 min for Caco-2). Then trypsin was inactivated by adding 8mL culture 
medium. Cell suspensions were repeatedly pipetted to disrupt cell 
aggregates, then cells were counted using a haemocytometer. An 
appropriate volume of cell suspension was then combined with fresh pre-
warmed culture medium for seeding into new flasks for maintenance, and/or 
onto other solid media for experiments. Typically, 1.0 × 106 cells were 
seeded into a new 75cm2 flask for maintenance, in 12mL medium. 
CCD-841 cells were subcultured every 7 – 10 days in a fashion similar to that 
described above for Caco-2 and HCT116 cells except for a few differences. 
Firstly, cell monolayers were washed using Dulbecco’s low-salt PBS instead 
of the typical PBS, prior to the addition of trypsin-EDTA. Secondly, cells were 
pelleted by centrifugation at 125 g for 5 min following detachment and then 
resuspended in fresh pre-warmed culture medium, in order to remove traces 
of trypsin-EDTA. 
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2.2 Western Blotting to Assay Proteins 
2.2.1 Cell Treatments to Assay the Effects of SFN on Proteins 
Cells were grown to 70-80% confluence in 6-well plates (surface area per 
well = 9.5cm2) and then treated by adding to culture medium dimethyl 
sulfoxide (DMSO)-diluted SFN (5, 10 or 20µM) or DMSO (control) for 24 h, or 
DMSO-diluted SFN (10µM) for 4, 8, 12, 24, 48 or 72 h; final DMSO 
concentrations were 0.05% (v/v). 
2.2.2 Total Protein Isolation 
Culture medium was removed and then cells were washed twice in ice-cold 
PBS, then covered in a lysis solution containing 20mM Tris-HCl (pH 8.0), 
150mM NaCl, 2mM EDTA, 10% (v/v) glycerol, 1% (v/v) Nonidet P-40, 
cOmplete™, Mini Protease Inhibitor (Roche), and 1mM PMSF Protease 
Inhibitor (Thermo Fisher). Cells were incubated under the lysis solution under 
agitation at 4°C for 30 min, then lysates were collected by scraping wells with 
a rubber policeman. Collected lysates were centrifuged at 12 000 g for 15 
min at 4°C and the pelleted debris was discarded. 
2.2.3 Nuclear Protein Isolation 
Nuclear protein fractions were isolated using the Nuclear Extract Kit (Active 
Motif, UK) according to the manufacturer’s instructions. Briefly, culture 
medium was removed and then cells were washed twice in ice-cold PBS 
supplemented with Phosphatase Inhibitor. Cells were then covered in fresh 
Phosphatase Inhibitor-supplemented PBS and lifted into suspension with a 
rubber policeman. Suspensions were collected in pre-chilled tubes, and then 
centrifuged at 200 g for 5 min at 4°C to pellet the cells, discarding the 
supernatants. Pelleted cells were resuspended in 1X Hypotonic Buffer then 
put on ice for 15 min to swell.  
Detergent was then added to swollen cell suspensions, which were 
subsequently vortexed and then centrifuged at 14 000 g for 30 sec at 4°C to 
separate the cytoplasmic and nuclear protein fractions, into supernatants and 
pellets respectively. Cytoplasmic protein-containing supernatants were 
transferred to separate tubes and stored at -80°C, then the nuclear protein-
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containing pellets were resuspended in Complete Lysis Buffer, incubated at 
4°C under rotation, vortexed for 30 sec, then centrifuged at 14 000 g for 10 
min at 4°C. Nuclear protein-containing supernatants were then collected and 
stored at -80°C; pellets were discarded. 
2.2.4 SDS-PAGE and Immunoblotting 
Protein concentrations were determined using the Brilliant Blue G dye-
binding assay of Bradford, after using known quantities of bovine serum 
albumin to generate standard curves, using Bradford Reagent (Sigma). From 
each sample, equal amounts of protein were combined with Loading Buffer 
(0.625M Tris, 2% (v/v) SDS, 10% (v/v) glycerol, 20mM DTT and 
bromophenol blue). 
2.2.4.1 Fluorescent Detection Protocol 
Protein-Loading Buffer mixtures were incubated at 95°C for 5 min to 
denature proteins, then loaded into 10% (v/v) sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels alongside Dual Color 
Precision Plus Protein™ Standards (Bio-Rad) molecular weight markers. 
Proteins were subsequently size-fractionated by SDS-PAGE at 25-35mA, 
then transferred to low-background Immun-Blot polyvinylidene difluoride 
(PVDF) membranes (Bio-Rad) by semi-dry electroblotting using either the 
Trans-Blot SD Semi Dry Transfer Cell (Bio-Rad) or the Trans-Blot Turbo 
system (Bio-Rad). The SD system was run at 15V/gel for 1 h, whilst the 
Turbo system was run at 25V for 30 min. 
Membranes were blocked by incubation in Pierce Protein—Free Blocking 
Buffer (Life Technologies) at room temperature for 1 h under agitation. 
Blocked membranes were incubated overnight under agitation at 4°C in a 1:1 
mixture of the blocking buffer and PBS supplemented with 0.5% (v/v) Tween 
20 detergent (PBS-T (0.5%)), in which were diluted primary antibodies 
against proteins of interest. Subsequently, membranes were washed for 8 
min four times in PBS-T (0.1%), and then incubated for 1 h at room 
temperature in a 1:1 mixture of the blocking buffer and PBS-T (0.5%) 
supplemented with 0.002% (v/v) SDS, in which were diluted secondary 
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antibodies against the primary antibodies used. Membranes were 
subsequently washed again for 8 min four times in PBS-T (0.1%), then once 
in PBS for 5 min. The fluorescence of bound secondary antibody was 
detected using the Odyssey Imager (LI-COR), and signals were 
densitometrically analysed to compare protein expression between samples, 
using β-actin as an internal control for normalisation. 
2.2.4.2 Chemiluminescent Detection Protocol 
Protein-Loading Buffer mixtures were incubated at 70°C for 10 min to 
denature proteins, then loaded into 10% (v/v) SDS-PAGE gels alongside 
Dual Color Precision Plus Protein™ Standards (Bio-Rad) molecular weight 
markers. Proteins were subsequently size-fractionated by SDS-PAGE at 25-
35mA, and then transferred to Immun-Blot PVDF membranes (Bio-Rad) by 
semi-dry electroblotting, using the Trans-Blot SD Semi Dry Transfer Cell 
(Bio-Rad) at 15V/gel for 1 h. 
Membranes were blocked by incubation in 5% (v/v) skimmed milk dissolved 
in PBS-T (0.1%), at room temperature for 1 h 30 min under agitation. 
Blocked membranes were incubated overnight at 4°C under agitation, in a 
solution of 5% (v/v) milk, and primary antibodies against the proteins of 
interest, diluted in PBS-T (0.1%). Subsequently, membranes were washed 
for 10 min four times in PBS-T (0.1%), then incubated at room temperature 
for 1 h in a solution of 5% (v/v) milk, and secondary antibodies against the 
primary antibodies used, diluted in PBS-T (0.1%).  Membranes were 
subsequently washed again for 10 min four times in PBS-T (0.1%). 
Membranes were then developed using the ECL Western Blotting Detection 
Kit (GE Healthcare) according to manufacturer’s instructions, by first 
equilibrating reagents to room temperature and then thoroughly mixing 
Solution A and Solution B in a 1:1 ratio. The membrane was covered in this 
mixture and incubated at room temperature for 5 min, whilst shielded from 
light. The chemiluminescence of bound secondary antibody was 
subsequently detected using the Fujifilm LAS3000 Imager, and signals were 
densitometrically analysed to compare protein expression between samples, 
using β-actin as an internal control for normalisation. 
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2.3 MicroRNA Library Construction and Sequencing 
2.3.1 Cell Treatments 
Cells were grown to 70-80% confluence and then treated by adding to 
culture medium in triplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or 
DMSO (control); final DMSO concentrations were 0.05% (v/v). 
2.3.2 Total RNA Extraction 
Total RNA was isolated by guanidium thiocyanate-phenol-chloroform 
extraction, using TRI Reagent (Sigma-Aldrich), largely according to the 
manufacturer’s protocol with minor modifications. Briefly, culture medium 
was removed and then TRI Reagent was added directly onto cells (1mL per 
10cm2 culture dish area) to lyse them. The procedure was either paused at 
this stage by storing lysates at -80°C (which were fully defrosted to resume), 
or continued by incubating lysates at room temperature for 5 min. 
200µL chloroform was mixed vigorously into every 1mL TRI Reagent lysate. 
Mixtures were incubated at room temperature for 10 min and then 
centrifuged at 16 000 g for 15 min, at 4°C, for phase separation. The 
aqueous (uppermost, clear) phases were then carefully transferred to fresh 
tubes, avoiding the other phases. RNA was precipitated from the aqueous 
phases by mixing in 500µL isopropanol and 5µg glycogen (co-precipitant for 
RNA) per 1mL TRI Reagent lysate processed, then storing at -20°C for ≥ 5 h. 
After storage, precipitated RNA was pelleted by centrifugation at ≥ 16 000 g 
for 30 min, at 4°C. Supernatants were removed from pellets, which were then 
washed with 1mL 75% (v/v) ethanol each. Ethanol was then removed and 
tubes were left open in a sterile hood to allow the evaporation of any residual 
ethanol (~5-10 min). Dried pellets were dissolved in water, supplemented 
with 10 units RNAse Inhibitor (Ambion), and stored at -80°C. 
2.3.3 MicroRNA Library Construction 
Total RNA sample concentrations were determined using the NanoDrop 
spectrophotometer. Each library was constructed from 2µg total RNA with 
Dalmay’s HD adapters, according to the protocol developed by Xu et al. (Xu, 
Billmeier et al. 2015), as described below. 
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2.3.3.1 Total RNA Purification 
Total RNA samples were purified using the Zymo RNA Clean & Concentrator 
-25 kit (Cambridge Bioscience) according to manufacturer’s instructions. 
Briefly, samples were mixed with RNA Binding Buffer and ethanol, and 
mixtures were centrifuged through Zymo-Spin™ IIC Columns to capture the 
RNA. Captured RNA was then treated with RNA Prep Buffer, washed with 
RNA Wash Buffer, and then eluted from the column in water. Eluted RNA 
was supplemented with RNAse Inhibitor (Ambion) and stored at -80°C. 
2.3.3.2 RNA Denaturation 
2µg of RNA was combined with water to a 10µL volume, to which 1µL 3’ HD 
Adapter was then added. The mixture was incubated at 70°C for 2 min to 
denature the RNA and adapter. 
2.3.3.3 3’ HD Adapter Ligation 
Into the mixture was added 2µL T4 RNA Ligase 2 10X Buffer (NEB or 
Epicentre), 1µL T4 RNA Ligase 2 (NEB or Epicentre), 0.75µL RNaseOUT 
(40 units/µL) (Invitrogen), 4µL 50% (v/v) polyethylene glycol (PEG) (NEB), 
and 1.25µL water. This mixture was then incubated at 26°C for 2 h. 
2.3.3.4 Degradation of Excess 3’ HD Adapter 
The products of the 3’ HD adapter ligation reaction were purified using the 
Zymo RNA Clean & Concentrator -5 kit (Cambridge Bioscience) according to 
manufacturer’s instructions, similarly to how total RNA samples were purified 
with the -25 kit prior to library construction, but eluting products in 13µL 
water. 
To the purified products were added 1.6µL 10X Deadenylase Buffer 
(Epicentre), 1µL 5’ Deadenylase (10 units/µL) (Epicentre), 0.8µL 100mM 
DTT, and 0.5µL RNase-OUT (40 units/µL) (Invitrogen). This mixture was 
incubated at 30°C for 30 min. 4µL 25mM EDTA was then added to stop the 
reaction. 
Then, 2µL 500mM Tris-HCl (pH 9.0) (Sigma), 7µL 50mM MgCl2, and 1µL 
RecJ Exonuclease (10 units/µL) (Epicentre) were added to the products. This 
mixture was incubated at 37°C for 30 min. 
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2.3.3.5 5’ HD Adapter Ligation 
2µL 5’ HD adapter was denatured by incubating at 70°C for 2 min. Then it 
was mixed with the products of the excess 3’ adapter degradation process, 
1µL 10X T4 RNA Ligase Buffer (Epicentre), 1µL T4 RNA Ligase (Epicentre), 
1µL 10mM ATP (Epicentre) and 7µL 50% (v/v) polyethylene glycol (PEG) 
(NEB). This mixture was incubated at 26°C for 2 h. 
After the reaction was finished, 7µL water was added to the products, which 
were then purified using the Zymo RNA Clean & Concentrator -5 kit 
(Cambridge Bioscience) according to manufacturer’s instructions. This was 
done in the same manner as the products of 3’ adapter ligation were earlier 
purified, but eluting in 30µL water. 
2.3.3.6 cDNA Synthesis 
To the purified ligation products were added 4µL 10X MMLV Reverse 
Transcription Buffer (Epicentre), 1µL High Performance MMLV Reverse 
Transcriptase (Epicentre), 2µL 10mM dNTP PreMix, 2µL 100mM DTT 
(Epicentre), and 1µL Reverse Transcription Primer (20µM) (Sigma). The 
mixture was incubated at 37°C for 20 min, and then the reaction was 
terminated by incubating at 85°C for 15 min. 
2.3.3.7 PCR Amplification 
4µL reverse transcription product was mixed with 0.5µL 10mM dNTPs, 4µL 
5X High Fidelity Phusion Buffer (Thermo Scientific), 0.2µL Phusion DNA 
Polymerase (2 units/µL) (Thermo Scientific), 1µL Illumina RP-1 Primer 
(10µM) (Sigma), 1µL Illumina Index Primer (10µM) (Sigma), and 9.3µL water. 
This mixture was then incubated in a thermocycler with the following 
programme: 
1. 98°C for 30 sec 
2. x cycles of [98°C for 10 sec, 60°C for 30 sec, 72°C for 15 sec], where 
12 ≤ x ≤ 16. 
3. 72°C for 10 min 
Different numbers of cycles (x) were tried at once for each library, in order to 
determine which number was optimal. 
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2.3.3.8 PAGE Separation and Elution 
The PCR products were size-fractionated by PAGE alongside DNA size 
markers to separate the miRNA-representing polynucleotides from those 
representing other RNA species of differing size. Electrophoresis was run in 
an 8% (v/v) gel at 120V for 2 h, which was then stained with SYBRGold, and 
scanned to visualise the location of the miRNA bands i.e. those located 
between 120 and 140 bp (since their sequences were products of 3’ and 5’ 
HD adapters, miRNAs and PCR primers). Pieces of gel corresponding to 
these bands were physically cut out. 
Gel-breakers were made by piercing the bottoms of 0.5mL Eppendorf tubes 
with a 21-gauge needle, then putting them inside 1.5mL Eppendorf tubes. 
Cut out pieces of gel were transferred to the 0.5mL compartments of the gel-
breakers, which were then centrifuged to force the gel through the holes, 
thus breaking it into small fragments. Then 200-400µL 1X Elution Buffer 
(NEB) was mixed into the gel fragments, and mixtures were incubated either 
at room temperature for 2 h, or 4°C overnight, with shaking. 
Gel fragment-buffer mixtures were then transferred to Spin-X filtration 
columns, which were centrifuged for 5 min to separate dissolved DNA from 
the gel debris. DNA was recovered from solutions by ethanol precipitation, by 
adding 2µL GlycoBlue, 30µL 3M NaOAc, and 975µL ethanol, to each 300µL 
solution. Mixtures were then stored at -80°C for ≥ 2 h, then centrifuged at 
16 000 g for 30 min to pellet precipitates. Pellets were washed in 75% (v/v) 
ethanol, dried, and then dissolved in 12µL water each. The solutions 
constituted the final constructed libraries. 
2.3.4 Deep Sequencing 
For each cell line, nine miRNA libraries were mixed in a pool which was then 
subjected to deep sequencing by the Earlham Institute on the Illumina HiSeq 
2500 platform, with 100 million reads. Relative library concentrations were 
compared by PAGE of 1µL of each library, followed by densitometric band 
analysis. Based on this densitometry, equal amounts of each library were 
pooled together. 
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2.3.5 Data Analysis (Performed by Claudia Paicu) 
Data were converted to FASTA format then quality-checked. Sequences 
containing ‘N’s were discarded. Adapter-adapter dimer sequences were 
removed from the data, and the common adapter sequence (TGGAATTCT) 
and NNNN ends of the HD adapters were trimmed from remaining read 
sequences. The quality of the data was assessed by checking for expected 
size class distributions and complexity (see Appendix for graphs and further 
detail). Replicate consistency was evaluated according to the Jaccard index, 
MA plots and box plots (see Appendix for data, plots and further detail).  
Non-redundant sequence data files were created and then sequences were 
mapped full-length against the human genome using PatMan (allowing no 
gaps or mismatches) after eliminating low-complexity reads. Any libraries in 
which a high proportion of reads did not match the human genome, and/or 
inter-replicate consistency was low, were disregarded. Remaining library 
data were initially normalised by three different methods: bootstrapping, 
reads-per-million normalisation and quantile normalisation. Whichever 
method implied the greatest inter-replicate consistency was considered to be 
the most appropriate to use. 
Read sequences were then annotated against the mature human miRNA 
sequences listed in MiRBase using PatMan, permitting ≤ 2 mismatches (0 
gaps) to account for post-transcriptional miRNA modifications and/or 
sequencing errors. MiRNA read numbers were then normalised by the 
method previously determined as most appropriate for the data. 
Most miRNAs were represented by multiple sequences, differing mostly by 
length. All reads of sequences annotated as the same miRNA were summed 
together. Fold changes in miRNA expression were estimated based upon the 
median values of replicates, with an offset of 20 added to each to reduce 
noise from very-low-abundance sequences. For example, if (0 h 1 = 11; 0 h 2 
= 13; 0 h 3 = 9; 8 h 1 = 34; 8 h 2 = 33; 8 h 3 = 35), fold change from 0 to 8 h 
= (Median(8 h)+20)/(Median(0 h)+20) = (34+20)/(11+20) = 1.7. Read 
numbers for each miRNA were compared between 0 h and 8 h, 0 h and 24 h, 
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and 8 h and 24 h; miRNAs with a reported fold change ≥ 1.9 in at least one 
of the comparisons were regarded as potential SFN-modulated miRNAs. 
2.4 Northern Blotting to Validate the Effects of SFN on 
MicroRNA Expression 
2.4.1 Cell Treatments  
Cells were grown to 70-80% confluence in 10cm cell culture dishes (surface 
area = 55cm2), and then treated in duplicate by adding to culture medium, 
DMSO alone (control) or DMSO-diluted SFN (10µM) for 8 or 24 h (final 
DMSO concentrations were 0.05% (v/v)). 
2.4.2 Total RNA Extraction 
Total RNA was isolated by guanidium thiocyanate-phenol-chloroform 
extraction, using TRI Reagent (Sigma-Aldrich), largely according to the 
manufacturer’s protocol with minor modifications. Briefly, culture medium 
was removed and then TRI Reagent was added directly onto cells (1mL per 
10cm2 culture dish area) to lyse them. The procedure was either paused at 
this stage by freezing lysates at -80°C (defrosted to resume), or continued. 
Lysates were incubated at room temperature for 5 min, then 200µL 
chloroform was mixed in vigorously per 1mL TRI Reagent. Mixtures were 
incubated at room temperature for 10 min, and then centrifuged at 16 000 g 
for 15 min at 4°C for phase separation. The aqueous (uppermost and clear) 
phases were carefully transferred to fresh tubes, avoiding the other phases. 
RNA was precipitated from the aqueous phases by adding 500µL 
isopropanol and 5µg glycogen per 1mL TRI Reagent lysate processed. 
Mixtures were stored at -20°C for ≥ 5 h, before centrifuging at ≥ 16 000 g for 
30 min, at 4°C, to pellet precipitated RNA. Supernatants were removed from 
pellets, which were then washed in 1mL 75% (v/v) ethanol each. Ethanol 
was then removed and tubes were left open in a sterile hood to allow the 
evaporation of residual ethanol (~5-10 min). Dried pellets were dissolved in 
water, supplemented with 10 units RNAse Inhibitor (Ambion), and then 
stored at -80°C. 
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2.4.3 Small RNA Extraction 
Small RNA fractions were isolated using the MirPremier™ MicroRNA 
Isolation Kit (Sigma-Aldrich) according to the manufacturer’s instructions.  
Briefly, culture medium was removed from cells, which were then washed 
twice with PBS, and then covered in a lysis mixture (MicroRNA Lysis Buffer 
and Binding Solution combined in a 7:3 ratio). Cells were left under the lysis 
mixture for ≥ 5 min with occasional rocking of plates, then lysates were 
collected and centrifuged at 16 000 g for 5 min to pellet cell debris, genomic 
DNA and larger RNA species. Small RNA-containing supernatants were 
collected, mixed with 1.1 volumes of ethanol, and then centrifuged through a 
Binding Column to capture RNA. Captured RNA was washed with ethanol 
then with Wash Solution 2, and finally eluted in 50µL Elution Solution.   
RNA was then concentrated by ethanol precipitation, which was done by 
adding 2 vol. ethanol, 0.1 vol. NaOAc (3M, pH 5.2) and 5µg glycogen, then 
storing at -80°C for ≥ 2 h. After storage, mixtures were centrifuged at 
16 000 g for 30 min, at 4°C, to pellet precipitates. Supernatants were 
removed and then pellets were washed in 70% (v/v) ethanol, before 
removing ethanol, allowing residual ethanol to evaporate in a sterile hood, 
and then dissolving dried pellets in water. RNA solutions were supplemented 
with 10 units RNAse Inhibitor (Ambion) and then stored at -80°C. 
2.4.4 RNA Electrophoresis and Blotting 
PAGE equipment was thoroughly cleaned using detergent to minimise the 
presence of RNAses, then 16% (v/v) Urea-PAGE gels were made. RNA 
concentrations were determined using the NanoDrop spectrophotometer, 
then equal amounts of RNA were combined with 2X Gel Loading Buffer II 
(Ambion). Mixtures were heat-denatured at 65°C for 5 min to denature RNA. 
The Urea-PAGE gel was pre-run at 80V for 20 min, and then the RNA-buffer 
mixtures were loaded into the gel. Electrophoresis was run at 100V for 2 h, in 
0.5X tris/borate/EDTA (TBE) buffer, to size-fractionate RNAs. 
Then RNA was transferred from gels to Hybond NX membranes by semi-dry 
electroblotting in 0.5X TBE. This was done at a constant current of 3mA per 
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cm2 transfer area for 1 h, in a ‘sandwich’ of Whatmann filter papers. After 
RNA transfer, the procedure was either paused by storing membranes 
at -20°C, or continued. 
RNA was chemically crosslinked to membranes using carbodiimide. The 
crosslinking solution was prepared by adding 122.5µL of 12.5M 1-
methylimidazole and 10µL of 1M HCl to 10mL water, and then dissolving 
0.373g 1-ethyl-3-(dimethylaminopropyl) carbodiimide (EDC) powder into it. 
The crosslinking solution was used to soak a Whatmann filter paper, onto 
which the membrane was placed (with the RNA side facing away from the 
paper). The membrane and filter paper were then sealed in clingfilm and 
incubated at 60°C for 1-2 h. After incubation, membranes were washed in 
water for 10 min, then stored at -20°C. 
2.4.5 Probe Hybridisation and Signal Detection 
PerfectHyb hybridisation buffer was pre-incubated at 37°C to dissolve any 
precipitate. Membranes were incubated at 37°C in 10mL hybridisation buffer 
each, under rotation, for 1-2 h. Radioactively-labelled probes were prepared 
from DNA oligonucleotides of sequence anti-sense to those of miRNAs of 
interest, by mixing 4µL 5X Forward Reaction Buffer (Thermo Scientific), 2µL 
DNA oligonucleotide (10µM), 1µL T4 kinase enzyme (Thermo Scientific), 10-
11µL water and 2-3µL ɣ-ATP (P-32), then incubating at 37°C for 1 h.  
Prepared probes were added directly into the hybridisation buffer in which 
the membranes were incubated. Membranes were incubated in the probe-
containing hybridisation buffer at 37°C overnight under rotation. Afterwards, 
the probe-containing buffer was discarded, and membranes were washed in 
0.2X SSC/0.1% (v/v) SDS solution. Firstly, they were shaken vigorously in 
the solution for 10 sec; secondly they were incubated with fresh solution at 
37°C under rotation for 15 min; thirdly, the solution was discarded and the 
rotating incubation was repeated with fresh solution; and finally, they were 
shaken vigorously in solution for 10 sec again. After washing, membranes 
were sealed in clingfilm and then placed onto phosphorimaging plates (RNA 
sides of membranes facing the reactive sides of plates), inside cassettes, for 
overnight exposure at 4°C. 
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Exposed phosphorimaging plates were scanned to detect signals generated 
by radiation-induced excitations of the plate, and the signal data were 
densitometrically analysed using the ImageJ software to compare relative 
miRNA expression between samples, using U6 as an internal loading 
control. Before re-probing, membranes were stripped of bound probe either 
by incubating in 0.1% (v/v) SDS at 95°C under rotation until radioactive 
signal could no longer be detected using the Geiger counter (usually 1-2 h), 
or by placing membranes into boiled 0.1% (v/v) SDS until cooled to room 
temperature (~45 min). Stripped membranes were returned to storage 
at -20°C. 
2.4.6 Dot Blots to Test Probe Cross-Reactivity 
In order to screen for potential cross-reactivity between probes and off-target 
miRNAs similar in sequence to the target, dot blots were prepared by 
pipetting serial dilutions of positive sense DNA oligomers of sequence 
equivalent to those of different miRNAs onto a Nylon NX membrane, and 
then crosslinking the DNA to the membrane in the same manner that RNA 
was crosslinked to membranes for Northern Blot preparation. Dot blots were 
then hybridised using anti-sense oligo probes as per the Northern Blot 
protocol. The amounts of positive sense oligo used ranged between 1fmol 
and 1pmol, in 1µL volumes. 
2.5 TaqMan® RT-qPCR to Assay the Effects of SFN on 
Messenger RNA 
2.5.1 Cell Treatments  
Cells were grown to 70-80% confluence in 6-well plates (surface area/well = 
9.5cm2), then treated by adding to culture medium in triplicate, DMSO 
(control) or DMSO-diluted SFN (5, 10 or 20µM) for 24 h, or DMSO-diluted 
SFN (10µM) for 4, 8, 12, 24 or 48 h; final DMSO concentrations were 0.05% 
(v/v). 
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2.5.2 RNA Extraction 
RNA was extracted using the GenElute™ Total Mammalian RNA Miniprep 
Kit (Sigma, UK) according to manufacturer’s instructions. Briefly, culture 
medium was removed from cells, which were then covered in Lysis Buffer. 
Lysates were centrifuged through a Filtration Column, and then the flow-
through liquid was mixed with ethanol and then centrifuged through an RNA 
binding column to capture the RNA on the column. Captured RNA was then 
washed with Wash Solution 1 then Wash Solution 2, eluted in Elution 
Solution, supplemented with 10 units of RNAse Inhibitor (Ambion), and then 
stored at -80°C. 
2.5.3 Reverse Transcription 
RNA concentrations were determined using the NanoDrop 
spectrophotometer (Thermo Scientific). Equal amounts of RNA were reverse 
transcribed to cDNA using the qScript SuperMix (Quanta BioSciences, USA) 
according to manufacturer’s instructions, heating reactions in a thermocycler 
at 25°C for 5 min, 42°C for 30 min, then 85°C for 5 min. 
2.5.4 Primers and Probes for TaqMan® RT-qPCR 
TaqMan® primers and probes had been designed previously by the Bao 
laboratory group with Primer Express based on the sequences of the human 
mRNAs as described in Table 3. 
Table 3: The sequences of the primers and probes used for RT-qPCR. 
Target Component Sequence Conc. (nM) 
18S 
Forward 
Primer 
5’-GGCTCATTAAATCAGTTATGGTTCCT-3’ 200 
Reverse 
Primer 
5’-GTATTAGCTCTAGAATTACCACAGTTATCCA-3’ 200 
Probe 5’-TGGTCGCTCGCTCCTCTCCCAC-3’ 100 
TrxR-1 
Forward 
Primer 
5’-CCACTGGTGAAAGACCACGTT-3’ 200 
Reverse 
Primer 
5’-AGGAGAAAAGATCATCACTGCTGAT-3’ 300 
Probe 5’-CAGTATTCTTTGTCACCAGGGATGCCCA-3’ 100 
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Probes were labelled with fluorescent reporter 6-carboxyfluorescein (FAM) 
and the tetramethylrhodamine (TAMRA) quencher at their 5’ and 3’ ends 
respectively. 
2.5.5 RT-qPCR 
PCR amplification was carried out in 96-well PCR plates using the TaqMan® 
Universal PCR Master Mix (Applied Biosystems), according to 
manufacturer’s instructions, with the following PCR programme: 
o 95°C for 10 min 
o 45 cycles of: 
 95°C for 15 sec 
 60°C for 1 min 
96-well PCR plates were used, and generated fluorescent signals were 
detected in real-time using the ABI 7500 Fast Real-Time PCR System 
(Applied Biosystems). Standard curves and ‘no template controls’ were 
included for each target. 
2.5.6 Data Analysis 
Relative mRNA expression was evaluated based on CT values (i.e. the 
number of cycles required before a defined threshold is reached) by the 
Pfaffl method, which takes into account the replication efficiency of each 
target as indicated by the standard curve data. 18S was used as an internal 
control for normalisation. 
Pfaffl’s Equation: 
Where A = amplification factor = efficiency + 1; G = transcript of interest; 18S 
= internal reference; 
	
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2.6 MicroRNA Assays by TaqMan® RT-qPCR 
2.6.1 Cell Treatments 
Cells were grown to 70-80% confluence in 6-well plates (surface area per 
well = 9.5cm2) then treated by adding to culture medium in triplicate, DMSO 
(control) or DMSO-diluted SFN (5, 10 or 20µM) for 24 h, or DMSO-diluted 
SFN (10µM) for 4, 8, 12, 24 or 48 h (final DMSO concentrations were 0.05% 
(v/v)). 
2.6.2 Small RNA Extraction 
Small RNA was extracted using the column-based miRPremier™ MicroRNA 
Isolation Kit (Sigma-Aldrich), as described above (see Northern Blotting to 
Validate the Effects of SFN on MicroRNA Expression: Small RNA 
Extraction). 
2.6.3 Total RNA Extraction 
Total RNA was extracted by guanidium thiocyanate-phenol-chloroform 
extraction using TRI Reagent (Sigma-Aldrich) as described above (see 
MicroRNA Library Construction and Sequencing: Total RNA Extraction). 
2.6.4 Reverse Transcription 
First strand cDNA for specific targets, including the internal control U6, was 
synthesised using the specific TaqMan® Small RNA Assay kit according to 
the manufacturer’s instructions, and TaqMan® Small RNA Assay kit primers 
specific to each target (Applied Biosystems). Reactions were heated in a 
thermocycler at: 
o 16°C for 30 min 
o 42°C for 30 min 
o 85°C for 5 min 
Relative mRNA abundance compared with controls was evaluated by the 
Pfaffl method, taking into account different efficiencies of replication during 
PCR as determined from standard curve data, using U6 as the internal 
control. 
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Pfaffl’s equation: 
Where A = amplification factor = efficiency + 1; G = transcript of interest; U6 
= reference transcript; 
	
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2.7 Cloning 3’-UTRs into Vectors for Luciferase Assays 
2.7.1 Making the Wild-Type 3’ UTR Clones 
The 3’-UTR sequences of genes of interest were obtained from Ensembl, 
and parts of 3’-UTRs containing the predicted miRNA binding sites were 
amplified from human genomic DNA by PCR with the In Fusion HD Cloning 
Plus Kit (Clontech) according to manufacturer’s instructions, using custom 
designed PCR primers.  
Each designed PCR primer consisted of an invariant manufacturer-specified 
vector-specific sequence (VSS) at the 5’ end – containing the SacI restriction 
site – and a custom gene-specific sequence (GSS) at the 3’ end. GSSs were 
designed using Primer-BLAST, aiming for a length of 18-25 bases, a GC 
content of 40-60%, and a melting temperature (TM) of 58-65°C. Differences 
in TM between the GSSs of forward and reverse primers in each pair were 
≤5°C. TMs were calculated with the Promega BioMath Calculator. Oligocalc 
was used to check that full primers would not exhibit high self-
complementarity. 
The manufacturer-specified VSSs to allow ligation at the SacI site of the 
vector (5’ to 3’) were: 
Forward CTAGTTGTTTAAACG 
Reverse GACTCGAGGCTAGCG 
 
The sequences of the designed PCR primers are described in  
Table 4. 
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Table 4: The sequences of the designed PCR primers. 
(Table 4 Continued) 
3’ UTR 
Target FW/RV 
Designed Primer Sequence (VSS 
Underlined) 
Product 
Length (bp) 
BACH1 
FW CTAGTTGTTTAAACGGGTGTAGGGGGAGGATATTGC 1239 
RV GACTCGAGGCTAGCGCACATGCAACCTGTATCGTCT 
CDC25A[a] 
FW CTAGTTGTTTAAACGGTGACATTTGGAGAGGGGGC 108 
RV GACTCGAGGCTAGCGACAGGGACAGAAGAGGCGTA 
CDC25A[b] 
FW CTAGTTGTTTAAACGCAGGGCATCTTGCTGGCTAC 1613 
RV GACTCGAGGCTAGCGGGCAGAGAGCATGGGTTCAA 
HMGA2[a] 
FW CTAGTTGTTTAAACGGTTCGATTTCTACCTCAGCAGC 1793 
RV GACTCGAGGCTAGCGCGTGTTCCTTTCTATCAAATGTC 
HMGA2[b] 
FW CTAGTTGTTTAAACGGCTGCTTCAGGGAGGTAGTT 479 
RV GACTCGAGGCTAGCGGCGACCAACAACAGCAAAGAA 
KRAS 
FW CTAGTTGTTTAAACGGGTCTCTGTGCCAGCTCTA 757 
RV GACTCGAGGCTAGCGTGCCTACTTGGGAACATTCACT 
MYC 
FW CTAGTTGTTTAAACGAATGTCCTGAGCAATCAC 112 
RV GACTCGAGGCTAGCGGAGGCAGTTTACATTATGGC 
 
Human gDNA was isolated from CCD-841 cells using the GenElute 
Mammalian Genomic DNA Miniprep Kit (Sigma) according to the 
manufacturer’s instructions. PCRs were set up by mixing 12.5µL CloneAmp 
HiFi PCR Premix, 0.6µL FW primer, 0.6µL RV primer, 2.0µL gDNA (44ng/µL) 
and 9.3µL water. The following PCR programme was run: 98°C for 10 sec, 
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followed by 35 cycles of [98°C for 10 sec; x°C for 15 sec; 72°C for y sec], 
where x = 0.3(lowest TM of primer pair) + 0.7(Product TM) - 14.9; y ≈ 
5(product length in kilobases). PCR products were visualised by 
electrophoresis in a 1.5% (w/v) agarose gel (60V for 1 h, with ethidium 
bromide), alongside a DNA marker (“100bp”, NEB). The PCR product lane 
was checked for the presence of a single band, indicating the specific 
amplification of one product, and the size of the product was checked against 
the marker.  
Alongside the 3’-UTR inserts, an insert containing several repeats antisense 
to the whole sequence of let-7f-5p was created, using two synthetic 
complementary oligomers (118 nucleotides in length) and annealing them 
together. The “sense” strand oligo contained the repeats antisense to let-7f-
5p and was of sequence:  
CTAGTTGTTTAAACGAACTATACAATCTACTACCTCAAACTATACAATCTA
CTACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTACCT
CACGCTAGCCTCGAGTC. 
The duplex was created by first purifying 2µL of each oligomer using the 
DNA Clean & Concentrator -5 kit (Zymo) according to the manufacturer’s 
instructions, eluting in 10µL supplied buffer each. Then 8µL of each eluate 
(concentration ≈ 75ng/µL) was combined with 4µL sodium chloride (10mM) 
and 20µL water in a single mixture. The mixture was incubated at 95°C for 5 
min, then the incubation temperature was reduced by 0.1°C/sec until 25°C 
was reached. The product was purified again with the DNA Clean & 
Concentrator -5 kit, and the presence of a single product of correct size was 
verified by agarose gel electrophoresis. 
The pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) 
was linearised by digestion with the SacI restriction enzyme, and then 
purified using the DNA Clean & Concentrator -5 kit (Zymo), according to the 
manufacturer’s instructions. Verified 3’-UTR PCR product inserts were then 
treated with Cloning Enhancer (In Fusion HD Cloning Plus Kit, Clontech) by 
mixing 5µL PCR product with 2µL Cloning Enhancer, then incubating at 37°C 
for 15 min and then at 80°C for 20 min. Then 2µL of this mixture was mixed 
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with 2µL 5X In Fusion HD Enzyme Premix, 50-200ng linearised pmiRGLO 
vector, and water up to a 10µL volume. This mixture was incubated at 50°C 
for 15 min, and then stored at 4°C (short-term) or -20°C (long-term). 
The ligation of “let-7f-5p repeat” duplex into linearised vector was performed 
similarly, except that the Cloning Enhancer treatment was skipped. 
2.7.2 Growing the Wild-Type Vectors in E. coli 
Competent DH5α E. coli cells were defrosted from -80°C storage, to be 
transformed with the vector ligation products. 5µL ligation product was mixed 
with 100µL defrosted bacterial suspension, then mixtures were put onto ice 
for 30 min. Then they were heat-shocked at 42°C for 45 sec in a heat-block, 
before further placement on ice for 2 min. 400µL lysogeny broth (LB) was 
then added per 100µL bacterial suspension, and mixtures were incubated at 
37°C for 1 h with shaking. LB-agar plates (with ampicillin) were prepared, 
onto which the bacteria-LB mixtures were spread following incubation (40-
100µL mixture over each plate). Spread plates were then incubated at 37°C 
overnight. 
Following overnight incubation, 10 colonies were picked from each plate, and 
used to separately inoculate 5mL aliquots of LB, which were then incubated 
at 37°C overnight with shaking. A600 of cultures between 2.0 and 4.0 
indicated that they were at a suitable stage of growth for plasmid extraction. 
Then, either cultures were put into 4°C storage, or plasmids were 
immediately isolated using the column-based QIAprep Spin Miniprep Kit 
(Qiagen) according to the manufacturer’s instructions. 
Briefly, bacteria were pelleted by centrifugation and then resuspended in 
Buffer P1 (supplemented with RNAse A). Then the suspensions were mixed 
with Buffer P2 to lyse the cells, and then Buffer N3 was added to stop the 
lysis reactions. Mixtures were centrifuged at 16 000 g for 10 min to pellet 
debris, then supernatants were centrifuged through QIAprep spin columns to 
capture DNA, which was then washed with Buffer PB, then with Buffer PE. 
Washed DNA was eluted from the columns in 50µL Buffer EB each and then 
stored at 4°C (short-term) or -20°C (long-term). 
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2.7.3 Testing Prepared Vectors for Presence of 3’-UTR Inserts in 
Correct Orientation 
The ligation of 3’-UTR inserts into the pmiRGLO vector is not 100% efficient; 
the products are a mixture of vectors with successful insertions, and vectors 
ligated back together without any insert. Thus, some of the bacterial 
minipreps will consist of the desired vector with insert, but some of vector 
without insert. The presence/absence of insert was determined by digestion 
with restriction enzymes such as SacI, followed by agarose gel 
electrophoresis (1% (w/v) gel; gel and running buffer both supplemented with 
6.25µL EtBr/100mL) against a ‘1kb’ DNA Ladder (NEB); SacI digestion of 
vector with the insert is expected to excise the insert, thus producing two 
linear fragments: one of the insert itself and the other of the rest of the 
vector. By contrast, digestion of vector without insert is expected to cut the 
vector once, thus forming one linear product only. However, SacI digestion 
usually failed, perhaps due to disruption of the SacI sites during the ligation 
process. Therefore, vectors were instead digested with HindIII, for which 
there are two restriction sites in the pmiRGLO vector, flanking the SacI site at 
which the UTRs are inserted. In this instance, two linear products are 
produced from digestion: one of 4771bp and another of 2579bp if no insert is 
present, or of 2579+[length of insert]bp. For some short inserts such as those 
for CDC25A[a] and MYC, plasmids were sequentially digested with both 
HindIII and NheI; NheI cleaved the HindIII-generated (2579+[length of 
insert]bp) product to 867bp and (1710+[length of insert]bp) fragments; the 
position of the latter being used to determine the presence or absence of the 
insert (see Appendix for further detail). 
The vectors verified as containing the desired inserts were then sent for 
Sanger sequencing (Eurofins) to check that the insertion occurred in the 
desired orientation. To prepare the samples for sequencing, 15µL volumes of 
each were prepared at concentrations of 100ng/µL, then 2µL of pmiRGLO 
forward sequencing primer (10µM) was added, of the following sequence:  
5’-CATTAAGGCCAAGAAGGGCGGC-3’. 
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Additionally, samples were similarly prepared each with the pmiRGLO 
reverse sequencing primer (10µM) for reverse sequencing: 
5’-CCTTTCGGGCTTTGTTAGCAGC-3’ 
2.7.4 Making Vectors with Mutated MicroRNA-Target Sites 
Mutations were directed to the seed regions in the predicted miRNA-target 
sites, such as to change them to restriction sites, whose restriction enzymes 
would cut the wild-type construct once only, as reported by Restriction 
Mapper. Forward primers for mutagenesis PCR were designed with regards 
to the guidelines for optimal primer design according to the Quikchange 
Mutagenesis Kit Manual (Agilent Technology), aiming to have the mutated 
site towards the middle, a TM ≥ 78°C and a GC content ≥ 40%, where: 
0 = 81.5 + 0.41%7 −
675
:;ℎ
−%==>ℎ 
In the above equation, %GC and %mismatch are both input as rounded 
integers (e.g. 43.9% as 44). Please see the Appendix for the full primer 
sequences. The mutations were directed as illustrated in Table 5. 
Table 5: A summary of where and what mutations were directed to. 
Clone Site Targeted Site (Wild-Type) 
Targeted Site 
After Mutation 
Newly Created 
Restriction Site 
BACH1 i CTACCT GATATC EcoRV ii TACCTC GGATCC BamHI 
CDC25Aa i TACCTC GATATC EcoRV 
CDC25Ab i TACCTC GGATCC BamHI ii TACCTC CAATTG MfeI 
HMGA2a 
i TACCTC GGATCC BamHI 
ii TACCTC GAATTC EcoRI 
iii TACCTC CAATTG MfeI 
iv TACCTC ACGCGT MluI 
v TACCTC CATATG NdeI 
HMGA2b 
vi TACCTC GATATC EcoRV 
vii TACCTC GGATCC BamHI 
viii TACCTC AGATCT BglII 
KRAS i TACCTC GATATC EcoRV 
MYC i CTGCCT GGATCC BamHI 
 
Sequences for the corresponding reverse primers were derived by taking the 
reverse complement of the designed forward primer sequences. PCR-based 
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mutagenesis was carried out using ‘wild-type’ constructs as the templates. 
PCRs were set up by mixing 5µL 10X Pfu Ultra II Reaction Buffer, 1µL Pfu 
Ultra II HS DNA Polymerase (2.5 units/µL), 25ng ‘wild-type’ construct, 1µL 
dNTP Mix (10mM), 125ng FW primer (10µM), 125ng RV primer (10µM), and 
water up to a 50µL volume. The PCR programme consisted of 95°C for 30 
sec, followed by 18 cycles of [95°C for 30 sec; 55°C for 1 min; 68°C for x 
min], and then 68°C for 10 min, where x = length of plasmid in kilobases. 
PCR products were purified using the Zymo DNA Clean & Concentrator kit 
(Zymo Research) according to manufacturer’s instructions.  
Remaining ‘wild-type’ vector templates in the purified products were 
destroyed using the DpnI restriction enzyme, which digests into fragments 
only methylated DNA (the ‘wild-type’ vector from bacteria is methylated, but 
the mutagenesis PCR products are unmethylated). Then competent DH5α E. 
coli were transformed with the products, as done previously for the wild-type 
constructs (see above). Vector-containing bacteria were selected with 
ampicillin as before, and minipreps were similarly isolated. Isolated minipreps 
were checked for successful mutation of the binding site(s) by digestion with 
a restriction enzyme targeting the new site that successful mutation would 
generate, and by which the non-mutated vector would be cut once only. 
Digestion products were then analysed by agarose gel electrophoresis (1% 
(w/v) gel; gel and running buffer both supplemented with 6.25µL EtBr/100mL) 
(see Appendix for images). Those indicated to be successful mutants 
according to digestion were then subject to Sanger sequencing (Eurofins) for 
verification (see the Appendix for sequencing data). 
One predicted binding site per construct was mutated at once, beginning with 
the first of each. A successful mutant was used as the template for mutating 
the next seed region. 
2.8 Transfection and Luciferase Reporter Assays 
2.8.1 Transfection 
HCT116 cells were simultaneously seeded in 96-well plates (surface area 
per well = 0.29cm2) with 3.0 × 104 cells/well, and ‘fast-forward’ transfected in 
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triplicate with luciferase reporter vector constructs along with miScript miRNA 
Mimic (Qiagen) and/or miScript miRNA Inhibitors (Qiagen) and/or AllStars 
Negative Control siRNA (Qiagen) using the Attractene Transfection Reagent 
(Qiagen), according to the manufacturer’s instructions. 
Briefly, cells were detached as for routine subculture, resuspended in 
complete medium, and then seeded into 96-well plates with volumes per well 
of 100µL. Per triplicate transfection, a 165µL transfection mixture was made 
by diluting 2.48µL Attractene, 660ng vector (and miRNA mimics and/or 
inhibitors and/or AllStars Negative Control siRNA at desired concentrations) 
in non-supplemented DMEM. Transfection mixtures were incubated at room 
temperature for 15 min, and then 50µL of each was mixed into each existing 
100µL cell suspension, so that final well volumes were 150µL. Additionally, 3 
wells of cells had 50µL non-supplemented DMEM added to them, for 
background luminescence measurements. Cells were then incubated under 
typical culture conditions for 48 h. 
2.8.2 Luciferase Reporter Assays 
The expression of the firefly luciferase is inhibited by the binding of miRNAs 
or their mimics to the 3’-UTR target sites that have been inserted into the 
pmiRGLO vector, whereas that of Renilla luciferase is not affected by this. 
Therefore, Renilla luminescence is a suitable internal control against which 
to normalise firefly luminescence, in order to account for any well-to-well 
variation in cell viability and/or nucleic acid transfection efficiency. 
Luciferase Assay Reagent was prepared by dissolving all supplied Dual-
Glo® Luciferase Substrate in the Dual-Glo® Luciferase Buffer at once, and 
the prepared reagent was stored at -80°C between uses. The Stop & Glo® 
Reagent was prepared immediately before use by mixing Dual-Glo® Stop & 
Glo® Substrate with Dual-Glo® Stop & Glo® Buffer in a 1:100 ratio. 
Reagents and cells were equilibrated at room temperature before beginning 
the assay reactions. 
After the 48 h incubation, 75µL medium was removed from each well and 
discarded, and then 75µL of Dual-Glo® Luciferase Assay Reagent 
(Promega) was mixed into the remaining suspension, to both lyse the cells 
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and to provide substrate for the firefly luciferase. After ≥ 15 min incubation at 
room temperature, luminescence was measured using the FLUOstar Omega 
microplate reader (BMG Labtech), and data were blank-corrected based on 
measurements from the non-transfected wells to which non-supplemented 
DMEM instead of transfection mixture had been added. 
After these measurements, 75µL Stop & Glo Reagent (Promega) was mixed 
into each well, to both quench the firefly luminescence and to provide 
substrate for Renilla luciferase. Following further incubation at room 
temperature for ≥ 15 min, luminescence was measured and blank-corrected 
similarly to as before.  
2.9 Clonogenicity Assays 
2.9.1 First Method 
Cells were seeded in 6-well plates (surface area/well = 9.5cm2) at low 
density (400 cells/well), allowed to attach for 48 h, and then treated by 
adding to culture medium in sextuplicate, DMSO-diluted SFN (5, 10 or 20µM) 
or DMSO (control); final DMSO concentrations were 0.05% (v/v). Following 
the addition of SFN, cells were incubated for 14 days to allow colony 
formation, after which cells were fixed by washing in PBS and then 
incubating under 4% (v/v) paraformaldehyde (PFA) for 10 min. Fixed cells 
were washed in PBS and then stained by incubating under Crystal Violet 
solution (0.1% (v/v) in water) for 30 min. Stained cells were washed in water 
and then the number of colonies in each well was counted under a 
microscope. 
2.9.2 Second Method 
Cells were grown to 70-80% confluence in 24-well plates (surface area per 
well = 1.9cm2), then treated by adding to culture medium in 6 replicates, 
DMSO-diluted SFN (5, 10 or 20µM) or DMSO (control); final DMSO 
concentrations were 0.05% (v/v). 24 h following the addition of SFN, cells 
from each well were detached using trypsin, then 400 from each were 
seeded into wells of a 6-well plate (surface area per well = 9.5cm2).  
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Subsequently, cells were incubated for 14 days to allow colony formation, 
after which cells were fixed by washing in PBS then incubating under 4% 
(v/v) PFA for 10 min, and then stained by washing fixed cells in PBS then 
incubating under Crystal Violet solution (0.1% (v/v) in water) for 30 min. 
Stained cells were washed in water and then the number of colonies in each 
well was counted. 
2.10 Cell Viability Assays 
Cell viability was measured using the MTT assay, which is based upon 
measuring the optical densities of DMSO-solutions of purple formazan, the 
solutes of which are generated by the metabolic reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by viable cells 
and precipitated. Equal amounts of DMSO are then added to each well to 
dissolve the precipitates, so the optical density (OD) of each solution is 
directly proportional to the amount of purple formazan formed, which is itself 
a proxy of the number of viable cells. 
Caco-2 and CCD-841 cells were seeded in 96-well plates (surface area per 
well = 0.29cm2) with 7.0 × 103 and 1.3 × 104 cells per well respectively, and 
grown until 70-80% confluent. Then cells were treated by adding to culture 
medium in 6 replicates, DMSO-diluted SFN (0.4 – 200.0µM) or DMSO 
(control); final DMSO concentrations were 0.05% (v/v). At 24 or 48 h 
following the addition of SFN, culture medium was supplemented with MTT 
(100µL of MTT per mL of culture medium) then cells were incubated for a 
further 1 h for MTT metabolism. Subsequently, medium was removed and 
purple formazan precipitates were dissolved in DMSO (100µL/well). OD570 
and OD670 of the solutions in each well were measured using the FLUORstar 
Omega microplate reader (BMG Labtech). 
%	7	?@ =
ABCDE= − AB/DE=
ABCDE> − AB/DE>
	× 100 
Data were analysed with the Calcusyn software (Biosoft, Cambridge, UK) to 
determine IC50 values. 
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2.11 Wound Healing Assays to Assess Cell Migration 
Cells were seeded in 12-well plates (surface area/well = 3.8cm2) at densities 
such that cells would be 90-100% confluent at 24 h after seeding. At 
confluence, a vertical scratch wound was created down the centre of each 
monolayer using a 1 mL pipette tip. Cells were then washed in culture 
medium, and then treated by adding to culture medium in triplicate, DMSO-
diluted SFN (5, 10 or 20µM) or DMSO (control); final DMSO concentrations 
were 0.05% (v/v). 
Following the addition of SFN, cells continued to be cultured under normal 
conditions and observed at 24 h intervals, until differences in wound closure 
between control and treated monolayers were noticeable by eye. Then, 
medium was removed and cells were washed in PBS before being fixed by 
incubation under 4% (v/v) PFA for 10 min. Fixed cells were washed in PBS 
and then stained by incubating under 0.1% (v/v) Crystal Violet solution (in 
water) for 30 min. Stained cells were washed in water and then 
photographed immediately or put into storage under PBS at 4°C. 
Five photographs were taken along the vertical axis of each scratch wound, 
through an inverted microscope. Average gap widths between leading cells 
of scratch wounds in every image were determined using the ImageJ 
software, by averaging the measured gap widths at 8 fixed loci down the 
vertical axes of the scratch wounds. Averages across the five photographs of 
each scratch wound were then taken. 
2.12 Statistics 
Where n ≥ 3, statistical comparisons were made using unpaired two-tailed 
Student’s T-tests, which were carried out using the Microsoft Excel 
spreadsheet software. Results are expressed as means ± S.E.M. 
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2.13 Rationale for Choice of Methods 
2.13.1 RNA Extraction Methods 
There are several types of method for the extraction of RNA from cultured 
cells, including organic extraction, filter-based extraction, magnetic particle-
based extraction, and direct lysis. 
2.13.1.1 Organic Extraction 
Organic extraction involves lysing cells in a phenol-containing solution, then 
phase-separating the RNA from DNA and proteins by mixing in chloroform 
and centrifuging. RNA is isolated from aqueous phases, typically by alcohol 
precipitation. Such methods reliably maintain RNA integrity, and efficiently 
recover RNA species of all sizes. However, they tend to be more time-
consuming than filter-based extraction methods, and are more hazardous 
due to the requirement of phenol and chloroform. 
2.13.1.2 Filter-Based Extraction Methods 
Filter-based extraction methods involve firstly lysing cells in a buffer 
supplemented with a strong inactivator of RNAses, such as 2-
mercaptoethanol, and secondly, isolating RNA from the lysates by capture 
on glass fibre or silicon membranes in columns. Subsequent steps include 
washing the bound RNA with alcohol-based solutions to remove impurities, 
then eluting the RNA in water or an aqueous buffer. Extraction methods of 
this type tend to be much quicker than organic extraction methods, and avoid 
the chemical hazards of phenol and chloroform. However, most filter-based 
methods cannot efficiently recover RNA species of all sizes at once, but kits 
are generally optimised or optimisable for the efficient extraction of either 
small or large RNA species. 
2.13.1.3 Direct Lysis 
A simple approach to extracting RNA is to simply lyse cells in a solution that 
is able to effectively stabilise nucleic acids and that is compatible with the 
intended downstream applications. While this is fast and inexpensive, the 
presence in the lysates of other cellular macromolecules such as DNA and 
proteins makes this approach unsuitable for the majority of downstream 
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RNA-based assays, as well as for RNA concentration determination by 
spectrophotometry. 
2.13.1.4 Choices of Methods 
All intended downstream applications required RNA to be separated from 
DNA and proteins, so direct lysis was disregarded as an option. 
The total RNA used for miRNA library construction was extracted by the 
organic guanidine thiocyanate-phenol-chloroform method, because it was 
necessary to effectively recover small RNA species such as miRNAs, whilst 
simultaneously recovering larger species in order to be able to evaluate 
overall RNA integrity via agarose gel electrophoresis and visualisation of 
28S/18S bands. The total RNA used for RT-qPCR mRNA transcript assays 
was extracted using the filter column-based GenElute Total Mammalian RNA 
Kit (Sigma), which was considerably quicker than organic extraction, and it 
was not necessary to capture smaller RNA species in this context. For 
Northern Blotting, either total RNA was extracted with by organic guanidine 
thiocyanate-phenol-chloroform extraction, or small RNA fractions were 
extracted using the filter column-based miRPremier MicroRNA Isolation Kit 
(Sigma). The latter method is not able to efficiently recover large and small 
RNA species in the same fractions, but this was considered unnecessary for 
these assays, and small RNA extraction with the filter column-based kit was 
much quicker than organic total RNA extraction. 
2.13.2 Protein Concentration Determination 
Protein concentrations were determined using the Brilliant Blue G dye-
binding assay of Bradford – a colorimetric assay based on the conversion of 
the Coomassie Brilliant Blue G-250 red dye to a blue compound upon 
reaction with protein. The dye donates electrons to ionisable groups on 
amino acid residues, which alters protein conformation in a manner that 
exposes hydrophobic pockets. The exposed hydrophobic pockets interact 
with the non-polar regions of the dye molecules, enabling the positively 
charged amine groups of amino acid residues to bind negatively charged 
regions of the dye molecules, which stabilises the dye in the blue form. While 
this assay is slightly less precise than some other methods of protein 
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concentration determination, such as the Lowry assay, it is significantly 
quicker and cheaper than such, and sufficiently precise for the intended 
application. 
2.13.3 Protein Expression Assay Methods 
There are several methods by which the relative abundance of specific 
proteins across samples can be compared, including Western Blotting, and 
the enzyme-linked immunosorbent assay (ELISA). In Western Blotting, 
proteins are denatured and size-fractionated by SDS-PAGE, transferred to a 
membrane, then incubated with antibodies specific to the proteins of interest, 
the binding of which is measured by various methods including those of a 
fluorescent or chemiluminescent nature. While it is considered to be slightly 
less precise than ELISA, it has several advantages over ELISA such as 
allowing the visualisation of protein degradation, and the assay of several 
proteins at once. Thus, Western Blotting was chosen, particularly since the 
aim was to detect significant, rather than subtle, differences. 
2.13.4 Measurement of Cell Viability 
There are several methods by which the effects of compounds on cell 
viability can be assayed, one of which is the MTT assay. There are several 
caveats to the use of the MTT assay to assess cell viability, such as the fact 
that the rate of MTT reduction by viable cells is not strictly consistent and that 
MTT has the potential to be reduced by superoxide (Wang, Yu et al. 2011), 
levels of which might be artificially altered by cell treatments. However, it is 
relatively fast and inexpensive, and should be sufficiently precise for the 
intended application. 
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Chapter 3: Establishing and Validating 
the Experimental System 
3.1 General Introduction 
SFN is known to be indiscriminately cytostatic and/or cytotoxic at very high 
doses, probably due to acute GSH depletion and/or DNA damage induction. 
Thus, the sub-cytotoxic range of concentrations suitable for experimental 
Caco-2 and CCD-841 treatment had to be determined. Therefore, both cell 
lines were treated with SFN across a range of concentrations, and effects on 
cell viability were assayed. Subsequently, the effects of SFN on two in vitro 
oncogenic ‘endpoints’: cell migration and clonogenicity, were assayed. 
As discussed in Chapter 1, it has long been established that sub-cytotoxic 
doses of SFN are able to activate Nrf2 and thus upregulate the expression of 
various oxidant-reducing Nrf2-driven genes, across a range of cell lines and 
contexts. However, of relatively novel interest are the potential roles of 
miRNAs in the anti-cancer effects of SFN at sub-cytotoxic doses. It was 
necessary to first validate the suitability of the experimental set-up 
conditions, such as the cell density at which SFN was administered, the 
mode and vehicle of SFN delivery, and the time points following SFN 
treatment at which effects were assayed.  Such validation was performed by 
assaying the effects of SFN treatment on both nuclear Nrf2 accumulation in 
Caco-2, and the expression of Nrf2-driven genes at the mRNA and/or protein 
levels in both cell lines. If the expected inductions were observed, similar 
conditions were to be maintained for later miRNA profiling experiments. 
It is known that many miRNAs can directly and/or indirectly modulate Nrf2 
activity. For example, several miRNAs of the let-7 family have been 
demonstrated to inhibit Bach1, which itself is able to repress Nrf2-mediated 
transcriptional activation by competing with Nrf2 for sMAF binding in the 
nucleus (Hou, Tian et al. 2012). Experimental overexpression of the let-7 
miRNAs has been demonstrated to upregulate HO-1 and thereby reduce 
oxidative stress in human hepatocytes (Hou, Tian et al. 2012). 
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3.2 Effects of Sulforaphane and Hydrogen Peroxide on Cell 
Viability in Caco-2 and CCD-841 
3.2.1 Sulforaphane 
The MTT assay was used to measure relative cell viability at 24 or 48 h 
following the treatment of cells with SFN at various concentrations. 
 
Figure 14: The effects of SFN on Caco-2 cell viability at 24 h and 48 h. Caco-2 cells 
were treated for 24 or 48 h, by adding to culture medium in sextuplicate, DMSO-
diluted SFN at various concentrations, or DMSO (control) (final DMSO concentrations 
were 0.1% (v/v)). Cell viability was measured by the MTT assay and evaluated as 
(OD670 – OD570) at each concentration in proportion to the same of the control, and 
data are represented as the mean ± S.E.M. of sextuplicates (*P<0.05). 
As illustrated in Figure 14, SFN significantly reduced Caco-2 cell viability at 
concentrations ≥25µM, at both 24 and 48 h, at which the half maximal 
inhibitory concentration (IC50) values were very similar: 40 and 42µM 
respectively. SFN cytotoxicity is not observable at concentrations ≤12.5µM, 
implying that 10µM should be an appropriate concentration for experimental 
use. 
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Figure 15: The effect of SFN on CCD-841 cell viability at 24 and 48 h. CCD-841 cells 
were treated for 24 or 48 h by adding to culture medium in sextuplicate, DMSO-diluted 
SFN at various concentrations, or DMSO (control) (final DMSO concentrations were 
0.1% (v/v)). Cell viability was measured by the MTT assay and evaluated as (OD670 – 
OD570) at each concentration in proportion to the same of the control, and data are 
represented as the mean ± S.E.M. of sextuplicates (*P<0.05). 
As illustrated in Figure 15, CCD-841 cell viability at 24 h appeared to be 
increased by SFN at concentrations ≤ 3.13µM, but reduced at those ≥ 
12.5µM. The concentrations of SFN that apparently increased viability at 24 
h had either a negligible or inhibitory effect at 48 h, while those inhibitory at 
24 h were even more so at 48 h. This could reflect a temporary promotion of 
proliferation at 24 h, which Nrf2 itself has been shown to induce in several 
cell lines (Homma, Ishii et al. 2009), (Gan, Sun et al. 2010), including those 
of a colonic nature (Arlt, Bauer et al. 2009). Considering that SFN probably 
induces pro- and anti-proliferative pathways simultaneously, it could be 
imagined that there exists a point in time between 24 and 48 h at which 
SFN’s net effects on proliferation switch from positive to negative. The acute 
oxidant effects of SFN may activate proliferative ERK and MAPK signalling 
pathways. On the other hand, it is possible that the apparent increase in cell 
viability is just an artefact of the MTT assay. The MTT assay is based upon 
the reduction of tetrazolium salts, which can be reduced by superoxide 
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(Wang, Yu et al. 2011), and superoxide levels are probably modulated by 
SFN. 
The IC50[24 h] and IC50[48 h] were 97 and 20µM respectively. Cytotoxicity is 
not evident at concentrations < 12.5µM, indicating that a concentration of 
10µM should be experimentally appropriate. 
3.2.2 Hydrogen Peroxide 
The cytotoxicity of hydrogen peroxide (H2O2) (25 to 3200µM) – itself a source 
of ROS - towards Caco-2 and CCD-841 cells was assessed in a similar 
fashion to that of SFN. 
 
Figure 16: The effects of H2O2 on Caco-2 cell viability at 24 h and 48 h. Caco-2 cells 
were treated for 24 or 48 h by adding to culture medium in sextuplicate, water-
dissolved H2O2 at various concentrations, or water (control). Cell viability was 
evaluated as (OD670 – OD570) at each concentration in proportion to the same of the 
control, and data are represented as the mean ± S.E.M. of sextuplicates (*P<0.05). 
As illustrated in Figure 16, H2O2 treatment inhibited Caco-2 cell viability at 
concentrations ≥ 50µM, albeit less so at 48 than at 24 h, indicating a partial 
recovery of cells between these two time points. IC50[24 h] and IC50[48 h] 
were 199 and 318µM respectively. 
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Figure 17: The effect of H2O2 on CCD-841 cell viability at 24 h and 48 h. CCD-841 cells 
were treated for 24 or 48 h by adding to culture medium in sextuplicate, water-
dissolved H2O2 at various concentrations, or water (control). Cell viability was 
evaluated as (OD670 – OD570) at each concentration in proportion to the same of the 
control, and data are represented as the mean ± S.E.M. of sextuplicates (*P<0.05). 
The data in Figure 17 indicate that H2O2 treatment significantly inhibited 
CCD-841 cell viability at concentrations ≥ 200µM at 24 h, and ≥100µM at 48 
h.  50µM H2O2 apparently increased cell viability at 24 h but not at 48 h. 
IC50[24 h] and IC50[48 h] were 197 and 68µM respectively. 
Unlike Caco-2 cells, CCD-841 cells do not appear to recover between 24 and 
48 h, implying greater sensitivity to H2O2-mediated cytotoxicity and/or the 
existence of delayed cytotoxic pathway induction. A possible explanation 
could be higher basal activity of p53 in CCD-841 vs. Caco-2, thus making the 
CCD-841 cells more sensitive to H2O2-induced cell cycle arrest and/or 
apoptosis. The gene coding for p53, TP53, is mutated in several CRC cell 
lines (Rodrigues, Rowan et al. 1990); its inactivation is considered to be the 
final critical step to metastasis in the Vogelstein model of pathogenesis 
(Fearon and Vogelstein 1990). 
It is also possible that H2O2 upregulates proliferative and anti-apoptotic 
pathways in Caco-2 via the activation of PKC proteins, upon binding to their 
regulatory domains (Gopalakrishna and Gundimeda 2002). 
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3.2.3 Sulforaphane vs. Hydrogen Peroxide 
The cell viability assays indicate that CCD-841 cells were much more 
sensitive than Caco-2 to H2O2; the IC50 of H2O2 at 48 h was 68µM in CCD-
841 cells vs. 318µM in Caco-2. Caco-2 cells appeared to ‘recover’ from H2O2 
significantly between 24 and 48 h, at which IC50 values were 199 and 318µM 
respectively. However, they did not similarly ‘recover’ from SFN treatment 
between 24 and 48 h, at which IC50 values were very similar at 40 and 42µM 
respectively. This may imply roles for oxidative stress-independent 
mechanisms in the suppression of Caco-2 cell proliferation by SFN. 
3.2.4 Methylselenocysteine (SeMSC) 
Methylselenocysteine (SeMSC) is a supplemental source of selenium, which 
is vital for the synthesis and activity of important cytoprotective reducing 
(antioxidant) enzymes such as TrxR-1. Selenoproteins, such as TrxR-1, 
incorporate a selenocysteine amino acid residue that is coded for by an 
alternative reading of the UGA ‘STOP’ codon. This alternative reading is 
initiated by the presence of a stem-loop-forming motif within the 3’-UTR, 
called the selenocysteine insertion sequence, and requires the presence of 
specific binding proteins in addition to a specific tRNA for selenocysteine 
(Mathers and Hesketh 2007). 
The effects of SeMSC on cell viability were assayed over a range of 
concentrations using the MTT assay, the data from which are shown in 
Figure 18. 
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Figure 18: The effects of SeMSC on Caco-2 cell viability at 24 h. Caco-2 cells were 
treated for 24 h by adding to culture medium in sextuplicate, water-dissolved SeMSC 
at various concentrations, or water (control). Cell viability was evaluated as (OD670 – 
OD570) at each concentration in proportion to the same of the control, and data are 
represented as the mean ± S.E.M. of sextuplicates (*P<0.05). 
3.3 Effects of Sulforaphane on Nrf2 and Nrf2-Controlled 
Phase II Enzyme Expression in Caco-2 and CCD-841 Cells 
3.3.1 Thioredoxin Reductase 1 
TrxR-1 is a phase II reductant (antioxidant) enzyme whose gene promoter 
contains the ARE, thus making it liable to Nrf2-mediated transcriptional 
activation. 
3.3.1.1 Messenger RNA Level 
The effects of 24 h SFN treatment on TrxR-1 at the mRNA level, in both 
Caco-2 and CCD-841 cells, were assayed by TaqMan RT-qPCR. Cells were 
treated for 24 h by adding to culture medium in triplicate, DMSO-diluted SFN 
(at concentrations of 2.5, 5, 10 or 20µM), or DMSO (control); final DMSO 
concentrations were 0.1% (v/v). 
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Figure 19: The effects of 24 h SFN treatment on the TrxR-1 mRNA transcript level in 
Caco-2 cells. Cells were treated by adding to culture medium in triplicate, DMSO-
diluted SFN (2.5, 5, 10 or 20µM) or DMSO (control) (final DMSO concentrations were 
0.1% (v/v)). Relative TrxR-1 mRNA levels were assayed via TaqMan RT-qPCR as 
described in Methods, using 18S as an internal control. Relative TrxR-1 expression is 
evaluated by the Pfaffl method from CT values, taking into account efficiencies 
derived from standard curve data. Data are represented as mean ± S.E.M. of triplicates 
(*P<0.05). 
As shown by the RT-qPCR data illustrated in Figure 19, TrxR-1 was clearly 
and dose-dependently upregulated in Caco-2 at the mRNA level by 24 h 
SFN (2.5 to 20µM) treatment. 
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Figure 20: The effects of 24 h SFN treatment on the TrxR-1 mRNA transcript level in 
CCD-841 cells. Cells were treated by adding to culture medium in triplicate, DMSO-
diluted SFN (2.5, 5, 10 or 20µM) or DMSO (control) (final DMSO concentrations were 
0.1% (v/v)). Relative TrxR-1 mRNA levels were assayed via TaqMan RT-qPCR as 
described in Methods, using 18S as an internal control. Relative TrxR-1 expression is 
evaluated by the Pfaffl method from CT values, taking into account efficiencies 
derived from standard curve data. Data are represented as mean ± S.E.M. of triplicates 
(*P<0.05). 
3.3.1.2 Protein Level With/Without Supplemental Selenium 
As is clear from the RT-qPCR data illustrated in Figure 19 and Figure 20, 
TrxR-1 was dose-dependently upregulated at the mRNA level at 24 h in both 
Caco-2 and CCD-841 cells, so effects of SFN at the protein level were then 
tested. 
As previously mentioned, TrxR-1 is a selenoprotein i.e. it contains 
selenocysteine residues that are coded for by the UGA codon, which is 
ordinarily a STOP codon, but can alternatively code for selenocysteine in the 
presence of the selenocysteine insertion sequence in the 3’-UTR and Sec-
tRNASec. Initially, the selenocysteine tRNAs are actually charged with serine 
to form Ser-tRNASec, whose serine residue can be converted to 
selenocysteine by selenocysteine synthase to form the required Sec-
tRNASec. This enzyme transfers the selenium from selenium phosphate, 
which itself is formed from selenide and ATP by selenophoshate synthetase 
1 (Low, Harney et al. 1995). Cells store selenium in the form of selenide. 
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Under selenium deficiency, the absence of selenide means that 
selenophosphate cannot be formed, and thus neither can Ser-tRNASec be 
converted to Sec-tRNASec. Ser-tRNASec itself cannot be incorporated into the 
peptide chain because it is not recognised by the translation elongation 
factor eEF1A, so translation stops in the absence of Sec-tRNASec (Xu, 
Carlson et al. 2007). For this reason, the full translation of TrxR-1 can be 
inhibited by selenium deficiency. 
Western Blotting was used to assay the effects of SFN on TrxR-1 at the 
protein level in both cells, either by treatment with SFN at different 
concentrations (2.5 to 20µM) for 48 h, or by treatment for different lengths of 
time (6 to 24 h) with a fixed concentration of 10µM. SFN treatment was 
performed in both the presence and absence of supplemental SeMSC. 
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Figure 21: The effect of 48 h SFN treatment on TrxR-1 protein levels in Caco-2 cells. 
Cells were treated for 48 h by adding to culture medium in duplicate, DMSO-diluted 
SFN (5, 10 or 20µM) or DMSO (control) (final DMSO concentrations were 0.1% (v/v)). 
Selenium was supplemented by adding SeMSC (200nM), to culture medium. Relative 
protein levels were assayed via Western Blotting as described in Methods, using β-
actin as an internal control for normalisation. Induction is evaluated and illustrated in 
the graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for each sample 
relative to the same for the control (see Methods). Data are represented as the mean 
of duplicates ± (upper value – lower value)/2. 
From the data illustrated in Figure 19, it is clear that TrxR-1 is dose-
dependently upregulated at the mRNA level by SFN treatment, without the 
need for selenium supplementation. However, those illustrated in Figure 21 
and Figure 22 demonstrate that corresponding upregulation at the protein 
level is largely dependent upon SeMSC supplementation. 
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Figure 22: The effect of SFN treatment on TrxR-1 protein levels in Caco-2 cells, with or 
without selenium supplementation. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) or DMSO (control) (final DMSO concentrations 
were 0.1% (v/v)). Selenium was supplemented by adding SeMSC (200nM). Relative 
protein abundance was assayed via Western Blotting as described in Methods, using 
β-actin as an internal control for normalisation. Induction is evaluated and illustrated 
in the graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for each 
sample relative to the same for the control (see Methods). Data are represented as the 
mean of duplicates ± (upper value – lower value)/2.  
The Western Blot data illustrated in Figure 22 demonstrate that following the 
treatment of Caco-2 cells with SFN (10µM) and SeMSC (200nM), TrxR-1 
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protein levels peaked at 24 h, before declining at 48 h, albeit to levels still 
significantly above baseline, which were apparently maintained up to 72 h. 
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Figure 23: The effect of SFN treatment on TrxR-1 protein levels in CCD-841 cells, with 
or without selenium supplementation. Cells were treated for 24 h by adding to culture 
medium, DMSO-diluted SFN (2.5 or 5µM) or DMSO (control) (final DMSO 
concentrations were 0.05% (v/v)). Selenium was supplemented by adding SeMSC 
(200nM), to culture medium. Relative protein levels were assayed via Western Blotting 
as described in Methods, using β-actin as an internal control. Induction is evaluated 
and illustrated in the graph as [(TrxR-1 band intensity)/(Internal control band 
intensity)] for each sample relative to the same for the control (see Methods). Data are 
representative of a single experiment. 
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Figure 24: The effect of SFN treatment on TrxR-1 protein levels in CCD-841 cells, with 
or without selenium supplementation. Cells were treated for 48 h by adding to culture 
medium in duplicate, DMSO-diluted SFN (5, 10 or 20µM) or DMSO (control) (final 
DMSO concentrations were 0.1% (v/v)). Selenium was supplemented by adding 
SeMSC (200nM), to culture medium. Relative protein levels were assayed via Western 
Blotting as described in Methods, using β-actin as an internal control for 
normalisation. Induction is evaluated and illustrated in the graph as [(TrxR-1 band 
intensity)/(Internal control band intensity)] for each sample relative to the same for the 
control (see Methods). Data are represented as the mean of duplicates ± (upper value 
– lower value)/2.  
As illustrated by the Western Blot data in Figure 23, 24 h SFN and SeMSC 
treatment synergistically upregulated the TrxR-1 protein in CCD-841, as did 
48 h treatment of the same as illustrated by the data in Figure 24. 
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Figure 25: The effect of SFN treatment on TrxR-1 protein levels in CCD-841 cells, with 
or without selenium supplementation. Cells were treated by adding to culture medium 
in duplicate, DMSO-diluted SFN (10µM) or DMSO (control) (final DMSO concentrations 
were 0.1% (v/v)). Selenium was supplemented by adding SeMSC (200nM) to culture 
medium. Relative protein abundance was assayed via Western Blotting as described 
in Methods, using β-actin as an internal control. Induction is evaluated and illustrated 
in the graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for each 
sample relative to the same for the control (see Methods). Data are represented as the 
mean of duplicates ± (upper value – lower value)/2. 
In the presence of supplemental SeMSC, SFN (10µM)-mediated induction of 
TrxR-1 at the protein level peaked at 48 h, as illustrated by the data in Figure 
25. At 72 h, TrxR-1 protein levels appear to be modestly elevated above 
baseline in response to SFN treatment, irrespective of selenium 
supplementation. 
Caco-2 vs. CCD-841 Cells 
In the presence of supplemental selenium, the induction of TrxR-1 in Caco-2 
is apparently dose-dependent at concentrations ≥10µM. In CCD-841, 
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induction at 24 h is slightly greater following treatment with a concentration of 
5µM vs. that following such with a concentration of 2.5µM, but induction at 48 
h does not significantly increase as the concentration is raised above 5µM. 
Perhaps factors other than selenium availability limit TrxR-1 translation in this 
context. 
3.3.2 UDP Glucuronosyltransferase 1 Family, Polypeptide A 
Cluster 
UGT1A is a phase II reducing (antioxidant) enzyme, whose gene promoter 
contains the ARE, the binding of Nrf2 to which activates the gene’s 
transcription. The effects of 24 h SFN (5 to 20µM) treatment on UGT1A 
expression in Caco-2 at the protein level were assayed by Western Blotting. 
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Figure 26: The effect of 24 h SFN treatment on UGT1A protein levels in Caco-2 cells. 
Cells were treated by adding to culture medium in duplicate, DMSO-diluted SFN (5, 10 
or 20µM) or DMSO (control) (final DMSO concentrations were 0.05% (v/v)). Relative 
protein abundance was assayed via Western Blotting as described in Methods, using 
β-actin as an internal control for normalisation. Induction is evaluated and illustrated 
in the graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for each 
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sample relative to the same for the control (see Methods). Data are represented as the 
mean of duplicates ± (upper value – lower value)/2. 
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Figure 27: The effect of 72 h SFN treatment on UGT1A protein levels in Caco-2 cells. 
Cells were treated by adding to culture medium in duplicate, DMSO-diluted SFN (5, 10 
or 20µM) or DMSO (control) (final DMSO concentrations were 0.05% (v/v)). Relative 
protein abundance was assayed via Western Blotting as described in Methods, using 
β-actin as an internal control for normalisation. Induction is evaluated and illustrated 
in the graph as [(TrxR-1 band intensity)/(Internal control band intensity)] for each 
sample relative to the same for the control (see Methods). Data are represented as the 
mean of duplicates ± (upper value – lower value)/2. 
The Western Blot data represented in Figure 26 and Figure 27 clearly 
indicate that 24 and 72 h SFN (5-20µM) treatment induced UGT1A in Caco-2 
at the protein level. At 24 h, induction was dose-dependent at concentrations 
≤10µM, but slightly lower at 20 than at 10µM. At 72 h, however, induction of 
UGT1A was dose-dependent throughout the range of concentrations. 
Perhaps SFN simultaneously induces UGT1A-repressing and UGT1A-
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stimulating pathways, with the latter gaining the upper hand in all cases 
tested except at 24 h following 20µM treatment. 
3.3.3 Nrf2 Nuclear Accumulation 
As previously discussed, Nrf2 induction involves the translocation of 
cytoplasmic Nrf2 to the nucleus, where it is able to exert activity. Western 
Blots were carried out with nuclear protein extracts from Caco-2 cells that 
had been treated with SFN across a 24 h time period, the data for which are 
shown in Figure 28. 
It is apparent from the data illustrated in Figure 28 that nuclear Nrf2 levels 
are dramatically increased by SFN treatment from as early as 4 h, although 
not dose-dependently (≥5µM). Nuclear Nrf2 levels appear to be highly 
variable, yet to remain significantly above baseline between 4 and 24 h post-
treatment. The apparent dose dependence of TrxR-1 and UGT1A SFN-
mediated induction may imply that factors other than Nrf2 translocation 
contribute to the upregulation of such Nrf2-controlled genes e.g. the 
inactivation of Bach1. 
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Figure 28: The effect of SFN treatment on nuclear accumulation of Nrf2 in Caco-2 
cells. Cells were treated for 4, 8, 12 or 24 h with SFN (10µM) or for 4 h with SFN (5 or 
20µM) by adding to culture medium in duplicate, DMSO-diluted SFN (5, 10 or 20µM) or 
DMSO (control) (final DMSO concentrations were 0.05% (v/v)). Relative protein levels 
were assayed via Western Blotting as described in Methods, using Sam68 as an 
internal control for normalisation. Induction is evaluated and illustrated in the graph 
as [(Nrf2 band intensity)/(Internal control band intensity)] for each sample relative to 
the same for the control (see Methods). Data are represented as the mean of 
duplicates ± (upper value – lower value)/2. 
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3.4 Effects of Sulforaphane on Oncogenic Characteristics 
3.4.1 Effects on Cell Migration 
The ability of cancer cells to migrate in vitro is considered to be a marker of 
oncogenicity, and thus agents that inhibit such migration are potentially 
tumour suppressive. The wound healing assay was used to evaluate the 
effects of SFN treatment on the migration of Caco-2 and CCD-841 cells 
across gaps created in confluent monolayers as described in Methods.  
The data shown in Figure 29 provide no evidence that SFN has any effect on 
Caco-2 cell migration at 72 h following treatment. 
By contrast, SFN significantly and dose-dependently inhibited the migration 
of CCD-841 cells over 48 h, as illustrated by the data presented in Figure 30. 
It was surprising that the migration of the CCD-841 (non-cancerous) cells 
was inhibited while that of the Caco-2 (cancerous) cells was not. Perhaps 
Caco-2 cells have mutations or epimutations that confer resistance to the 
pathway(s) by which SFN (at 5-20µM) inhibits cell migration. However, the 
lack of effect on Caco-2 migration observed here does not necessarily prove 
that colonic adenocarcinoma cells are always resistant to SFN-induced 
migration repression. A possible confounding issue encountered with the 
Caco-2 cells was that it took longer than 24 h for all cells to attach following 
seeding. However, incubating the cells for longer than 24 h allowed strong 
intercellular adhesions to form, which resulted in the failure of attempts to 
create scratch wounds due to the entire monolayer peeling. Therefore, 
scratch wounds had to be created at 24 h. Inevitably, this selected for cells 
that attached more quickly, since those not attached by 24 h were discarded. 
Also, the highly adhesive nature of the Caco-2 cells may have meant that 
very little or no migration took place following wound creation, with or without 
SFN. 
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Figure 29: Caco-2 cells were seeded at densities sufficient that confluent monolayers 
were formed by 24 h. Scratch wounds were created in confluent monolayers using a 
pipette tip, and cells were then treated by adding to culture medium in triplicate SFN 
(5 to 20µM) or DMSO; final DMSO concentrations were 0.05% (v/v). Cells were 
subsequently incubated for 72 h, then fixed, stained and photographed (with 5 
photographs along the vertical axis of each scratch wound). The 4th image of every 
wound is shown. The average gap width between leading cells was calculated in each 
image, then data across all 5 images per well were averaged. Data from image 
analyses are represented in the graph as the means of three biological replicates ± 
S.E.M. 
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The data for the assays in CCD-841 cells clearly indicate that SFN 
significantly inhibited wound healing in a dose-dependent manner - even at 
the lowest concentration (5µM) - indicating that SFN can inhibit cell migration 
independently of cytotoxicity. The implications of this for the effects of SFN 
on healthy colonic tissues are unclear, in terms of whether or not SFN could 
impair healing and/or renewal of the colonic epithelium. It might be 
postulated that the effects observed in this colonic cell line - CCD-841 – are 
likely to similarly occur in early-stage colonic tumour cells. 
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Figure 30: CCD-841 cells were seeded so as to form confluent monolayers at 24 h. 
Scratch wounds were then created in confluent monolayers with a pipette tip, and 
cells were then treated by adding to culture medium in triplicate SFN (5 to 20µM) or 
DMSO; final DMSO concentrations were 0.05% (v/v). Cells were subsequently 
incubated for 48 h, then fixed, stained and photographed (with 5 photographs along 
the vertical axis of each scratch wound). The 4th image of every wound is shown. The 
average gap width between leading cells was calculated in each image, then data 
across all 5 images per well were averaged. Data from image analyses are 
represented in the graph as the means of three biological replicates ± S.E.M. 
(*P<0.05). 
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3.4.2 Effects on Clonogenicity 
The impact of SFN (5-20µM) on the ability of Caco-2 cells to form colonies 
(≥50 cells) over several weeks after being seeded at very low density, i.e. 
cell clonogenicity, was tested. The potential of cells to form colonies following 
seeding at very low densities is regarded as a marker of oncogenicity in vitro, 
since it implies that the cells survive and undergo many cycles of division, as 
an oppose to undergoing apoptosis and/or senescence, in spite of their 
isolation. The effects of SFN treatment on the clonogenicity of Caco-2 cells 
were assayed, as described in Methods. 
The data shown in Figure 31 clearly show that the addition of SFN (5, 10 or 
20µM) to culture medium after low-density seeding inhibited the 14-day 
colony-forming potential of Caco-2 cells in a dose-dependent fashion. 
However, it must be considered that since cell density was very low upon the 
addition of SFN, the cells were exposed more highly to SFN than if the same 
concentrations of SFN had been added to cells present at 70% confluence. 
Therefore, it cannot be ruled out that the inhibition of clonogenicity here 
observed was at least partly attributable to general cytotoxicity via oxidative 
and/or genotoxic stress. It is not known how rapidly SFN accumulated in 
cells following its addition to culture medium (Zhang 2000). 
Subsequently, a similar colony forming assay was done but testing a 
different mode of SFN treatment i.e. the SFN pre-treatment of cells at 70-
80% confluence prior to low-density seeding. Cells were cultured until 70-
80% confluent in 24-well plates, and then treated by adding SFN/DMSO to 
culture medium for 24 h. Then the cells were detached using trypsin and re-
seeded at low densities in 6-well plates. These cells were cultured as before, 
except that SFN was not present in the culture medium once the cells had 
been re-seeded at low density. Colonies were then stained and counted as 
before. The data from this second assay are summarised and illustrated in 
Figure 32. 
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Figure 31: Caco-2 cells were seeded at low density (400 cells/well) in 6-well plates 
(surface area/well = 9.5cm2) and then incubated for 48 h prior to treatment. After 48 h, 
cells were treated by adding to culture medium in sextuplicate, DMSO-diluted SFN (5-
20µM) or DMSO (control); final DMSO concentrations were 0.05% (v/v). Cells were 
then incubated for a further 14 days, after which cells were fixed and stained, and the 
number of colonies in each well was counted under an inverted microscope. Absolute 
colony counts are presented in the table and relative colony formation is illustrated in 
the graph, where data are represented as means of six biological replicates ± S.E.M. 
(*P<0.05). 
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Figure 32: Caco-2 cells were cultured to 70-80% confluence in 24-well plates (surface 
area/well = 1.9cm2), then treated with DMSO-diluted SFN (5, 10 or 20µM) or DMSO; 
final DMSO concentrations were 0.05% (v/v). Subsequently, cells were detached using 
trypsin and then re-seeded at low density (400 cells/well) in 6-well plates (surface 
area/well = 9.5cm2). Cells were then incubated for a further 14 days after which cells 
were fixed and stained, and the number of colonies in each well was counted. Relative 
colony formation is illustrated in the graph, where data are represented as means of 
six biological replicates ± S.E.M. 
It is apparent from the data illustrated in Figure 32 that the SFN pre-
treatment of Caco-2 cells at 70-80% confluence prior to their detachment and 
re-seeding at low density did not affect clonogenicity. Perhaps single 
exposures to such sub-cytotoxic doses of SFN do not affect clonogenicity. 
However, this second assay did not monitor the effects of repeated sub-
cytotoxic SFN exposure upon the clonogenicity of cells already in isolation, 
which may be more relevant from the perspective of tumour metastasis in 
vivo. It is also possible that effects were masked by cellular stress from the 
trypsin detachment and re-seeding process. 
3.5 Conclusions 
It is clear from the data presented in this Chapter that the tested 
experimental set-up is functional in terms of demonstrating the expected 
effects of SFN treatment on Nrf2 nuclear translocation and Nrf2-mediated 
gene expression in both Caco-2 and CCD-841 cells. Therefore, such set-up 
is appropriate for miRNA profiling experiments. 
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Chapter 4: Profiling MicroRNA 
Expression 
4.1 General Introduction 
The previous Chapter describes how the experimental system was validated 
by demonstrating the ability of sub-cytotoxic doses of SFN to induce the 
nuclear translocation of Nrf2, and upregulate the expression of Nrf2-
controlled genes such as TrxR-1 in Caco-2 and CCD-841 cells, at the 
transcriptional and/or translational levels. Thus, similar conditions of cell 
culture and treatment were determined suitable for the miRNA profiling 
experiments. 
Known human miRNAs number in the thousands, so it was deemed sensible 
to begin with a wide-scale assay of SFN’s effects on miRNA expression in 
each cell line, in order to highlight miRNAs to which attention is best drawn. 
As discussed in previous chapters, there are several techniques for wide-
scale miRNA expression profiling, the miRNA library cloning and deep 
sequencing approach of which was determined to be the most suitable. 
Following the wide-scale profiling process, miRNAs apparently modulated by 
SFN and relevant to cancer (according to reports in the literature) were 
selected for further study. 
Due to the sheer complexity of data and required normalisation processes, 
analyses of miRNA library cloning and deep sequencing data inevitably 
generate artefacts i.e. false indications of modulation. Therefore, the actual 
SFN-mediated modulation of any miRNA of interest was confirmed by an 
individually targeted miRNA assay, such as RT-qPCR or the Northern Blot. 
4.2 Caco-2 and CCD-841 MicroRNA Library Deep 
Sequencing  
As outlined in the Methods chapter, Caco-2 and CCD-841 cells were treated 
by adding to culture medium in triplicate, DMSO-diluted SFN (10µM) or 
DMSO (control) for 24 h; final DMSO concentrations were 0.05% (v/v). Total 
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RNA was extracted 8 or 24 h following treatment, from which miRNA libraries 
were constructed, that were subsequently subjected to deep sequencing. For 
gel images and other data obtained during the cloning process, see the 
Appendix. The deep sequencing data were quality checked, and then 
processed to remove adapter-adapter reads, as outlined in Methods. 
Caco-2 library data quality assessment: 
Table 6: The identity of each Caco-2 miRNA library, the proportion of reads of each 
remaining after the quality check and removal of adapter-adapter reads, and the 
subsequent proportion of reads mapping to the human genome. Libraries were 
constructed with three biological replicates per time point; ‘A’ libraries represent 
controls, ‘B’ 8 h SFN treatment, and ‘C’ 24 h SFN treatment. 
Lib. Time (h) Rep. 
Raw Read 
Number 
Proportion 
After QC 
and 
Adapter 
Removal 
(%) 
Matching 
Human 
Genome 
(%) 
Reads 
Remaining 
After 
t/rRNA 
Removal 
A1 
0 
1 19 985 254 93 82 13 539 159 
A2 2 26 152 561 95 80 19 211 757 
A3 3 16 176 855 96 80 12 200 936 
B1 
8 
1 16 002 804 93 78 11 096 534 
B2 2 14 603 739 92 80 10 258 639 
B3 3 13 554 322 93 78 9 484 717 
C1 
24 
1 23 029 947 95 79 16 136 765 
C2 2 22 223 346 95 79 15 459 590 
C3 3 26 035 997 93 80 17 208 841 
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CCD-841 library data quality assessment: 
Table 7: The identity of each CCD-841 miRNA library, the proportion of reads of each 
remaining after the quality check and removal of adapter-adapter reads, and the 
subsequent proportion of reads mapping to the human genome. Libraries highlighted 
in red were excluded from further analysis because very low proportions of their 
reads were mappable to the human genome, potentially due to contamination of 
samples with non-human RNA during the construction of these libraries. Libraries 
were constructed with three biological replicates per time point; ‘X’ libraries represent 
controls, ‘Y’ 8 h SFN treatment, and ‘Z’ 24 h SFN treatment. 
Lib. Time (h) Rep. 
Raw Read 
Number 
Proportion 
After QC 
and 
Adapter 
Removal 
(%) 
Matching 
Human 
Genome 
(%) 
Reads 
Remaining 
After t/rRNA 
Removal 
X1 
0 
1 20 670 894 88 81 10 604 163 
X2 2 12 051 340 71 78 4 169 711 
X3 3 15 407 379 82 79 6 710 224 
Y1 
8 
1 26 704 185 98 9 - 
Y2 2 28 258 638 98 6 - 
Y3 3 21 036 399 59 76 6 120 616 
Z1 
24 
1 24 901 235 52 78 10 597 858 
Z2 2 14 611 109 96 82 8 441 483 
Z3 3 34 231 130 96 63 17 598 456 
 
The data from the CCD-841 libraries Y1 and Y2 would not be meaningful for 
miRNA expression profiling, as indicated by several factors: 
• The size class and complexity distributions do not at all resemble 
those expected for human miRNAs (see Appendix for distribution data 
and further detail). 
• Very low proportions of reads are mappable to the human genome 
(see Table 7). 
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These issues may indicate heavy contamination with degraded RNA from 
another species during miRNA library preparation. Therefore, these two 
libraries were disregarded. 
Inter-replicate library similarity was evaluated as described in Methods.  
Libraries A3 (Caco-2; 0 h) and B3 (Caco-2; 8 h) were hence excluded from 
further analysis, since they were significantly dissimilar to their replicate 
counterparts according to the Jaccard top 1000 and box plot tests. Library Z3 
(CCD-841; 24 h) was also excluded, since it had more than double the 
number of genome-mapping reads vs. its replicate counterparts: Z1 and Z2. 
Library data were then normalised, and SFN-mediated miRNA modulation at 
the two time points was determined as described in Methods. The names of 
all miRNAs thus determined as SFN-modulated in Caco-2 and CCD-841 
cells are listed in Table 9 and Table 10 respectively, alongside the medians 
of their respective normalised read numbers across replicates. 
Table 8: A summary of the numbers of total and differentially expressed known 
miRNAs detected in each cell line. 
MicroRNA 
Library Set 
Total 
MicroRNAs 
Detected 
DE MicroRNAs 
Proportion of 
MicroRNAs 
Apparently DE 
Caco-2 1288 52 4.0% 
CCD-841 1014 113 11.1% 
 
4.2.1 MicroRNAs Modulated by Sulforaphane Treatment in Caco-2 
According to Libraries 
 
Table 9: The identities and normalised read number medians for miRNAs in Caco-2 
for which the calculated fold change of expression between 0 and 8 h, 8 and 24 h, or 0 
and 24 h of SFN (10µM) treatment was ≥ 1.9. vA = Median((Reads in A1),(Reads in 
A2)); vB = Median((Reads in B1),(Reads in B2)); vC = Median((Reads in C1),(Reads in 
C2),(Reads in C3)). 
(Table 9 Continued) 
MicroRNA vA (0 h) vB (8 h) vC (24 h) Total 
hsa-let-7a-5p MIMAT0000062 57905 77092 113506 248503 
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(Table 9 Continued) 
MicroRNA vA (0 h) vB (8 h) vC (24 h) Total 
hsa-let-7b-5p MIMAT0000063 375 381 984 1740 
hsa-let-7d-3p MIMAT0004484 742 503 331 1576 
hsa-let-7e-5p MIMAT0000066 26519 37243 56000 119762 
hsa-let-7f-5p MIMAT0000067 55615 75116 110493 241224 
hsa-let-7g-5p MIMAT0000414 55595 75115 110355 241065 
hsa-miR-9-5p MIMAT0000441 1760 2549 3391 7699 
hsa-miR-10a-5p MIMAT0000253 31055 38797 63272 133124 
hsa-miR-10b-5p MIMAT0000254 31054 38797 63272 133123 
hsa-miR-15a-3p MIMAT0004488 46 27 10 83 
hsa-miR-17-3p MIMAT0000071 5064 3256 2557 10877 
hsa-miR-18a-3p MIMAT0002891 1986 1352 930 4268 
hsa-miR-19b-1-5p MIMAT0004491 585 414 255 1253 
hsa-miR-19b-2-5p MIMAT0004492 104 37 41 182 
hsa-miR-20a-3p MIMAT0004493 333 251 119 703 
hsa-miR-25-5p MIMAT0004498 657 272 302 1231 
hsa-miR-27a-5p MIMAT0004501 407 130 248 785 
hsa-miR-27b-5p MIMAT0004588 1898 580 1100 3577 
hsa-miR-33b-3p MIMAT0004811 510 128 366 1003 
hsa-miR-34a-3p MIMAT0004557 221 153 89 463 
hsa-miR-98-5p MIMAT0000096 388 394 1022 1804 
hsa-miR-181a-3p MIMAT0000270 2154 1253 780 4187 
hsa-miR-188-3p MIMAT0004613 98 49 40 187 
hsa-miR-193b-3p MIMAT0002819 7353 4880 3767 16000 
hsa-miR-197-3p MIMAT0000227 138 104 47 289 
hsa-miR-200c-5p MIMAT0004657 2206 1160 950 4315 
hsa-miR-210-5p MIMAT0026475 110 43 34 187 
hsa-miR-219a-1-3p 
MIMAT0004567 68 83 152 303 
hsa-miR-296-5p MIMAT0000690 1466 758 654 2878 
hsa-miR-331-3p MIMAT0000760 4493 2540 2039 9071 
hsa-miR-339-5p MIMAT0000764 5688 3174 1914 10776 
hsa-miR-504-5p MIMAT0002875 54 25 12 90 
hsa-miR-532-3p MIMAT0004780 5377 3753 2648 11778 
hsa-miR-548b-3p MIMAT0003254 201 133 95 429 
hsa-miR-590-5p MIMAT0003258 248 172 118 538 
hsa-miR-625-3p MIMAT0004808 2570 1516 836 4921 
hsa-miR-934 MIMAT0004977 5793 3846 2637 12275 
hsa-miR-1257 MIMAT0005908 242 196 450 888 
hsa-miR-1296-5p MIMAT0005794 8151 4639 3792 16582 
hsa-miR-1297 MIMAT0005886 55 41 154 250 
hsa-miR-1827 MIMAT0006767 102 112 399 613 
hsa-miR-2277-3p MIMAT0011777 95 57 32 184 
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(Table 9 Continued) 
MicroRNA vA (0 h) vB (8 h) vC (24 h) Total 
hsa-miR-3135b MIMAT0018985 264 118 76 458 
hsa-miR-3200-3p MIMAT0015085 157 108 69 334 
hsa-miR-3611 MIMAT0017988 38 22 10 69 
hsa-miR-4286 MIMAT0016916 4671 1613 3172 9456 
hsa-miR-4454 MIMAT0018976 154 50 99 303 
hsa-miR-4517 MIMAT0019054 74 121 41 236 
hsa-miR-5585-3p MIMAT0022286 47 15 45 107 
hsa-miR-6130 MIMAT0024614 102 112 399 613 
hsa-miR-7975 MIMAT0031178 144 42 84 270 
hsa-miR-7977 MIMAT0031180 733 361 534 1628 
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4.2.2 MicroRNAs Modulated by Sulforaphane Treatment in CCD-
841 According to Libraries 
 
Table 10: The identities and normalised read number medians for miRNAs in CCD-841 
for which the calculated fold change of expression between 0 and 8 h, 8 and 24 h, or 0 
and 24 h of SFN (10µM) treatment was ≥ 1.9.  vX = Median((Reads in X1),(Reads in 
X2),(Reads in X3)); vY = (Reads in Y3); vZ = Median((Reads in Z1),(Reads in Z2)). 
(Table 10 Continued) 
MicroRNA vX (0 h) vY (8 h) vZ (24 h) Total 
hsa-let-7d-3p MIMAT0004484 1106 700 1679 3485 
hsa-miR-9-5p MIMAT0000441 161 230 13 404 
hsa-miR-9-3p MIMAT0000442 42 54 8 104 
hsa-miR-10a-5p MIMAT0000253 188157 223910 83597 495664 
hsa-miR-10b-5p MIMAT0000254 187938 223699 83531 495168 
hsa-miR-17-3p MIMAT0000071 143 117 316 576 
hsa-miR-18a-5p MIMAT0000072 549 455 1036 2040 
hsa-miR-19a-3p MIMAT0000073 2446 2040 4437 8923 
hsa-miR-19b-3p MIMAT0000074 2446 2040 4437 8923 
hsa-miR-27a-5p MIMAT0004501 325 355 696 1376 
hsa-miR-29a-5p MIMAT0004503 553 494 1001 2048 
hsa-miR-29b-3p MIMAT0000100 30838 21374 48781 100993 
hsa-miR-31-5p MIMAT0000089 13418 14309 6773 34500 
hsa-miR-31-3p MIMAT0004504 1020 883 516 2419 
hsa-miR-32-5p MIMAT0000090 417 275 858 1550 
hsa-miR-33a-5p MIMAT0000091 125 42 103 270 
hsa-miR-33b-5p MIMAT0003301 43 19 55 117 
hsa-miR-33b-3p MIMAT0004811 30 9 42 81 
hsa-miR-34a-3p MIMAT0004557 65 44 111 220 
hsa-miR-34b-5p MIMAT0000685 20 20 236 276 
hsa-miR-34b-3p MIMAT0004676 11 6 35 52 
hsa-miR-34c-5p MIMAT0000686 90 65 731 886 
hsa-miR-34c-3p MIMAT0004677 27 33 89 149 
hsa-miR-96-5p MIMAT0000095 1048 1292 299 2639 
hsa-miR-99a-5p MIMAT0000097 66887 70822 25579 163288 
hsa-miR-100-5p MIMAT0000098 67082 71019 25643 163744 
hsa-miR-101-3p MIMAT0000099 493 471 1036 2000 
hsa-miR-103a-3p MIMAT0000101 16872 14658 29747 61277 
hsa-miR-106b-5p MIMAT0000680 1878 1816 4934 8628 
hsa-miR-126-5p MIMAT0000444 114 109 232 455 
hsa-miR-130b-3p MIMAT0000691 4824 4776 11637 21237 
hsa-miR-135a-5p MIMAT0000428 144 127 9 280 
hsa-miR-135b-5p MIMAT0000758 144 127 9 280 
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(Table 10 Continued) 
MicroRNA vX (0 h) vY (8 h) vZ (24 h) Total 
hsa-miR-136-5p MIMAT0000448 1827 955 3817 6599 
hsa-miR-136-3p MIMAT0004606 1519 1304 2531 5354 
hsa-miR-138-5p MIMAT0000430 10001 8572 3744 22317 
hsa-miR-138-1-3p MIMAT0004607 183 180 52 415 
hsa-miR-143-5p MIMAT0004599 374 214 614 1202 
hsa-miR-146a-5p MIMAT0000449 1455 1932 946 4333 
hsa-miR-152-5p MIMAT0026479 26 16 55 97 
hsa-miR-154-5p MIMAT0000452 541 384 965 1890 
hsa-miR-155-5p MIMAT0000646 5434 6991 2059 14484 
hsa-miR-181a-5p MIMAT0000256 42655 44144 83238 170037 
hsa-miR-182-5p MIMAT0000259 13615 18594 2490 34699 
hsa-miR-183-5p MIMAT0000261 1258 1214 278 2750 
hsa-miR-183-3p MIMAT0004560 42 26 10 78 
hsa-miR-193a-5p MIMAT0004614 638 570 194 1402 
hsa-miR-193b-3p MIMAT0002819 2145 1449 2852 6446 
hsa-miR-194-5p MIMAT0000460 188 311 459 958 
hsa-miR-199a-5p MIMAT0000231 14195 16450 41602 72247 
hsa-miR-199b-5p MIMAT0000263 14059 16257 41319 71635 
hsa-miR-203a-3p MIMAT0000264 34 27 7 68 
hsa-miR-210-3p MIMAT0000267 340 240 513 1093 
hsa-miR-218-5p MIMAT0000275 8 10 145 163 
hsa-miR-221-5p MIMAT0004568 266 266 105 637 
hsa-miR-221-3p MIMAT0000278 127694 142812 72165 342671 
hsa-miR-296-3p MIMAT0004679 69 25 65 159 
hsa-miR-299-3p MIMAT0000687 123 97 221 441 
hsa-miR-301a-3p MIMAT0000688 475 432 1850 2757 
hsa-miR-301b-3p MIMAT0004958 442 418 1728 2588 
hsa-miR-331-3p MIMAT0000760 677 622 1262 2561 
hsa-miR-340-5p MIMAT0004692 183 178 518 879 
hsa-miR-342-3p MIMAT0000753 373 405 757 1535 
hsa-miR-345-5p MIMAT0000772 640 519 1613 2772 
hsa-miR-374b-3p MIMAT0004956 124 106 260 490 
hsa-miR-376a-5p MIMAT0003386 180 151 352 683 
hsa-miR-376c-5p MIMAT0022861 28 22 62 112 
hsa-miR-424-5p MIMAT0001341 3490 2666 15112 21268 
hsa-miR-424-3p MIMAT0004749 306 229 662 1197 
hsa-miR-450a-5p MIMAT0001545 327 283 1473 2083 
hsa-miR-450a-1-3p MIMAT0022700 13 14 61 88 
hsa-miR-450a-2-3p MIMAT0031074 9 7 51 67 
hsa-miR-450b-5p MIMAT0004909 142 140 634 916 
hsa-miR-486-5p MIMAT0002177 18553 21591 3503 43647 
hsa-miR-486-3p MIMAT0004762 603 761 202 1566 
hsa-miR-490-3p MIMAT0002806 2267 1465 5152 8884 
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(Table 10 Continued) 
MicroRNA vX (0 h) vY (8 h) vZ (24 h) Total 
hsa-miR-497-5p MIMAT0002820 141 104 65 310 
hsa-miR-500a-3p MIMAT0002871 1181 1177 465 2823 
hsa-miR-503-5p MIMAT0002874 432 346 1793 2571 
hsa-miR-504-5p MIMAT0002875 25 22 212 259 
hsa-miR-542-5p MIMAT0003340 111 85 646 842 
hsa-miR-542-3p MIMAT0003389 195 146 1068 1409 
hsa-miR-543 MIMAT0004954 2787 1957 1306 6050 
hsa-miR-550a-3p MIMAT0003257 143 92 228 463 
hsa-miR-550b-2-5p MIMAT0022737 131 85 214 430 
hsa-miR-561-5p MIMAT0022706 13 13 86 112 
hsa-miR-584-5p MIMAT0003249 2473 2460 935 5868 
hsa-miR-584-3p MIMAT0022708 38 32 10 80 
hsa-miR-590-5p MIMAT0003258 23 7 66 96 
hsa-miR-545-3p MIMAT0003165 11 1 36 48 
hsa-miR-615-3p MIMAT0003283 1243 737 2023 4003 
hsa-miR-618 MIMAT0003287 4 6 117 127 
hsa-miR-625-5p MIMAT0003294 44 39 133 216 
hsa-miR-671-5p MIMAT0003880 138 100 226 464 
hsa-miR-708-5p MIMAT0004926 1 2 26 29 
hsa-miR-744-5p MIMAT0004945 1662 1104 3505 6271 
hsa-miR-769-5p MIMAT0003886 335 235 867 1437 
hsa-miR-769-3p MIMAT0003887 45 40 135 220 
hsa-miR-887-3p MIMAT0004951 49 46 199 294 
hsa-miR-935 MIMAT0004978 63 41 22 126 
hsa-miR-1185-1-3p MIMAT0022838 405 307 609 1321 
hsa-miR-1185-2-3p MIMAT0022713 405 307 609 1321 
hsa-miR-1197 MIMAT0005955 27 22 78 127 
hsa-miR-1287-5p MIMAT0005878 50 50 141 241 
hsa-miR-1296-5p MIMAT0005794 598 337 955 1890 
hsa-miR-1301-3p MIMAT0005797 33 40 110 183 
hsa-miR-1307-5p MIMAT0022727 121 106 295 522 
hsa-miR-2110 MIMAT0010133 147 155 68 370 
hsa-miR-2355-5p MIMAT0016895 42 38 97 177 
hsa-miR-3074-5p MIMAT0019208 6361 9018 17243 32622 
hsa-miR-3120-3p MIMAT0014982 14 16 56 86 
hsa-miR-3934-5p MIMAT0018349 34 34 8 76 
hsa-miR-6720-5p MIMAT0027345 11 2 39 52 
 
4.2.3 Examination of the Library Data Analysis and IsomiRs 
For each miRNA named in miRBase (e.g. hsa-miR-29b-3p), only the 
sequence of the canonical form is presently catalogued. However, each 
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miRNA has multiple isoforms (isomiRs), whose sequences vary from those 
of the canonical forms by having extra or missing nucleotides at the 5’ and 3’ 
ends, or substituted bases in some cases. These originate, in part, from the 
‘imprecise’ cleavage of pri-miRNAs and pre-miRNAs by Drosha and Dicer 
respectively, generating end deletions or templated additions. Another 
source of variation is the susceptibility of mature miRNAs and pre-miRNAs to 
post-transcriptional modification by exonucleases and/or base-modifying 
enzymes. The canonical miRNA sequence catalogued in miRBase tends to 
be either a consensus from pooled sequencing data, or the form most 
abundant in the experimental data from which the miRNA acceded to 
miRBase. 
The algorithm that was used to match sequencing reads to miRBase-
catalogued human miRNAs allowed up to 2 mismatches, in order to ensure 
the inclusion of non-canonical isomiRs. As a result, the summed read 
numbers reported for “hsa-miR-29b-3p” – for example – were not all from the 
miRBase-canonical isoform of hsa-miR-29b-3p, but included reads from 
various isomiRs. Non-canonical isomiRs are important to consider, because 
they can be much more abundant than their canonical counterparts in some 
contexts. 
Unfortunately, some distinct miRNAs differ from one another in canonical 
sequence by only 1 or 2 nucleotides; the tolerance of mismatches inevitably 
leads to some misannotation. The annotated library data first appeared to 
imply that hsa-let-7a-5p was highly abundant and upregulated by SFN. 
However, further inspection of the reads annotated as hsa-let-7a-5p revealed 
that none of them actually matched the hsa-let-7a-5p sequence. Most of the 
reads strictly matched the canonical hsa-let-7f-5p and hsa-let-7g-5p 
sequences, each of which differ in sequence from hsa-let-7a-5p by only 1 
and 2 nucleotides respectively, as illustrated in Table 11. 
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Table 11: The canonical sequences of hsa-let-7a-5p, hsa-let-7f-5p and hsa-let-7g-5p. 
7a u g a g g u a g u a g g u u g u a u a g u u 
7f u g a g g u a g u a g a u u g u a u a g u u 
7g u g a g g u a g u a g u u u g u a c a g u u 
 
Therefore, the summed reads for miRNAs of interest were carefully 
scrutinised before further study. Incorrect annotation was relatively rare, and 
in most cases, the majority (70-80%) of the reads annotated as a specific 
miRBase entry were in fact perfect matches to the canonical sequence. 
However non-canonical isomiRs dominated in some contexts; these isomiRs 
varied from the canonicals by having 1 or 2 extra or missing nucleotides at 
the (often 3’) end. 
For example, of the Caco-2 library reads annotated as hsa-miR-17-3p: 
• 43% represented an isomiR with an extra nucleotide at the 3’ end. 
• 18% perfectly matched the canonical sequence. 
• 18% represented an isomiR missing a nucleotide at the 3’ end. 
• 10% represented an isomiR missing 2 nucleotides at the 3’ end. 
• 5% represented an isomiR missing one nucleotide at the 5’ end. 
Thus, it was decided that the first isomiR of miR-17-3p would be more 
appropriate for validation due to its apparent dominance. Using the isomiR 
nomenclature proposed by Coonan et al. and described in MicroRNA 
Nomenclature in the Appendix, this isomiR was named hsa-miR-17-
3p|[isomiR]|50_72|. 
 
4.3 Validating Differential MicroRNA Expression in 
Response to Sulforaphane 
Northern Blotting and TaqMan RT-qPCR were used to assay SFN’s effects 
on miRNA expression individually. Caco-2 and CCD-841 cells were treated 
with SFN or DMSO (for controls); final DMSO concentrations were 0.05% 
(v/v). Northern Blot experiments were performed in duplicate, whilst RT-
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qPCR experiments were performed in triplicate. U6 was used as an internal 
control for normalisation. 
4.3.1 The Let-7 Family 
Anti-cancer effects of the let-7 miRNAs are frequently reported, due to the 
tendency of these miRNAs to repress proliferation, promote differentiation 
and/or promote apoptosis, particularly in CRC cells. Reads perfectly 
matching the canonical sequences of hsa-let-7f-5p and hsa-let-7g-5p were 
highly abundant in the data from both cell lines. 
4.3.1.1 Let-7f-5p in Caco-2 
The Caco-2 library data suggested that SFN (10µM) treatment induced let-7f-
5p 1.4- and 2.1-fold at 8 and 24 h respectively, as illustrated in Figure 33. 
 
Figure 33: Normalised read numbers for hsa-let-7f-5p in Caco-2 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
The Northern Blot data for let-7f-5p, as illustrated in Figure 34 corroborate a 
sequential trend of upregulation, albeit with more subtle inductions of 1.2- 
and 1.4-fold at 8 and 24 h respectively. 
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Figure 34: The effect of SFN treatment on the level of hsa-let-7f-5p in Caco-2 cells at 8 
and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-diluted 
SFN (10µM) for 8 or 24 h, or DMSO; final DMSO concentrations were 0.05% (v/v). 
Relative miRNA abundance was assayed via Northern Blotting as described in 
Methods, using U6 as an internal control for normalisation. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the control 
mean, and data are represented as means of duplicates ± (upper value – lower 
value)/2. 
4.3.1.2 Let-7g-5p in Caco-2 
The Caco-2 library data suggested that let-7g-5p was also upregulated by 
SFN (10µM) treatment, 1.3- and 2.0-fold at 8 and 24 h respectively, as 
illustrated in Figure 35. 
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Figure 35: Normalised read numbers for hsa-let-7g-5p in Caco-2 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
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The Northern Blot data for let-7g-5p as illustrated in Figure 36 imply 
inductions of 1.1- and 1.6-fold at 8 and 24 h respectively, thus confirming that 
let-7g-5p expression is upregulated by SFN treatment at 24 h.
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Figure 36: The effect of SFN treatment on the level of hsa-let-7g-5p in Caco-2 cells at 8 
and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-diluted 
SFN (10µM) for 8 or 24 h, or DMSO; final DMSO concentrations were 0.05% (v/v). 
Relative miRNA abundance was assayed via Northern Blotting as described in 
Methods, using U6 as an internal control for normalisation. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the control 
mean, and data are represented as means of duplicates ± (upper value – lower 
value)/2. 
4.3.1.3 Let-7f-5p and Let-7g-5p in CCD-841 
The effects of SFN treatment on the expression of let-7f-5p and let-7g-5p in 
CCD-841 was subsequently tested, to determine whether or not they 
responded similarly to the Caco-2 cells. As illustrated in Figure 39 and Figure 
40, the Northern Blot data actually indicate that SFN does not affect these 
two miRNAs in CCD-841, as corroborated by the CCD-841 library data read 
numbers (which are illustrated in Figure 37 and Figure 38). 
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Figure 37: Normalised read numbers for hsa-let-7f-5p in CCD-841 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
 
Figure 38: Normalised read numbers for hsa-let-7g-5p in CCD-841 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
Let-7f-5p and let-7g-5p have important anti-proliferative, pro-differentiative 
and pro-apoptotic functions, so it is potentially significant that their induction 
by SFN appears to occur selectively in the CRC and not the non-cancerous 
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colonic cell line. This could have implications for SFN’s therapeutic potential.
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Figure 39: The effect of SFN treatment on the level of hsa-let-7f-5p in CCD-841 cells at 
8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-diluted 
SFN (10µM) for 8 or 24 h, or DMSO; final DMSO concentrations were 0.05% (v/v). 
Relative miRNA abundance was assayed via Northern Blotting as described in 
Methods, using U6 as an internal control for normalisation. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the control 
mean, and data are represented as means of duplicates ± (upper value – lower 
value)/2. 
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Figure 40: The effect of SFN treatment on the level of hsa-let-7g-5p in CCD-841 cells at 
8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-diluted 
SFN (10µM) for 8 or 24 h, or DMSO; final DMSO concentrations were 0.05% (v/v). 
Relative miRNA abundance was assayed via Northern Blotting as described in 
Methods, using U6 as an internal control for normalisation. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the control 
mean, and data are represented as means of duplicates ± (upper value – lower 
value)/2. 
It was speculated that the Northern Blot data may have ‘underreported’ the 
fold inductions of let-7f-5p and let-7g-5p, if the anti-let-7f-5p and anti-let-7g-
5p probes cross-hybridised with other miRNAs that were close in sequence. 
Particularly similar in sequence are other members of the let-7 family, 
including hsa-let-7x-5p where x = a, b, c, d, e, f, g, i.  
An approach for testing the potential for such cross-hybridisation is to make 
dot-blots by blotting positive-sense oligomers composed of the sequences of 
let-7x-5p, where x = a, b, c, d, e, f, g, i. The dot-blots are then probed using 
the anti-let-7f-5p and anti-let-7g-5p Northern Blot probes to compare the 
intensity of binding between the different blotted oligomers. 
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4.3.1.4 Dot-blots Probed with Anti-Let-7f-5p Probe 
a b c d e f g
hsa-let-7 Family Member (-5p)
Let-7 Member a b c d e f g i
Relative Density (%) 16 1 3 3 3 100 1 0
i
 
Figure 41: A test of the cross-reactivity of the probe anti-sense to hsa-let-7f-5p with 
other let-7 family members. Positive sense oligomers composed of the sequences of 
each miRNA were blotted onto a membrane, which was then probed against hsa-let-
7f-5p. 
4.3.1.5 Dot blots Probed with Anti-Let-7g-5p Probe 
a b c d e f g i
hsa-let-7 Family Member (-5p)
Let-7 Member a b c d e f g i
Relative Density (%) 2 1 0 1 0 0 100 19
 
Figure 42: A test of the cross-reactivity of the probe anti-sense to hsa-let-7g-5p with 
other let-7 family members. Positive sense oligomers composed of the sequences of 
each miRNA were blotted onto a membrane, which was then probed against hsa-let-
7g-5p. 
The dot-blot data illustrated in Figure 41 and Figure 42 indicate little cross-
hybridisation between the anti-let-7f-5p and anti-let-7g-5p probes, and other 
let-7 miRNA dot-blots. Notably, almost no reactivity between anti-let-7f-5p 
and let-7g-5p, or between anti-let-7g-5p and let-7f-5p, is observable. This 
suggests that both miRNAs are really upregulated, rather than the apparent 
upregulation of one being an artefact arising from cross-hybridisation of the 
probe targeted against the other. Both probes cross-reacted to a small extent 
with other let-7 members; the anti-let-7f-5p probe with let-7a-5p, and the anti-
let-7g-5p probe with let-7i-5p. However, reads matching neither let-7a-5p nor 
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let-7i-5p were found in the Caco-2 library data, implying that these miRNAs 
were either absent or very low in abundance, and thus unlikely to confound 
the Northern Blot data. 
4.3.2 The MiR-10 Family 
Caco-2 library data reads annotated to miR-10a-5p and miR-10b-5p were 
abundant, and also implied that these miRNAs are regulated by SFN. 
Reports in the literature regarding the roles of miR-10a-5p and miR-10b-5p in 
cancer vary from oncogenic to tumour-suppressive. 
Scrutiny of the miR-10a-5p-annotated reads reveals that those strictly 
matching the canonical sequence indicate induction by SFN (10µM) 
treatment of 1.1- and 1.5-fold at 8 and 24 h respectively, as illustrated in 
Figure 43. 
 
Figure 43: Normalised read numbers for hsa-miR-10a-5p in Caco-2 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
The reads annotated as miR-10a-5p|[isomiR]|21_42| imply induction of 1.2- 
and 1.5-fold  at 8 and 24 h respectively. 
 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
0 8 24
hs
a
-
m
iR
-
10
a
-
5p
 
N
o
rm
a
lis
e
d 
R
e
a
d 
N
u
m
be
r
Time (h)
178 | P a g e  
 
4.3.2.1 MiR-10a-5p in Caco-2 
 
 
Figure 44: The effect of SFN treatment on the level of hsa-miR-10a-5p in Caco-2 cells 
at 4, 8, 12, 24 and 48 h. Cells were treated by adding to culture medium in triplicate, 
DMSO-diluted SFN (10µM) for 4, 8, 12, 24 or 48 h, or DMSO; final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed via TaqMan 
RT-qPCR as described in Methods, using U6 as an internal control for normalisation. 
Induction was evaluated by the Pfaffl method as described in Methods, and data are 
represented as means of triplicates ± S.E.M. (*p<0.05). 
The time-course RT-qPCR data illustrated in Figure 44 indicate a statistically 
significant (according to an unpaired two-tailed Student’s T-test) induction of 
canonical miR-10a-5p in Caco-2, by 1.6- and 1.9-fold at the 8 and 24 h time 
points respectively, thus confirming that it is induced by SFN treatment. The 
trend observed in the data shown in Figure 45 suggests that there is a dose-
dependent induction of miR-10a-5p by SFN (5 to 20µM) in Caco-2. 
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Figure 45: The effect of 24 h SFN treatment on the level of hsa-miR-10a-5p in Caco-2 
cells. Cells were treated for 24 h by adding to culture medium in triplicate, DMSO-
diluted SFN (5, 10 or 20µM) or DMSO (control); final DMSO concentrations were 0.05% 
(v/v). Relative miRNA abundance was assayed via TaqMan RT-qPCR as described in 
Methods, using U6 as an internal control for normalisation. Induction was evaluated 
by the Pfaffl method as described in Methods, and data are represented as means of 
triplicates ± S.E.M. (*p<0.05). 
The Northern Blot data illustrated in Figure 46 for miR-10a-
5p|[isomiR]|21_42| partially corroborate its modulation by SFN at 8 h. 
However, in contrast to the Caco-2 library data, the Northern Blot data imply 
that expression at 24 h falls back to levels similar to those in controls. 
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Figure 46: The effect of SFN treatment on the level of hsa-miR-10a-5p|[isomiR]|21_42| 
in Caco-2 cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance was assayed via 
Northern Blotting as described in Methods, using U6 as an internal control for 
normalisation. Induction is expressed as [(miRNA band intensity)/(U6 band intensity)] 
for each sample relative to the control mean, and data are represented as means of 
duplicates ± (upper value – lower value)/2. 
This also contrasts with the pattern of canonical miR-10a-5p expression 
observed in the RT-qPCR data illustrated in Figure 44. Perhaps extended 
SFN treatment promotes the dominance of one isomiR over the other. 
However, it is difficult to draw conclusions from the Northern Blot data shown 
in Figure 46 due to the weak band signals. 
4.3.2.2 MiR-10b-5p in Caco-2 
The Caco-2 library data indicated that canonical miR-10b-5p was induced by 
SFN 1.4- and 2.4-fold at 8 and 24 h respectively, as illustrated in Figure 47. 
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Figure 47: Normalised read numbers for hsa-miR-10b-5p in Caco-2 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
However, the RT-qPCR data (see Appendix) did not show any significant 
differences nor trend. Likewise, the Northern Blot data for miR-10b-
5p|[isomiR]|26_47| (see Appendix) did not corroborate the changes in 
expression of this miRNA inferred from the library data analysis. 
4.3.3 MiR-29b-3p 
MiR-29b-3p is an miRNA whose function apparently varies according to 
context, since it is reported as both a tumour suppressor and an oncogene. 
Interestingly, it has been demonstrated to be repressed by Nrf2, probably at 
the transcriptional level via the binding of Nrf2 to an ARE in the promoter 
region of the miR-29b-1 gene (Shah, Zaitseva et al. 2015). The Northern Blot 
data illustrated in Figure 48 show that this miRNA is downregulated by SFN 
treatment in Caco-2.  
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Figure 48: The effect of SFN treatment on the level of hsa-miR-29b-3p in Caco-2 cells 
at 8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-
diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO concentrations were 0.05% 
(v/v). Relative miRNA abundance was assayed via Northern Blotting as described in 
Methods, using U6 as an internal control for normalisation. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the control 
mean, and data are represented as means of duplicates ± (upper value – lower 
value)/2. 
Analysis of the Caco-2 library data did not actually imply the modulation of 
miR-29b-3p by SFN, although such modulation may have been masked by 
high inter-replicate read number variation, as illustrated in Figure 49. 
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Figure 49: Normalised read numbers for hsa-miR-29b-3p in Caco-2 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
The implications of the finding that SFN treatment downregulates miR-29b-
3p expression in Caco-2 cells are unclear, since this miRNA has received 
both tumour suppressive and oncogenic reports. For example, it has been 
demonstrated to suppress EMT in CRC by targeting Tiam1 (Wang, Li et al. 
2014), and to inhibit the Wnt signalling pathway (Subramanian, Rao et al. 
2014). On the other hand, it has been reported to be overexpressed in, and 
enhance the invasiveness of, breast cancer cells (Yan, Guo et al. 2015). 
Interestingly, a different ITC – PEITC – has been shown to inhibit the 
environmental cigarette smoke-mediated upregulation of miR-29b-3p in the 
mouse lung (Izzotti, Larghero et al. 2010). The ability of ITCs such as SFN 
and PEITC to downregulate miR-29b-3p may be due to Nrf2 induction, since 
Nrf2 has been demonstrated to be able to downregulate miR-29b-3p by 
repressing transcription at the miR-29b-1 genetic locus in acute myeloid 
leukaemia cells (Shah, Zaitseva et al. 2015). 
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4.3.4 MiR-193b-3p 
MiR-193b-3p is a potential oncomiR that was indicated by the library data to 
be downregulated by SFN (10µM) treatment 1.5- and 2.0-fold at 8 and 24 h 
respectively, as illustrated in Figure 50. 
 
Figure 50: Normalised read numbers for hsa-miR-193b-3p in Caco-2 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
However, the Northern Blot data as illustrated in Figure 51 do not strongly 
support this; they corroborate downregulation at 8 h, but not at 24 h. This 
miRNA is similar in sequence to hsa-miR-193a-3p. However, the lack of 
effect observable at 24 h in the Northern Blot is unlikely to be an artefact of 
the anti-miR-193b-3p probe cross-hybridising with miR-193a-3p, because the 
library data suggested that the latter was also downregulated at 24 h. 
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Figure 51: The effect of SFN treatment on the level of hsa-miR-193b-3p in Caco-2 cells 
at 8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-
diluted SFN (10µM) for 8 or 24 h, or DMSO; final DMSO concentrations were 0.05% 
(v/v). Relative miRNA abundance was assayed via Northern Blotting as described in 
Methods, using U6 as an internal control for normalisation. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the control 
mean, and data are represented as means of duplicates ± (upper value – lower 
value)/2. 
As a potential oncomiR downregulated by SFN treatment, it would be 
interesting to validate the modulation of miR-193b-3p by additional Northern 
Blots and/or RT-qPCR experiments in the future, and then if it is confirmed to 
be differentially expressed, to study it further. 
4.3.5 Other MiRNAs 
4.3.5.1 Caco-2 
The library data implied that miR-182-5p was upregulated by SFN (10µM) in 
Caco-2 by 1.4- and 1.6-fold at 8 and 24 h respectively, as illustrated in Figure 
52. 
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Figure 52: Normalised read numbers for hsa-miR-182-5p in Caco-2 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
However, the Northern Blot (see Appendix for data) did not convincingly 
corroborate this. MiR-192-5p was also indicated by the library data as 
upregulated by SFN (10µM) 1.7-fold at 24 h, as illustrated in Figure 53, but 
this also was not supported by the Northern Blot (see Appendix for data). 
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Figure 53: Normalised read numbers for hsa-miR-192-5p in Caco-2 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
The library data had implied miR-17-3p to be downregulated by SFN (10µM) 
1.6- and 2.0-fold at 8 and 24 h respectively, as illustrated in Figure 54; this 
neither was supported by the Northern Blot (see Appendix for data). 
 
Figure 54: Normalised read numbers for hsa-miR-17-3p in Caco-2 cells following SFN 
treatment for 8 or 24 h, or in controls. Data are represented as medians across library 
replicates, with the maximum and minimum values of replicate sets represented as 
the upper and lower bounds of error bars. 
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Finally, miR-1296-5p appeared to be downregulated by SFN as illustrated in 
Figure 55. The Northern Blot data (see Appendix) were unable to confirm 
this, although this may have been due to very weak band signals, which 
themselves imply low overall expression. 
 
Figure 55: Normalised read numbers for hsa-miR-1296-5p in Caco-2 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
4.3.5.2 CCD-841 
The library data indicated that hsa-miR-182-5p was upregulated in CCD-841 
by SFN (10µM) 1.4-fold at 8 h, then downregulated 5.5-fold at 24 h, as 
illustrated in Figure 56. 
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Figure 56: Normalised read numbers for hsa-miR-182-5p in CCD-841 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
However, the Northern Blot (see Appendix for data) did not corroborate this. 
Although it is possible that the anti-miR-182-5p probe cross-hybridised with 
miR-183-5p due to sequence similarity, the latter was suggested to be 
downregulated in a similar fashion by the library data. 
It appeared from library data analysis that miR-106b-5p was upregulated by 
SFN (10µM) in CCD-841 2.6-fold at 24 h (illustrated in Figure 57). 
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Figure 57: Normalised read numbers for hsa-miR-106b-5p in CCD-841 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
However, this effect was not supported by the Northern Blot experiments 
(see Appendix for data). It is not clear whether or not this is an artefact of 
cross-reactivity of the anti-miR-106b-5p oligo with other close-in-sequence 
miRNAs such as miR-17-5p and miR-106a-5p, both of which have more 
reads in the library data and are not shown to be differentially expressed. 
The upregulation of miR-181a-5p by SFN at 24 h in CCD-841 was inferred 
from the library data (as illustrated in Figure 58), but not confirmed by 
Northern Blot experiments. Nor did the time course Northern Blots indicate 
any changes at the 4, 8, 12 or 48 h time points (see Appendix for data). 
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Figure 58: Normalised read numbers for hsa-miR-181a-5p in CCD-841 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
It was initially speculated that miR-181a-5p modulation might have been 
masked by cross-hybridisation of the anti-miR-181a-5p Northern Blot probe 
with the closely-related hsa-miR-181b-5p, but subsequent dot-blot 
experiments did not imply the potential for such cross-hybridisation to occur 
to a significant extent (see Appendix for data). 
Finally, the library data analysis implied that miR-345-5p was upregulated by 
SFN (10µM) in CCD-841 2.5-fold at 24 h (as illustrated in Figure 59). 
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
0 8 24
hs
a
-
m
iR
-
18
1a
-
5p
 
N
o
rm
a
lis
e
d 
R
e
a
d 
N
u
m
be
r
Time (h)
192 | P a g e  
 
 
Figure 59: Normalised read numbers for hsa-miR-345-5p in CCD-841 cells following 
SFN treatment for 8 or 24 h, or in controls. Data are represented as medians across 
library replicates, with the maximum and minimum values of replicate sets 
represented as the upper and lower bounds of error bars. 
However, subsequent RT-qPCR experiments did not corroborate this (see 
Appendix for data). In fact, the RT-qPCR data actually indicated 
downregulation by 20µM SFN at 24 h, which may have been due to mild 
cytotoxicity. 
4.4 Summary 
Caco-2 and CCD-841 cells were treated with SFN (10µM) for 8 or 24 h in 
triplicate, and then total RNA samples were extracted and used to clone 
miRNAs in libraries using the method and HD adapters developed by the 
Dalmay laboratory. The libraries were deep sequenced, and the sequencing 
data were quality-checked and normalised. Reads were then annotated 
against the list of known human miRNAs. Medians read numbers for each 
miRNA were taken across replicate libraries, and compared to identify 
apparently SFN-modulated miRNAs. Out of such miRNAs, those with 
apparent relevance to cancer and/or for which library reads were relatively 
high were selected for further study. 
A number of cancer-related miRNAs were confirmed by either Northern Blots 
or RT-qPCR to be SFN-modulated in Caco-2 cells: 
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• Let-7f-5p was indicated by the library data as upregulated in Caco-2 
by 8 and 24 h SFN treatment 1.4- and 2.1-fold respectively, and was 
shown by Northern Blot experiments to be upregulated 1.2- and 1.4-
fold at 8 and 24 h respectively. 
• Let-7g-5p was indicated by the library data as upregulated in Caco-2 
by 1.3- and 2.0-fold at 8 and 24 h respectively, and was shown by the 
Northern Blot experiments to be upregulated 1.6-fold at 24 h. 
• By contrast, neither let-7f-5p nor let-7g-5p were modulated by SFN 
treatment in CCD-841 according to the Northern Blot data. 
• Dot-blot data suggested that the apparent increases of let-7f-5p and 
let-7g-5p in Caco-2 were not artefacts of probe cross-hybridisation 
with other let-7 family members. 
• MiR-10a-5p|[isomiR]|21_42| was indicated by the library data as being 
upregulated 1.2- and 1.5-fold in Caco-2 by 8 and 24 h SFN treatment 
respectively, and also shown by the Northern Blot data to be 
upregulated 1.4-fold at 8 h, although not at 24 h. 
• A Northern Blot experiment for miR-29b-3p showed that it was 
downregulated 1.4 and 1.6-fold in Caco-2, by 8 and 24 h SFN 
treatment respectively. 
• MiR-193b-3p was indicated by the library data as being 
downregulated in Caco-2 by 8 and 24 h SFN treatment 1.5- and 2.0-
fold respectively, and shown to be downregulated 1.4-fold at 8 h but 
not at 24 h, by the Northern Blot data. 
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Chapter 5: MicroRNA Target Validation 
5.1 General Introduction 
The two-step miRNA profiling process, i.e. library construction-sequencing-
analysis followed by individual assays, has confirmed that SFN treatment 
modulates the expression of several reportedly cancer-related miRNAs in 
Caco-2 cells. Since miRNA-mRNA base pairing need not be perfect for the 
repression of translation, any given miRNA potentially regulates many 
different mRNA transcripts. Computational algorithms such as miRanda are 
often used to predict which mRNAs a given miRNA will bind to, based on 
factors such as miRNA seed region-mRNA 3‘-UTR complementarity and 
binding energy. However, such algorithms inevitably make many incorrect 
predictions when loose parameters are used, and/or fail to predict 
interactions that actually occur if stricter parameters are input. Actual miRNA-
mRNA interactions cannot thus be conclusively demonstrated by 
computational predictions alone; a cell-based assay such as the luciferase 
assay is necessary to confirm the ability of a given miRNA to bind (a) 
predicted mRNA target site(s). 
5.2 Let-7f-5p 
Analysis of the library data implied that let-7f-5p was upregulated by SFN 
(10µM) treatment in Caco-2 cells, and was highly abundant. This modulation 
was then confirmed by Northern Blots (as shown in Chapter 4). 
Let-7 miRNAs, such as let-7f-5p, have been repeatedly demonstrated to 
have anti-proliferative, pro-differentiative and pro-apoptotic effects, thereby 
acting as tumour suppressors. Interestingly, let-7 miRNAs have been 
demonstrated to repress the translation of Bach1: a protein that competes 
with Maf proteins for binding to Nrf2 in the nucleus and thus represses Nrf2-
mediated gene activation. Nrf2-Maf heterodimers are more transcriptionally 
activating of ARE-controlled genes than are Bach1-Maf heterodimers. In fact, 
let-7 miRNAs reportedly upregulated the Nrf2-activated reducing enzyme 
HO-1 via Bach1 repression (Hou, Tian et al. 2012). The potential for a given 
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miRNA to repress tumour cell growth in spite of the cytoprotective Nrf2-
mediated antioxidant response is very interesting from a therapeutic point of 
view. 
Let-7f-5p was initially selected for further study, based on its apparent high 
abundance and high likelihood of influencing carcinogenesis. Of interest are 
its effects at the mRNA and protein levels, as well as consequent effects on 
cancer ‘endpoints’ in vitro such as cell migration and invasion. 
5.2.1 Selection of Predicted Target Genes 
As discussed previously, algorithms that predict the mRNA binding sites of a 
miRNA often return thousands of predictions, many of which are likely to be 
false positives. 5467 genes were predicted as targets of let-7f-5p by the 
miRanda algorithm (http://www.microrna.org). Amongst those with mirSVR 
scores ≤ -1.2, several were selected for validation and further study after 
scouting the literature to ascertain their apparent relevance to cancer 
(particularly CRC), and existing reports of interactions between them and let-
7 miRNAs. Thus selected were: 
• BACH1 – a repressor of Nrf2-mediated gene transcription, but also 
reported to promote CRC proliferation (Yun, Jo et al. 2013). 
• CDC25A – a phosphatase that promotes cell cycle progression, and is 
reported to be overexpressed in many cancers (Boutros, Lobjois et al. 
2007). 
• HMGA2 – a promoter of EMT, proliferation, motility and invasion in 
CRC (Li, Zhao et al. 2014). 
• KRAS – a growth promoter that is mutationally over-activated and/or 
overexpressed in many cancers, including CRC. 
• MYC - a promoter of proliferation, migration and invasion that is 
mutationally over-activated and/or overexpressed in many cancers, 
including CRC. 
5.2.2 Luciferase Assays 
The 3’-UTRs of the genes of interest, as listed above, were cloned into the 
pmiRGLO vector as described in Chapter 2, for use in luciferase assays to 
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detect the binding of miRNAs to the 3’-UTRs. Variations of the 3’-UTRs 
produced by mutating the predicted miRNA-binding sites were also cloned 
into the vector as described in Chapter 2, to use as controls (see Appendix 
for plasmid verification and sequencing data). ‘Positive control’ experiments 
were performed to confirm that the let-7f-5p mimic and inhibitor were actually 
decreasing and increasing let-7f-5p functionality, respectively. For these 
experiments, an artificial insert containing four repeats of sequence 
antisense to that of let-7f-5p was created, and inserted into pmiRGLO vector 
in a similar fashion to the 3’-UTR clones. 
HCT116 cells were co-transfected with insert-containing pmiRGLO vector 
(200ng) and let-7f-5p mimic (100nM) (Qiagen) and/or let-7f-5p inhibitor 
(100nM) (Qiagen) and/or AllStars Negative Control siRNA (100-200nM) 
(Qiagen), equalising ‘RNA’ concentrations to 200nM across all transfected 
wells. Luciferase assays were performed at 48 h post-transfection using the 
Dual-Glo Luciferase Assay Kit (Promega). Relative Firefly and Renilla 
luciferase expression levels were evaluated by measuring luminescence. 
[Firefly luminescence]/[Renilla luminescence] ratios were calculated for each 
well, and then normalised to controls (no mimic or inhibitor; AllStars Negative 
Control siRNA at 200nM). 
5.2.2.1 Control Experiments 
As illustrated by the data in Figure 60, the control experiments confirmed the 
expected alteration of let-7f-5p functionality by the let-7f-5p mimic and 
inhibitor. The data show both a dramatic repression of relative Firefly 
luciferase expression by the mimic alone (69%), and a strong upregulation of 
such by the inhibitor alone (195%). As expected, the effects of the mimic 
neutralised those of the inhibitor, and vice versa. 
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Figure 60: Data from luciferase assays performed after co-transfecting HCT116 cells 
with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-7f-5p inhibitor (Qiagen) 
and/or AllStars Negative Control siRNA (Qiagen). The pmiRGLO vector contained an 
insert consisting of four repeats of sequence antisense to that of let-7f-5p. Luciferase 
assays were performed at 48 h post-transfection using the Dual-Glo Luciferase Assay 
Kit, and then relative Firefly and Renilla luciferase expression levels were evaluated 
by measuring the luminescence of metabolised substrates. Blank-corrected Firefly 
luminescence values were divided by blank-corrected Renilla luminescence values, 
and then ratios were normalised to controls (AllStars Negative Control siRNA at 
200nM). Normalised data are represented as triplicate means ± S.E.M. (*p<0.05 
according to two-tailed Student’s T-test). 
5.2.2.2 BACH1 
As illustrated by the data presented in Figure 61, the let-7f-5p mimic appears 
to inhibit relative Firefly luciferase expression from the vector containing the 
‘wild-type’ form of part of the BACH1 3’-UTR, by 27% vs. control (albeit 
below significance; p=0.07, according to unpaired two-tailed Student’s T-
test), but has no apparent effect on expression from the vector containing the 
‘mutated’ form of the BACH1 3’-UTR segment. This may indicate that let-7f-
5p actually binds to one or both of the predicted binding sites in its 3’-UTR, 
but a repetition of the experiment would be necessary to confirm this, due to 
failing to reach statistical significance. The let-7f-5p inhibitor had no obvious 
effect alone, but in combination with the mimic, abrogated the mimic’s effect. 
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Figure 61: Data from luciferase assays performed after co-transfecting HCT116 cells 
with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-7f-5p inhibitor (Qiagen) 
and/or AllStars Negative Control siRNA (Qiagen). The pmiRGLO vector contained an 
insertion of either a part of the BACH1 3’-UTR containing two predicted let-7f-5p 
binding sites, or a modified form of this 3’-UTR portion with the predicted binding 
sites mutated. Luciferase assays were performed at 48 h post-transfection using the 
Dual-Glo Luciferase Assay Kit, and then relative Firefly and Renilla luciferase 
expression levels were evaluated by measuring the luminescence of metabolised 
substrates. Blank-corrected Firefly luminescence values were divided by blank-
corrected Renilla luminescence values, and then ratios were normalised to controls 
(AllStars Negative Control siRNA at 200nM). Normalised data are represented as 
triplicate means ± S.E.M. (*p<0.05 according to two-tailed Student’s T-test). 
5.2.2.3 CDC25A(a) 
The data presented in Figure 62 indicate that although the mimic alone had 
no effect on relative Firefly luciferase expression, the inhibitor alone 
significantly increased such expression from the ‘wild-type’ vector by 43% 
(p=0.04), but not from the mutant vector. This implies that let-7f-5p is able to 
bind to the predicted site in the 3’-UTR of CDC25A. The combination of the 
mimic with the inhibitor did not abolish the inhibitor’s upregulatory effects. 
The lack of observable effect of the mimic alone potentially implies that at the 
basal level of let-7f-5p in HCT116, the binding site is already saturated with 
respect to bound let-7f-5p. 
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Figure 62: Data from luciferase assays performed after co-transfecting HCT116 cells 
with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-7f-5p inhibitor (Qiagen) 
and/or AllStars Negative Control siRNA (Qiagen). The pmiRGLO vector contained an 
insertion of either a part of the CDC25A 3’-UTR containing a predicted let-7f-5p 
binding site, or a modified form of this 3’-UTR portion with the predicted binding site 
mutated. Luciferase assays were performed at 48 h post-transfection using the Dual-
Glo Luciferase Assay Kit, and then relative Firefly and Renilla luciferase expression 
levels were evaluated by measuring the luminescence of metabolised substrates. 
Blank-corrected Firefly luminescence values were divided by blank-corrected Renilla 
luminescence values, and then ratios were normalised to controls (AllStars Negative 
Control siRNA at 200nM). Normalised data are represented as triplicate means ± 
S.E.M. (*p<0.05 according to two-tailed Student’s T-test). 
5.2.2.4 HMGA2(b) 
It is apparent from the data presented in Figure 63 that the let-7f-5p mimic 
significantly repressed relative Firefly expression from the ‘wild-type’ HMGA2 
vector containing three predicted let-7f-5p binding sites, by 36% (P=0.02), 
but had no effect on that from the vector with mutated binding sites. The 
inhibitor alone appeared to slightly de-repress expression, but not to 
statistical significance (P=0.13), although the combination of the inhibitor with 
the mimic significantly abrogated mimic-induced repression. This confirms 
that one or more of the three predicted binding sites are bound by let-7f-5p in 
a transcription-repressing fashion. The lack of observable effect from the 
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inhibitor alone potentially implies that the binding sites are mostly unoccupied 
by let-7f-5p anyway at basal levels. 
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Figure 63: Data from luciferase assays performed after co-transfecting HCT116 cells 
with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-7f-5p inhibitor (Qiagen) 
and/or AllStars Negative Control siRNA (Qiagen). The pmiRGLO vector contained an 
insertion of either a part of the HMGA2 3’-UTR containing three predicted let-7f-5p 
binding sites, or a modified form of this 3’-UTR portion with the predicted binding 
sites mutated. Luciferase assays were performed at 48 h post-transfection using the 
Dual-Glo Luciferase Assay Kit, and then relative Firefly and Renilla luciferase 
expression levels were evaluated by measuring the luminescence of metabolised 
substrates. Blank-corrected Firefly luminescence values were divided by blank-
corrected Renilla luminescence values, and then ratios were normalised to controls 
(AllStars Negative Control siRNA at 200nM). Normalised data are represented as 
triplicate means ± S.E.M. (*p<0.05 according to two-tailed Student’s T-test). 
5.2.2.5 MYC 
The let-7f-5p mimic alone did not impact relative Firefly luciferase expression 
from the MYC ‘wild-type’ vector, according to the data presented in Figure 
64. However, the inhibitor alone increased expression from the ‘wild-type’ 
vector by 35% (P=0.03) but not that from the mutant vector. The transfection 
of the mimic together with the inhibitor reduced the inhibitor’s effect. 
Surprisingly, the co-transfection of mimic and inhibitor dramatically increased 
relative Firefly luciferase expression from the mutant vector, although not 
from the ‘wild-type’ vector. Neither the mimic nor inhibitor had any such effect 
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alone. Perhaps the new sequence created by the artificial mutation was 
transcriptionally upregulated by this particular combination of mimic and 
inhibitor via unknown mechanisms. 
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Figure 64: Data from luciferase assays performed after co-transfecting HCT116 cells 
with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-7f-5p inhibitor (Qiagen) 
and/or AllStars Negative Control siRNA (Qiagen). The pmiRGLO vector contained an 
insertion of either a part of the MYC 3’-UTR containing a predicted let-7f-5p binding 
site, or a modified form of this 3’-UTR portion with the predicted binding site mutated. 
Luciferase assays were performed at 48 h post-transfection using the Dual-Glo 
Luciferase Assay Kit, and then relative Firefly and Renilla luciferase expression levels 
were evaluated by measuring the luminescence of metabolised substrates. Blank-
corrected Firefly luminescence values were divided by blank-corrected Renilla 
luminescence values, and then ratios were normalised to controls (AllStars Negative 
Control siRNA at 200nM). Normalised data are represented as triplicate means ± 
S.E.M. (*p<0.05 according to two-tailed Student’s T-test). 
No effects of the let-7f-5p mimic or inhibitor on relative Firefly luciferase 
expression from the ‘wild-type’ KRAS vector are observable from the data 
illustrated in Figure 65. However, the mimic unexpectedly upregulated 
expression from the mutant vector only. The mutation had been generated 
by the creation of a ‘GATATC’ sequence (EcoRV restriction site). The 
‘GATATC’ sequence per se is unlikely to have been solely responsible for 
the mimic-induced upregulation, because such upregulation was not 
observed with the mutant BACH1, CDC25A(a) and HMGA2(b) vectors, for 
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which the ‘GATATC’ motif was also introduced. Perhaps the mutation in this 
specific context of surrounding bases facilitated indirect transcriptional 
upregulation by let-7f-5p mimic via unknown mechanisms. Interestingly, the 
combination of let-7f-5p inhibitor with the mimic significantly diminished 
upregulation vs. the mimic alone (p=0.001). 
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Figure 65: Data from luciferase assays performed after co-transfecting HCT116 cells 
with pmiRGLO vector and let-7f-5p mimic (Qiagen) and/or let-7f-5p inhibitor (Qiagen) 
and/or AllStars Negative Control siRNA (Qiagen). The pmiRGLO vector contained an 
insertion of either a part of the KRAS 3’-UTR containing a predicted let-7f-5p binding 
site, or a modified form of this 3’-UTR portion with the predicted binding site mutated. 
Luciferase assays were performed at 48 h post-transfection using the Dual-Glo 
Luciferase Assay Kit, and then relative Firefly and Renilla luciferase expression levels 
were evaluated by measuring the luminescence of metabolised substrates. Blank-
corrected Firefly luminescence values were divided by blank-corrected Renilla 
luminescence values, and then ratios were normalised to controls (AllStars Negative 
Control siRNA at 200nM). Normalised data are represented as triplicate means ± 
S.E.M. (*p<0.05 according to two-tailed Student’s T-test). 
5.3 Conclusions 
It is apparent from the data presented in this Chapter that let-7f-5p is able to 
bind to sites in the 3’-UTRs of CDC25A, HMGA2 and MYC predicted as 
binding sites. Therefore, it would be informative to perform experiments in 
the future to: 
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• Assay the effects of let-7f-5p mimic and/or inhibitor on the expression 
of these genes at the mRNA and protein levels. 
• Determine whether or not sub-cytotoxic doses of SFN directly 
modulate such expression. 
• Test for synergistic or antagonistic interactions between SFN and let-
7f-5p mimic or inhibitor. 
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Chapter 6: General Discussion 
6.1 Recapitulation of Study Rationale and Objectives 
The risk of CRC, an increasingly important cause of morbidity and mortality 
globally whose symptoms tend not to become apparent until the disease has 
advanced to a terminal stage, is apparently linked to diet and lifestyle. 
Interest in the anti-cancer potential of phytochemicals from fruits, vegetables 
and herbs, has intensified in recent decades.  Given the inconclusiveness of 
studies into the relationship between overall fruit and vegetable intake and 
cancer incidence, yet observation of marked inverse correlations between 
the consumption of cruciferous vegetables and cancer incidence, interest in 
the potentially protective roles of ITCs from these vegetables has gained 
traction in recent decades. CRC is a particular interesting target, since the 
colorectal tissues are inevitably better predisposed than many others to be 
exposed to ingested ITCs prior to their metabolism. Chemopreventative 
properties of ITCs have classically been attributed to hormetic Nrf2-mediated 
antioxidant effects, by which low-to-moderate doses tend to be 
cytoprotective, whilst high doses are potentially cytotoxic, although several 
studies indicate that the plasma concentrations reasonably attainable by 
cruciferous vegetable consumption are well below the cytotoxic threshold for 
healthy cells. 
The roles of Nrf2 in cancer are very complex, since its cytoprotective effects 
in healthy cells are usually beneficial, whereas its activity in tumour cells is 
often considered undesirable because it may increase their 
chemoresistance. On the other hand, tumour cell Nrf2 activation can in some 
cases have counter-intuitive anti-proliferative and anti-metastatic effects. The 
interactions between ITCs and carcinogenesis clearly extend beyond Nrf2 
activation, such as to the direct inhibition of HDACs. 
MiRNAs are small non-coding RNAs that post-transcriptionally modulate 
gene expression, whose importance in human health (particularly in cancer) 
has gained increasing recognition over the past 15 years. It is also 
increasingly apparent that dietary, lifestyle and environmental factors can 
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influence miRNA expression levels, which themselves could be important 
mediators of the effects of such factors on health. The existence of evidence 
that SFN may modulate miRNA expression, the known ability of miRNAs to 
modulate carcinogenesis, and the attribution of ITCs with chemopreventative 
and/or chemotherapeutic effects, together form the rationale for investigating 
the potential roles of miRNAs in the anti-cancer effects of SFN, with a view to 
the development of more effective and/or less toxic chemotherapeutic 
strategies. CRC adenocarcinoma Caco-2 and non-cancerous colonic 
epithelial CCD-841 cells were used for the profiling of miRNA expression 
following SFN treatment (after an initial experimental validation of the 
system), which included a wide-scale miRNA expression analysis via deep 
sequencing, followed by individually-targeted miRNA assays for verification.  
6.2 General Summary of Findings 
6.2.1 Validation of the System 
6.2.1.1 Cell Viability Assays 
The cytotoxicity of SFN towards the Caco-2 and CCD-841 cell lines was 
evaluated, by using the MTT assay to measure cell viability at 24 or 48 h 
following the addition of SFN to the medium of cells in the logarithmic growth 
phase. Cytotoxicity was clearly demonstrated towards both lines at high 
doses, with IC50 values of ~ 40µM at both 24 and 48 h in Caco-2, and 
IC50[24h] and IC50[48h] of 97 and 20µM in CCD-841. It was concluded that 
concentrations ≤10µM were not cytotoxic and thus were suitable for 
experimental use. 
The cytotoxicity of a source of ROS, H2O2, was tested against both cell lines, 
giving IC50[24h] and IC50[48h] values of 200 and 320µM in Caco-2, and 
IC50[24h] and IC50[48h] values of 200 and 70µM in CCD-841. The data 
clearly showed that Caco-2 cells were able to recover from H2O2-mediated 
inhibition between 24 and 48 h, whilst CCD-841 cells were not, suggesting 
important differences between the cells that may be due to differential 
apoptotic and/or cell cycle arrest signalling. 
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6.2.1.2 The Effects of Sulforaphane on Nrf2 and Nrf2-Mediated 
Gene Expression 
A clear SFN-induced upregulation of TrxR-1 at both the mRNA and protein 
level was demonstrated in both cell lines, according to RT-qPCR and 
Western Blot assays. Induction at the mRNA level was dose-dependent at 24 
h (SFN ≤ 20µM) in both cell lines, but the effects on the actual levels of this 
selenoprotein (at 48 h) were highly dependent upon the availability of 
selenium. Protein-level upregulation in the presence of supplemented 
selenium (in the form of SeMSC (0.2µM)) was apparently maintained for at 
least 72 h. Another Nrf2-activated reducing enzyme, UGT1A, was clearly 
demonstrated to be upregulated by SFN in a dose-dependent fashion, at 
both 24 and 72 h, in Caco-2. 
A dramatic increase in nuclear Nrf2 levels was demonstrably induced by 
SFN in Caco-2 cells from 4 h. Such increases in nuclear Nrf2 did not appear 
to be dose dependent (5-20µM SFN), implying that the dose-dependent 
effects on TrxR-1 mRNA transcript levels may point to the influence of 
pathways complementary to Nrf2 nuclear translocation, such as the 
activation of Nrf2 co-factors and/or the inhibition of competitive inhibitors of 
Nrf2-ARE binding e.g. Bach1 (Reichard, Motz et al. 2007). 
In conclusion, the data confirmed the ability of sub-cytotoxic doses of SFN to 
induce the nuclear translocation and transcription-activating activity of Nrf2 in 
the experimental set-up used, implying that such conditions would be 
appropriate for miRNA-profiling experiments. 
6.2.2 Effects of Sulforaphane on Oncogenic Characteristics 
6.2.2.1 Cell Migration: Wound Healing Assays 
The wound healing assay assesses the migration of cells into a linear gap 
‘wound’ created by scratching a confluent cell monolayer, by measuring the 
average distance between leading cells down the gap axis after a fixed 
period of time post-scratch (usually 48 h). In this instance, treatment-induced 
repression of migration was inferred from increases in endpoint average gap 
width in treated (SFN) vs. control (DMSO) monolayers. SFN treatment 
clearly inhibited CCD-841 cell migration in a dose dependent fashion (SFN ≤ 
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20µM), at concentrations demonstrated to be sub-cytotoxic by MTT assays. 
It is unclear whether or not this implies that SFN can impair the healing and 
renewal of non-cancerous colonic tissue. It might be expected that early 
tumour cells would probably react in a similar manner. No effects on 
migration were apparent in the Caco-2 cell line, which is derived from an 
advanced colorectal adenocarcinoma. It could be postulated that Caco-2 
cells are resistant to SFN-mediated repression of migration due to mutations 
and/or epimutations. On the other hand, the highly ‘adhesive’ nature of Caco-
2 cells may have prevented them from migrating whether or not SFN was 
present. A future experiment in a different CRC cell line, such as HCT116, 
might be more informative. 
6.2.2.2 Clonogenic Assays 
The clonogenic assay measures the ability of cells to divide and form 
colonies, following seeding at densities so low that cells are isolated from 
one another. The ability to survive and divide many times in spite of isolation 
is characteristic of highly oncogenic cells. 
Cells were seeded at very low density, and then SFN was added to culture 
medium at different concentrations. Cultures were then incubated for 2 
weeks, at the end of which the numbers of colonies (clusters of ≥50 cells) 
formed in SFN-treated wells were compared to those in control (DMSO only 
added) wells. This showed a very clear and dose-dependent inhibition of 
Caco-2 clonogenicity in response to the addition of SFN to culture medium, 
by 50 and 90% at 5 and 20µM SFN respectively. However, it was considered 
that these effects were not necessarily independent of SFN-induced 
oxidative stress and/or genotoxicity, because the addition of SFN to the 
culture medium of cells present at very low density results in much greater 
per-cell SFN exposure than if cells are present at 70% confluence. 
Therefore, another experiment was done in which cells were grown to 70% 
confluence, then pre-treated with the same concentrations of SFN for 24 h, 
and then detached and replated at low density for 2 week incubation without 
any further addition of SFN. Such acute sub-cytotoxic dose pre-treatment 
had no discernible effect on colony formation.  
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6.2.3 Profiling MicroRNA Expression Following Sulforaphane 
Treatment 
Conditions similar to those in which SFN-mediated Nrf2 and antioxidant gene 
induction was demonstrated were used to treat Caco-2 and CCD-841 cells, 
and then total RNA was extracted for miRNA profiling. Cells were treated for 
8 or 24 h with SFN at a concentration of 10µM. 
6.2.3.1 MicroRNA Libraries 
MiRNA libraries were constructed from total RNA samples using HD 
adapters (Sorefan, Pais et al. 2012) and the cloning method (Xu, Billmeier et 
al. 2015), both developed by the Dalmay laboratory. The main purpose of 
miRNA library construction, sequencing and analysis was to highlight 
apparently SFN-modulated cancer-related miRNAs upon which further 
studies should be focussed. Constructed libraries were deep sequenced on 
the Illumina HiSeq 2500 platform by the Earlham Institute, Norwich (formerly 
The Genome Analysis Centre). Deep sequencing data were quality-checked, 
reads were annotated against the list of known human miRNAs using 
PatMan, and then annotated data were manually scrutinised to check for 
misannotations. Apparent fold-changes in miRNA expression were 
determined by comparing normalised read numbers for each miRNA 
between the different libraries. 
Analysis of the data revealed the presence of isomiRs, varying in sequence 
with respect to the canonical forms by having several missing or extra 
nucleotides at either end. In most cases, the canonical form of a given 
miRNA dominated the read population, but alternative isomiRs dominated in 
a number of cases. IsomiR dominance may be influenced by cell and tissue 
type, and may also vary between tumour cells and their non-cancerous 
counterparts in a given tissue (Tan, Chan et al. 2014). 
6.2.3.2 MicroRNAs that were Individually Confirmed to be 
Modulated 
Of miRNAs indicated to be modulated by SFN according to the library 
sequencing data, several were selected for validation, including: let-7f-5p, 
let-7g-5p, miR-10a-5p, miR-10b-5p, miR-193b-3p, miR-182-5p, miR-17-3p, 
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miR-1296-5p, miR-106b-5p, miR-181a-5p and miR-345-5p. Additionally, 
miR-29b-3p was individually assayed. 
The let-7 miRNAs are frequently reported as tumour suppressors by 
promoting cell cycle arrest, differentiation and/or apoptosis, and inhibiting 
proliferation. Interestingly, several let-7 miRNAs have been demonstrated to 
repress Bach1, which is a competitive inhibitor of Nrf2-ARE binding (Hou, 
Tian et al. 2012). Let-7f-5p and let-7g-5p both appeared to be highly 
abundant and upregulated by SFN in Caco-2 according to the library data; 
these upregulations were subsequently corroborated by Northern Blot 
experiments. For the sake of comparison, Northern Blots were performed to 
test the effects of similar SFN treatment in CCD-841, in which interestingly, 
SFN appeared to have no effect on the expression of let-7f-5p or let-7g-5p. 
In order to rule out the possibility of the Northern Blot data for these miRNAs 
being confounded by non-specific cross-hybridisation of the probes, 
oligomers composed of sense let-7 miRNA sequences were blotted onto a 
membrane, and then the anti-let-7f-5p and anti-let-7g-5p Northern Blot 
probes were tested to see if they would cross-hybridise with the other let-7 
family members. The dot-blots indicated very little-to-no potential for cross-
hybridisation. 
MiR-10a-5p was also indicated to be upregulated by SFN in Caco-2 
according to the library data, and this was corroborated by Northern Blot and 
RT-qPCR experiments. The library data conversely indicated miR-193b-3p to 
be downregulated by SFN in Caco-2 at 8 and 24; a Northern Blot 
corroborated reduced expression at 8 h but not at 24 h. Given that the library 
data exhibited high inter-replicate variability, the Northern Blot data are likely 
to be more representative of reality. 
Interestingly, miR-29b-3p was shown to be downregulated by SFN in Caco-2 
according to a Northern Blot. This had not been highlighted by the library 
data analysis, most likely because the normalised read numbers for this 
miRNA had wide inter-replicate variation. The downregulation of miR-29b-3p 
could have been mediated by Nrf2-mediated repression of transcription from 
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the miR-29b-1 locus, which has been demonstrated in acute myeloid 
leukaemia cells (Shah, Zaitseva et al. 2015). 
6.2.3.3 MicroRNAs Unable to be Validated and Possible 
Explanations 
However, the apparent modulations of some other miRNAs were not 
corroborated by Northern Blots and/or RT-qPCR experiments, particularly in 
CCD-841. Based on the data for miRNAs individually assayed in CCD-841 
thus far, it is apparent that the CCD-841 library data are unlikely to reflect 
reality. Several significant fold-changes at 24 h were apparent from the CCD-
841 library data, but were not corroborated by the Northern Blot and/or RT-
qPCR experiments, such as for miRNAs including miR-181a-5p, miR-182-5p 
and miR-345-5p. A potential contributor to these discrepancies is the fact 
that the total RNA samples used for 24 h library construction were extracted 
in a separate instance (different experiment) from those samples used for the 
construction of the other libraries. Cells used in the second instance had 
been treated under the same conditions as those used in the first, but were 
at a different passage number. At the time, this was inevitable because the 
previously-extracted 24 h total RNA samples had been used up in previous 
library construction attempts. 
For future miRNA library construction-sequencing-analysis experiments, it 
would be advisable, where possible, to ensure that all samples used for 
library construction are extracted in the same experiment. This should help to 
minimise inter-replicate variation with respect to normalised read numbers. 
Therefore, preferably large quantities of RNA ought to be extracted at once, 
so that unsuccessful attempts at library construction can be repeated using 
the same RNA samples. This was taken into account when carrying out 
subsequent experiments for the Caco-2 libraries, all of the RNA samples 
used for which were extracted in the same experiment. 
At the time of CCD-841 library construction, it was not expected that RNA 
samples extracted from a separate experiment would exhibit wildly different 
miRNA expression profiles if similar experimental conditions were 
maintained. However, given that relatively high inter-replicate variation is 
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already observable across normalised read numbers for some miRNAs even 
in the Caco-2 library data, it is prudent to minimise unnecessary potential 
sources of variation. As to the question of why such inter-replicate variation 
was observed in the Caco-2 library data, it is possible that the long RNAse-
sensitive nature of the 5’- and 3’-adapter ligation process facilitated some 
stochastic RNAse-mediated miRNA degradation, which could perhaps be 
ameliorated by increasing the concentrations of RNAse inhibitors in the 
reactions. 
6.2.4 Validating Predicted MicroRNA Targets and Functions 
6.2.4.1 Predicted MicroRNA-Target Genes 
Let-7f-5p was selected for initial further study, given the validation of its 
sequential upregulation by SFN treatment in Caco-2, its apparent high 
abundance, and the frequency with which it is reported as a tumour 
suppressor. The ‘microRNA.org – Targets and Expression’ database 
catalogues miRNA-mRNA 3’-UTR interactions predicted by miRanda. The 
predicted target mRNAs of let-7f-5p according to this database, with mirSVR 
score ≤ -1.2, were searched in the literature for existing reports of relevance 
to cancer. On this basis, BACH1, CDC25A, HMGA2, KRAS and MYC were 
selected for validation. 
There are limitations to such algorithms that currently make predictions 
based upon several factors including complementarity between the miRNA 5’ 
seed region and mRNA 3’-UTR, binding energy and conservation across 
species. Inevitably, false positives arise since there are cases in which an 
miRNA and mRNA are not shown to actually bind in an experimental setting, 
despite strong or perfect 5’ seed region-3’-UTR complementarity. 
Conversely, algorithms can fail to predict actual miRNA-mRNA interactions, 
particularly those of a non-canonical nature that do not depend upon 5’ seed 
region-3’-UTR complementarity. This has been evidenced by crosslinking, 
ligation and sequencing of hybrids (CLASH) experiments in HEK293 cells, 
which revealed the AGO-mediated targeting of mRNAs via miRNAs in the 
absence of miRNA 5’ seed region-mRNA 3’-UTR complementarity (Helwak, 
Kudla et al. 2013). 
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6.2.4.2 Luciferase Assays to Confirm MicroRNA-3’-UTR 
Interactions 
The luciferase reporter assay was used to determine whether or not let-7f-5p 
was able to actually bind to computationally-predicted sites in the 3’-UTRs of 
the BACH1, CDC25A, HMGA2, KRAS and MYC transcripts. Portions of 3’-
UTRs containing predicted let-7f-5p binding sites were cloned from human 
genomic DNA and then inserted into the pmiRGLO Dual Reporter vector 
(Promega), upstream of the Firefly luciferase coding region. Prepared 
vectors were co-transfected with let-7f-5p mimic and/or inhibitor into HCT116 
cells. ‘Mutant’ forms of each vector were created in which the predicted let-
7f-5p binding sites were destroyed. Additionally, a vector was prepared with 
an artificial insert based upon four repeats of sequence antisense to that of 
let-7f-5p, for initial ‘control’ experiments to confirm that the mimic and 
inhibitor were in fact impacting let-7f-5p function as intended. Assays using 
the ‘mutant’ and ‘wild-type’ vectors were run in parallel, in order to determine 
whether or not the predicted binding sites were actually responsible for the 
observed mimic and/or inhibitor-induced transcriptional regulation. 
The initial ‘control’ luciferase assay confirmed that the let-7f-5p mimic and 
inhibitor did indeed increase and decrease let-7f-5p functionality, 
respectively. Data from subsequent luciferase assays confirmed that let-7f-
5p was able to interact with predicted binding sites in the 3’-UTRs of 
CDC25A, HMGA2 and MYC, and probably BACH1 (although the mimic-
induced repression of relative Firefly expression from BACH1 did not reach 
statistical significance; p=0.07), to induce transcriptional repression. 
Originally it was expected that if let-7f-5p was able to bind to a particular site, 
the mimic alone would repress relative Firefly luciferase expression from the 
‘wild-type’ vector and the inhibitor alone would upregulate such expression. 
However, while the mimic alone significantly repressed Firefly luciferase 
expression from the HMGA2 ‘wild-type’ vector, the inhibitor alone did not 
significantly upregulate it. Conversely, the mimic alone had no significant 
effect on expression from the CDC25A ‘wild-type’ vector, but the inhibitor 
alone significantly upregulated it. This implies that the dynamics of 3’-UTR-
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let-7f-5p binding, with respect to let-7f-5p concentration, differ according to 
3’-UTR. Hypothetically, the observed data could be explained if: 
• The basal let-7f-5p concentration in HCT116 cells is such that the 
CDC25A sites are already saturated, while the HMGA2 binding sites 
are largely unoccupied.  
• The addition of inhibitor reduces the effective let-7f-5p concentration 
below a critical threshold for CDC25A, above which the CDC25A let-
7f-5p binding sites become saturated. 
• The addition of mimic increases the effective let-7f-5p concentration 
above a critical threshold for HMGA2, above which the HMGA2 let-7f-
5p binding site rapidly transitions from being largely unoccupied to 
being nearly or completely saturated with let-7f-5p. 
This hypothesis is illustrated by the sketch in Figure 66. 
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Figure 66: A sketch illustrating the hypothesis that the let-7f-5p site-binding dynamics 
are distinctly non-linear and differ between different 3’-UTRs. In the hypothetical 
situation here illustrated, the basal effective let-7f-5p concentration means that the 
CDC25A and MYC binding sites are already saturated with let-7f-5p but the BACH1 
and HMGA2 sites are largely unbound. Thus, addition of let-7f-5p mimic has little to 
no effect on CDC25A and MYC, but strong effects on BACH1 and HMGA2, whilst the 
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addition of let-7f-5p inhibitor has little to no effect on BACH1 and HMGA2 but 
significantly decreases the occupancy of CDC25A and MYC sites by let-7f-5p. 
No effects of let-7f-5p mimic nor of inhibitor on relative Firefly luciferase 
expression from the ‘wild-type’ KRAS vector were observed. However, an 
unexpected and strong upregulation of relative Firefly luciferase expression 
from the KRAS ‘mutant’ vector by the let-7f-5p mimic occurred, and this 
upregulation was significantly reduced by combining the inhibitor with the 
mimic (p=0.001). This suggests that the newly generated sequence by 
mutation was susceptible to let-7f-5p-induced upregulation by unknown 
mechanisms. 
6.3 MicroRNA Library Construction: Technical Challenges 
6.3.1 Initial Set of Caco-2 Libraries 
An initial set of Caco-2 miRNA libraries was constructed using the 
ScriptMiner™ Small RNA-Seq Library Preparation Kit (Epicentre), rather than 
the individual reagents and improved protocol later developed by Xu et al. 
(2015). This initial set of libraries was unsuccessful in terms of there being 
several issues with the deep sequencing data. Firstly, very high proportions 
of reads in each library (50-85%) were ‘wasted’ because they were of 5’-
adapter-3’-adapter dimers (AADs). Secondly, of non-AAD reads, very low 
proportions in each library could be mapped to the human genome (1-44%; 
15% across libraries overall). It is to be expected for 20-25% of reads not to 
map to the human genome when considering post-transcriptional 
modifications, reverse transcription/PCR artefacts, and/or sequencing errors. 
However, the fact that 85% of reads overall could not be mapped to the 
human genome was a major concern, and possibly indicated contamination 
with non-human RNA during the library construction process. Upon removing 
the non-genome-mapping reads, remaining reads varied widely between 
libraries (from 50 794 to 2 481 053), making them unsuitable for profiling 
differential miRNA expression. 
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6.3.2 New Sets of Libraries for Caco-2 and CCD-841 
An improved library construction protocol was developed in the laboratory by 
Xu et al. (2015), based upon the ScriptMiner™ Small RNA-Seq Library 
Preparation Kit, but using individual reagents and including adjustments to 
the kit manufacturer’s protocol to improve cloning efficiency (Xu, Billmeier et 
al. 2015). A second set of Caco-2 libraries was constructed using this 
improved protocol, in order to maximise the chances of generating useful 
data. This new protocol was also used for the construction of the CCD-841 
libraries. 
PAGE size separation and analysis performed prior to sequencing clearly 
showed that the formation of 5’-adapter-3’-adapter dimers (AADs) was 
drastically reduced by the new method of library construction, and that 
miRNAs were more efficiently captured by the adapters. Following the 
reverse transcription and PCR amplification of captured small RNAs, the 
products were size-separated by PAGE, so that those of cloned miRNAs 
were separated from those of other sRNA species and from AADs, and 
formed visible bands between 120 and 140 bp. Following PAGE, gel pieces 
represented by bands appearing between 120 and 140 bp were cut out, and 
the DNA was eluted out of the gel fragments then purified. 
Following PAGE separation, the stained bands can look discrete by eye, but 
the actual size-separation of the nucleic acids is never perfect. Inevitably, 
excised gel pieces will be contaminated with at least some clones of other 
sRNA species and AADs, so PAGE-extraction serves to minimise, rather 
than completely eliminate, such contamination. Evidently, this was 
insufficient for the first set of libraries, because > 50% of the sequencing 
reads were of AADs. This was probably a result of inefficient adapter-RNA 
ligation producing low ‘adapter-miRNA-adapter’:AAD ratios. Although the 
PAGE-extraction would have discarded the vast majority of the AAD 
molecules, the remaining minority present in the excised gel pieces might still 
have exceeded the captured RNA sequences in number.  
For instance, one might imagine a hypothetical situation in which 1000 AADs 
are generated for every 1 captured miRNA. Gel extraction discards 99% of 
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the AADs but 1% remain present in the visible “microRNA” bands and are 
eluted. 1% of 1000 is 10, so there would still be 10 times as many AAD 
molecules as captured miRNA molecules in the final library preparation. 
Thus, the formation of AADs during the preparation of the first set of libraries 
may have been so great that the gel extraction performed could not 
sufficiently remove them.  
The ‘adapter-miRNA-adapter’:AAD dimer ratio was significantly increased by 
the new protocol, as apparently from the bands visualised in the PCR-PAGE 
gels. Example PAGE gel images for two Caco-2 libraries – one constructed 
via the old protocol and the other by the improved protocol – are shown in 
Figure 67. 
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Figure 67: Images of SYBR Gold-stained PCR PAGE gels for Caco-2 libraries; one 
constructed by the old protocol (A), and the other by the new protocol (B). Although 
prominent AAD bands are apparent in both gels, their intensities relative to those of 
the higher miRNA bands are much lower in the gel image for the library constructed 
by the new protocol than in that for that constructed by the old protocol. 
As expected, the sequencing data for the new libraries had far fewer AAD 
reads by proportion, which comprised only 0-30% and 0-36% of total reads 
from the new Caco-2 and CCD-841 libraries respectively. 
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6.4 MicroRNA Library Data vs. Findings in Literature  
6.4.1 Inconclusive Observations 
MiR-27b-5p was reported by Slaby et al. (2013) as upregulated by 48 h SFN 
treatment in NCM356 and NCM460 cells, but the CCD-841 and Caco-2 
library data implied that SFN affected miR-27b-5p and miR-27b-3p 
expression neither at 8 nor 24 h. However, it is unknown whether or not 
modulation would have been observed in either cell line had expression been 
profiled at 48 h. 
A number of miRNAs - miR-30a-3p, miR-505-3p and miR-629-5p - were 
found to be upregulated by 48 h SFN (10µM) treatment in the NCM356 and 
NCM460 non-cancerous colonic cell lines by Slaby et al. (2013), but 
indicated by the library data as being modulated by SFN (10µM) neither in 
CCD-841 nor in Caco-2 cells (time ≤ 24 h). It cannot be ruled out that effects 
may have been observed had expression been profiled at later time points, 
however. Slaby et al. (2013) also found miR-758-3p to be upregulated in 
NCM356 and NCM460 cells by 48 h SFN treatment, but the CCD-841 library 
data highlighted no such modulation, whilst the Caco-2 library data had no 
reads for this miRNA. 
6.4.2 Undetected MicroRNAs 
A few miRNAs found to be differentially expressed by Slaby et al. (2013) did 
not have any reads at all in the Caco-2 and/or CCD-841 library deep 
sequencing data. These include miR-633, miR-106a-3p, miR-23b-3p, miR-
145-5p and miR-372-5p/3p. The failure to detect these miRNAs could be due 
to several possible factors, including very low or no expression of these 
miRNAs in CCD-841 and Caco-2 cells. Another possibility is that there was a 
strong ligation bias against them during the miRNA cloning process. MiR-
758-3p – upregulated by 48 h SFN treatment in NCM356 and NCM460 
according to Slaby et al. (2013) – had reads in the CCD-841 library data, but 
was not indicated by such to be SFN-modulated. Reads for this miRNA were 
absent from the Caco-2 library data, however. Perhaps its expression has a 
tendency to be lost or highly downregulated in CRC, or is specifically absent 
in the Caco-2 cell line. 
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MiR-9-5p and miR-9-3p were reported by Slaby et al. (2013) to be 
upregulated in the non-cancerous NCM356 and NCM460 cell lines by 48 h 
SFN (10µM) treatment. However, the library data did not imply that either of 
these miRNAs were modulated by SFN in CCD-841 cells, although 
suggested slight upregulation in Caco-2 cells.  
6.5 Future Perspectives 
The data clearly show that sub-cytotoxic SFN treatment (at 10µM) 
upregulates the expression of let-7f-5p and let-7g-5p in the CRC cell line 
Caco-2, but not in the non-cancerous colonic cell line CCD-841. These data 
are not necessarily conclusive in demonstrating that SFN-mediated let-7 
induction occurs exclusively in cancerous cells, but it would be interesting to 
test SFN-mediated let-7 induction in several other CRC and non-cancerous 
colonic cell lines, in order to observe any trends. Any such selectivity would 
be interesting and potentially very useful for limiting cytotoxicity towards non-
cancerous cells; let-7 miRNAs are well-characterised for their pro-apoptotic 
and anti-proliferative effects in a raft of contexts, including in non-cancerous 
neural cells, in which such effects could promote neurodegeneration 
(Lehmann, Kruger et al. 2012).  
The mechanisms by which SFN actually upregulates let-7 miRNA expression 
are unclear, but might involve SFN’s HDAC-inhibiting activity, leading to the 
increased acetylation and thus transcriptional de-repression of the genetic 
loci that give rise to the let-7 miRNAs. It cannot be ruled out that yet-
uncharacterised effects of SFN on miRNA-processing machinery and/or let-7 
stability may have contributed to let-7 induction. The relationship between 
redox status and let-7 miRNA expression is unclear, although it has been 
reported that H2O2 can actually downregulate let-7g-5p expression in gastric 
cancer cells – a downregulation that promoted their resistance to X-ray-
mediated cytotoxicity (Hu, Zhao et al. 2015). H2O2 is also reported to 
downregulate let-7a-5p and let-7b-5p in HCT116 cells, but surprisingly, in a 
p53-dependent fashion, whereby p53 represses transcription at loci giving 
rise to those miRNAs (Saleh, Savage et al. 2011). On the other hand, p53 is 
reported to positively regulate let-7 levels in PA1 human ovarian cancer cells 
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by inducing tristetraprolin, which downregulated the let-7 repressor, lin28a 
(Lee, Kim et al. 2013). Therefore, the links between SFN’s acute pro-oxidant 
and/or Nrf2-inducing effects, and let-7 induction, are apparently complex and 
context-dependent. 
As illustrated by the data presented in Chapter 3, It is clear that SFN 
significantly upregulates several cytoprotective phase II enzymes in both the 
tumour Caco-2 and non-tumour CCD-841 cell lines. Although such 
cytoprotective responses are generally considered to be undesirable in 
tumour (particularly advanced) cells, the net effects of such Nrf2-mediated 
responses on migration and/or invasion can counterintuitively be negative in 
some cases. As previously described, members of the let-7 family have been 
reported to upregulate the Nrf2-induced cytoprotective enzyme HO-1 in 
human hepatocytes via Bach1 repression, thus helping to protect against 
oxidative stress (Hou, Tian et al. 2012). Interestingly, Bach1 knockdown has 
been shown to upregulate TrxR-1 at the mRNA level in HepG2 cells (Hintze, 
Katoh et al. 2007), so it is conceivable that miRNA-mediated Bach1 
repression is a contributing factor to SFN-mediated TrxR-1 induction. 
It is possible that miRNAs such as those of the let-7 family may contribute to 
the apparent selectively of SFN-mediated cytostatic and/or cytotoxic effects 
towards tumour cells vs. their non-cancerous counterparts that is frequently 
reported for given doses or concentrations used in vitro. Given that Nrf2-
induced cytoprotective responses to SFN occur indiscriminately in both 
cancerous and non-cancerous cells, one might consider that a selective 
induction of let-7 miRNAs in the cancerous cells might help to 
counterbalance their Nrf2-induced cytoprotection, whilst sparing the non-
cancerous cells from let-7-induced cytostasis and/or cytotoxicity. 
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6.5.1 Possible Future Experiments 
6.5.1.1 Effects of let-7f-5p Mimic and Inhibitor on Target 
Expression 
For those genes whose transcripts have been confirmed by luciferase 
assays to be bound in their 3’-UTRs by let-7f-5p, it would be a good idea to 
assay the effects of let-7f-5p mimic or inhibitor on protein-level expression by 
Western Blots, in order to confirm that the miRNA-3’-UTR binding actually 
downregulates translation. It would also be interesting to test for any effects 
at the mRNA level by RT-qPCR, although these will not necessarily occur for 
let-7f-5p-regulated genes. For target genes confirmed to be downregulated 
or upregulated at the protein level by let-7f-5p mimics or inhibitors 
respectively, the effects of SFN (5-20µM) could then be tested, alone and/or 
in combination with miRNA mimic or inhibitor, in order to test for antagonistic 
or synergistic effects. Additionally, the effects of specific protein-targeted 
siRNA knockdown on cancerous cell characteristics such as migration and 
invasion could be tested, in order to evaluate their significance with regards 
to SFN’s and/or let-7f-5p’s anti-tumour effects. 
Data from these experiments could shed light on particular let-7f-5p-targeted 
oncogenes that are downregulated in CRC cells by sub-cytotoxic SFN 
exposure, and on the potential for such exposure to inhibit tumour 
progression despite Nrf2-induced cytoprotective responses in the tumour 
cells. 
6.5.1.2 Other Potential Let-7 Targets and Sulforaphane-Modulated 
MicroRNAs 
In the microrna.org database are listed miRanda-based predictions for a 
number of other mRNAs that are targets of let-7f-5p and/or let-7g-5p, with 
mirSVR scores ≤ -1.2. These are described in Figure 68. 
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Figure 68: A diagram illustrating potentially oncogenic miRNAs that are predicted by 
miRanda (with mirSVR scores ≤ -1.2) to be targeted by let-7f-5p and/or let-7g-5p. 
It would be interesting to validate some of these other target predictions by 
luciferase assays, and then further study their roles in SFN’s anti-cancer 
effects. Considering that miR-10a-5p is also potentially upregulated by SFN, 
it may be relevant to also consider the potentially oncogenic miRanda-
predicted target genes of that miRNA, including: ALCAM, BCL9, BDNF, 
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CNTN1, DYP24A1, DPAGT1, EIF4E, GALNT1, GATA6, PHF20L1, PIK3CA, 
SMC4 and WDR26. 
Regarding potentially oncogenic and SFN-downregulated miRNAs, miR-29b-
3p and miR-193b-3p would be interesting to study further using miRNA 
mimics and inhibitors, since both of these miRNAs are predicted to target a 
number of potential TSGs, as described in Figure 69. 
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Figure 69: A diagram illustrating potentially tumour-suppressive miRNAs that are 
predicted by miRanda (with mirSVR scores ≤ -1.2) to be targeted by miR-29b-3p or 
miR-193b-3p. 
6.5.1.3 Crosslinking, Ligation and Sequencing of Hybrids 
In a CLASH experiment performed by Helwak et al, cells were UV-irradiated 
to covalently crosslink RNAs to proteins with which they were interacting, 
and then tagged AGO-RNA complexes were isolated. Long mRNAs in the 
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complexes were firstly trimmed with an exonuclease, and then fused by 
ligation to miRNAs present in the same complexes; this generated miRNA-
mRNA ‘hybrids’, which were subject to deep sequencing and analysis to 
identify any AGO-mediated miRNA-mRNA interactions occurring in vitro at 
the time of cell irradiation (Helwak, Kudla et al. 2013). 
Based on currently published protocols (Helwak, Kudla et al. 2013), 
individual CLASH experiments are likely to be expensive and time 
consuming, and thus not a viable endeavour for all researchers. However, 
already-published CLASH data such as those from Helwak et al. could be 
used to complement algorithm-based miRNA-mRNA interaction predictions, 
by confirming that predicted canonical miRNA-mRNA interactions actually 
occur and/or highlighting any non-canonical interactions that are not 
computationally predicted. Perhaps such CLASH data may be useful for the 
future development of miRNA target prediction algorithms. 
Inevitably, the sensitivity of the CLASH approach depends upon miRNA and 
mRNA abundances, both of which vary widely according to context. 
Therefore, new CLASH experiments may be worth performing where 
economically viable. Such experiments could be done using SFN-treated 
and/or non-treated Caco-2 and/or CCD-841 cells; experiments in SFN-
treated cells may be more sensitive to interactions involving SFN-
upregulated miRNAs, while those in non-treated cells may be more sensitive 
to those involving SFN-downregulated miRNAs. CLASH experiments could 
help to uncover novel (particularly non-canonical) cancer-related miRNA-
mRNA interactions, and/or reduce the amount of time wasted on studying 
falsely-predicted mRNA targets. 
6.5.1.4 Xenograft Studies in Mice 
Interestingly, in vivo studies have shown that let-7a-5p mimics can 
significantly inhibit the growth of tumour xenografts (Wang, Zhang et al. 
2012), as can the experimentally-forced downregulation of Bach1 in 
HCT116-based xenografts; Bach1 is a validated target of some let-7 miRNA 
family members. 
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SFN itself has already been shown to inhibit tumour xenograft growth in vivo, 
although often at high doses not representative of those reasonably 
obtainable through diet. In a study establishing tumours in severe combined 
immunodeficient (SCID) mice by xenografting human CRC cell lines, 
supplementation of the mice with 400µmol SFN per kg body mass per day 
dramatically inhibited xenograft growth, reducing mean tumour weight by 
70% (Chen, Tang et al. 2012).  
According to United States Food and Drug Administration guidelines, 
approximate human dose equivalents can be extrapolated from laboratory 
mouse doses by the following equation (USFDA 2005): 
GH=	
IH	B	=;/K; = LH	B	=;/K;	×	
3
37
 
One study reported that the amount of SFN able to be formed from extracts 
of 7-day-old broccoli sprouts was 5µmol SFN per gram of sprout (Guo, Yang 
et al. 2014). On this basis, a human dose equivalent to that used in the 
above-mentioned mouse xenograft study could be obtained by consuming 
about 390g of 7-day-old broccoli sprouts, assuming optimal SFN formation. 
Therefore, such doses may warrant study for their chemotherapeutic 
potential against moderately advanced CRCs. 
It would be interesting to conduct a xenograft experiment with human CRC 
cell line in mice, and then supplementing mice with low-to-moderate sub-
cytotoxic doses of SFN that are most likely to find use in chemoprevention or 
prophylaxis in high-risk and/or cured CRC patients. There is one published 
study in which mice were xenografted with K-ras-driven lung tumours and 
then treated with low-dose SFN for 3 months, showing that such 
supplementation did not promote tumorigenesis, despite the cytoprotective 
tendencies of SFN at sub-cytotoxic doses (Kombairaju, Ma et al. 2012). The 
daily administered doses were about 35% of those used in the study by 
Cheng et al. thus hypothetically obtainable from about 140g of the 7-day-old 
broccoli sprouts studied by Guo et al. (2014). 
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Regarding synergistic effects, another study tested the ability of much lower 
doses of SFN to act in synergy with gemcitabine to suppress the growth of 
human pancreatic carcinoma MIA PaCa-2-based xenografts. In this study, 
doses of only 16.9µmol SFN per kg body mass were administered to mice 
bearing MIA PaCa-2-based xenograft tumours, and significantly repressed 
tumour growth over several days in synergy with gemcitabine (Kallifatidis, 
Labsch et al. 2011). The theoretically equivalent human dose would be 
1.37µmol per kg i.e. 82.2µmol for a human weighing 60kg – potentially 
obtainable from about 17g of the 7-day-old broccoli sprouts studied by Guo 
et al. (2014). This could be interesting regarding the potential use of SFN 
itself and/or dietary recommendations to boost the efficacy of ongoing 
chemotherapy. 
6.5.1.5 Potential Clinical Applications of MicroRNA Manipulation 
As mentioned above, several studies have demonstrated the ability of 
mimics of miRNAs, including those of the let-7 family, to both repress the 
growth, migration and invasion of tumour cell lines in vitro, and to inhibit 
tumour xenograft growth in mouse models. Chemotherapy that is based on 
miRNAs is likely to be more potent than that based on specific oncogene-
targeted siRNAs, since miRNAs such as let-7f-5p are demonstrably able to 
downregulate a plethora of proliferative and anti-apoptotic genes. The broad-
spectrum nature of such effects is particularly attractive in light of recent 
evidence from genomic studies to suggest that driver mutations observed in 
CRCs do not tend to converge with regards to which specific genes they 
occur in, but tend to do so with regards to which signalling pathways are 
impacted; such convergence is often on the Wnt, TGFβ, PI3K, receptor 
tyrosine kinase-RAS and p53 signalling pathways (Yamagishi, Kuroda et al. 
2016). 
Challenges presented by the clinical application of miRNAs include ensuring 
their stability in the body and efficient delivery to target cells, in addition to 
concerns over potential side effects of the nucleic acid delivery vehicles, 
and/or off-target effects of the mimic itself. However, research in recent years 
has focussed on overcoming such challenges, to be able to develop 
potentially safe and effective miRNA-based drugs. 
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MRX34 was developed by Mirna Therapeutics (Texas, USA) and consists of 
natural miR-34a-5p – a miRNA reported to target a number of oncogenes - 
encapsulated by a liposomal nanoparticle. However, a phase I clinical trial of 
injection-based MRX34 chemotherapy was recently terminated due to the 
occurrence of serious immune-related adverse events (ClinicalTrials.gov: 
NCT01829971). An alternative to liposomal delivery is to package miRNA 
mimics within bacterium-based nano-cells, such as the EDV™ Nanocells 
(EDVs) developed by EnGeneIC, and then coat the EDVs with antibodies 
raised against antigens known to be abundant on the target cancer cell 
plasma membrane (Reid, Kao et al. 2016). A phase I clinical safety trial of a 
drug based on EDVs containing mimics based on the miR-15/107 consensus 
sequence, coated with EGFR-targeting antibody, is currently recruiting 
participants with malignant pleural mesothelioma or non-small cell lung 
cancer (ClinicalTrials.gov: NCT02369198).  
An alternative method of upregulating miRNA-mediated repression is to 
target endogenous repressors of miRNA activity, such as the lncRNA H19, 
which has been demonstrated to act oncogenically in CRC. H19 has been 
shown to act as a decoy for let-7 miRNAs, amongst other miRNAs, thereby 
inhibiting let-7-mediated repression of oncogenic mRNA translation (Liang, 
Fu et al. 2015). Interestingly, another lncRNA, ncNRFR, also appears to 
inhibit let-7-mediated gene repression, but by competitively binding to the 
mRNA let-7 target sites, rather than by binding to the miRNAs themselves 
(Franklin, Rankin et al. 2013). 
The approach of targeting such lncRNAs might be more effective than the 
administration of let-7 miRNA mimics in elevating let-7-mediated oncogene 
repression, particularly in contexts of high endogenous let-7 miRNA levels. 
Caco-2 cells appear to have high basal let-7f-5p and let-7g-5p expression, as 
implied by relatively high normalised library read numbers and strong 
Northern Blot signals for these miRNAs in Caco-2 samples. That they were 
significantly upregulated by SFN treatment in terms of fold-change implies a 
steep increase in absolute miRNA levels. High endogenous let-7f-5p levels in 
Caco-2 were the most probable cause of the difficulty in detecting effects of 
let-7f-5p mimic via luciferase assays in those cells, even when vectors 
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containing ‘positive-control’ repeats of sequence anti-sense to that of let-7f-
5p were used. The targeting of lncRNAs such as H19 by siRNA-based 
knockdown is a potential alternative and/or complementary means of 
increasing let-7-mediated oncogene repression in CRC. 
6.5.1.6 Clinical Applications of Sulforaphane 
A synthetic SFN supplement called Sulforadex®, developed by Evgen 
Pharma, has now entered phase II safety trials for the treatment of 
metastatic breast cancer patients in combination with aromatase inhibitors, 
tamoxifen and fulvestrant (ClinicalTrails.gov: NCT02970682). 
With regards to the efficacy of SFN and/or SFN-rich extracts in the treatment 
of cancer patients, a pilot study is currently recruiting participants to 
determine the feasibility of a randomised controlled trial treating advanced 
pancreatic ductal adenocarcinoma patients – receiving palliative treatment - 
with freeze-dried broccoli sprouts (ClinicalTrials.gov: NCT01879878). 
It would be interesting to follow such clinical trials, particularly to see whether 
broccoli sprout and/or SFN supplementation prove to be beneficial, neutral, 
or detrimental to patient outcomes. Since SFN induces Nrf2, whose 
cytoprotective effects can inhibit the carcinogenic transformation of healthy 
cells, yet can promote tumour growth when occurring in tumour cells (Ohta, 
Iijima et al. 2008), concerns have been raised over the possibility of low-to-
moderate doses of SFN being detrimental to patients with advanced cancers 
via tumour protection, as previously discussed. However, no clinical studies 
published to date have actually demonstrated such detrimental effects in 
practice. Besides, SFN is known to affect a wide range of Nrf2-independent 
signalling pathways, such as those modulating cell cycle arrest, apoptosis 
and chromatin status, as previously discussed. Such effects may outweigh 
the oncogenic potential of Nrf2 induction in tumour cells, and it is important to 
remember that Nrf2 induction in tumour cells can itself be tumour 
suppressive rather than oncogenic, as discussed in Chapter 1. Additionally, 
the systemic effects of Nrf2 activators will inevitably extend far beyond those 
observable in vitro due to potential impacts upon immune system-mediated 
tumour suppression and/or promotion. 
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Appendix 
7.1 Additions to Chapter 1 
7.1.1 MicroRNA Nomenclature 
7.1.1.1 Introduction of the -5p/-3p Suffix 
As mentioned in the MicroRNAs section in Chapter 1, it was once considered 
that only one strand of a Dicer-generated duplex tended to exert activity 
(Mah, Buske et al. 2010). The other ‘alternative’ strand was thus denoted by 
a “*” suffix in previous versions of miRBase. For example, of the two mature 
products of pre-hsa-miR-29b-1/pre-hsa-miR-29b-2 cleavage, the ‘dominant’ 
product from the 3’ end was named “hsa-miR-29b”, whilst the ‘alternative’ 
product from the 5’ end was named “hsa-miR-29b*”. 
As accumulating evidence continued to challenge the notion that this was the 
case for the majority of miRNAs, this dominant/alternative strand notation 
was discontinued by miRBase; instead, a -5p or -3p suffix is appended to 
indicate the arm of the pre-miRNA from which the mature miRNA strand 
originates. For example: 
Old miRBase Nomenclature New miRBase Nomenclature 
hsa-miR-29b hsa-miR-29b-3p 
hsa-miR-29b* hsa-miR-29b-5p 
 
According to this current nomenclature, the lack of a -5p or -3p suffix on a 
named mature miRNA in miRBase implies that only a single mature product 
has been thus far reported. 
7.1.1.2 IsomiRs 
Currently in miRBase, only a single consensus (canonical) sequence is listed 
for any named mature miRNA, such as “hsa-miR-29b-3p”. MiRBase does not 
currently employ nomenclature to define different isomiRs. 
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Canonical isoforms (as catalogued in miRBase) were here referred to 
according to standard miRBase nomenclature, while to non-canonical 
isomiRs were appended extensions according to a system proposed by 
Cloonan et al. (Cloonan, Wani et al. 2011); “|[isomiR]|x_y|”, where x is the 
position of the pre-miRNA at which the miRNA isoform begins, and y is the 
position of the pre-miRNA at which it ends, where the first nucleotide of the 
pre-miRNA is at position 0. 
For example: 
 Isoform Name Used Here 
hsa-miR-
29b-3p 
Canonical – spans positions 
51 to 73 according to miRBase 
(first position = 1). 
hsa-miR-29b-3p 
IsomiR – misses the first 
nucleotide, and has 2 extra 
nucleotides at the end from the 
precursor; spans positions 52 
to 75 according to miRBase 
(where the first position is 
defined as position 1). 
hsa-miR-29b-
3p|[isomiR]|51_74| 
 
If an isomiR has any base ‘substitutions’ compared with the canonical 
sequence, these are denoted with a further extension: “sub.P.A>B”, where P 
is the position of substitution in the pre-miRNA (where the first position is 
defined as position 0), and A and B are the bases found in the canonical and 
the described isomiR respectively. For example, a hsa-miR-29b-3p isomiR 
that differs from the canonical form by missing the first nucleotide, having 2 
extra nucleotides at the end from the precursor, and having a substitution of 
A for G at position 61 (where the first position is defined as position 0) with 
respect to the pre-miRNA, would be described as: 
 “hsa-miR-29b-3p|[isomiR]|51_74|sub.61.G>A” 
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7.2 Additions to Chapter 4 
7.2.1 MicroRNA Library Construction 
7.2.1.1 Checking RNA Integrity 
The integrity of extracted total RNA samples was checked prior to library 
construction, to make sure that RNA was not degraded. When denatured 
and then subject to agarose gel electrophoresis, intact RNA is expected to 
show clearly defined 28S and 18S bands, with the intensity of the latter being 
about half that of the former. 
28S
18S
B1 A1 A2 A3B2 B3 C1 C2 C3
 
Figure 70: Ethidium bromide-stained images of the agarose gel through which Caco-2 
total RNA samples were electrophoresed, in order to check RNA integrity prior to 
library construction. The samples subsequently used for library construction are 
annotated below the gel image. 
Figure 70 shows the electrophoresis images for all of the RNA samples used 
for the construction of the Caco-2 libraries, while Figure 71 shows those from 
CCD-841 cells used for CCD-841 library construction. 
 
28S
18S
Y1 (combined) Y2 (combined)
Z1 (combined) Z2 (combined)
28S
18S
 
232 | P a g e  
 
28S
18S
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Figure 71: Ethidium bromide-stained image of the agarose gel through which CCD-
841 total RNA samples were electrophoresed, in order to check RNA integrity prior to 
library construction. The samples subsequently used for library construction are 
annotated below the gel image. 
It is clear from the images in Figure 70 and Figure 71 that no RNA 
degradation is apparent for any of the samples, since all lanes have clearly 
defined 28S and 18S bands, and the intensities of the 18S bands are lower 
than those of their respective 28S bands. Thus, these samples were 
considered to be of suitable quality for library construction. 
7.2.1.2 Elution of the Libraries 
Following the ligation of 5’ and 3’ HD adapters to small RNAs, reverse 
transcription and subsequent PCR amplification, the PCR products were 
separated by PAGE. The desired microRNA cloning products were to be 
found in the band located at around 150bp, while the adapter-adapter dimers 
formed bands below 140bp and were avoided. Pieces of the gel at the loci of 
the desired (150bp, microRNA) bands were carefully cut out, and the DNA 
eluted from the gel to form the library. 
Different numbers of PCR cycles to test which number would produce the 
most of the desired products without the adapter-adapter dimer bands 
diffusing over and contaminating the microRNA bands. If there was a clear 
gap between all of the microRNA and adapter-adapter dimer bands then all 
of the desired bands were cut out for elution. However, if the PCR cycle 
number appeared to be too high in any lanes, then PCR of the original cDNA 
was performed again using the ‘optimal’ number of cycles, and another 
PAGE separation was performed for elution. Images of all of the PAGE gels 
from which the microRNAs libraries that were sent for deep sequencing were 
cut out and eluted are shown in Figure 72. 
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Figure 72: Images of ethidium bromide-stained gels with PAGE-separated PCR 
products of cDNA that was reverse transcribed from small RNAs captured from 
samples by the 5’ and 3’ HD adapters. The bands visible between 140 and 160bp are 
the desired microRNA bands, which were cut out and from which libraries were 
eluted, while those visible below are from the adapter-adapter dimers, which care was 
taken to avoid. 
7.2.1.3 Quality Check and Quantification 
All Caco-2 libraries were combined into one pool, while those of CCD-841 
were combined into another pool. Prior to mixing libraries together into pools, 
aliquots of each were separated by PAGE to both check the specificity of the 
library gel extraction (i.e. that other products were not extracted at the same 
time, particularly AADs), and to quantify the relative concentration of each 
library preparation, so that equal amounts of each could be pooled together. 
7.2.1.3.1 Caco-2 Libraries 
1µL of each library preparation was electrophoresed in a PAGE gel and then 
bands were quantified to estimate relative concentrations. The data are 
shown in Figure 73. 
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200
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Figure 73: Ethidium bromide-stained gel with Caco-2 libraries electrophoresed for 
quality checking and quantification of concentrations. 
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As apparent from the image in Figure 73, there does not appear to be 
contamination of the eluates with significant amounts of AADs or other 
undesired products. Band intensities were densitometrically analysed to 
estimate relative library concentrations, based on which, equal amounts of 
each library were then combined into a pool to be sent for deep sequencing. 
7.2.1.3.2 CCD-841 Libraries 
1µL of each library preparation was electrophoresed by PAGE across two 
gels, alongside a reference product that was loaded onto both gels in order 
to normalise results across the gels. Data are shown in Figure 74 and Figure 
75. 
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Figure 74: The first of two ethidium bromide-stained gels with CCD-841 libraries 
electrophoresed for quality checking and quantification of concentrations. 
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Figure 75: The second of two ethidium bromide-stained gels with CCD-841 libraries 
electrophoresed for quality checking and quantification of concentrations. 
The images in Figure 74 and Figure 75 indicate that none of the CCD-841 
libraries have significant contamination with undesired products of differing 
length, such as adapter-adapter dimers. Band intensities were 
densitometrically analysed to estimate relative library concentrations, based 
on which, equal amounts of each library were then combined into a pool to 
be sent for deep sequencing. 
7.2.2 MicroRNA Library Deep Sequencing Data Analysis 
7.2.2.1 Size Class Distributions 
The size class distribution data presented here were generated by Claudia 
Paicu (School of Computing Sciences, University of East Anglia, Norwich, 
UK). 
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7.2.2.1.1 Caco-2 Libraries 
 
Table 12: A summary of the size class distributions of reads from the sequencing of 
the Caco-2 libraries. 
  A1 A2 A3 B1 B2 B3 C1 C2 C3 
17 624415 493750 57600 314086 106181 303613 679836 607286 885765 
18 702375 709236 119727 442857 194891 480731 811991 809983 976872 
19 681733 806697 271418 562627 312534 517538 951718 1003180 1067874 
20 1108053 1429021 758037 931522 637199 803716 1537759 1623031 1688904 
21 2300053 2968175 2313316 1980115 1532961 1469488 3155053 2979848 3425674 
22 5086505 6830196 4502954 3669751 3914985 3574137 5387507 5417295 6052942 
23 4098896 5942047 4128015 3381937 3541925 2982853 4773403 4352262 4862898 
24 1493362 2797371 1903376 1687144 1612057 1410744 2153280 1930011 1949966 
25 255787 695766 450264 414743 374633 353870 467457 418809 356968 
26 92174 355808 215215 216962 174323 157146 180850 149924 123869 
27 43841 278925 166925 176860 124388 84574 102241 77921 73807 
28 22546 226934 147281 153529 98718 43733 58625 41158 39077 
29 11028 149533 94516 112945 76652 21558 31058 22416 17929 
30 5942 93150 44172 71686 51893 12808 15062 11252 8437 
31 4535 83132 28601 72839 57296 9942 13312 9403 7180 
32 3404 57704 13664 63435 57555 7662 8135 5679 4966 
 
 
 
Figure 76: A graph representing the Caco-2 size class distribution data for A1, A2 and 
A3. 
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Figure 77: A graph representing the Caco-2 size class distribution data for B1, B2 and 
B3. 
 
Figure 78: A graph representing the Caco-2 size class distribution data for C1, C2 and 
C3. 
The size class distributions for all of the Caco-2 libraries are as expected for 
human miRNAs; peaks at 22 nucleotides are clearly visible in all of them as 
visible in Figure 76, Figure 77 and Figure 78. 
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7.2.2.1.2 CCD-841 Libraries 
 
Table 13: A summary of the size class distributions of reads from the sequencing of 
the CCD-841 libraries. 
 X1 X2 X3 Y1 Y2 Y3 Z1 Z2 Z3 
17 262327 169940 121180 734821 786455 95181 353461 172476 100725 
18 373405 246985 178375 1488664 1596769 203134 384207 236563 249435 
19 407730 278480 236282 3971359 4318924 303211 523853 309847 480325 
20 701314 336343 416106 5465803 5630577 514593 843315 604590 1053300 
21 1898162 764814 1143511 11537303 12283235 1234124 2214310 1658868 3262699 
22 7153520 3643959 4400003 885721 595400 5207008 6911060 5160677 16322852 
23 3114046 1174147 1994755 390896 260824 1836384 3042014 2474774 5244878 
24 1235674 537488 829381 229058 202690 787236 1137255 871717 2217329 
25 675070 361386 466871 61949 47778 539070 613103 324351 1362024 
26 189270 130877 163416 35156 29818 206295 259810 177234 424485 
27 150294 109653 161369 31801 25917 180326 234863 167306 341679 
28 108387 90111 138006 20276 24207 133383 219426 161044 306067 
29 77843 81122 151905 13356 26787 109389 220000 152752 328587 
30 39059 49499 107476 6368 24899 72613 174305 131087 231297 
31 23740 33875 110670 3317 25948 56761 152283 117127 198552 
32 16304 19851 97463 1883 26419 35390 166449 113240 157016 
 
 
 
Figure 79: A graph representing the CCD-841 size class distribution data for X1, X2 
and X3. 
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Figure 80: A graph representing the CCD-841 size class distribution data for Y1, Y2 
and Y3. 
 
Figure 81: A graph representing the CCD-841 size class distribution data for Z1, Z2 
and Z3. 
The size distributions for CCD-841 libraries X1, X2, X3, Y3, Z1, Z2 and Z3 
are as expected; Figure 79, Figure 80 and Figure 81 all show peaks for these 
at 22 nucleotides, as expected for human miRNAs. However, it is apparent 
from Figure 80 that Y1 and Y2 do not have the expected size class 
distributions, since they show peaks at 21 nucleotides, then sudden drops ≥ 
22 nucleotides, thus indicating issues with these libraries. 
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7.2.2.2 Complexity Checks 
The size class distribution data presented here were generated by Claudia 
Paicu (School of Computing Sciences, University of East Anglia, Norwich, 
UK). 
7.2.2.2.1 Caco-2 Libraries 
Table 14: A summary of the complexity scores at each sequence length, in each 
Caco-2 library. 
 A1 A2 A3 B1 B2 B3 C1 C2 C3 
17 0.119 0.106 0.203 0.128 0.161 0.127 0.101 0.106 0.100 
18 0.118 0.099 0.164 0.119 0.143 0.112 0.098 0.100 0.101 
19 0.108 0.085 0.111 0.098 0.121 0.112 0.076 0.077 0.081 
20 0.061 0.048 0.056 0.058 0.069 0.073 0.045 0.046 0.048 
21 0.033 0.027 0.025 0.031 0.037 0.046 0.024 0.028 0.026 
22 0.016 0.014 0.016 0.019 0.018 0.022 0.016 0.017 0.016 
23 0.018 0.015 0.017 0.020 0.019 0.025 0.017 0.020 0.018 
24 0.038 0.028 0.032 0.036 0.037 0.045 0.031 0.037 0.035 
25 0.150 0.094 0.113 0.123 0.125 0.138 0.112 0.127 0.134 
26 0.260 0.157 0.204 0.205 0.214 0.222 0.219 0.250 0.257 
27 0.305 0.171 0.226 0.218 0.230 0.258 0.261 0.293 0.267 
28 0.326 0.170 0.212 0.208 0.220 0.291 0.271 0.308 0.292 
29 0.365 0.197 0.222 0.217 0.218 0.337 0.284 0.325 0.334 
30 0.414 0.232 0.278 0.251 0.254 0.359 0.344 0.379 0.391 
31 0.359 0.199 0.235 0.198 0.204 0.317 0.261 0.292 0.300 
32 0.357 0.213 0.283 0.195 0.195 0.301 0.295 0.330 0.326 
 
 
Figure 82: A graph illustrating the complexity distribution data for A1, A2 and A3. 
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Figure 83: A graph illustrating the complexity distribution data for B1, B2 and B3. 
 
 
 
Figure 84: A graph illustrating the complexity distribution data for C1, C2 and C3. 
The complexity distribution refers to the sequence complexity (i.e. how many 
unique sequences there are) at each given length of sequence. It is expected 
that there will inevitably be some random RNA degradation products present, 
distributed randomly per length. Human miRNAs tend to be between 18 and 
25 nucleotides in length. The sequence variation of actual miRNAs will be 
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lower than that of random degradation products, so there should be a trough 
in complexity between 18 and 25 nucleotides, centred around 22. This 
expected trough is clearly visible for all of the Caco-2 libraries according to 
Figure 82, Figure 83 and Figure 84, suggesting that the data do not have too 
much noise from degradation products. 
7.2.2.2.2 CCD-841 Libraries 
Table 15: A summary of the complexity scores at each sequence length, in each CCD-
841 library. 
 X1 X2 X3 Y1 Y2 Y3 Z1 Z2 Z3 
17 0.101 0.118 0.107 0.013 0.009 0.131 0.086 0.137 0.116 
18 0.104 0.102 0.113 0.007 0.005 0.107 0.103 0.135 0.082 
19 0.097 0.092 0.108 0.003 0.002 0.099 0.086 0.124 0.065 
20 0.059 0.077 0.073 0.002 0.002 0.068 0.059 0.073 0.039 
21 0.025 0.038 0.034 0.001 0.001 0.033 0.026 0.031 0.016 
22 0.008 0.009 0.010 0.016 0.020 0.009 0.010 0.012 0.004 
23 0.017 0.028 0.023 0.039 0.049 0.026 0.022 0.023 0.012 
24 0.036 0.053 0.055 0.126 0.144 0.054 0.051 0.056 0.024 
25 0.054 0.065 0.068 0.114 0.115 0.067 0.081 0.127 0.032 
26 0.165 0.162 0.172 0.146 0.135 0.162 0.175 0.209 0.092 
27 0.180 0.174 0.163 0.142 0.146 0.169 0.176 0.206 0.108 
28 0.198 0.187 0.177 0.184 0.145 0.207 0.172 0.200 0.113 
29 0.198 0.179 0.147 0.203 0.129 0.221 0.155 0.189 0.099 
30 0.242 0.231 0.182 0.272 0.133 0.263 0.170 0.186 0.123 
31 0.231 0.239 0.159 0.314 0.130 0.223 0.149 0.170 0.121 
32 0.218 0.245 0.143 0.387 0.125 0.208 0.102 0.134 0.113 
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Figure 85: A graph illustrating the complexity distribution data for X1, X2 and X3. 
 
Figure 86: A graph illustrating the complexity distribution data for Y1, Y2 and Y3. 
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Figure 87: A graph illustrating the complexity distribution data for Z1, Z2 and Z3. 
It is apparent from the CCD-841 library complexity distributions illustrated in 
Figure 85, Figure 86 and Figure 87 that libraries X1, X2, X3, Y3, Z1, Z2 and 
Z3 have the expected distributions i.e. with troughs centred around the 
average human miRNA length, 22 nucleotides, indicating that there is not 
much too noise from RNA degradation products. However, libraries Y1 and 
Y2 do not have the expected complexity distributions at all, as visible in 
Figure 86; complexity appears to be very low ≤ 21 nucleotides and then 
relatively high between 24 and 32 nucleotides. This suggests that these data 
may have a very high ratio of noise from RNA degradation products and are 
thus probably not useful. 
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7.2.3 Northern Blot/RT-qPCR Data 
7.2.3.1 MicroRNAs Not Confirmed by Northern Blots/RT-qPCR 
7.2.3.1.1 hsa-miR-10b-5p in Caco-2 
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Figure 88: The effect of SFN treatment on the level of hsa-miR-10b-5p|[isomiR]|26_47| 
in Caco-2 cells at 8 and 24 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 8 or 24 h, or DMSO (control); final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance in RNA extracts was 
assayed via Northern Blotting as described in Methods, using U6 as an internal 
control. Induction is expressed as [(miRNA band intensity)/(U6 band intensity)] for 
each sample relative to the control mean, and data are represented as means of 
duplicates ± (upper value – lower value)/2. 
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Figure 89: The effect of SFN treatment on the level of hsa-miR-10b-5p in Caco-2 cells 
at 4, 8, 12, 24 and 48 h. Cells were treated by adding to culture medium in triplicate, 
DMSO-diluted SFN (10µM) for 4, 8, 12, 24 or 48 h, or DMSO (control); final DMSO 
concentrations were 0.05% (v/v). Relative miRNA abundance in RNA extracts was 
assayed via TaqMan RT-qPCR as described in Methods, using U6 as an internal 
control. Induction was evaluated by the Pfaffl method as described in Methods, and 
data are represented as means of triplicates ± S.E.M. (*p<0.05). 
 
Figure 90: The effect of 24 h SFN treatment on the level of hsa-miR-10b-5p in Caco-2 
cells. Cells were treated for 24 h by adding to culture medium in triplicate, DMSO-
diluted SFN (5, 10 or 20µM) or DMSO (control); final DMSO concentrations were 0.05% 
(v/v). Relative miRNA abundance in RNA extracts was assayed via TaqMan RT-qPCR 
as described in Methods, using U6 as an internal control. Induction was evaluated by 
the Pfaffl method as described in Methods, and data are represented as means of 
triplicates ± S.E.M. (*p<0.05). 
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7.2.3.1.2 hsa-miR-17-3p in Caco-2 
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Figure 91: The effect of SFN treatment on the level of hsa-miR-17-3p in Caco-2 cells at 
8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-diluted 
SFN (10µM) for 8 or 24 h, or DMSO (control); final DMSO concentrations were 0.05% 
(v/v). Relative miRNA abundance in RNA extracts was assayed via Northern Blotting 
as described in Methods, using U6 as an internal control. Induction is expressed as 
[(miRNA band intensity)/(U6 band intensity)] for each sample relative to the control 
mean, and data are represented as means of duplicates ± (upper value – lower 
value)/2. 
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7.2.3.1.3 hsa-miR-182-5p in Caco-2 
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Figure 92: The effect of SFN treatment on the level of hsa-miR-182-5p in Caco-2 cells 
at 8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-
diluted SFN (10µM) for 8 or 24 h, or DMSO (control); final DMSO concentrations were 
0.05% (v/v). Relative miRNA abundance in RNA extracts was assayed via Northern 
Blotting as described in Methods, using U6 as an internal control. Induction is 
expressed as [(miRNA band intensity)/(U6 band intensity)] for each sample relative to 
the control mean, and data are represented as means of duplicates ± (upper value – 
lower value)/2. 
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7.2.3.1.4 hsa-miR-192-5p in Caco-2 
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Figure 93: The effect of SFN treatment on the level of hsa-miR-192-5p in Caco-2 cells 
at 8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-
diluted SFN (10µM) for 8 or 24 h, or DMSO (control); final DMSO concentrations were 
0.05% (v/v). Relative miRNA abundance in RNA extracts was assayed via Northern 
Blotting as described in Methods, using U6 as an internal control. Induction is 
expressed as [(miRNA band intensity)/(U6 band intensity)] for each sample relative to 
the control mean, and data are represented as means of duplicates ± (upper value – 
lower value)/2. 
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7.2.3.1.5 hsa-miR-1296-5p in Caco-2 
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Figure 94: The effect of SFN treatment on the level of hsa-miR-1296-5p in Caco-2 cells 
at 8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-
diluted SFN (10µM) for 8 or 24 h, or DMSO (control); final DMSO concentrations were 
0.05% (v/v). Relative miRNA abundance in RNA extracts was assayed via Northern 
Blotting as described in Methods, using U6 as an internal control. Induction is 
expressed as [(miRNA band intensity)/(U6 band intensity)] for each sample relative to 
the control mean, and data are represented as means of duplicates ± (upper value – 
lower value)/2. 
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7.2.3.1.6 hsa-miR-106b-5p in CCD-841 
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Figure 95: The effect of SFN treatment on the level of hsa-miR-106b-5p in CCD-841 
cells at 4, 8, 12, 24 and 48 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 4, 8, 12, 24 or 48 h, or DMSO (control); final 
DMSO concentrations were 0.05% (v/v). Relative miRNA abundance in RNA extracts 
was assayed via Northern Blotting as described in Methods, using U6 as an internal 
control. Induction is expressed as [(miRNA band intensity)/(U6 band intensity)] for 
each sample relative to the control mean, and data are represented as means of 
duplicates ± (upper value – lower value)/2. 
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7.2.3.1.7 hsa-miR-345-5p in CCD-841 
 
Figure 96: The effect of 24 h SFN treatment on the level of hsa-miR-345-5p in CCD-841 
cells. Cells were treated for 24 h by adding to culture medium in triplicate, DMSO-
diluted SFN (5, 10 or 20µM) or DMSO (control); final DMSO concentrations were 0.05% 
(v/v). Relative miRNA abundance in RNA extracts was assayed via TaqMan RT-qPCR 
as described in Methods, using U6 as an internal control. Induction was evaluated by 
the Pfaffl method as described in Methods, and data are represented as means of 
triplicates ± S.E.M. (*P<0.05). 
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7.2.3.1.8 hsa-miR-181a-5p in CCD-841 
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Figure 97: The effect of SFN treatment on the level of hsa-miR-181a-5p in CCD-841 
cells at 4, 8, 12, 24 and 48 h. Cells were treated by adding to culture medium in 
duplicate, DMSO-diluted SFN (10µM) for 4, 8, 12, 24 or 48 h, or DMSO (control); final 
DMSO concentrations were 0.05% (v/v). Relative miRNA abundance in RNA extracts 
was assayed via Northern Blotting as described in Methods, using U6 as an internal 
control. Induction is expressed as [(miRNA band intensity)/(U6 band intensity)] for 
each sample relative to the control mean, and data are represented as means of 
duplicates ± (upper value – lower value)/2. 
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Hsa-miR-181a-5p (Target) Hsa-miR-181b-5p (Off-Target)
Oligo Blotted (1pmol)
Blot Density Relative Density (%)
hsa-miR-181a-5p 28339 100
hsa-miR-181b-5p 1690 6
 
Figure 98: A test of the cross-reactivity of the probe anti-sense to hsa-miR-181a-5p 
with hsa-miR-181b-5p. Positive sense oligomers representing the sequence of each 
miRNA were blotted onto a membrane, which was then probed against hsa-miR-181a-
5p 
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7.2.3.1.9 hsa-miR-182-5p in CCD-841 
 
Figure 99: The effect of SFN treatment on the level of hsa-miR-182-5p in CCD-841 cells 
at 8 and 24 h. Cells were treated by adding to culture medium in duplicate, DMSO-
diluted SFN (10µM) for 8 or 24 h, or DMSO (control); final DMSO concentrations were 
0.05% (v/v). Relative miRNA abundance in RNA extracts was assayed via Northern 
Blotting as described in Methods, using U6 as an internal control. Induction is 
expressed as [(miRNA band intensity)/(U6 band intensity)] for each sample relative to 
the control mean, and data are represented as means of duplicates ± (upper value – 
lower value)/2. 
7.3 Additions to Chapter 2 and Chapter 5  
7.3.1 Construction of pmiRGLO Vectors with 3’ UTRs 
7.3.1.1 Cloning the 3’ UTRs 
As described in Methods, parts of 3’ UTRs containing predicted miRNA 
binding sites were cloned from human gDNA by PCR using designed 
primers. Listed below are the primers used for amplification, followed by the 
sequences of the amplified products (the predicted hsa-let-7f-5p binding sites 
are highlighted in yellow). 
7.3.1.1.1 BACH1 
Forward primer: CTAGTTGTTTAAACGGGTGTAGGGGGAGGATATTGC 
Reverse primer: GACTCGAGGCTAGCGCACATGCAACCTGTATCGTCT 
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Sequence of the amplified product (1239bp):  
GTGTAGGGGGAGGATATTGCTAGTATATTTTCAGTGGTTTGTATGTTCT
CTCTGTCACTGACTTATTTGTAAGAGAAAATTAGTTGGACTTGTTTATTTT
CTAGTAGCTTTTATAAGTACACTCAAGAATTTGTCAGGGAGAATAATTCT
GATAGTGCATCCCATACTGCAAAAGAATTTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTATGTGTATGTATACATATATATCTCTCCATATAGG
TATTTCTTTGATACTTGTAATTTTAAATTTCAGCTTCACGATATAAAATAAT
ATAAGAACTTCTGGTTTACAAAATGTAAAATCTTAAGCCAATGGAACCCT
TGATTTCCTACCTCAGTGTACACCCAACTATTGGTTGTATCAGTTTGTGT
ATGTGCAAATGTCAAATAATCTTTTGCTTTAATTGCTACTGTACTTGCTTT
GAAAGATTACCTACTATTTTATGATAAAATGTAGTTGTCTCCAGAGCTTA
AATATAATTTGTAAAGCACTTGGTTTAAATTTCTCTCTACCTATAAACAGT
TTAGCATTAAGGGTTTCTATTAATGACACAGAATTATTGGCCAAGTGTAA
TTTCTTAAAATTTAGCATTACTTTAAATAGCCAGCATGTAATACAAGTAAC
TACACTACCTCATATCTACATGATTTTCAAGTTGTAATGCAGATGGACAG
ATAAAAAAGATTTTACGTTTGTCTTTTGGCCATAAGTGGGAAAGTTTTCT
GTATATTGCATAGCATTACACATTTATGCCTATTTTAACATTAACTTCTAA
AGAAGTTTTTTCTAAGAAAATGTTTCAAGGCAATATTTTTTTTGAGGCTG
CCGAAGACAAATGACAGGATTATGAGTATACAGTGTATGCCTTTTCCTT
CATGCAGAATTTTGAAATGTTTTCAGTTTGTATATTGCATATTCACATGAT
CATTGTTCACTATTTTATGAACTGGCCTTCTCAATGTTTGATGATTTTTTA
AAAGCTGTTATGTTGAATTCAGTAAAATAACATTACCTTATTTTTTTTCTT
ATTCAAATTCTGGAACTATAGCAAATAATTCGTTAAATTGTCATATTCAAA
ACAAATGTGGATACAGTCTTGGTTCTCCATCTGTAATTTTTTTTAACAGTT
TGCTATAGCTTACTGCTTAACTAATTTTAAATAAGGAAATAAGTATGTTAG
ATGCAGTAGACGATACAGGTTGCATGTG 
7.3.1.1.2 CDC25A[a] 
Forward primer: CTAGTTGTTTAAACGGTGACATTTGGAGAGGGGGC 
Reverse primer: GACTCGAGGCTAGCGACAGGGACAGAAGAGGCGTA 
Sequence of the amplified product (108bp): 
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GTGACATTTGGAGAGGGGGCCTGGGACTTCCATGCCTTAAACCTACCT
CCCACACTCCCAAGGTTGGAGCCCAGGGCATCTTGCTGGCTACGCCTC
TTCTGTCCCTGT 
7.3.1.1.3 CDC25A[b] 
Forward primer: CTAGTTGTTTAAACGCAGGGCATCTTGCTGGCTAC 
Reverse primer: GACTCGAGGCTAGCGGGCAGAGAGCATGGGTTCAA 
Sequence of the amplified product (1613bp): 
CAGGGCATCTTGCTGGCTACGCCTCTTCTGTCCCTGTTAGACGTCCTCC
GTCCATATCAGAACTGTGCCACAATGCAGTTCTGAGCACCGTGTCAAGC
TGCTCTGAGCCACAGTGGGATGAACCAGCCGGGGCCTTATCGGGCTCC
AGCCATCTCATGAGGGGAGAGGAGACGGAGGGGAGTAGAGAAGTTAC
ACAGAAATGCTGCTGGCCAAATAGCAAAGACAACCTGGGAAGGAAAGG
TCTTTGTGGGATAATCCATATGTTTAATTTATTCAACTTCATCAATCACTT
TATTTTATTTTTTTTTCTAACTCCTGGAGACTTATTTTACTGCTTCATTAG
GTTGAAATACTGCCATTCTAGGTAGGGTTTTATTATCCCAGGGACTACC
TCGGCTTTTAATTTAAAAAAAAAAAAGAAGTGGGTAAGAAAATGCAAACC
TGTTATAAGTTATCGGACAGAAAGCTAGGTGCTCTGTCACCCCCAGGAG
GCGCTGTGGTACTGGGGCTGCTGCTATTTAAGCCAAGAACTGAGGTCC
TGGTGAGAGCGTTGGACCCAGGCTTGGCTGCCTGACATAAGCTAAATC
TCCCAGACCCACCACTGGCTACCGATATCTATTTGGTGGGAGGTGTGG
CCCTGTTCTTCCTCACCCCAGTTCCATGACATTGGCTGGTATAGGAGCC
ACAGTCAGGAAAGCACTTGAGGCAGCATCTGTTGGGCCACCCCCGGCT
CAGTGCTGGAATGTTGCAGTGTAGGTTTCCCAGGGAAGGGGGGTGGG
GGTAGGTGGGCTCCACAGGATGGGGGAGGAGCATGTCCACTGAGTAT
CTTCCTTATGTTGCTGTGATATTGATAGCTTTTATTTTCTAATTTTTAAAA
AATGGTCATATTATGAGTCAAAGAGTATCAAATCAGTGTTGGATGGACC
ACCCAAGGGTGAGGAGAGGGGCTGGAAGCCCTGGGCATTAGGAGAAG
GGAGTGGGTGCTGGCATGGACATGACTGGATAGAATTTTCTCAGGAGG
GAGCTTGGTGGATTTTGAAGGTAAAACTTTCTGGGTTTATCATGTTTTAA
TTTTAGAGACAGGGAGTGATGAATCATCACCGGTTGTCCCCTTATCTAA
CTCCATAAAAGTGGGAATTTCAAAAGAACACCTCATCCAAGGAGCTGGG
GCAGACTTCATTGATTCTAGAGAGACCTGTTTCAGTGCCTACTCATCCC
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TGCCCTCTGGTGCCAGCCTCCTTACCATCACGGCTTCACTGAGGTGTA
GGTGGGTTTTTCTTAAACAGGAGACAGTCTCTCCCCTCTTACCTCAACT
TCTTGGGGTGGGAATCAGTGATACTGGAGATGGCTAGTTGCTGTGTTAC
GGGTTTGAGTTACATTTGGCTATAAAACAATCTTGTTGGGAAAAATGTG
GGGGAGAGGACTTCTTCCTACACGCGCATTGAGACAGATTCCAACTGG
TTAATGATATTGTTTGTAAGAAAGAGATTCTGTTGGTTGACTGCCTAAAG
AGAAAGGTGGGATGGCCTTCAGATTATACCAGCTTAGCTAGCATTACTA
ACCAACTGTTGGAAGCTCTGAAAATAAAAGATCTTGAACCCATGCTCTC
TGCC 
7.3.1.1.4 HMGA2[a] (Failed, Re-Done) 
Forward primer: CTAGTTGTTTAAACGGTTCGATTTCTACCTCAGCAGC 
Reverse primer: GACTCGAGGCTAGCGCGTGTTCCTTTCTATCAAATGTC 
Sequence of the amplified product (1793bp): 
GTTCGATTTCTACCTCAGCAGCAGTTGGATCTTTTGAAGGGAGAAGACA
CTGCAGTGACCACTTATTCTGTATTGCCATGGTCTTTCCACTTTCATCTG
GGGTGGGGTGGGGTGGGGTGGGGGAGGGGGGGGTGGGGTGGGGAG
AAATCACATAACCTTAAAAAGGACTATATTAATCACCTTCTTTGTAATCCC
TTCACAGTCCCAGGTTTAGTGAAAAACTGCTGTAAACACAGGGGACACA
GCTTAACAATGCAACTTTTAATTACTGTTTTCTTTTTTCTTAACCTACTAA
TAGTTTGTTGATCTGATAAGCAAGAGTGGGCGGGTGAGAAAAACCGAAT
TGGGTTTAGTCAATCACTGCACTGCATGCAAACAAGAAACGTGTCACAC
TTGTGACGTCGGGCATTCATATAGGAAGAACGCGGTGTGTAACACTGT
GTACACCTCAAATACCACCCCAACCCACTCCCTGTAGTGAATCCTCTGT
TTAGAACACCAAAGATAAGGACTAGATACTACTTTCTCTTTTTCGTATAA
TCTTGTAGACACTTACTTGATGATTTTTAACTTTTTATTTCTAAATGAGAC
GAAATGCTGATGTATCCTTTCATTCAGCTAACAAACTAGAAAAGGTTATG
TTCATTTTTCAAAAAGGGAAGTAAGCAAACAAATATTGCCAACTCTTCTA
TTTATGGATATCACACATATCAGCAGGAGTAATAAATTTACTCACAGCAC
TTGTTTTCAGGACAACACTTCATTTTCAGGAAATCTACTTCCTACAGAGC
CAAAATGCCATTTAGCAATAAATAACACTTGTCAGCCTCAGAGCATTTAA
GGAAACTAGACAAGTAAAATTATCCTCTTTGTAATTTAATGAAAAGGTAC
AACAGAATAATGCATGATGAACTCACCTAATTATGAGGTGGGAGGAGCG
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AAATCTAAATTTCTTTTGCTATAGTTATACATCAATTTAAAAAGCAAAAAA
AAAAAAGGGGGGGGCAATCTCTCTCTGTGTCTTTCTCTCTCTCTCTTCC
TCTCCCTCTCTCTTTTCATTGTGTATCAGTTTCCATGAAAGACCTGAATA
CCACTTACCTCAAATTAAGCATATGTGTTACTTCAAGTAATACGTTTTGA
CATAAGATGGTTGACCAAGGTGCTTTTCTTCGGCTTGAGTTCACCATCT
CTTCATTCAAACTGCACTTTTAGCCAGAGATGCAATATATCCCCACTACT
CAATACTACCTCTGAATGTTACAACGAATTTACAGTCTAGTACTTATTAC
ATGCTGCTATACACAAGCAATGCAAGAAAAAAACTTACTGGGTAGGTGA
TTCTAATCATCTGCAGTTCTTTTTGTACACTTAATTACAGTTAAAGAAGCA
ATCTCCTTACTGTGTTTCAGCATGACTATGTATTTTTCTATGTTTTTTTAA
TTAAAAATTTTTAAAATACTTGTTTCAGCTTCTCTGCTAGATTTCTACATT
AACTTGAAAATTTTTTAACCAAGTCGCTCCTAGGTTCTTAAGGATAATTTT
CCTCAATCACACTACACATCACACAAGATTTGACTGTAATATTTAAATATT
ACCCTCCAAGTCTGTACCTCAAATGAATTCTTTAAGGAGATGGACTAATT
GACTTGCAAAGACCTACCTCCAGACTTCAAAAGGAATGAACTTGTTACT
TGCAGCATTCATTTGTTTTTTCAATGTTTGAAATAGTTCAAACTGCAGCT
AACCCTAGTCAAAACTATTTTTGTAAAAGACATTTGATAGAAAGGAACAC
G 
7.3.1.1.5 HMGA2[a] (Re-try with New Primers) 
Forward primer: CTAGTTGTTTAAACGGGGGCGCCAACGTTCGATTT 
Reverse primer: GACTCGAGGCTAGCGTGACTAGGGTTAGCTGCAGTTTG 
Sequence of the amplified product (1764bp): 
GGGGCGCCAACGTTCGATTTCTACCTCAGCAGCAGTTGGATCTTTTGAA
GGGAGAAGACACTGCAGTGACCACTTATTCTGTATTGCCATGGTCTTTC
CACTTTCATCTGGGGTGGGGTGGGGTGGGGTGGGGGAGGGGGGGGT
GGGGTGGGGAGAAATCACATAACCTTAAAAAGGACTATATTAATCACCT
TCTTTGTAATCCCTTCACAGTCCCAGGTTTAGTGAAAAACTGCTGTAAAC
ACAGGGGACACAGCTTAACAATGCAACTTTTAATTACTGTTTTCTTTTTT
CTTAACCTACTAATAGTTTGTTGATCTGATAAGCAAGAGTGGGCGGGTG
AGAAAAACCGAATTGGGTTTAGTCAATCACTGCACTGCATGCAAACAAG
AAACGTGTCACACTTGTGACGTCGGGCATTCATATAGGAAGAACGCGG
TGTGTAACACTGTGTACACCTCAAATACCACCCCAACCCACTCCCTGTA
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GTGAATCCTCTGTTTAGAACACCAAAGATAAGGACTAGATACTACTTTCT
CTTTTTCGTATAATCTTGTAGACACTTACTTGATGATTTTTAACTTTTTATT
TCTAAATGAGACGAAATGCTGATGTATCCTTTCATTCAGCTAACAAACTA
GAAAAGGTTATGTTCATTTTTCAAAAAGGGAAGTAAGCAAACAAATATTG
CCAACTCTTCTATTTATGGATATCACACATATCAGCAGGAGTAATAAATT
TACTCACAGCACTTGTTTTCAGGACAACACTTCATTTTCAGGAAATCTAC
TTCCTACAGAGCCAAAATGCCATTTAGCAATAAATAACACTTGTCAGCCT
CAGAGCATTTAAGGAAACTAGACAAGTAAAATTATCCTCTTTGTAATTTA
ATGAAAAGGTACAACAGAATAATGCATGATGAACTCACCTAATTATGAG
GTGGGAGGAGCGAAATCTAAATTTCTTTTGCTATAGTTATACATCAATTT
AAAAAGCAAAAAAAAAAAAGGGGGGGGCAATCTCTCTCTGTGTCTTTCT
CTCTCTCTCTTCCTCTCCCTCTCTCTTTTCATTGTGTATCAGTTTCCATGA
AAGACCTGAATACCACTTACCTCAAATTAAGCATATGTGTTACTTCAAGT
AATACGTTTTGACATAAGATGGTTGACCAAGGTGCTTTTCTTCGGCTTGA
GTTCACCATCTCTTCATTCAAACTGCACTTTTAGCCAGAGATGCAATATA
TCCCCACTACTCAATACTACCTCTGAATGTTACAACGAATTTACAGTCTA
GTACTTATTACATGCTGCTATACACAAGCAATGCAAGAAAAAAACTTACT
GGGTAGGTGATTCTAATCATCTGCAGTTCTTTTTGTACACTTAATTACAG
TTAAAGAAGCAATCTCCTTACTGTGTTTCAGCATGACTATGTATTTTTCTA
TGTTTTTTTAATTAAAAATTTTTAAAATACTTGTTTCAGCTTCTCTGCTAGA
TTTCTACATTAACTTGAAAATTTTTTAACCAAGTCGCTCCTAGGTTCTTAA
GGATAATTTTCCTCAATCACACTACACATCACACAAGATTTGACTGTAAT
ATTTAAATATTACCCTCCAAGTCTGTACCTCAAATGAATTCTTTAAGGAG
ATGGACTAATTGACTTGCAAAGACCTACCTCCAGACTTCAAAAGGAATG
AACTTGTTACTTGCAGCATTCATTTGTTTTTTCAATGTTTGAAATAGTTCA
AACTGCAGCTAACCCTAGTCA 
7.3.1.1.6 HMGA2[b] 
Forward primer: CTAGTTGTTTAAACGGCTGCTTCAGGGAGGTAGTT 
Reverse primer: GACTCGAGGCTAGCGGCGACCAACAACAGCAAAGAA 
Sequence of the amplified product (479bp): 
GCTGCTTCAGGGAGGTAGTTTCAAAGGCCACATACCTCTCTGAGACTG
GCAGATCGCTCACTGTTGTGAATCACCAAAGGAGCTATGGAGAGAATTA
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AAACTCAACATTACTGTTAACTGTGCGTTAAATAAGCAAATAAACAGTGG
CTCATAAAAATAAAAGTCGCATTCCATATCTTTGGATGGGCCTTTTAGAA
ACCTCATTGGCCAGCTCATAAAATGGAAGCAATTGCTCATGTTGGCCAA
ACATGGTGCACCGAGTGATTTCCATCTCTGGTAAAGTTACACTTTTATTT
CCTGTATGTTGTACAATCAAAACACACTACTACCTCTTAAGTCCCAGTAT
ACCTCATTTTTCATACTGAAAAAAAAAGCTTGTGGCCAATGGAACAGTAA
GAACATCATAAAATTTTTATATATATAGTTTATTTTTGTGGGAGATAAATT
TTATAGGACTGTTCTTTGCTGTTGTTGGTCGC 
7.3.1.1.7 KRAS 
Forward primer: CTAGTTGTTTAAACGGGTCTCTGTGCCAGCTCTA 
Reverse primer: GACTCGAGGCTAGCGTGCCTACTTGGGAACATTCACT 
Sequence of the amplified product (757bp): 
GGTCTCTGTGCCAGCTCTATAATTGTTTTGCTACGATTCCACTGAAACTC
TTCGATCAAGCTACTTTATGTAAATCACTTCATTGTTTTAAAGGAATAAAC
TTGATTATATTGTTTTTTTATTTGGCATAACTGTGATTCTTTTAGGACAAT
TACTGTACACATTAAGGTGTATGTCAGATATTCATATTGACCCAAATGTG
TAATATTCCAGTTTTCTCTGCATAAGTAATTAAAATATACTTAAAAATTAA
TAGTTTTATCTGGGTACAAATAAACAGGTGCCTGAACTAGTTCACAGAC
AAGGAAACTTCTATGTAAAAATCACTATGATTTCTGAATTGCTATGTGAA
ACTACAGATCTTTGGAACACTGTTTAGGTAGGGTGTTAAGACTTACACA
GTACCTCGTTTCTACACAGAGAAAGAAATGGCCATACTTCAGGAACTGC
AGTGCTTATGAGGGGATATTTAGGCCTCTTGAATTTTTGATGTAGATGG
GCATTTTTTTAAGGTAGTGGTTAATTACCTTTATGTGAACTTTGAATGGTT
TAACAAAAGATTTGTTTTTGTAGAGATTTTAAAGGGGGAGAATTCTAGAA
ATAAATGTTACCTAATTATTACAGCCTTAAAGACAAAAATCCTTGTTGAA
GTTTTTTTAAAAAAAGCTAAATTACATAGACTTAGGCATTAACATGTTTGT
GGAAGAATATAGCAGACGTATATTGTATCATTTGAGTGAATGTTCCCAA
GTAGGCA 
7.3.1.1.8 MYC 
Forward primer: CTAGTTGTTTAAACGAATGTCCTGAGCAATCAC 
Reverse primer: GACTCGAGGCTAGCGGAGGCAGTTTACATTATGGC 
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Sequence of the amplified product (112bp): 
AATGTCCTGAGCAATCACCTATGAACTTGTTTCAAATGCATGATCAAATG
CAACCTCACAACCTTGGCTGAGTCTTGAGACTGAAAGATTTAGCCATAA
TGTAAACTGCCTC 
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Figure 100: A diagram illustrating the expected cleavage of the pmiRGLO vector by 
the HindIII restriction enzyme. 
7.3.1.2 Checking Prepared Plasmids for the Presence of Desired 
Inserts 
 
Table 16: A summary of the expected HindIII digestion fragments. 
Insert 
Insert 
Length 
(bp) 
Length of Fragment 
with Insertion Site 
(bp) 
Length of Other 
Fragment (bp) 
None 0 2579 4771 
BACH1 1239 3818 4771 
CDC25A[b] 1613 4192 4771 
KRAS 757 3336 4771 
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Figure 101: An ethidium bromide-based image of a 1% agarose gel into which HindIII 
digestion products for BACH1, BACH2, BACH3, BACH4, CDC25A[b] 1, CDC25A[b] 2, 
CDC25A[b] 3, CDC25A[b] 4, KRAS 1, KRAS 2, KRAS 3 and KRAS 4 were loaded, 
alongside a 1kb molecular weight marker (NEB), and electrophoresed at 80V for 2 h. 
The band positions in Figure 101 clearly show that CDC25A 1, CDC25A 3, 
CDC25A 4, KRAS 2, KRAS 3 and KRAS 4 plasmids all have the desired 
inserts, while all of the other plasmids have no insert. 
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Figure 102: An ethidium bromide-based image of a 1% agarose gel into which HindIII 
digestion products for BACH5, BACH6, BACH7, BACH8, BACH9 and BACH10 were 
loaded, alongside a 1kb molecular weight marker (NEB), and electrophoresed at 80V 
for 2h. 
According to the band positions in Figure 102, only BACH1 8 had the BACH1 
3’-UTR insert. 
Table 17: A summary of the expected HindIII digestion products. *The HMGA2[b] 
region has one HindIII digestion site within it. 
Insert 
Insert 
Length 
(bp) 
Length of 
Fragment(s) with 
Insertion Site (bp) 
Length of 
Other 
Fragment (bp) 
None 0 2579 4771 
HMGA2[a] 1793 4372 4771 
HMGA2[b] 479 2080 and 978* 4771 
MYC 112 2691 4771 
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Figure 103: An ethidium bromide-based image of a 1% agarose gel into which the 
HindIII digestion products of the HMGA2[a] 1, HMGA2[a] 2, HMGA2[a] 3, HMGA2[a] 4, 
HMGA2[b] 1, HMGA2[b] 2, HMGA2[b] 3, HMGA2[b] 4, MYC 1, MYC 2, MYC 3 and MYC 4 
plasmids were loaded along a 1kb ladder (NEB), and electrophoresed at 100V for 2 h 
30 min. 
Although the gel image shown in Figure 103 shows distortion, it is still clear 
that HMGA2[a] 3, HMGA[a] 4, and all four HMGA2[b] plasmids contain the 
desired inserts (however, it later became apparent that these HMGA2[a] 
constructs were unsuccessful). For the MYC inserts, it is unclear whether or 
not the insert is present due to the relatively short length of the insert. 
Table 18: A summary of expected products following digestion with both HindIII and 
NheI. 
Insert 
Insert 
Length 
(bp) 
Lengths of 
Fragments 
Following HindIII 
Digestion (bp) 
Lengths of Fragments 
Following Subsequent 
NheI Digestion (bp) 
None 0 2579 4771 867 1710 4771 
CDC25A[a] 1793 4372 4771 867 1818 4771 
MYC 112 2691 4771 867 1822 4771 
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Figure 104: An ethidium bromide-based image of a 1% agarose gel into which the 
HindIII and NheI digestion products of the CDC25A[a] 5, CDC25A[a] 6, CDC25A[a] 7, 
CDC25A[a] 8, CDC25A[a] 9, MYC 1, MYC 2, MYC 3 and MYC 4 plasmids were loaded 
alongside 1kb and 100bp ladders (NEB), and electrophoresed at 80V for 1 h. 
It is clear from the image in Figure 104 that the CDC25A[a] 5, CDC25A[a] 6 
and CDC25A[a] 8 plasmids have the insert, whereas CDC25A[a] 7 does not. 
It is also clear that all of the MYC plasmids except for MYC 2 have the 
desired insert. 
The artificial “let-7f-5p antisense repeat” insert was 118bp in length, so if 
present in the plasmid, HindIII digestion should produce fragments at 2697 
and 4771bp instead of at 2579 and 4771bp. 
7.3.1.3 Sequencing Data for the Wild-Type Vector Constructs 
The Sanger sequencing data for the wild-type vector constructs are shown 
below, with the 3’-UTR inserts highlighted in yellow. “…” following a 
sequence indicates that the sequencing did not extend far enough to 
sequence the full insert, as was the case for the longer inserts. 
7.3.1.3.1 BACH1 8 
GTTTAACGGGTGTAGGGGGAGGATATTGCTAGTATATTTTCAGTGGTTT
GTATGTTCTCTCTGTCACTGACTTATTTGTAAGAGAAAATTAGTTGGACT
TGTTTATTTTCTAGTAGCTTTTATAAGTACACTCAAGAATTTGTCAGGGA
GAATAATTCTGATAGTGCATCCCATACTGCAAAAGAATTTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTATGTGTATGTATACATATATATCTCTCCATAT
AGGTATTTCTTTGATACTTGTAATTTTAAATTTCAGCTTCACGATATAAAA
TAATATAAGAACTTCTGGTTTACAAAATGTAAAATCTTAAGCCAATGGAA
276 | P a g e  
 
CCCTTGATTTCCTACCTCAGTGTACACTCAACTATTGGTTGTATCAGTTT
GTGTATGTGCAAATGTCAAATAATCTTTTGCTTTAATTGCTACTGTACTT
GCTTTGAAAGATTACCTACTATTTTATGATAAAATGTAGTTGTCTCCAGA
GCTTAAATATAATTTGTAAAGCACTTGGTTTAAATTTCTCTCTACCTATAA
ACAGTTTAGCATTAAGGGTTTCTATTAATGACACAGAATTATTGGCCAAG
TGTAATTTCTTAAAATTTAGCATTACTTTAAATAGCCAGCATGTAATACAA
GTAACTACACTACCTCATATCTACATGATTTTCAAGTTGTAATGCAGATG
GACAGATAAAAAAGATTTTACGTTTGTCTTTTGGCCATAAGTGGGAAAGT
TTTCTGTATATTGCATAGCATTACACATTTATGCCTATTTTAACATTAACT
TCTAAAGAAGTTTTTTCTAAGAAAATGTTTCAAGGCAATATTTTTTTTGAG
GCTGCCGAAGACAAATGACAGGATTATGAGTATACAGTGTATGCCTTTT
CCTTCATGCAGAATTTTGAAATGTTTTCAGTTTGTATATTGCATATTCACA
TGATCATTGCTCACTATTTTATGAACTGGCCTTCTCAATGTTTGATGATTT
TTTAAAAGCTGTTATG… 
7.3.1.3.2 CDC25Aa 5 
AGTTGTTTAACGGTGACATTTGGAGAGGGGGCCTGGGACTTCCATGCC
TTAAACCTACCTCCCACACTCCCAAGGTTGGAGCCCAGGGCATCTTGCT
GGCTACGCCTCTTCTGTCCCTGTCGCTAGCCTCGAGTCTAGAGTCGAC
CTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAAG
CTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTG
GGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGA
CAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTG
TGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAA
CAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGG
GAGGTTTTTTTAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGAATT
TTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTAC
GCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCACCA
TGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAG
GCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGT
CCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATT
AGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAA
GTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCT
AACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCC
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GCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGC
CT 
7.3.1.3.3 CDC25Aa 6 
AACGGTGACATTTGGAGAGGGGGCCTGGGACTTCCATGCCTTAAACCT
ACCTCCCACACTCCCAAGGTTGGAGCCCAGGGCATCTTGCTGGCTACG
CCTCTTCTGTCCCTGTCGCTAGCCTCGAGTCTAGAGTCGACCTGCAGG
CATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTT
GGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGC
CGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCAC
AACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTA
TTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAAC
AATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTT
TTTTAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGAATTTTAACAA
AATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCT
GTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCACCATGGCCT
GAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAA
AGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAG
GCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAG
CAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGC
AAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCC
GCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCA
TGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCC
TCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCT
TTTGCAAAAGCTTGATTCTTCTGAC 
7.3.1.3.4 CDC25Ab 1 
TTAACGCAGGGCATCTTGCTGGCTACGCCTCTTCTGTCCCTGTTAGACG
TCCTCCGTCCATATCAGAACTGTGCCACAATGCAGTTCTGAGCACCGTG
TCAAGCTGCTCTGAGCCACAGTGGGATGAACCAGCCGGGGCCTTATCG
GGCTCCAGCCATCTCATGAGGGGAGAGGAGACGGAGGGGAGTAGAGA
AGTTACACAGAAATGCTGCTGGCCAAATAGCAAAGACAACCTGGGAAG
GAAAGGTCTTTGTGGGATAATCCATATGTTTAATTTATTCAACTTCATCA
ATCACTTTATTTTATTTTTTTTTCTAACTCCTGGAGACTTATTTTACTGCTT
278 | P a g e  
 
CATTAGGTTGAAATACTGCCATTCTAGGTAGGGTTTTATTATCCCAGGG
ACTACCTCGGCTTTTAATTTAAAAAAAAAAAGAAGTGGGTAAGAAAATGC
AAACCTGTTATAAGTTATCGGACAGAAAGCTAGGTGCTCTGTCACCCCC
AGGAGGCGCTGTGGTACTGGGGCTGCTGCTATTTAAGCCAAGAACTGA
GGTCCTGGTGAGAGCGTTGGACCCAGGCTTGGCTGCCTGACATAAGCT
AAATCTCCCAGACCCACCACTGGCTACCGATATCTATTTGGTGGGAGGT
GTGGCCCTGTTCTTCCTCACCCCAGTTCCATGACATTGGCTGGTATAGG
AGCCACAGTCAGGAAAGCACTTGAGGCAGCATCTGTTGGGCCACCCCC
GGCTCAGTGCTGGAATGTTGCAGTGTAGGTTTCCCAGGGAAGGGGGGT
GGGGGTAGGTGGGCTCCACAGGATGGGGGAGGAGCATGTCCACTGAG
TATCTTCCTTATGTTGCTGTGATATTGATAGCTTTTATTTTCTAATTTTTAA
AAAATGGTCATATTATGAGTCAAAGAGTATCAAATCAGTGTTGGATGGA
CCACCCAAGGGTGAGGAAAGGGGCTGGAAGCCCTGGGCATTAGGAG… 
7.3.1.3.5 CDC25Ab 2 
TGATCTAGTTGTTTAACGCAGGGCATCTTGCTGGCTACGCCTCTTCTGT
CCCTGTTAGACGTCCTCCGTCCATATCAGAACTGTGCCACAATGCAGTT
CTGAGCACCGTGTCAAGCTGCTCTGAGCCACAGTGGGATGAACCAGCC
GGGGCCTTATCGGGCTCCAGCCATCTCATGAGGGGAGAGGAGACGGA
GGGGAGTAGAGAAGTTACACAGAAATGCTGCTGGCCAAATAGCAAAGA
CAACCTGGGAAGGAAAGGTCTTTGTGGGATAATCCATATGTTTAATTTAT
TCAACTTCATCAATCACTTTATTTTATTTTTTTTTCTAACTCCTGGAGACT
TATTTTACTGCTTCATTAGGTTGAAATACTGCCATTCTAGGTAGGGTTTT
ATTATCCCAGGGACTACCTCGGCTTTTAATTTAAAAAAAAAAAAGAAGTG
GGTAAGAAAATGCAAACCTGTTATAAGTTATCGGACAGAAAGCTAGGTG
CTCTGTCACCCCCAGGAGGCGCTGTGGTACTGGGGCTGCTGCTATTTA
AGCCAAGAACTGAGGTCCTGGTGAGAGCGTTGGACCCAGGCTTGGCTG
CCTGACATAAGCTAAATCTCCCAGACCCACCACTGGCTACCGATATCTA
TTTGGTGGGAGGTGTGGCCCTGTTCTTCCTCACCCCAGTTCCATGACAT
TGGCTGGTATAGGAGCCACAGTCAGGAAAGCACTTGAGGCAGCATCTG
TTGGGCCACCCCCGGCTCAGTGCTGGAATGTTGCAGTGTAGGTTTCCC
AGGGAAGGGGGGTGGGGGGTAGGTGGGCTCCACAGGATGGGGGAGG
AGCATGTCCACTGAGTATCTTCCTTATGTTGCTGTGATATTGATAGCTTT
TATTTTCTAATTTTTAAAAAATGGTCATATTATGAGTCAAAGAGTATCAAA
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TCAGTGTTGGATGGACCACCCAAGGGTGAGGAAAGGGGCTGGAAGCC
CTGGGCATTAGG[AAAAAG]*GGA… *Apparent sequencing error. 
7.3.1.3.6 CDC25Ab 4 
TAACGCAGGGCATCTTGCTGGCTACGCCTCTTCTGTCCCTGTTAGACGT
CCTCCGTCCATATCAGAACTGTGCCACAATGCAGTTCTGAGCACCGTGT
CAAGCTGCTCTGAGCCACAGTGGGATGAACCAGCCGGGGCCTTATCGG
GCTCCAGCCATCTCATGAGGGGAGAGGAGACGGAGGGGAGTAGAGAA
GTTACACAGAAATGCTGCTGGCCAAATAGCAAAGACAACCTGGGAAGG
AAAGGTCTTTGTGGGATAATCCATATGTTTAATTTATTCAACTTCATCAAT
CACTTTATTTTATTTTTTTTTCTAACTCCTGGAGACTTATTTTACTGCTTCA
TTAGGTTGAAATACTGCCATTCTAGGTAGGGTTTTATTATCCCAGGGACT
ACCTCGGCTTTTAATTTAAAAAAAAAAAAGAAGTGGGTAAGAAAATGCAA
ACCTGTTATAAGTTATCGGACAGAAAGCTAGGTGCTCTGTCACCCCCAG
GAGGCGCTGTGGTACTGGGGCTGCTGCTATTTAAGCCAAGAACTGAGG
TCCTGGTGAGAGCGTTGGACCCAGGCTTGGCTGCCTGACATAAGCTAA
ATCTCCCAGACCCACCACTGGCTACCGATATCTATTTGGTGGGAGGTGT
GGCCCTGTTCTTCCTCACCCCAGTTCCATGACATTGGCTGGTATAGGAG
CCACAGTCAGGAAAGCACTTGAGGCAGCATCTGTTGGGCCACCCCCGG
CTCAGTGCTGGAATGTTGCAGTGTAGGTTTCCCAGGGAAGGGGGGTGG
GGGTAGGTGGGCTCCACAGGATGGGGGAGGAGCATGTCCACTGAGTA
TCTTCCTTATGTTGCTGTGATATTGATAGCTTTTATTTTCTAATTTTTAAAA
AATGGTCATATTATGAGTCAAAGAGTATCAAATCAGTGTTGGATGGACC
ACCCAAGGGTGAGGAGAGGGGCTGGAAGCCCTGGGCATTAGGAGAAG
GGAG… 
7.3.1.3.7 HMGA2a 3 
TCAGTTGTTTAACGGTTCGATTTCTACCTCAGCAGCAGTTGGATCTTTTG
AAGGGAGAAGACACTGCAGTGACCACTTATTCTGTATTGCCATGGTCTT
TCCACTTTCATCTGGGGTGGGGTGGGGTGGGGTGGGG[GAAAAAA]* 
*Apparent sequencing error. 
7.3.1.3.8 HMGA2a 4 
TCAGTTGTTTAACGGTTCGATTTCTACCTCAGCAGCAGTTGGATCTTTTG
AAGGGAGAAGACACTGCAGTGACCACTTATTCTGTATTGCCATGGTCTT
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TCCACTTTCATCTGGGGTGGGGTGGGGTGGGGTGGGGGA[TGAGAGT]* 
*Apparent sequencing error. 
7.3.1.3.9 HMGA2b 1 
TTGTTTAACGGCTGCTTCAGGGAGGTAGTTTCAAAGGCCACATACCTCT
CTGAGACTGGCAGATCGCTCACTGTTGTGAATCACCAAAGGAGCTATG
GAGAGAATTAAAACTCAACATTACTGTTAACTGTGCGTTAAATAAGCAAA
TAAACAGTGGCTCATAAAAATAAAAGTCGCATTCCATATCTTTGGATGGG
CCTTTTAGAAACCTCATTGGCCAGCTCATAAAATGGAAGCAATTGCTCAT
GTTGGCCAAACATGGTGCACCGAGTGATTTCCATCTCTGGTAAAGTTAC
ACTTTTATTTCCTGTATGTTGTACAATCAAAACACACTACTACCTCTTAAG
TCCCAGTATACCTCATTTTTCATACTGAAAAAAAAAGCTTGTGGCCAATG
GAACAGTAAGAACATCATAAAATTTTTATATATATAGTTTATTTTTGTGGG
AGATAAATTTTATAGGACTGTTCTTTGCTGTTGTTGGTCGCCGCTAGCCT
CGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCTAAC
AAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAA
CTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACATGATAAGATA
CATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGC
TTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC
TGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTTCAG 
7.3.1.3.10 HMGA2b 2 
TGTTTACGGCTGCTTCAGGGAGGTAGTTTCAAAGGCCACATACCTCTCT
GAGACTGGCAGATCGCTCACTGTTGTGAATCACCAAAGGAGCTATGGA
GAGAATTAAAACTCAACATTACTGTTAACTGTGCGTTAAATAAGCAAATA
AACAGTGGCTCATAAAAATAAAAGTCGCATTCCATATCTTTGGATGGGC
CTTTTAGAAACCTCATTGGCCAGCTCATAAAATGGAAGCAATTGCTCAT
GTTGGCCAAACATGGTGCACCGAGTGATTTCCATCTCTGGTAAAGTTAC
ACTTTTATTTCCTGTATGTTGTACAATCAAAACACACTACTACCTCTTAAG
TCCCAGTATACCTCATTTTTCATACTGAAAAAAAAAGCTTGTGGCCAATG
GAACAGTAAGAACATCATAAAATTTTTATATATATAGTTTATTTTTGTGGG
AGATAAATTTTATAGGACTGTTCTTTGCTGTTGTTGGTCGCCGCTAGCCT
CGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCTAAC
AAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAA
CTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACATGATAAGATA
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CATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGC
TTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC
TGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTT
CAGGGGGAGATGTGGGAAGGTTTTTTTAAGCAAGTAAAACCTCTACAAA
TGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGAT
GCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGC
C 
7.3.1.3.11 HMGA2b 3 
AGTTGTTTAACGGCTGCTTCAGGGAGGTAGTTTCAAAGGCCACATACCT
CTCTGAGACTGGCAGATCGCTCACTGTTGTGAATCACCAAAGGAGCTAT
GGAGAGAATTAAAACTCAACATTACTGTTAACTGTGCGTTAAATAAGCAA
ATAAACAGTGGCTCATAAAAATAAAAGTCGCATTCCATATCTTTGGATGG
GCCTTTTAGAAACCTCATTGGCCAGCTCATAAAATGGAAGCAATTGCTC
ATGTTGGCCAAACATGGTGCACCGAGTGATTTCCATCTCTGGTAAAGTT
ACACTTTTATTTCCTGTATGTTGTACAATCAAAACACACTACTACCTCTTA
AGTCCCAGTATACCTCATTTTTCATACTGAAAAAAAAAGCTTGTGGCCAA
TGGAACAGTAAGAACATCATAAAATTTTTATATATATAGTTTATTTTTGTG
GGAGATAAATTTTATAGGACTGTTCTTTGCTGTTGTTGGTCGCCGCTAG
CCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCT
AACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAA
TAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACATGATAAG
ATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAAT
GCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAA
GCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAG
GTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACA
AATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGA
TGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACG
CGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTG 
7.3.1.3.12 HMGA2b 4 
CTAGTTGTTTAACGGCTGCTTCAGGGAGGTAGTTTCAAAGGCCACATAC
CTCTCTGAGACTGGCAGATCGCTCACTGTTGTGAATCACCAAAGGAGCT
ATGGAGAGAATTAAAACTCAACATTACTGTTAACTGTGCGTTAAATAAGC
AAATAAACAGTGGCTCATAAAAATAAAAGTCGCATTCCATATCTTTGGAT
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GGGCCTTTTAGAAACCTCATTGGCCAGCTCATAAAATGGAAGCAATTGC
TCATGTTGGCCAAACATGGTGCACCGAGTGATTTCCATCTCTGGTAAAG
TTACACTTTTATTTCCTGTATGTTGTACAATCAAAACACACTACTACCTCT
TAAGTCCCAGTATACCTCATTTTTCATACTGAAAAAAAAAGCTTGTGGCC
AATGGAACAGTAAGAACATCATAAAATTTTTATATATATAGTTTATTTTTG
TGGGAGATAAATTTTATAGGACTGTTCTTTGCTGTTGTTGGTCGCCGCT
AGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTG
CTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGC
AATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACATGATA
AGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAA
AATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTA
TAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTC
AGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTA
CAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCT
GATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATA
CGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGA 
7.3.1.3.13 KRAS 2 
GTATCTAGTTGTTTAACGGGTCTCTGTGCCAGCTCTATAATTGTTTTGCT
ACGATTCCACTGAAACTCTTCGATCAAGCTACTTTATGTAAATCACTTCA
TTGTTTTAAAGGAATAAACTTGATTATATTGTTTTTTTATTTGGCATAACT
GTGATTCTTTTGGGACAATTACTGTACACATTAAGGTGTATGTCAGATAT
TCATATTGACCCAAATGTGTAATATTCCAGTTTTCTCTGCATAAGTAATTA
AAATATACTTAAAAATTAATAGTTTTATCTGGGTACAAATAAACAGGTGC
CTGAACTAGTTCACAGACAAGGAAACTTCTATGTAAAAATCACTATGATT
TCTGAATTGCTATGTGAAACTACAGATCTTTGGAACACTGTTTAGGTAGG
GTGTTAAGACTTACACAGTACCTCGTTTCTACACAGAGAAAGAAATGGC
CATACTTCAGGAACTGCAGTGCTTATGAGGGGATATTTAGGCCTCTTGA
ATTTTTGATGTAGATGGGCATTTTTTTAAGGTAGTGGTAATTACCTTTAT
GTGAACTTTGAATGGTTTAACAAAAGATTTGTTTTTGTAGAGATTTTAAA
GGGGGAGAATTCTAGAAATAAATGTTACCTAATTATTACAGCCTTAAAGA
TAAAAATCCTTGTTGAAGTTTTTTAAAAAAAAGCTAAATTACATAGACTTA
GGCATTAACATGTTTGTGGAAGAATATAGCAGACGTATATTGTATCATTT
GAGTGAATGTTCCCAAGTAGGCACGCTAGCCTCGAGTCTAGAGTCGAC
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CTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAAG
CTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTG
GGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGA
CAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTG
GGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAC 
7.3.1.3.14 KRAS 3 
GTTTAACGGGTCTCTGTGCCAGCTCTATAATTGTTTTGCTACGATTCCAC
TGAAACTCTTCGATCAAGCTACTTTATGTAAATCACTTCATTGTTTTAAAG
GAATAAACTTGATTATATTGTTTTTTTATTTGGCATAACTGTGATTCTTTT
GGGACAATTACTGTACACATTAAGGTGTATGTCAGATATTCATATTGACC
CAAATGTGTAATATTCCAGTTTTCTCTGCATAAGTAATTAAAATATACTTA
AAAATTAATAGTTTTATCTGGGTACAAATAAACAGGTGCCTGAACTAGTT
CACAGACAAGGAAACTTCTATGTAAAAATCACTATGATTTCTGAATTGCT
ATGTGAAACTACAGATCTTTGGAACACTGTTTAGGTAGGGTGTTAAGAC
TTACACAGTACCTCGTTTCTACACAGAGAAAGAAATGGCCATACTTCAG
GAACTGCAGTGCTTATGAGGGGATATTTAGGCCTCTTGAATTTTTGATG
TAGATGGGCATTTTTTTAAGGTAGTGGTAATTACCTTTATGTGAACTTTG
AATGGTTTAACAAAAGATTTGTTTTTGTAGAGATTTTAAAGGGGGAGAAT
TCTAGAAATAAATGTTACCTAATTATTACAGCCTTAAAGATAAAAATCCTT
GTTGAAGTTTTTTAAAAAAAAGCTAAATTACATAGACTTAGGCATTAACAT
GTTTGTGGAAGAATATAGCAGACGTATATTGTATCATTTGAGTGAATGTT
CCCAAGTAGGCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATG
CAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCT
GCTGCCACCGCTGAACAATAACTAGCATAACCCCTTGGGGCGGCCGCT
TCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACT
AGAATGCAGTGAAAAAAATGCTTTATTTGGGAAATTTGGGATGCT 
 
7.3.1.3.15 KRAS 4 
GTTGTTTAAACGGGTCTCTGTGCCAGCTCTATAATTGTTTTGCTACGATT
CCACTGAAACTCTTCGATCAAGCTACTTTATGTAAATCACTTCATTGTTTT
AAAGGAATAAACTTGATTATATTGTTTTTTTATTTGGCATAACTGTGATTC
TTTTGGGACAATTACTGTACACATTAAGGTGTATGTCAGATATTCATATT
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GACCCAAATGTGTAATATTCCAGTTTTCTCTGCATAAGTAATTAAAATATA
CTTAAAAATTAATAGTTTTATCTGGGTACAAATAAACAGGTGCCTGAACT
AGTTCACAGACAAGGAAACTTCTATGTAAAAATCACTATGATTTCTGAAT
TGCTATGTGAAACTACAGATCTTTGGAACACTGTTTAGGTAGGGTGTTA
AGACTTACACAGTACCTCGTTTCTACACAGAGAAAGAAATGGCCATACT
TCAGGAACTGCAGTGCTTATGAGGGGATATTTAGGCCTCTTGAATTTTT
GATGTAGATGGGCATTTTTTTAAGGTAGTGGTAATTACCTTTATGTGAAC
TTTGAATGGTTTAACAAAAGATTTGTTTTTGTAGAGATTTTAAAGGGGGA
GAATTCTAGAAATAAATGTTACCTAATTATTACAGCCTTAAAGATAAAAAT
CCTTGTTGAAGTTTTTTAAAAAAAAGCTAAATTACATAGACTTAGGCATTA
ACATGTTTGTGGAAGAATATAGCAGACGTATATTGTATCATTTGAGTGAA
TGTTCCCAAGTAGGCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGG
CATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTT
GGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGC
CGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCAC
AACTAGAATGCAGTGAAAAAAATGCTTTATTTGGGAAATTTGGGATG 
7.3.1.3.16 MYC 1 
TTAACGAATGTCCTGAGCAATCACCTATGAACTTGTTTCAAATGCATGAT
CAAATGCAACCTCACAACCTTGGCTGAGTCTTGAGACTGAAAGATTTAG
CCATAATGTAAACTGCCTCCGCTAGCCTCGAGTCTAGAGTCGACCTGCA
GGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAG
TTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCG
GCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACC
ACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGC
TATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAA
CAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTT
TTTTTAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGAATTTTAACA
AAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATC
TGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCACCATGGCC
TGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGA
AAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCA
GGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCA
GCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATG
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CAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTC
CGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCC
ATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGC
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGG
CTTTTGCAAAAAGCTTGATTCTTCTGACCC 
7.3.1.3.18 MYC 2 
GTTGTTTAACGAATGTCCTGAGCAATCACCTATGAACTTGTTTCAAATGC
ATGATCAAATGCAACCTCACAACCTTGGCTGAGTCTTGAGACTGAAAGA
TTTAGCCATAATGTAAACTGCCTCCGCTAGCCTCGAGTCTAGAGTCGAC
CTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAAG
CTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTG
GGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGA
CAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTG
TGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAA
CAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGG
GAGGTTTTTTTAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGAATT
TTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTAC
GCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCACCA
TGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAG
GCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGT
CCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATT
AGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAA
GTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCT
AACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCC
GCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGC
CTA 
7.3.1.3.19 MYC 3 
ACTTGTTTAACGAATGTCCTGAGCAATCACCTATGAACTTGTTTCAAATG
CATGATCAAATGCAACCTCACAACCTTGGCTGAGTCTTGAGACTGAAAG
ATTTAGCCATAATGTAAACTGCCTCCGCTAGCCTCGAGTCTAGAGTCGA
CCTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTT
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GGGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGG
ACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTT
GTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTT
AACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGT
GGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGAA
TTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTT
ACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCAC
CATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTG
AGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAA
GTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAA
TTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAG
AAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCT
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCG
CCT 
7.3.1.3.20 “Let-7f-5p Antisense Repeats” 1 
TCATCTAGTTGTTTAACGAACTATACAATCTACTACCTCAAACTATACAAT
CTACTACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTA
CCTCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTG
ATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCA
CCGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCA
GACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGC
AGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTG
TAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCAT
TTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGT
AAAACCTCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCT
TACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTC
ACACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCT
GAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTG
TGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTG
GAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATC
TCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCC
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CCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT
TTTTTTATTTATGCAGA 
7.3.1.3.21 “Let-7f-5p Antisense Repeats” 2 
TATCTAGTTGTTTAACGAACTATACAATCTACTACCTCAAACTATACAATC
TACTACCTCAAACTATACAATCTACTACCTCAAACTATACAAACCTACTA
CCTCACGCTAGCCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCT
GATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCC
ACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGC
AGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATG
CAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTT
GTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCA
TTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAG
TAAAACCTCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGC
TTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTT
CACACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTC
TGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCT
GTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGC
AGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGT
GGAAAGTCCCCAGGCTCCCCAGCAGCAGAAGTATGCAAAGCATGCATC
TCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCC
CCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT
TTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGGCCTCTGAGCTATTC
C 
7.3.1.3.22 “Let-7f-5p Antisense Repeats” 4 
TATCTAGTTGTTTAACGAACTATACAATCTACTACCTCAAACTATACAATC
TACTACCTCAAACTATACAATCTACTACCCTCAAACTATACAATCTACTA
CCTCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTG
ATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCA
CCGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCA
GACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGC
AGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTG
TAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCAT
TTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGT
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AAAACCTCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCT
TACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTC
ACACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCT
GAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTG
TGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTG
GAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATC
TCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCC
CCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT
TTTTTATTTATGCAGAGGC 
7.3.1.3.23 “Let-7f-5p Antisense Repeats” 5 
TATCTAGTTGTTTAACGAACTATACAATCTACTACCTCAAACTATACAATC
TACTACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTAC
CTCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGA
TCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCAC
CGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAG
ACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCA
GTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGT
AACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATT
TTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTA
AAACCTCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTT
ACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCA
CACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTG
AAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGT
GGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAG
GCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGG
AAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCT
CAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCC
CCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT
TTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCC
A 
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7.3.1.3.24 “Let-7f-5p Antisense Repeats” 9 
ATCTAGTTGTTTAACGAACTATACAATCTACTACCTCAAACTATACAATCT
ACTACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTACC
TCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGAT
CCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACC
GCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGA
CATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAG
TGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTA
ACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTT
TATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAA
AACCTCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTA
CAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCAC
ACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTGA
AAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGTG
GAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGG
CAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGA
AAGTCCCCAGGCTCCCCAGCAGCAGAAGTATGCAAAGCATGCATCTCA
ATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCC
TAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTT
TTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCC 
7.3.1.3.25 “Let-7f-5p Antisense Repeats” 10 
CTAGTTGTTTACGAACTATACAATCTACTACCTCAAACTATACAATCTACT
ACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTACCTCA
CGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCG
GCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCT
GAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACAT
GATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA
AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACC
ATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATG
TTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACC
TCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATT
TCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCG
CATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGA
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GGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGTGGAAT
GTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGA
AGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGT
CCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATT
AGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAA
CTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTT
ATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAG
TAGTGAGG 
7.3.1.3.26 “Let-7f-5p Antisense Repeats” 11 
CTAGTTGTTTACGAACTATACAATCTACTACCTCAAACTATACAATCTACT
ACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTACCTCA
CGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCG
GCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCT
GAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACAT
GATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA
AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACC
ATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATG
TTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACC
TCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATT
TCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCG
CATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGA
GGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGTGGAAT
GTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGA
AGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGT
CCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATT
AGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAA
CTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTT
TATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAG
TAGTGAGGAGGCTTTTTTGGA 
7.3.1.3.27 “Let-7f-5p Antisense Repeats” 13 
ATCTAGTTGTTTAACGAACTATACAATCTACTACCTCAAACTATACAATCT
ACTACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTACC
TCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGAT
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CCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACC
GCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGA
CATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAG
TGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTA
ACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTT
TATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAA
AACCTCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTA
CAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCAC
ACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTGA
AAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGTG
GAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGG
CAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGA
AAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTC
AATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCC
CTAACTCCGCCCAGTTCGCCCATCTCCGCCCCATGCTGACTAATTTTTT
TATTTATG 
7.3.1.3.28 “Let-7f-5p Antisense Repeats” 15 
TTTCTAGTTGTTTAACGAACTATACAATCTACTACCTCAAACTATACAATC
TACTACCTCAAACTATACAATCTACTACCTCAAACTATACAATCTACTAC
CTCACGCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGA
TCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCAC
CGCTGAGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAG
ACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCA
GTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGT
AACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATT
TTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTA
AAACCTCTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTT
ACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCA
CACCGCATACGCGGATCTGCGCAGCACCATGGCCTGAAATAACCTCTG
AAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACCAGCTGT
GGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAG
GCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGG
AAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCT
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CAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCC
CCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATT
TTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCC 
7.3.1.4 Primer Design for PCR Mutagenesis of Predicted Target 
Loci 
As described in the Methods, primers were designed to mutate the predicted 
miRNA-targeted loci, particularly at seed regions. The full sequences of the 
primers used are listed in Table 19. 
Table 19: A list of the full sequences of forward and reverse primers designed for the 
PCR mutagenesis of predicted miRNA-targeted loci in 3’-UTRs. 
 (Table 19 Continued) 
Primer Sequence (5' to 3' Order) 
BACH1-i-mut-FW CCAATGGAACCCTTGATTTCGATATCCAGTGTACACCCAACTATTGGTTGTATCAG 
BACH1-i-mut-RV CTGATACAACCAATAGTTGGGTGTACACTGGATATCGAAATCAAGGGTTCCATTGG 
BACH1-ii-mut-FW GCCAGCATGTAATACAAGTAACTACAGGATCCCATATCTACATGATTTTCAAGTTGTAATGCAGATGG 
BACH1-ii-mut-RV CCATCTGCATTACAACTTGAAAATCATGTAGATATGGGATCCTGTAGTTACTTGTATTACATGCTGGC 
CDC25Aa-mut-FW CTTCCATGCCTTAAACCGATATCCCACACTCCCAAGGTTG 
CDC25Aa-mut-RV CAACCTTGGGAGTGTGGGATATCGGTTTAAGGCATGGAAG 
CDC25Ab-i-mut-FW CTAGGTAGGGTTTTATTATCCCAGGGACGGATCCGGCTTTTAATTTAAAAAAAAAAAAGAAGTGGG 
CDC25Ab-i-mut-RV CCCACTTCTTTTTTTTTTTTAAATTAAAAGCCGGATCCGTCCCTGGGATAATAAAACCCTACCTAG 
CDC25Ab-ii-mut-FW CAGGAGACAGTCTCTCCCCTCTCAATTGAACTTCTTGGGGTGGGAATC 
CDC25Ab-ii-mut-RV GATTCCCACCCCAAGAAGTTCAATTGAGAGGGGAGAGACTGTCTCCTG 
HMGA2a-i-mut-FW TAATTCTAGTTGTTTAAACGGTTCGATTTCGGATCCAGCAGCAGTTGGATCTTTTGAAG 
HMGA2a-i-mut-RV CTTCAAAAGATCCAACTGCTGCTGGATCCGAAATCGAACCGTTTAAACAACTAGAATTA 
HMGA2a-ii-mut-FW CCATGAAAGACCTGAATACCACTGAATTCAAATTAAGCATATGTGTTACTTCAAG 
HMGA2a-ii-mut-RV CTTGAAGTAACACATATGCTTAATTTGAATTCAGTGGTATTCAGGTCTTTCATGG 
HMGA2a-iii-mut-FW GCCAGAGATGCAATATATCCCCACTACTCAATACCAATTGTGAATGTTACAACGAATTTACAGTCTAG 
HMGA2a-iii-mut-RV CTAGACTGTAAATTCGTTGTAACATTCACAATTGGTATTGAGTAGTGGGGATATATTGCATCTCTGGC 
HMGA2a-iv-mut-FW GATTTGACTGTAATATTTAAATATTACCCTCCAAGTCTGACGCGTAAATGAATTCTTTAAGGAGATGGAC 
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 (Table 19 Continued) 
Primer Sequence (5' to 3' Order) 
HMGA2a-iv-mut-RV GTCCATCTCCTTAAAGAATTCATTTACGCGTCAGACTTGGAGGGTAATATTTAAATATTACAGTCAAATC 
HMGA2a-v-mut-FW GGAGATGGACTAATTGACTTGCAAAGACCCATATGCAGACTTCAAAAGGAATGAACTTGTTAC 
HMGA2a-v-mut-RV GTAACAAGTTCATTCCTTTTGAAGTCTGCATATGGGTCTTTGCAAGTCAATTAGTCCATCTCC 
HMGA2b-vi-mut-FW GAGGTAGTTTCAAAGGCCACAGATATCTCTGAGACTGGCAGATCGCTC 
HMGA2b-vi-mut-RV GAGCGATCTGCCAGTCTCAGAGATATCTGTGGCCTTTGAAACTACCTC 
HMGA2b-vii-mut-FW CCTGTATGTTGTACAATCAAAACACACTACGGATCCTTAAGTCCCAGTATACCTCATTTTTCATAC 
HMGA2b-vii-mut-RV GTATGAAAAATGAGGTATACTGGGACTTAAGGATCCGTAGTGTGTTTTGATTGTACAACATACAGG 
HMGA2b-viii-mut-FW GTACAATCAAAACACACTACTACCTCTTAAGTCCCAGTAAGATCTATTTTTCATACTGAAAAAAAAAGCTTGTGGCCAATGG 
HMGA2b-viii-mut-RV CCATTGGCCACAAGCTTTTTTTTTCAGTATGAAAAATAGATCTTACTGGGACTTAAGAGGTAGTAGTGTGTTTTGATTGTAC 
KRAS-mut-FW GGGTGTTAAGACTTACACAGGATATCGTTTCTACACAGAGAAAGAAATG 
KRAS-mut-RV CATTTCTTTCTCTGTGTAGAAACGATATCCTGTGTAAGTCTTAACACCC 
MYC-mut-FW GAGACTGAAAGATTTAGCCATAATGTAAAGGATCCCAAATTGGACTTTGGGCATAAAAGAAC 
MYC-mut-RV GTTCTTTTATGCCCAAAGTCCAATTTGGGATCCTTTACATTATGGCTAAATCTTTCAGTCTC 
294 | P a g e  
 
7.3.1.5 Checking Mutant Vectors for Successful Binding Site 
Mutations by Digestion 
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Figure 105: A diagram (not to scale) illustrating the loci of the existing restriction sites 
in the BACH1 construct, and those of new restriction sites created by successful seed 
region mutagenesis 
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Figure 106: A diagram (not to scale) illustrating the loci of the existing restriction sites 
in the CDC25Aa construct, and those of new restriction sites created by successful 
seed region mutagenesis 
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Figure 107: A diagram (not to scale) illustrating the loci of the existing restriction sites 
in the CDC25Ab construct, and those of new restriction sites created by successful 
seed region mutagenesis 
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Figure 108: A diagram (not to scale) illustrating the loci of the existing restriction sites 
in the HMGA2a construct, and those of new restriction sites created by successful 
seed region mutagenesis 
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Figure 109: A diagram (not to scale) illustrating the loci of the existing restriction sites 
in the HMGA2b construct, and those of new restriction sites created by successful 
seed region mutagenesis 
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Figure 110: A diagram (not to scale) illustrating the loci of the existing restriction sites 
in the KRAS construct, and those of new restriction sites created by successful seed 
region mutagenesis 
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Figure 111: A diagram (not to scale) illustrating the loci of the existing restriction sites 
in the MYC construct, and those of new restriction sites created by successful seed 
region mutagenesis 
Figure 105, Figure 106, Figure 107, Figure 108, Figure 109, Figure 110 and 
Figure 111 all show the existing restriction sites present in the wild-type 
constructs, and the loci of those newly created by successful seed region 
mutation. The expected products following digestion are listed alongside 
each diagram. 
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7.3.1.5.1 Agarose Electrophoresis of Digestion Products 
7.3.1.5.1.1 First-Site Mutagenesis: Bach1, CDC25Ab, HMGA2a, HMGA2b 
and KRAS 
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Figure 112: An ethidium bromide-based image of a 1% (w/v) agarose gel into which 
the EcoRV digestion products of BACH1 and HMGA2b first-site mutants, and the 
BamHI digestion products of CDC25Ab, HMGA2a and KRAS first-site mutants were 
loaded, alongside a 1kb molecular weight marker (NEB), and electrophoresed at 80V 
for 2h. 
It is clear from the gel image in Figure 112 that the first binding site of the 
BACH1 construct was successfully mutagenized, creating a new EcoRV 
restriction site, resulting in the expected 2281 and 6308bp products, as 
described in Figure 105. Mutageneses of the first binding sites of CDC25Ab 
and HMGA2b were also successful, as illustrated by the presence of 
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expected 4053 and 4910bp, and 1850 and 5975bp bands, respectively (see 
Figure 107 and Figure 109 for detail about expected products). For 
HMGA2a, there should be 4533 and 4610bp products (see Figure 108), 
which may not be separate from one another as discrete bands due to their 
proximity. However, the band in this lane according to Figure 112 actually 
appears between 3.0 and 4.0 kb, thus lower than expected. 
7.3.1.5.1.2 Second-Site Mutagenesis: Bach1, CDC25Ab and HMGA2b 
Ladder BACH1 M2t CDC25Ab M2t HMGA2b M2t
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Figure 113: An ethidium bromide-based image of a 1% (w/v) agarose gel into which 
the BamHI digestion products of BACH1 and HMGA2b double mutants, and the MfeI 
digestion product of CDC25Ab double mutant were loaded, alongside a 1kb molecular 
weight marker (NEB), and electrophoresed at 60V for 1h. 
7.3.1.6 Sequencing Data for the Mutant Vectors 
7.3.1.6.1 BACH1 – 1st Seed Mutation 
The FW and antiparallel of RV sequences were combined: 
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CTAGTTGTTTAACGGGTGTAGGGGGAGGATATTGCTAGTATATTTTCAG
TGGTTTGTATGTTCTCTCTGTCACTGACTTATTTGTAAGAGAAAATTAGT
TGGACTTGTTTATTTTCTAGTAGCTTTTATAAGTACACTCAAGAATTTGTC
AGGGAGAATAATTCTGATAGTGCATCCCATACTGCAAAAGAATTTGTGT
GTGTGTGTGTGTGTGTGTGTGTGTATGTGTATGTATACATATATATCTCT
CCATATAGGTATTTCTTTGATACTTGTAATTTTAAATTTCAGCTTCACGAT
ATAAAATAATATAAGAACTTCTGGTTTACAAAATGTAAAATCTTAAGCCAA
TGGAACCCTTGATTTCGATATCCAGTGTACACCCAACTATTGGTTGTATC
AGTTTGTGTATGTGCAAATGTCAAATAATCTTTTGCTTTAATTGCTACTGT
ACTTGCTTTGAAAGATTACCTACTATTTTATGATAAAATGTAGTTGTCTCC
AGAGCTTAAATATAATTTGTAAAGCACTTGGTTTAAATTTCTCTCTACCTA
TAAACAGTTTAGCATTAAGGGTTTCTATTAATGACACAGAATTATTGGCC
AAGTGTAATTTCTTAAAATTTAGCATTACTTTAAATAGCCAGCATGTAATA
CAAGTAACTACACTACCTCATATCTACATGATTTTCAAGTTGTAATGCAG
ATGGACAGATAAAAAAGATTTTACGTTTGTCTTTTGGCCATAAGTGGGAA
AGTTTTCTGTATATTGCATAGCATTACACATTTATGCCTATTTTAACATTA
ACTTCTAAAGAAGTTTTTTCTAAGAAAATGTTTCAAGGCAATATTTTTTTT
GAGGCTGCCGAAGACAAATGACAGGATTATGAGTATACAGTGTATGCCT
TTTCCTTCATGCAGAATTTTGAAATGTTTTCAGTTTGTATATTGCATATTC
ACATGATCATTGCTCACTATTTTATGAACTGGCCTTCTCAATGTTTGATG
ATTTTTTAAAAGCTGTTATGTTGAATTCAGTAAAATAACATTACCTTATTT
TTTTTCTTATTCAAATTCTGGAACTATAGCAAATAATTCGTTAAATTGTCA
TATTCAAAACAAATGTGGATACAGTCTTGGTTCTCCATCTGTAATTTTTTT
TAACAGTTTGCTATAGCTTACTGCTTAACTAATTTTAAATAAGGAAATAAG
TATGTTAGATGCAGTAGACGATACAGGTTGCATGTGCGCTAGCCTCGAG
TCTAGAGTCGACAGCA 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
These sequencing data confirm that the directed mutation of the 1st seed 
region in BACH1 was successful. 
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7.3.1.6.2 BACH1 – 2nd Seed Mutation 
FW and the antiparallel of the RV sequencing data were combined: 
GTATTCTAGTTGTTTAACGGGTGTAGGGGGAGGATATTGCTAGTATATT
TTCAGTGGTTTGTATGTTCTCTCTGTCACTGACTTATTTGTAAGAGAAAA
TTAGTTGGACTTGTTTATTTTCTAGTAGCTTTTATAAGTACACTCAAGAAT
TTGTCAGGGAGAATAATTCTGATAGTGCATCCCATACTGCAAAAGAATTT
GTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTATGTATACATATATAT
CTCTCCATATAGGTATTTCTTTGATACTTGTAATTTTAAATTTCAGCTTCA
CGATATAAAATAATATAAGAACTTCTGGTTTACAAAATGTAAAATCTTAAG
CCAATGGAACCCTTGATTTCGATATCCAGTGTACACCCAACTATTGGTT
GTATCAGTTTGTGTATGTGCAAATGTCAAATAATCTTTTGCTTTAATTGCT
ACTGTACTTGCTTTGAAAGATTACCTACTATTTTATGATAAAATGTAGTTG
TCTCCAGAGCTTAAATATAATTTGTAAAGCACTTGGTTTAAATTTCTCTCT
ACCTATAAACAGTTTAGCATTAAGGGTTTCTATTAATGACACAGAATTAT
TGGCCAAGTGTAATTTCTTAAAATTTAGCATTACTTTAAATAGCCAGCAT
GTAATAAAGTAACTACAGGATCCCATATCTACATGATTTTCAAGTTGTAA
TGCAGATGGACAGATAAAAAAGATTTTACGTTTGTCTTTTGGCCATAAGT
GGGAAAGTTTTCTGTATATTGCATAGCATTACACATTTATGCCTATTTTAA
CATTAACTTCTAAAGAAGTTTTTTCTAAGAAAATGTTTCAAGGCAATATTT
TTTTTGAGGCTGCCGAAGACAAATGACAGGATTATGAGTATACAGTGTA
TGCCTTTTCCTTCATGCAGAATTTTGAAATGTTTTCAGTTTGTATATTGCA
TATTCACATGATCATTGCTCACTATTTTATGAACTGGCCTTCTCAATGTTT
GATGATTTTTTAAAAGCTGTTATGTTGAATTCAGTAAAATAACATTACCTT
ATTTTTTTTCTTATTCAAATTCTGGAACTATAGCAAATAATTCGTTAAATT
GTCATATTCAAAACAAATGTGGATACAGTCTTGGTTCTCCATCTGTAATT
TTTTTTAACAGTTTGCTATAGCTTACTGCTTAACTAATTTTAAATAAGGAA
ATAAGTATGTTAGATGCAGTAGACGATACAGGTTGCATGTGCGCTAGCC
TCGAGTCTAGAGTCGACTGCA 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
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7.3.1.6.3 CDC25Aa – Seed Mutation 
FW and Antiparallel of RV sequencing combined: 
CTAGTTGTTTAACGCAGGGCATCTTGCTGGCTACGCCTCTTCTGTCCCT
GTTAGACGTCCTCCGTCCATATCAGAACTGTGCCACAATGCAGTTCTGA
GCACCGTGTCAAGCTGCTCTGAGCCACAGTGGGATGAACCAGCCGGG
GCCTTATCGGGCTCCAGCCATCTCATGAGGGGAGAGGAGACGGAGGG
GAGTAGAGAAGTTACACAGAAATGCTGCTGGCCAAATAGCAAAGACAAC
CTGGGAAGGAAAGGTCTTTGTGGGATAATCCATATGTTTAATTTATTCAA
CTTCATCAATCACTTTATTTTATTTTTTTTTCTAACTCCTGGAGACTTATTT
TACTGCTTCATTAGGTTGAAATACTGCCATTCTAGGTAGGGTTTTATTAT
CCCAGGGACGGATCCGGCTTTTAATTTAAAAAAAAAAAAGAAGTGGGTA
AGAAAATGCAAACCTGTTATAAGTTATCGGACAGAAAGCTAGGTGCTCT
GTCACCCCCAGGAGGCGCTGTGGTACTGGGGCTGCTGCTATTTAAGCC
AAGAACTGAGGTCCTGGTGAGAGCGTTGGACCCAGGCTTGGCTGCCTG
ACATAAGCTAAATCTCCCAGACCCACCACTGGCTACCGATATCTATTTG
GTGGGAGGTGTGGCCCTGTTCTTCCTCACCCCAGTTCCATGACATTGG
CTGGTATAGGAGCCACAGTCAGGAAAGCACTTGAGGCAGCATCTGTTG
GGCCACCCCCGGCTCAGTGCTGGAATGTTGCAGTGTAGGTTTCCCAGG
GAAGGGGGGTGGGGGGTAGGTGGGCTCCACAGGATGGGGGAGGAGC
ATGTCCACTGAGTATCTTCCTTATGTTGCTGTGATATTGATAGCTTTTATT
TTCTAATTTTTAAAAAATGGTCATATTATGAGTCAAAGAGTATCAAATCAG
TGTTGGATGGACCACCCAAGGGTGAGGAGAGGGGCTGGAAGCCCTGG
GCATTAGGAGAAGGGAGTGGGTGCTGGCATGGACATGACTGGATAGAA
TTTTCTCAGGAGGGAGCTTGGTGGATTTTGAAGGTAAAACTTTCTGGGT
TTATCATGTTTTAATTTTAGAGACAGGGAGTGATGAATCATCACCGGTTG
TCCCCTTATCTAACTCCATAAAAGTGGGAATTTCAAAAGAACACCTCATC
CAAGGAGCTGGGGCAGACTTCATTGATTCTAGAGAGACCTGTTTCAGTG
CCTACTCATCCCTGCCCTCTGGTGCCAGCCTCCTTACCATCACGGCTTC
ACTGAGGTGTAGGTGGGTTTTTCTTAAACAGGAGACAGTCTCTCCCCTC
TTACCTCAACTTCTTGGGGTGGGAATCAGTGATACTGGAGATGGCTAGT
TGCTGTGTTACGGGTTTGAGTTACATTTGGCTATAAAACAATCTTGTTGG
GAAAAATGTGGGGGAGAGGACTTCTTCCTACACGCGCATTGAGACAGA
TTCCAACTGGTTAATGATATTGTTTGTAAGAAAGAGATTCTGTTGGTTGA
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CTGCCTAAAGAGAAAGGTGGGATGGCCTTCAGATTATACCAGCTTAGCT
AGCATTACTAACCAACTGTTGGAAGCTCTGAAAATAAAAGATCTTGAACC
CATGCTCTCTGCCCGCTAGCCTCGAGTCTAGAGTCGACCGCA 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
7.3.1.6.4 CDC25Ab – 1st Seed Mutation 
The FW and antiparallel of RV sequences were combined: 
CTAGTTGTTTAACGCAGGGCATCTTGCTGGCTACGCCTCTTCTGTCCCT
GTTAGACGTCCTCCGTCCATATCAGAACTGTGCCACAATGCAGTTCTGA
GCACCGTGTCAAGCTGCTCTGAGCCACAGTGGGATGAACCAGCCGGG
GCCTTATCGGGCTCCAGCCATCTCATGAGGGGAGAGGAGACGGAGGG
GAGTAGAGAAGTTACACAGAAATGCTGCTGGCCAAATAGCAAAGACAAC
CTGGGAAGGAAAGGTCTTTGTGGGATAATCCATATGTTTAATTTATTCAA
CTTCATCAATCACTTTATTTTATTTTTTTTTCTAACTCCTGGAGACTTATTT
TACTGCTTCATTAGGTTGAAATACTGCCATTCTAGGTAGGGTTTTATTAT
CCCAGGGACGGATCCGGCTTTTAATTTAAAAAAAAAAAAGAAGTGGGTA
AGAAAATGCAAACCTGTTATAAGTTATCGGACAGAAAGCTAGGTGCTCT
GTCACCCCCAGGAGGCGCTGTGGTACTGGGGCTGCTGCTATTTAAGCC
AAGAACTGAGGTCCTGGTGAGAGCGTTGGACCCAGGCTTGGCTGCCTG
ACATAAGCTAAATCTCCCAGACCCACCACTGGCTACCGATATCTATTTG
GTGGGAGGTGTGGCCCTGTTCTTCCTCACCCCAGTTCCATGACATTGG
CTGGTATAGGAGCCACAGTCAGGAAAGCACTTGAGGCAGCATCTGTTG
GGCCACCCCCGGCTCAGTGCTGGAATGTTGCAGTGTAGGTTTCCCAGG
GAAGGGGGGTGGGGGGTAGGTGGGCTCCACAGGATGGGGGAGGAGC
ATGTCCACTGAGTATCTTCCTTATGTTGCTGTGATATTGATAGCTTTTATT
TTCTAATTTTTAAAAAATGGTCATATTATGAGTCAAAGAGTATCAAATCAG
TGTTGGATGGACCACCCAAGGGTGAGGAGAGGGGCTGGAAGCCCTGG
GCATTAGGAGAAGGGAGTGGGTGCTGGCATGGACATGACTGGATAGAA
TTTTCTCAGGAGGGAGCTTGGTGGATTTTGAAGGTAAAACTTTCTGGGT
TTATCATGTTTTAATTTTAGAGACAGGGAGTGATGAATCATCACCGGTTG
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TCCCCTTATCTAACTCCATAAAAGTGGGAATTTCAAAAGAACACCTCATC
CAAGGAGCTGGGGCAGACTTCATTGATTCTAGAGAGACCTGTTTCAGTG
CCTACTCATCCCTGCCCTCTGGTGCCAGCCTCCTTACCATCACGGCTTC
ACTGAGGTGTAGGTGGGTTTTTCTTAAACAGGAGACAGTCTCTCCCCTC
TTACCTCAACTTCTTGGGGTGGGAATCAGTGATACTGGAGATGGCTAGT
TGCTGTGTTACGGGTTTGAGTTACATTTGGCTATAAAACAATCTTGTTGG
GAAAAATGTGGGGGAGAGGACTTCTTCCTACACGCGCATTGAGACAGA
TTCCAACTGGTTAATGATATTGTTTGTAAGAAAGAGATTCTGTTGGTTGA
CTGCCTAAAGAGAAAGGTGGGATGGCCTTCAGATTATACCAGCTTAGCT
AGCATTACTAACCAACTGTTGGAAGCTCTGAAAATAAAAGATCTTGAACC
CATGCTCTCTGCCCGCTAGCCTCGAGTCTAGAGTCGACCGCA 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
These sequencing data confirm that the directed mutation of the 1st seed 
region of CDC25Ab was successful. 
7.3.1.6.5 CDC25Ab – 2nd Seed Mutation 
FW and the antiparallel of the RV sequencing data were combined: 
AGTTGTTTAACGCAGGGCATCTTGCTGGCTACGCCTCTTCTGTCCCTGT
TAGACGTCCTCCGTCCATATCAGAACTGTGCCACAATGCAGTTCTGAGC
ACCGTGTCAAGCTGCTCTGAGCCACAGTGGGATGAACCAGCCGGGGC
CTTATCGGGCTCCAGCCATCTCATGAGGGGAGAGGAGACGGAGGGGA
GTAGAGAAGTTACACAGAAATGCTGCTGGCCAAATAGCAAAGACAACCT
GGGAAGGAAAGGTCTTTGTGGGATAATCCATATGTTTAATTTATTCAACT
TCATCAATCACTTTATTTTATTTTTTTTTCTAACTCCTGGAGACTTATTTTA
CTGCTTCATTAGGTTGAAATACTGCCATTCTAGGTAGGGTTTTATTATCC
CAGGGACGGATCCGGCTTTTAATTTAAAAAAAAAAAAGAAGTGGGTAAG
AAAATGCAAACCTGTTATAAGTTATCGGACAGAAAGCTAGGTGCTCTGT
CACCCCCAGGAGGCGCTGTGGTACTGGGGCTGCTGCTATTTAAGCCAA
GAACTGAGGTCCTGGTGAGAGCGTTGGACCCAGGCTTGGCTGCCTGAC
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ATAAGCTAAATCTCCCAGACCCACCACTGGCTACCGATATCTATTTGGT
GGGAGGTGTGGCCCTGTTCTTCCTCACCCCAGTTCCATGACATTGGCT
GGTATAGGAGCCACAGTCAGGAAAGCACTTGAGGCAGCATCTGTTGGG
CCACCCCCGGCTCAGTGCTGGAATGTTGCAGTGTAGGTTTCCCAGGGA
AGGGGGGTGGGGGTAGGTGGGCTCCACAGGATGGGGGAGGAGCATG
TCCACTGAGTATCTTCCTTATGTTGCTGTGATATTGATAGCTTTTATTTTC
TAATTTTTAAAAAATGGTCATATTATGAGTCAAAGAGTATCAAATCAGTGT
TGGATGGACCACCCAAGGGTGAGGAGAGGGGCTGGAAGCCCTGGGCA
TTAGGAGAAGGGAGTGGGTGCTGGCATGGACATGACTGGATAGAATTT
TCTCAGGAGGGAGCTTGGTGGATTTTGAAGGTAAAACTTTCTGGGTTTA
TCATGTTTTAATTTTAGAGACAGGGAGTGATGAATCATCACCGGTTGTC
CCCTTATCTAACTCCATAAAAGTGGGAATTTCAAAAGAACACCTCATCCA
AGGAGCTGGGGCAGACTTCATTGATTCTAGAGAGACCTGTTTCAGTGC
CTACTCATCCCTGCCCTCTGGTGCCAGCCTCCTTACCATCACGGCTTCA
CTGAGGTGTAGGTGGGTTTTTCTTAAACAGGAGACAGTCTCTCCCCTCT
CAATTGAACTTCTTGGGGTGGGAATCAGTGATACTGGAGATGGCTAGTT
GCTGTGTTACGGGTTTGAGTTACATTTGGCTATAAAACAATCTTGTTGG
GAAAAATGTGGGGGAGAGGACTTCTTCCTACACGCGCATTGAGACAGA
TTCCAACTGGTTAATGATATTGTTTGTAAGAAAGAGATTCTGTTGGTTGA
CTGCCTAAAGAGAAAGGTGGGATGGCCTTCAGATTATACCAGCTTAGCT
AGCATTACTAACCAACTGTTGGAAGCTCTGAAAATAAAAGATCTTGAACC
CATGCTCTCTGCCCGCTAGCCTCGAGTCTAGAGTCGACCTGCAG 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
 
7.3.1.6.6 HMGA2b – 1st Seed Mutation 
FW sequencing only: 
TTGTTTAACGGCTGCTTCAGGGAGGTAGTTTCAAAGGCCACAGATATCT
CTGAGACTGGCAGATCGCTCACTGTTGTGAATCACCAAAGGAGCTATG
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GAGAGAATTAAAACTCAACATTACTGTTAACTGTGCGTTAAATAAGCAAA
TAAACAGTGGCTCATAAAAATAAAAGTCGCATTCCATATCTTTGGATGGG
CCTTTTAGAAACCTCATTGGCCAGCTCATAAAATGGAAGCAATTGCTCAT
GTTGGCCAAACATGGTGCACCGAGTGATTTCCATCTCTGGTAAAGTTAC
ACTTTTATTTCCTGTATGTTGTACAATCAAAACACACTACTACCTCTTAAG
TCCCAGTATACCTCATTTTTCATACTGAAAAAAAAAGCTTGTGGCCAATG
GAACAGTAAGAACATCATAAAATTTTTATATATATAGTTTATTTTTGTGGG
AGATAAATTTTATAGGACTGTTCTTTGCTGTTGTTGGTCGCCGCTAGCCT
CGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGGCTGCTAAC
AAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAA
CTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACATGATAAGATA
CATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGC
TTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC
TGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTT
CAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAAT
GTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTTCCTGATG
CGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGCG
GATCTGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGG 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
These sequencing data confirm that the directed mutation of the 1st seed 
region of HMGA2b was successful. 
 
 
7.3.1.6.7 HMGA2b – 2nd Seed Mutation 
FW sequencing only:  
TATCTAGTTGTTTAACGGCTGCTTCAGGGAGGTAGTTTCAAAGGCCACA
GATATCTCTGAGACTGGCAGATCGCTCACTGTTGTGAATCACCAAAGGA
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GCTATGGAGAGAATTAAAACTCAACATTACTGTTAACTGTGCGTTAAATA
AGCAAATAAACAGTGGCTCATAAAAATAAAAGTCGCATTCCATATCTTTG
GATGGGCCTTTTAGAAACCTCATTGGCCAGCTCATAAAATGGAAGCAAT
TGCTCATGTTGGCCAAACATGGTGCACCGAGTGATTTCCATCTCTGGTA
AAGTTACACTTTTATTTCCTGTATGTTGTACAATCAAAACACACTACGGA
TCCTTAAGTCCCAGTATACCTCATTTTTCATACTGAAAAAAAAAGCTTGT
GGCCAATGGAACAGTAAGAACATCATAAAATTTTTATATATATAGTTTATT
TTTGTGGGAGATAAATTTTATAGGACTGTTCTTTGCTGTTGTTGGTCGCC
GCTAGCCTCGAGTCTAGAGTCGACCTGCAGGCATGCAAGCTGATCCGG
CTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTG
AGCAATAACTAGCATAACCCCTTGGGGCGGCCGCTTCGAGCAGACATG
ATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAA
AAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCA
TTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGT
TTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTTAAGCAAGTAAAACCT
CTACAAATGTGGTAAAATCGAATTTTAACAAAATATTAACGCTTACAATTT
CCTGATGCGGTATTTTCTCCTTACGCATCTGTGC 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
7.3.1.6.8 HMGA2b – 3rd Seed Mutation 
Antiparallel of RV sequencing only: 
CCCATGATCATGAGCGGCTACGTTAACACCCCGAGGCTACAAACGCTC
TCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGG
GACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGAGCCTGATC
AAATACAAGGGCTACAGGTAGCCCCAGCCGAACTGGAGAGCATCGTGC
TGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGAC
GACGATGCCGGCGAGCTGCCCGCCGCAGTCGTCGTGCTGGAACACGG
TAAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGCCAGCCAGGT
TACAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGT
GCCTAAAGGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGAT
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TCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAATTCTAGTTG
TTTAAACGGCTGCTTCAGGGAGGTAGTTTCAAAGGCCACAGATATCTCT
GAGACTGGCAGATCGCTCACTGTTGTGAATCACCAAAGGAGCTATGGA
GAGAATTAAAACTCAACATTACTGTTAACTGTGCGTTAAATAAGCAAATA
AACAGTGGCTCATAAAAATAAAAGTCGCATTCCATATCTTTGGATGGGC
CTTTTAGAAACCTCATTGGCCAGCTCATAAAATGGAAGCAATTGCTCAT
GTTGGCCAAACATGGTGCACCGAGTGATTTCCATCTCTGGTAAAGTTAC
ACTTTTATTTCCTGTATGTTGTACAATCAAAACACACTACGGATCCTTAA
GTCCCAGTAAGATCTATTTTTCATACTGAAAAAAAAAGCTTGTGGCCAAT
GGAACAGTAAGAACATCATAAAATTTTTATATATATAGTTTATTTTTGTGG
GAGATAAATTTTATAGGACTGTTCTTTGCTGTTGTTGGTCGCCGCTAGC
CTCGAGTCTAGAGTCGACCTGCA 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
7.3.1.6.9 KRAS – Seed Mutation 
Antiparallel of RV sequencing only: 
CGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAATT
CTAGTTGTTTAAACGGGTCTCTGTGCCAGCTCTATAATTGTTTTGCTACG
ATTCCACTGAAACTCTTCGATCAAGCTACTTTATGTAAATCACTTCATTG
TTTTAAAGGAATAAACTTGATTATATTGTTTTTTTATTTGGCATAACTGTG
ATTCTTTTGGGACAATTACTGTACACATTAAGGTGTATGTCAGATATTCA
TATTGACCCAAATGTGTAATATTCCAGTTTTCTCTGCATAAGTAATTAAAA
TATACTTAAAAATTAATAGTTTTATCTGGGTACAAATAAACAGGTGCCTG
AACTAGTTCACAGACAAGGAAACTTCTATGTAAAAATCACTATGATTTCT
GAATTGCTATGTGAAACTACAGATCTTTGGAACACTGTTTAGGTAGGGT
GTTAAGACTTACACAGGATATCGTTTCTACACAGAGAAAGAAATGGCCA
TACTTCAGGAACTGCAGTGCTTATGAGGGGATATTTAGGCCTCTTGAAT
TTTTGATGTAGATGGGCATTTTTTTAAGGTAGTGGTAATTACCTTTATGT
GAACTTTGAATGGTTTAACAAAAGATTTGTTTTTGTAGAGATTTTAAAGG
GGGAGAATTCTAGAAATAAATGTTACCTAATTATTACAGCCTTAAAGATA
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AAAATCCTTGTTGAAGTTTTTTAAAAAAAAGCTAAATTACATAGACTTAGG
CATTAACATGTTTGTGGAAGAATATAGCAGACGTATATTGTATCATTTGA
GTGAATGTTCCCAAGTAGGCACGCTAGCCTCGAGTCTAGAGTCGACAT
C 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
These sequencing data confirm that the directed mutation of the KRAS seed 
region was successful. 
7.3.1.6.10 MYC – Seed Mutation 
FW sequencing only: 
CTAGTTGTTTAACGAATGTCCTGAGCAATCACCTATGAACTTGTTTCAAA
TGCATGATCAAATGCAACCTCACAACCTTGGCTGAGTCTTGAGACTGAA
AGATTTAGCCATAATGTAAGATATCTCCGCTAGCCTCGAGTCTAGAGTC
GACCTGCAGGCATGCAAGCTGATCCGGCTGCTAACAAAGCCCGAAAGG
AAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCC
TTGGGGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTT
GGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAAT
TTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAG
TTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATG
TGGGAGGTTTTTTTAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGA
ATTTTAACAAAATATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCT
TACGCATCTGTGCGGTATTTCACACCGCATACGCGGATCTGCGCAGCA
CCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCT
GAGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAA
AGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCA
ATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCA
GAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCC
CCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTC
TCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCC
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GCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGA
GGCCTAGGCTTTTGCAAAAAGCTTGATTCTTCTGA 
• Start of insert 
• End of insert 
• Seed region 
• Successfully mutated site 
7.3.2 Luciferase Assay Optimisation 
Caco-2 cells were seeded in 96-well plates with 20 000 cells/well, and 
simultaneously ‘fast-forward’ transfected with the ‘CDC25Ab 5 WT’ vector 
using the Attractene Transfection Reagent, with varying amounts of vector 
and Attractene to determine the optimum combination. 
The luciferase assay was done 2 days after seeding/transfection: 
7.3.2.1 Firefly Data (Blank-Corrected) 
DNA (µg) None 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.3
Attr. (µL) None 0.25 0.375 0.75 0.5 0.75 1.5 0.75 1.125 2.25
15973 12708 19347 18360 24862 7437 18813 25022 5856
16995 13110 18944 21603 25792 4996 9317 23554 2638
16561 15563 19330 22239 23115 7730 21013 23523 4428
Mean 16510 13794 19207 20734 24590 6721 16381 24033 4308
S.E.M. 242 729 107 981 641 708 2930 404 760
 
7.3.2.2 Renilla Data (Blank-Corrected) 
DNA (µg) None 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.3
Attr. (µL) None 0.25 0.375 0.75 0.5 0.75 1.5 0.75 1.125 2.25
15973 12708 19347 18360 24862 7437 18813 25022 5856
16995 13110 18944 21603 25792 4996 9317 23554 2638
16561 15563 19330 22239 23115 7730 21013 23523 4428
Mean 16510 13794 19207 20734 24590 6721 16381 24033 4308
S.E.M. 242 729 107 981 641 708 2930 404 760
 
7.3.2.3 Firefly/Renilla 
DNA (µg) None 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.3
Attr. (µL) None 0.25 0.375 0.75 0.5 0.75 1.5 0.75 1.125 2.25
0.90 0.97 0.94 1.04 0.95 1.08 1.02 0.97 0.97
1.01 1.06 0.98 1.01 0.94 1.07 1.41 0.97 1.23
0.96 0.98 1.07 1.02 1.04 1.07 1.13 1.05 0.91
Mean 0.96 1.01 1.00 1.02 0.97 1.07 1.19 0.99 1.04
S.E.M. 0.03 0.02 0.03 0.01 0.03 0.00 0.09 0.02 0.08
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Figure 114: The luminescent signals from the experiments to optimise the amounts of 
DNA and Attractene transfection reagent to use are represented in this graph as 
means ± S.E.M. 
It is clear from the data illustrated in Figure 114 that the optimal amounts of 
DNA and Attractene to use per well are 0.2µg and 0.75µL respectively, since 
these give the highest luminescent signals, hence these will be used for 
experiments. It is also clear that using more than 1.125µL Attractene/well 
results in significant cytotoxicity. 
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Figure 115: The [Firefly luminescence]/[Renilla luminescence] ratios are represented 
as means ± S.E.M. 
The data in Figure 115 confirm that as expected, varying the amounts of 
DNA and Attractene did not affect Firefly/Renilla ratios, indicating that the 
measurement of Renilla luciferase activity is suitable for use as an internal 
control. 
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